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ABSTRACT 
Abstract   
ii 
 
Due to the error-prone nature of RNA virus replication, each dengue virus (DV) exists 
as a quasispecies within the host.  To investigate the hypothesis that DV quasispecies 
populations affect disease severity, serum samples were obtained from dengue 
patients hospitalised in Ragama, Sri Lanka.  From the patient sera, DV envelope 
glycoprotein (E) genes were amplified by high-fidelity RT-PCR, cloned, and multiple 
clones per sample sequenced to identify mutations within the quasispecies population.  
A mean quasispecies diversity of 0.018% was observed, consistent with reported error 
rates for viral RNA polymerases (0.01%; Smith et al., 1997).  However, previous studies 
reported 8.9 to 21.1-fold greater mean diversities (0.16% to 0.38%; Craig et al., 2003; 
Lin et al., 2004; Wang et al., 2002a).  This discrepancy was shown to result from the 
lower fidelity of the RT-PCR enzymes used by these groups for viral RNA amplification.  
Previous studies should therefore be re-examined to account for the high number of 
mutations introduced by the amplification process.   
Nonsynonymous mutation locations were modelled to the crystal structure of DV E, 
identifying those with the potential to affect virulence due to their proximity to 
important structural features.  No correlation was observed between the extent of 
quasispecies variation and disease severity.  However, genome-defective quasispecies 
variants, and variants with surface accessible amino acid substitutions, or those 
proximal to the fusion peptide, proposed receptor binding sites, or other E oligomers, 
were observed predominantly in patients with severe dengue.  Recombinant virus-like 
particles were produced for nine quasispecies variants, and the effects of the 
mutations on protein function assessed.  Altered heparin binding abilities were 
demonstrated for four of the nine variants, indicative of differing cell attachment 
capabilities.  Further work is required to assess differences in antibody binding, 
replication efficiency, virion and oligomer assembly, low pH-induced conformational 
changes required for fusion, and transmissibility of variants. 
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1.1 Thesis overview 
This thesis describes the investigation of dengue virus (DV) quasispecies populations, 
specifically examining the envelope glycoprotein (E) gene, within individual patient 
samples from an outbreak in Sri Lanka in 2006.  Chapter 1 provides an introduction to 
dengue disease and the epidemiology and biology of the aetiological agents, the DVs.  
The diversity and variability of DVs are examined at the species, genotype and 
quasispecies level.  The effect of this variation on virus virulence and disease 
pathogenicity is also discussed, with particular attention to the effect of mutations in 
the E gene.  The hypothesis, aims and objectives of the project are stated at the end of 
Chapter 1.  The methods used throughout the course of the investigation are detailed 
in Chapter 2, and the amplification, cloning and sequencing of the quasispecies E genes 
from the patient samples is described in Chapter 3.  The extent of variation observed in 
the virus populations within the individual patients, and how the results from this 
study compare to previous studies is assessed.  The effect of the quasispecies 
mutations on E function is hypothesised based on the proximity of the mutations to 
important structural features within the E.  Chapter 4 describes the construction of 
recombinant E for several of the quasispecies variants in the form of virus-like particles 
(VLPs).  In Chapter 5, the host cell attachment functions of these recombinant VLPs are 
assessed, as is their utility as a source of antigen for the serodiagnosis of dengue.  A 
summary and discussion of the results of the investigation, and opportunities for 
future work are provided in Chapter 6, which details correlations between 
quasispecies variation, virus virulence and disease severity. 
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1.2 Dengue  
Dengue is the most common mosquito-borne viral disease, with 50 million human 
cases estimated to occur annually (World Health Organisation, 2009).  Dengue is of 
major global concern as 40% of the world population (2.5 billion people) are at risk of 
contracting the disease, and the morbidity and mortality associated with dengue 
constitute an enormous public health burden.  There are thought to be around 
500,000 cases of severe dengue requiring hospitalisation every year with at least a 
2.5% fatality rate (World Health Organisation, 1997b).   
1.2.1 Aetiology of dengue  
Dengue is caused by four distinct but closely related viruses; dengue virus (DV) types 1, 
2, 3 and 4 which are transmitted by female Aedes mosquitoes, predominantly Ae. 
aegyptii.  The occurrence of dengue has increased 30-fold in the last 50 years due to 
the failure of vector eradication programmes and the geographical spread of vector 
and virus populations (World Health Organisation, 2009).  Epidemics of severe disease 
were not recorded until the 1950s and since then have spread geographically from 
South East Asia to every continent except Europe and Antarctica (World Health 
Organisation, 1997b).  The four DVs are now endemic in more than 100 countries 
across Africa, the Americas, the Eastern Mediterranean, South East Asia and the 
Western Pacific (Figure 1.1), with more areas becoming hyperendemic for multiple DV 
types.  Severe disease epidemics that include a higher proportion of severe dengue 
cases and a greater number of fatalities are becoming more common (World Health 
Organisation, 2008).   
DVs belong to the genus flavivirus within the family Flaviviridae.  Within the flavivirus 
genus, the viruses can be classified in terms of their transmission vector as either 
mosquito-borne, tick-borne or vector unknown (Figure 1.2).  Other flaviviruses of 
global concern include yellow fever virus (YFV), Japanese encephalitis virus (JEV), West 
Nile virus (WNV) and tick-borne encephalitis virus (TBEV).   
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Figure 1.1.  Areas at risk of dengue virus transmission in the Western hemisphere (A) and the 
Eastern hemisphere (B). 
The maps show areas at risk of DV transmission based on dengue fever cases reported in 2008 (Centers 
for Disease Control and Prevention, 2009). 
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B
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Atlantic ocean
Pacific ocean
Dengue risk area
No known dengue risk
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Dengue risk area
No known dengue risk
Chapter 1: Introduction 
5 
 
Figure 1.2.  Flavivirus phylogenetic tree.   
This phylogenetic tree was constructed for this study. The red box encloses mosquito-borne flaviviruses 
and the blue box encloses mammalian tick-borne flaviviruses.  The evolutionary history was inferred 
from complete genome sequences using the Neighbour-Joining method. The percentage of replicate trees 
in which the associated taxa clustered together in the bootstrap test (1000 replicates) is shown next to the 
branches. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary 
distances used to infer the phylogenetic tree. The evolutionary distances were computed using the 
Maximum Composite Likelihood method and are in the units of the number of base substitutions per site. 
Phylogenetic analyses were conducted in MEGA4. Sequences were NCBI RefSeq numbers: NC002031 
(Yellow fever virus, YFV), NC001437 (Japanese encephalitis virus, JEV),  NC001672 (tick-borne 
encephalitis virus, TBEV),  NC001477 (DV type 1),  NC001474 (DV type 2), NC001475 (DV type 3),  
NC002640 (DV type 4),  NC000943 (Murray Valley encephalitis virus, MVEV), NC007580 (St Louis 
encephalitis virus, SLEV), NC009942 (West Nile virus, WNV), NC006551 (Usutu virus), NC005064 
(Kamiti river virus), NC005062 (Omsk haemorrhagic fever virus), NC004355 (Alkhurma virus), 
NC003687 (Powassan virus), NC003675 (Rio Bravo virus), NC003676 (Apoi virus), NC001809 
(Louping ill virus), NC008718 (Entebbe bat virus), NC006947 (Karshi virus), NC004119 (Montana 
myotis leukoencephalitis virus), NC003670 (Langat virus), NC003635 (Modoc virus), NC009027 (Iguape 
virus), NC009026 (Bussuquara virus), NC009028 (lheus virus), NC009029 (Kokobera virus), NC008719 
(Sepik virus) and NC005039 (Yokose virus).   
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1.2.2 Symptoms of dengue  
In infants and young children, dengue most commonly presents as a non-specific 
febrile illness with a rash.  In older children and adults there can be a mild febrile 
syndrome or classical disease with pain behind the eyes and a rash.  Severe disease 
occurs in about 1% of cases and symptoms can include high fever, haemorrhagic 
phenomena, enlarged liver, circulatory failure and hypovolemic shock.  Death can 
occur within 12-24 hours unless appropriate treatment is given (World Health 
Organisation, 2008).  There are no specific antiviral therapies available for dengue and 
there is no vaccine.  Treatment is intensive supportive care such as maintenance of 
circulating fluid volume and ventilatory support, but this is less widely available in 
developing countries. 
Most flavivirus infections are thought to be under-reported because the wide 
spectrum of disease severity and a lack of effective case definition make diagnosis 
difficult.  Symptoms common to all flavivirus infections include: fever, headache, chills, 
muscle aches, loss of appetite, nausea, and vomiting.  The most common presentation 
is of a mild febrile illness and flavivirus infections can sometimes even be 
asymptomatic.   However, severe complications occur in a significant proportion of 
infected individuals.  For infections caused by YFV, JEV, WNV and TBEV these severe 
complications tend to be neurological rather than the abnormalities of haemostasis 
and vascular permeability observed with severe dengue. 
1.2.3 Clinical and laboratory diagnosis of dengue 
During diagnosis, flavivirus infections must be differentiated from other viral infections 
with similar clinical presentation (for example Chikungunya virus, an alphavirus), 
bacterial infections (such as Salmonella typhi, which causes typhoid fever or Leptospira 
species which cause leptospirosis), or parasitic infections (for example the Plasmodium 
parasites that cause malaria).  The diagnosis may then be narrowed to a specific 
flavivirus infection, although according to the World Health Organisation (WHO) many 
laboratories only report a diagnosis of ‘acute flavivirus infection’, rather than 
identifying the precise virus using serological or molecular techniques (World Health 
Organisation, 1997c).  
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Cases of symptomatic dengue have historically been classified by severity according to 
WHO guidelines first published in 1975, which differentiate between cases of dengue 
fever (DF), dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS; World 
Health Organisation 1997a; Figure 1.3). However, dengue epidemiology has changed 
considerably since these guidelines were first published, leading to difficulties with the 
use of this classification system in a clinical setting (reviewed in Bandyopadhyay, Lum, 
and Kroeger, 2006; Deen et al., 2006).  Examples of severe dengue that do not meet 
the WHO criteria for DHF include: dengue with haemorrhage but without evidence of 
plasma leakage; dengue with shock but not fulfilling all four DHF criteria; and severe 
dengue with organ dysfunction but a low degree of plasma leakage (Bandyopadhyay, 
Lum, and Kroeger, 2006). 
Regional WHO publications since 1997 have acknowledged these difficulties by 
relaxing the criteria in some circumstances to aid clinical assessment of dengue cases.  
For example, in small hospitals in India, guidelines state that DHF is any probable case 
of dengue with haemorrhaging and any one (not all) of the DHF indications shown in 
Figure 1.3 (World Health Organisation, 1999).  Another example is in the treatment of 
children, where the term ‘severe dengue’ has been proposed to include any case of 
dengue fever with signs of vascular permeability resulting in plasma leakage (Deen, 
2005).  In the most recent WHO guidelines (World Health Organisation, 2009), a 
classification system has been proposed that distinguishes between patients with 
severe dengue, and those with non-severe dengue with or without warning signs 
(Figure 1.4).  This classification system has been tested in 18 countries by comparison 
with the existing WHO case classification and published results are expected soon. 
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Dengue fever
Acute febrile illness with two or more of the following:
headache
retro-orbital pain
myalgia
arthralgia
rash
haemorrhagic manifestations
leukopenia
and either supportive serology or proximity to laboratory confirmed cases.
Dengue haemorrhagic fever
The following indications must all be present:
fever or a history of fever
haemorrhagic tendencies evidenced by one or more of the following:
- a positive tourniquet test
- petechiae, ecchymoses or purpura
- bleeding from the mucosa, gastrointestinal tract, injection sites or other locations
- haematemesis or melaena
thrombocytopenia (100,000 cells per mm3 or less)
evidence of plasma leakage due to increased vascular permeability, manifested by at least one of 
the following:
- a rise in the haematocrit equal to or greater than 20% above average for age, sex and population
- a drop in the haematocrit following volume-replacement treatment equal to or greater than 20% 
of baseline
- signs of plasma leakage such as pleural effusion, ascites and hypoproteinaemia
Dengue shock syndrome
All four of the above DHF criteria must be present, plus evidence of circulatory failure manifested by 
either of the following:
rapid, weak pulse and narrow pulse pressure (<20mmHg)
hypotension for age (systolic pressure <80mmHg for those less than 5 years of age, or <90mmHg 
for those greater than or equal to 5 years of age) and cold, clammy skin and restlessness 
 
 
 
 
Figure 1.3.  World Health Organisation dengue case classification guidance.  
Adapted from World Health Organisation, 1997a.  Cases of dengue are classified as dengue fever (DF), 
dengue haemorrhagic fever (DHF) or dengue shock syndrome (DSS) according to the clinical 
observations described in the figure. 
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Figure 1.4.  2009 updated World Health Organisation dengue case classification guidance. 
Figure is from World Health Organisation, 2009. Cases of dengue are classified as dengue with or 
without warning signs, and severe dengue according to the clinical observations described in the figure. 
Abbreviations are: haematocrit (HCT), dengue shock syndrome (DSS), aspartate transaminase (AST), 
alanine transaminase (ALT), central nervous system (CNS). 
     
Diagnostic laboratory tests most commonly used for dengue include those that detect 
the DVs (isolation by tissue culture or reverse transcription-polymerase chain reaction, 
RT-PCR) and those that detect antibodies to the virus (enzyme-linked immunosorbent 
assay (ELISA), immunofluorescence (IF), haemagglutination inhibition (HI) and 
neutralisation tests).  The gold standard for the laboratory diagnosis of any flavivirus 
infection is isolation, culture and further characterisation of the virus (for example by 
antigen detection) from the patient sample which is time consuming, taking over a 
week to complete.  However, RT-PCR allows rapid diagnosis and could therefore 
improve patient care.  Both of these virus detection methodologies are more 
expensive than serology-based methods and require well-equipped laboratories.  They 
are also only of use within approximately seven days of the onset of symptoms as the 
virus is present in the sera typically for the duration of fever (World Health 
Organisation, 1997c).  After this time, antibodies to the virus can be identified using 
serological methods.  The antibodies neutralise the virus and therefore it is not 
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possible to detect or culture the virus once the immune response is significantly 
underway. 
There are several difficulties with serological diagnosis of flavivirus infections.  Many 
different flaviviruses circulate in the same regions and there is a large degree of 
antigenic cross-reactivity between them, so it can be difficult to identify which 
flavivirus is causing the current infection.  In addition, the presence of antibodies from 
previous flavivirus infections or vaccinations makes it difficult to diagnose the type of 
infection (primary or secondary; past, present or recent; Shu and Huang, 2004).  
Primary antibody responses occur in people who have not previously been infected (or 
immunised) and are characterised by the presence of immunoglobulin M (IgM) 
antibodies after several days of fever, or after the fever has passed.  Secondary 
responses occur as a result of a second flavivirus infection (for example sequential 
infection with different DV types) and it is the IgG response that is dominant (Shu and 
Huang, 2004).  IgG antibodies from secondary dengue infections can persist in the 
blood for more than 10 months (Gubler, 1996). Serological studies on dengue patients 
have shown that antibodies to the envelope glycoprotein (E) are more commonly 
detected than those raised against the capsid (C), pre-membrane (prM), membrane 
(M), nonstructural (NS) 1, NS3 or NS5 proteins in both primary and secondary 
infections (Valdes et al., 2000).  This shows that serology-based diagnostic tests should 
be directed towards E antigens or antibodies for them to stand the best chance of 
early detection. 
In the UK, travellers falling ill on returning home from flavivirus endemic areas require 
laboratory diagnosis of their diseases.  Currently at the Health Protection Agency (HPA) 
Centre for Emergency Preparedness and Response (CEPR) approximately 2500 clinical 
samples are tested for evidence of arboviruses each year, and this includes a flavivirus 
screen.  Samples are received from patients in the early stages of infection (in which 
antigen is present) and later after the immune response has occurred.  Screening for 
arbovirus infections is done by RT-PCR, IF, and IgM and IgG ELISA.  Cross-reactivity 
between antibodies to the different flaviviruses often complicates interpretation of the 
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serology results.  There is a need for improved reagents for serodiagnosis (flavivirus 
antibodies and antigens) that are species specific, and do not cross-react. 
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1.3 Dengue viruses  
1.3.1 Dengue virus structure and genome organisation 
DVs, like all flaviviruses, are single positive strand ribonucleic acid (RNA)-encoded 
viruses.  DV genomes are around 10,700 nucleotides in length, and act directly as 
messenger RNA (mRNA) for all viral proteins, which are synthesised in one long open 
reading frame as a polyprotein which is then proteolytically processed (Figure 1.5).  
The genome consists of non-coding (NC) regions at the 5’ and 3’ ends, with the genes 
encoding the three structural proteins (C, prM and E) followed by those encoding the 
seven NS proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b and NS5; Lindenbach and Rice, 
2001). The non-structural proteins are involved in replication and processing of the 
viral polyprotein (Ball, 2001), and inhibition of host interferon responses to infection 
(Ho et al., 2005; Munoz-Jordan et al., 2005).  Mature virions are spherical and around 
50nm in diameter, containing the three structural proteins (C, M and E).  M and E are 
embedded in a host-derived lipid bilayer forming the outer surface of the virion, 
surrounding the C proteins that encapsulate the viral RNA (Figure 1.6; Kaufmann and 
Rossmann, 2011). 
 
Figure 1.5.  Dengue virus genome organisation.   
Figure is from Petersen and Roehrig, 2001. The approximately 10.7kb genome has non-coding (NC) 
regions at the 5’ and 3’ ends, with the protein-coding genes in the order C, prM, E, NS1, NS2a, NS2b, 
NS3, NS4a, NS4b and NS5.  PrM is the membrane protein precursor which is cleaved by furin to produce 
the M protein.    
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Figure 1.6.  Structure of the flavivirus virion. 
Figure and legend are from Kaufmann and Rossmann, 2011. (A) Three-dimensional (3D) rendering of a 
cryoelectron microscopy density map of DV. The cut-out window allows the view inside the virion at the 
nucleocapsid core (magenta/orange) composed of the C protein and the RNA genome. The core is 
surrounded by a host-derived lipid envelope (green). The outer icosahedral shell of the virus (blue) is 
formed by two membrane-anchored glycoproteins, E and M. (B) Pre-fusion arrangement of E on the 
surface of the mature flavivirion, viewed down an icosahedral twofold axis. Domains I, II, and III of each 
E monomer are coloured red, yellow, and blue, respectively. The fusion loop is shown in green. A total of 
180 E monomers are associated in 30 rafts of three, nearly parallel E homodimers that form a distinct 
herringbone pattern. One icosahedral asymmetric unit (ASU), the smallest unit from which the particle 
can be generated by applying icosahedral symmetry, is outlined by a black triangle. The positions of the 
neighbouring icosahedral five-, three- and two-fold symmetry axes are marked with symbols (pentagons, 
triangles, and ovals, respectively). Each ASU contains the equivalent of three E monomers. (C) 
Arrangement of E and pr peptides on the surface of an immature, fusion-incompetent flavivirion, viewed 
down an icosahedral twofold axis. Domains I, II, and III of each E monomer and the fusion loop are 
coloured as in (A). The pr peptide is shown in magenta. One ASU is outlined by a black triangle and the 
positions of the symmetry axes are indicated. E are icosahedrally arranged in 60 trimeric spikes, 
composed of prM/E heterodimers. The pr peptide of prM covers the fusion peptide in domain II of E (on 
the tip of each spike) to prevent premature fusion. 
 
1.3.2 Dengue virus replication 
The host range of DVs includes humans, monkeys and mosquitoes, and virus 
replication is able to occur in diverse tissues within all of these organisms.  During 
infection (Figure 1.7), the virus attaches to host cell surface receptors via E (Chen, 
Maguire, and Marks, 1996) and enters the cell by receptor-mediated endocytosis.  The 
acidic pH within the endosome triggers conformational changes in the viral envelope 
that allow fusion of viral and cell membranes.  The viral RNA is released into the 
cytoplasm, and once delivered to cellular ribosomes, is translated to form the 
polyprotein precursor.  This undergoes proteolytic processing to release the structural 
and non-structural proteins.  The non-structural proteins catalyse replication via the 
production of anti-genomic RNA, which is itself replicated to produce more genomic 
RNA for translation.  Virus particles are assembled on the surface of the endoplasmic 
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reticulum (ER), in the form of immature virions containing prM.  These bud off from 
the ER and are transported through the trans-Golgi network (TGN).  The prM are then 
cleaved by the host cell’s furin protease, to yield M.  This exposes the E fusion peptide, 
which results in mature infectious virions that are fusion-competent and can be 
released to infect more host cells (Ball, 2001; Mukhopadhyay, Kuhn, and Rossmann, 
2005). 
 
Figure 1.7.  Flavivirus replication.   
The virus attaches to its target cell and gains access via receptor-mediated endocytosis.  Viral and cell 
membranes fuse, releasing the viral RNA (vRNA) genome into the cell. The genomic RNA is translated 
into a polyprotein which is then cleaved to release the structural and non-structural proteins.  Replication 
of the viral genome and new virus assembly takes place at the surface of the ER.  Immature virions are 
transported out of the cell via the TGN, and virus maturation occurs.  Diagram is from Ball, 2001. 
 
NC regions at the ends of the genome play an important role during replication and 
translation.  Long-range RNA-RNA interactions between the 5’ and 3’ non-coding 
regions are thought to circularise the genome, which prevents replication and 
translation of truncated or damaged mRNAs (Alvarez et al., 2005).  Both non-coding 
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regions are capable of recruiting translation-initiation factors.  The 5’ end of the viral 
RNA is capped but the 3’ end is not polyadenylated (poly(A)) unlike host cellular 
mRNAs.  However, the 3’ non-coding region plays roles in both regulation of 
translation and mRNA stability similar to that of the cellular mRNA poly(A) tail (Chiu, 
Kinney, and Dreher, 2005).  DVs (and therefore potentially other flaviviruses) are able 
to initiate viral protein synthesis using interacting 5’ and 3’ non-coding regions even 
under conditions where cap-dependent translation is inhibited (Edgil, Polacek, and 
Harris, 2006).   The start codon for translation initiation in dengue and other mosquito-
borne flaviviruses is an adenine-uracil-guanine (AUG) sequence at the start of the 
coding region for the capsid protein.  A hairpin loop in the RNA secondary structure 
near this site is thought to increase site recognition by the ribosome complex by 
stalling it over the start codon (Clyde and Harris, 2006). 
1.3.3 Dengue virus binding to target host cells 
Immature dendritic cells (DCs) in the skin are considered the initial site of DV 
replication in humans after inoculation by the mosquito vector (Ho et al., 2001; 
Palucka, 2000; Wu et al., 2000).  Migration of infected DCs to the lymph nodes permits 
antigen presentation leading to an immune response, infection and replication in 
lymphoid tissues and release of DV into the circulation.  Monocytes, macrophages, B 
and T lymphocytes and endothelial cells have also been shown to support DV infection 
in vitro (Bielefeldt-Ohmann et al., 2001; Halstead and O'Rourke, 1977; Lee et al., 2006; 
Miller et al., 2008) and different cellular receptors have been implicated in virus-cell 
attachment.  These receptors vary between cell-types, species of origin and DV type.  
Monocytes and macrophages can be infected by DV in an antibody-dependent manner 
via binding of non-neutralised virus-antibody complexes to immunoglobulin fcγ 
receptors on the cell surface (Halstead and O'Rourke, 1977).  However, primary 
infections, and infections of cells that do not have immunoglobulin fcγ receptors on 
the cell surface must occur via a different mechanism. 
Heparan sulphate expressed on the surface of target cells has been shown to bind the 
DV E (Chen et al., 1997).  Interactions between heparan sulphate and clusters of basic 
amino acids within E are thought to concentrate the virus on the cell surface, enabling 
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subsequent higher-affinity interactions with specific receptors.  Lectins such as  DC-
specific intracellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin (DC-SIGN), 
DC-SIGN relatives (DC-SIGNR) and the mannose receptor have been proposed as 
dengue receptors on dendritic cells, endothelial cells and macrophages (Miller et al., 
2008; Navarro-Sanchez et al., 2003; Tassaneetrithep et al., 2003).  This is consistent 
with a role for the E glycans in infectivity and virus growth in mammalian cells (Bryant 
et al., 2007; Mondotte et al., 2007) as lectins such as DC-SIGN bind high-mannose 
glycans in the presence of calcium ions (Feinberg et al., 2001).  Cryoelectron 
microscopy of the DV/DC-SIGN complex has shown interaction of the lectin with the 
asparagine (N or Asn)-linked glycan at Asn-67 (Pokidysheva et al., 2006).   
One mechanism of virus neutralisation by antibodies is prevention of virus attachment 
to host cells, as the antibody obscures the receptor-binding site on the virion, making it 
unable to bind to the target host cell (Roehrig, 2003).  Viruses are able to escape 
neutralisation by antibodies if they contain gene mutations that lead to amino acid 
substitutions that prevent neutralising antibodies from binding.    
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1.4 Determinants of viral replication and disease pathogenesis 
The causes of dengue pathogenesis are poorly understood at present.  Work in this 
area has been hampered by the lack of appropriate animal models for severe disease.  
Mouse neurovirulence models are commonly used (Gualano et al., 1998; Holzmann et 
al., 1990; Kawano et al., 1993) even though dengue rarely causes encephalitis in 
human infections (Solomon et al., 2000).  Factors in addition to host genetics 
(reviewed in Coffey et al., 2009) that have been proposed as having an effect on 
pathogenicity include: the antibody-dependent enhancement (ADE) of infection by the 
presence of antibodies to previous infection with a different DV type, and the virulence 
of the infecting virus strain (Halstead, 1988; Rosen, 1977).  Consistent with both of 
these hypotheses is that increased disease severity has been correlated with high 
viraemia early in the course of illness (Libraty et al., 2002; Vaughn et al., 2000).  DVs 
isolated from patients with severe disease have been observed to replicate more 
rapidly and to higher titres in DCs than viruses isolated from patients with less severe 
disease (Takhampunya et al., 2009).   It has been observed that during the febrile 
stage, DHF patients display higher dengue viral loads than DF patients, and that during 
defervescence (when the symptoms of DHF/DSS occur) these high viral loads are 
maintained in the DHF patients but not the DF patients for up to six days (Wang et al., 
2003a).  This could be indicative of slower virus clearance as a result of ADE or 
increased efficiency of virus infection or replication by a more virulent strain. 
1.4.1 Antibody-dependent enhancement of dengue virus infection 
Recovery from infection by one DV type provides lifelong immunity to that virus type 
and transient immunity lasting just two to three months against the other DV types.  
There is an increased risk of severe disease after secondary infection with different DV 
types or in primary infection of infants born to dengue-immune mothers (Halstead, 
1988).  This is thought to be due to ADE of infection.  When there are existing 
antibodies to a previous infection with a different DV type, these antibodies are unable 
to neutralise the current infecting virus and there is enhanced uptake of non-
neutralised virus into leukocytes.  The production and secretion of chemokines and 
cytokines by the cell in response to the increased viral replication that follows is 
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thought to lead to the increase in vascular permeability that is the hallmark of severe 
dengue.  During a DV type 2 epidemic in Cuba in 1997, in which there were an 
estimated 5208 symptomatic (febrile) cases, 92% of the dengue fever cases and over 
98% of the 205 severe disease cases had serologically confirmed secondary infections 
(Guzmán et al., 2000).  Cuba had no other endemic flaviviruses at this time so the 
primary infections for the majority of these individuals were attributed to a DV type 1 
epidemic 20 years previously.  The explanation given for the high occurrence of 
secondary infections was that the infection rate may have been higher in those that 
had DV type 1 antibodies than in those that did not.   
This ADE hypothesis is the basis for the current emphasis on development of 
tetravalent dengue vaccines that are active against all four DV types.  However, severe 
cases of dengue also occur as a result of primary infections (Barnes and Rosen, 1974; 
Gubler et al., 1978; Thomas et al., 2008), and some ethnic groups appear to be 
‘immune’ to severe disease despite living in areas of hyperendemicity (Halstead et al., 
2001).  A study in Haiti found no recorded cases of DHF amongst the indigenous 
population (Halstead et al., 2001).  This was despite the presence of DV type 2 
genotype I viruses (which are associated with DHF in Southeast Asia and America) and 
antibodies to multiple DV types in 85% of the children tested, as well as annual 
transmission rates consistent with countries endemic for DHF.  This indicates that 
dengue pathogenesis is due to a combination of factors rather than just ADE. 
1.4.2 Dengue virus sequence variation and virulence 
The four DVs are thought to have evolved from a common ancestor of either African or 
Asian origin around 1000 years ago.  A predominantly sylvatic cycle was maintained 
with non-human primates as hosts until the establishment of endemic transmission to 
humans as recently as 100 to 320 years ago, coinciding with a large increase in 
population growth (reviewed in Holmes and Twiddy, 2003); Figure 1.8).  All four DV 
types have the potential to cause severe disease, and each DV type can be divided into 
genotypes based on the extent of sequence diversity between strains.  In some cases 
the genotypes correspond to particular geographical regions, with strains diverging 
from a founding strain after its introduction into a new area.   
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Figure 1.8.  Dengue virus genetic relationships and evolutionary history.   
Figure is from Holmes and Twiddy, 2003. Phylogenetic analyses were based on E gene comparisons 
between strains from all four DV types.  The approximate divergence times in years are shown above key 
nodes and the bootstrap values are shown below selected nodes.  
 
Differences in strain virulence within DV types and across genotypes have been 
attributed to the presence or absence of severe dengue cases during an outbreak 
(Gubler et al., 1978; Lanciotti et al., 1994; Rico-Hesse et al., 1997b).  There is evidence 
for both DV types 2 and 3 that some genotypes appear to cause only mild disease 
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whilst others have the potential to cause epidemics of DHF/DSS (Gubler et al., 1981; 
Messer et al., 2003a; Rico-Hesse et al., 1997b; Vitarana, Jayakuru, and Withane, 1997).  
Sylvatic DVs are not associated with epidemics in humans.  They are transmitted by 
sylvatic Aedes species with non-human primates as hosts.  There have been few 
reports of sylvatic DVs isolated from humans and for the most part they were 
asymptomatic or the clinical descriptions are not detailed enough to confirm 
symptomatic dengue (reviewed in Vasilakis, Weaver, and Maramorosch, 2008). 
Sequence variation between the five DV type 1 genotypes has been shown to be up to 
9%, using comparisons of nucleotide sequence data for a 240 nucleotide region across 
the E/NS1 junction (Figure 1.9; Rico-Hesse, 1990).  When the E gene sequences from 
147 strains of DV type 2 were compared, it was found that the five non-sylvatic 
genotypes differed by an average of 7.3% (Figure 1.10; Twiddy et al., 2002).  Severe 
dengue was not epidemic in the Americas until 1981 despite the co-circulation of 
several DV types and a high incidence of secondary infection within the population.  
The emergence of epidemic severe dengue coincided with the introduction of the 
more virulent Southeast Asian genotype of DV type 2, replacing the previous American 
genotype which was associated with non-severe disease (Rico-Hesse et al., 1997a).  
Subsequent investigations identified sequence differences between the two genotypes 
in the 5’ and 3’ NC regions that were predicted to change RNA secondary structures 
involved in translation initiation and virus replication, and in the E gene which led to an 
amino acid substitution in the host cell-binding region of E (Leitmeyer et al., 1999).  In 
comparison with Southeast Asian genotype DV type 2 strains, American genotype 
strains exhibit reduced virus output from human monocyte-derived macrophage 
(Cologna and Rico-Hesse, 2003; Pryor et al., 2001) and DC cultures but not mosquito 
cell cultures (Cologna and Rico-Hesse, 2003).  The main determinant of replication 
efficiency was shown by both groups to be the E amino acid substitution.    The 
American genotype strains have also been shown to replicate and disseminate less 
efficiently in Aedes aegypti mosquitoes when compared to Southeast Asian genotype 
strains (Armstrong and Rico-Hesse, 2001). 
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There are four genotypes of DV type 3 (Figure 1.11) with a maximum nucleotide 
sequence difference between them of around 10% and a protein sequence difference 
of less than 5% (Lanciotti et al., 1994).  Genotype III clusters into two distinct clades, 
IIIa and IIIb.  Those strains that comprise genotype IIIa are all from outbreaks during or 
prior to 1989 which were not associated with DHF epidemics.  Those that form 
genotype IIIb are all from 1989 or later and have been associated with epidemics of 
severe dengue (Lanciotti et al., 1994; Messer et al., 2003a).  Interestingly, genotype IV 
strains have never been associated with DHF, although the reason for this is not known 
(Lanciotti et al., 1994).  A comparison of 19 DV type 4 E gene sequences from viruses 
across several decades and geographical regions revealed two genotypes (Figure 1.12) 
with less than 8% nucleotide sequence diversity and 4% amino acid difference 
(Lanciotti, Gubler, and Trent, 1997). 
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Figure 1.9.  Phylogenetic tree showing dengue virus type 1 evolutionary relationships.   
Figure is from Goncalvez et al., 2002. Genotype I contains strains from Japan, Hawaii, Asia and Djibouti.  
Genotype II contains strains from Thailand.  Genotype III contains a Malaysian sylvatic strain.  Genotype 
IV contains strains from Australia, South East Asia and the South Pacific.  Genotype IV contains strains 
from Africa, the Americas and South East Asia.  
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Figure 1.10.  Phylogenetic tree showing dengue virus type 2 evolutionary relationships.  
Figure is from Twiddy et al., 2002. Of the five non-sylvatic DV type 2 genotypes, two contain strains 
solely from South East Asia, one contains strains from the Americas and older isolates from India and the 
Pacific Islands, one contains strains from Asia and the Americas and one genotype contains strains with 
an almost global distribution.   
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Figure 1.11.  Phylogenetic tree showing dengue virus type 3 evolutionary relationships.   
Figure is from Lanciotti et al., 1994. Genotype I strains are mostly from South East Asia.  Genotype II 
strains are all from Thailand.  Genotype III strains are from Sri Lanka, India, Samoa and Mozambique.  
Genotype IV strains are from Puerto Rico and Tahiti.   
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Figure 1.12.  Phylogenetic tree showing dengue virus type 4 evolutionary relationships.  
Figure is from Lanciotti, Gubler, and Trent, 1997. Genotype I comprises strains from Thailand, Sri Lanka 
and the Philippines.  Genotype II strains are from Indonesia, Tahiti, the Caribbean islands, and Central 
and South America.   
 
1.4.3 Dengue in Sri Lanka 
Prior to 1989 there was a low incidence of severe dengue in Sri Lanka despite it being a 
region of hyperendemicity for all four DV types, but since 1989 dengue epidemiology 
in the region has been characterised by severe disease epidemics (Figure 1.13; Messer 
et al., 2002).  No significant differences were found in the relative distribution of DV 
types, virus transmission rates or the proportion of secondary infections between data 
collected pre and post 1989 (Messer et al., 2002).  A genetic shift in DV type 3 
genotype III strains, favouring genotype IIIb strains over the previously dominant 
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genotype IIIa strains, has been proposed as an explanation for the emergence of 
epidemic severe disease in Sri Lanka since 1989 (Lanciotti et al., 1994).  A similar DV 
type 3 clade replacement has been suggested as the cause of a further increase in 
severe dengue in Sri Lanka since 2000 (Kanakaratne et al., 2009). 
 
Figure 1.13.  Dengue haemorrhagic fever in Sri Lanka between 1980 and 1998.   
Figure is from Messer et al., 2002. These data are based on cases reported to the Sri Lankan Ministry of 
Health Epidemiology Unit and samples tested at the Medical Research Institute in Colombo.  In this case, 
the case definition for DHF was at least fever, haemorrhagic symptoms and a platelet count less than 
100,000/mm3.  Serological confirmation was based on the HI test. 
 
1.4.4 Recombination in dengue viruses 
Phylogenetic analyses of DV genome sequences have demonstrated that DVs undergo 
recombination between genotypes within the same DV type (AbuBakar, Wong, and 
Chan, 2002; Holmes, Worobey, and Rambaut, 1999; Tolou et al., 2001; Worobey, 
Rambaut, and Holmes, 1999).  This may be as a result of the RNA polymerase changing 
templates mid-way through replication in a cell that contains more than one DV 
genotype, as has been suggested for polio virus recombination (Cooper et al., 1974).  
This is able to occur in areas of hyperendemicity where multiple DV types and several 
genotypes of the same DV type are endemic.  Evidence for co-infection with multiple 
DV types in humans is documented (Bharaj et al., 2008; Wang et al., 2003b; Wenming 
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et al., 2005), whereas the evidence for co-infection with multiple genotypes is scarce.  
This is because diagnostic tests are able to distinguish between DV types whilst not 
being able to discern the presence of multiple genotypes within a DV type.  The 
presence of multiple DV type 2 genotypes within a single mosquito, including a 
recombinant virus along with both parental strains has been documented (Craig et al., 
2003).  Similar findings were also reported from a human DV type 1 sample (Aaskov et 
al., 2007). 
These findings suggest the potential for emergence of recombinant DVs with altered 
pathogenicity compared to parental strains.  Whilst there is no evidence for 
recombination between DV types, there may also be implications for vaccine design 
and safety in relation to potential recombination of attenuated live vaccine strains, 
either with other strains within a multivalent vaccine or with non-vaccine strains 
(Worobey, Rambaut, and Holmes, 1999).  This could lead to the production of 
unattenuated recombinant viruses and vaccine-associated disease as has been 
observed with polio virus (Georgescu et al., 1994).   
1.4.5 Dengue virus as a quasispecies  
Within a single host, a RNA virus exists as a population of many variant forms due to 
the error-prone nature of RNA virus replication.  These populations are termed 
quasispecies and they contain enough phenotypic variants to be able to respond 
rapidly to new selection pressures (DeFilippis and Villarreal, 2001; Domingo, 1998).  
Rates of spontaneous mutation among RNA viruses have been estimated at 
approximately one mutation in every 10,000 nucleotides (1x10-4) during natural 
replication (Smith et al., 1997) which equates to around one nucleotide mutation per 
DV genome per replication (Drake, 1993).  These quasispecies populations must be 
regulated to maintain genetic and antigenic diversity in a stable manner.  The 
replication rate and mutation rate must remain within acceptable limits to ensure the 
survival of both virus and host whilst allowing the virus to avoid clearance by the host 
immune system. 
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Quasispecies populations have been well studied in viral infections such as human 
immunodeficiency virus (HIV; Garcia-Arriaza, Domingo, and Briones, 2007), hepatitis E 
(Grandadam et al., 2004), foot and mouth disease virus (FMDV; Domingo et al., 2002) 
and hepatitis C (Martell et al., 1992).  There are few publications of quasispecies 
investigations in flaviviruses.  DV quasispecies populations were first identified in 2002 
in DV type 3 populations from six human plasma samples (from an outbreak in Taiwan 
in 1998; Wang et al., 2002a).  The same group then compared DV type 3 populations 
from naturally infected mosquitoes collected during the 1998 outbreak with the viral 
populations found in the human samples.  Less quasispecies diversity was identified in 
the mosquito-derived viruses than in the human-derived viruses (Lin et al., 2004).  A 
study of DV type 2 populations also examined samples from both humans and 
mosquitoes (from samples collected in Myanmar between 1998 and 2000), and 
reported multiple genotypes as well as recombinant viruses within the same host 
(Craig et al., 2003).  These studies used RT-PCR, cloning and sequencing of partial (Lin 
et al., 2004; Wang et al., 2002a) or complete (Craig et al., 2003) E genes to study the 
extent of sequence diversity within the virus populations of individual hosts.   
During HIV-1 infection, the detection of minor quasispecies variants (between 0.1 and 
10% of the genome population) is becoming increasingly important in genotyping the 
virus and predicting the response to different anti-viral treatments throughout the 
course of the infection (Garcia-Arriaza, Domingo, and Briones, 2007).  Little progress 
has been made in linking elements of the flavivirus quasispecies population to disease 
pathogenesis, although a higher frequency of genome-defective virus with in-frame 
stop codons due to insertion or deletion mutations has been reported in patients with 
DHF compared to patients with DF (Wang et al., 2002a).  
The nature of the regulatory mechanisms that maintain population stability whilst 
allowing genetic and antigenic diversity is not well understood but it has been 
proposed that certain RNA viruses are able to autoregulate genetic mutation via 
interaction with the viral RNA polymerase itself (Sallie, 2005).  The theory is that in 
viruses capable of persistent infection the actions of the RNA polymerase are 
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influenced by the viral E gene.  Wild-type and variant E genes show different 
interactions with the polymerase in order to alter fidelity and processivity, and 
maintain a stable quasispecies population.  Accumulation of variant E genes inhibits 
processivity of the polymerase and improves its fidelity so that the genes that are 
produced are closer to the original wild-type sequence.  These wild-type E genes in 
turn interact with the RNA polymerase and encourage the production of more variants 
by increasing processivity and infidelity.  This mechanism for mediating stable viral 
replication and promoting antigenic diversity has been termed ‘replicative 
homeostasis’ (Sallie, 2005). 
Mosquito-borne flaviviruses are rarely capable of persistent infection in humans, 
(although it has been documented in neuronal tissues; reviewed in Burke and Monath, 
2001) but they do cause persistent non-cytolytic infections in their mosquito vectors 
(Lindenbach and Rice, 2001).  The observation of less DV sequence diversity in 
mosquitoes compared to human hosts (Lin et al., 2004) may be explained by 
regulatory mechanisms such as replicative homeostasis acting during the persistent 
infection to maintain evolutionary conservation of the virus.  Replicative homeostasis 
may also play a role in maintaining population stability during acute RNA-virus 
infections.  Arthropod-borne flaviviruses must be able to infect and replicate 
effectively in both the insect vector and vertebrate host cells, which imposes 
significant evolutionary constraints on viral genetic variation.  This is supported by the 
finding that high levels of intrahost (quasispecies) short-term variation are not 
maintained in the long-term at an interhost level (Holmes and Twiddy, 2003). 
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1.5 Flavivirus envelope proteins and their role in virulence 
The majority of the surface of flavivirus virions is composed of E, which are heavily 
involved in mediating attachment of the virus to the host cell and in membrane fusion.  
Mutations within the E gene that alter E antibody binding, cell-attachment or 
membrane fusion therefore have the potential to affect virulence or cell tropism, and 
consequently disease severity.     
1.5.1 Flavivirus envelope protein structure 
Much of the early knowledge about the antigenic structure of flavivirus E came from 
diagnostic serology experiments.  These experiments classified the flaviviruses into 
groups using techniques such as virus neutralisation, heamagglutination inhibition and 
complement fixation (reviewed in Roehrig, 2003).  MAbs were used in conjunction 
with denaturation, low pH, proteolysis and reduction of disulphide bridges to construct 
epitope maps (Heinz and Maramorosch, 1986; Mandl et al., 1989).  Flavivirus gene 
sequence data began to be reported from 1985 (Deubel, Kinney, and Trent, 1986; 
Mandl, Heinz, and Kunz, 1988; Mason et al., 1987; Rice et al., 1985; Zhao et al., 1986), 
which enabled the epitope maps to be linked to the sequence data.  The locations of 6 
disulphide bridges formed between the 12 cysteine residues in the WNV E were 
established (Nowak and Wengler, 1987) and were subsequently shown to be 
conserved in both mosquito and tick-borne flaviviruses (Rey et al., 1995). A model of 
the antigenic structure of flavivirus E was produced based on TBEV (Figure 1.14; Mandl 
et al., 1989).  The model proposed that flavivirus E have three antigenic domains; A, B 
and C containing 16 epitopes.  Domain A contains epitopes that are cross-reactive as 
well as those that are specific for tick-borne flaviviruses.  Domain B also contains 
epitopes that are specific for tick-borne flaviviruses, whereas domain C epitopes are 
mostly sub-type specific (Mandl et al., 1989). 
The first flavivirus E crystal structure was determined for TBEV in 1995 (Figure 1.15; 
Rey et al., 1995).  This revealed a molecular architecture very different from other 
viruses (e.g. influenza) known at the time, with E lying flat as homodimers along the 
outer surface of the virus lipid bilayer, rather than forming spike-like projections.  
Three structural domains were identified: I, II and III, corresponding to the previously  
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Figure 1.14.  Flavivirus envelope protein antigenic model.  
Figure and legend are from Mandl et al., 1989. Open circles represent hydrophilic amino acid residues 
(Arg, Lys, Asn, Asp, Gln, Glu, His), dotted circles show intermediate amino acid residues (Pro, Tyr, Ser, 
Trp, Thr, Gly), and solid circles show hydrophobic amino acid residues (Ile, Val, Leu, Phe, Cys, Met, 
Ala). Position numbers are shown every 50 amino acids. Cysteine residues forming disulphide bridges are 
connected by solid lines. Arrows depict cleavage sites that liberate immune-reactive fragments; IRF1 
(trypsin) and IRF3 (CNBr), respectively. Small arrows indicate potential cleavage sites within these 
fragments that are not utilized. Two solid lines stand for the lipid membrane that is spanned by two 
transmembrane regions of E. The polypeptide chain is folded to indicate the antigenic domains A, B, and 
C. Arrows together with the names of neutralizing monoclonal antibodies (mAbs) depict the locations of 
the mutations identified in the respective antigenic variants of TBEV by sequence analysis. A line of solid 
triangles indicates the almost perfectly conserved sequence within domain A. A line of open triangles 
marks the region of a potential T-cell determinant. A solid diamond represents a site of N-glycosylation 
common to TBEV, MVEV, SLEV, JEV and dengue (DEN) viruses. YFV and SLEV have an additional 
potential N-glycosylation site within domain B, DVs within domain A. 
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defined C, A and B antigenic domains respectively (Rey et al., 1995).  Domain I is an 
eight-stranded β-barrel with an additional short amino-terminal strand at one edge.  It 
has an N-linked glycosylation site at Asn-153 which is conserved amongst most 
flaviviruses and is central to the other two domains.  Domain II is an elongated 
dimerisation region consisting of twelve β-strands and two α-helices with the fusion 
peptide at its base.  The fusion peptide is within a region (amino acids 98-113) 
conserved amongst most flaviviruses.  Domain III is an immunoglobulin-like module 
with ten β-strands which form a barrel structure closed by an additional sheet.  It is 
thought to contain the flavivirus receptor-binding motif (Rey et al., 1995). 
 
Figure 1.15.  Tick-borne encephalitis virus envelope protein structure.   
Figure is from Rey et al., 1995. The two E polypeptide chains form a head-to-tail homodimer.  β-strands 
are represented by ribbons with arrowheads; alpha helices by coiled ribbons; connecting loops by thin 
tubes.  The disulphide bridges are shown by ball-and-stick representations of the cystine residues (green).  
The single glycan on each dimer, labelled CHO is also drawn as ball-and-stick.  Domains I (red), II 
(yellow) and III (blue) are shown. (a) The dimer viewed as if looking down on the outside surface of the 
virus particle. (b)  The dimer viewed from the side as if looking along the surface of the virus particle. 
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DV E crystal structures were not published until much later (Kuhn et al., 2002; Modis et 
al., 2003) but were shown to closely resemble the TBEV E so that determinants of host 
range, tropism or virulence map to the same locations in the DV and TBEV structures 
(Modis et al., 2003).  The major differences between the TBEV and DV E crystal 
structures are that DVs have an additional N-linked glycosylation site within domain II 
at Asn-67, and an additional four amino acids in domain III that form a surface-exposed 
loop implicated in receptor binding (Modis et al., 2003).  The DV N-glycosylation sites 
at Asn-67 and Asn-153 are involved in infection, propagation and secretion of the virus 
(Mondotte et al., 2007).  Mutations at these sites could therefore affect infectivity. 
1.5.2 Flavivirus envelope gene mutations and altered pathogenesis 
For many flaviviruses, single nucleotide mutations within the E gene have been shown 
to be associated with altered virulence or pathogenicity (Cecilia and Gould, 1991; 
Guirakhoo et al., 2004; Hahn et al., 1987; Hasegawa et al., 1992; Holzmann et al., 
1990; Jiang et al., 1993; Nitayaphan et al., 1990).  Mutations in the flavivirus E gene 
that alter the properties of the virus tend to cluster at three sites on E.  These sites are 
the distal face of domain III, the base of domain II, and the domain I/III interface with 
the domain II conserved region at residues 97-113 (Figure 1.16; Rey et al., 1995).  
Mutations causing residue substitutions at the base of domain II or at the domain I/III 
interface with the domain II conserved region at residues 98-113  are thought to affect 
virulence or antibody neutralisation of virus by impacting upon the conformational 
rearrangements triggered by fusion (Rey et al., 1995).  Some of these mutations have 
been shown to affect fusion by altering the pH required for the fusion-activating 
conformational change (Mandl et al., 1989; Modis et al., 2003; Rey et al., 1995).  Most 
of these mutations involve substitution of residues with side-chains that project into 
the ligand-binding pockets between the dimers, and it has been reported that lowering 
of the pH threshold for conformational change is due to the substitution of longer 
hydrophobic side chains for shorter ones (Modis et al., 2003).  During routine passage 
of a chimeric YFV/DV type 1 vaccine strain, a mutation became incorporated which 
substituted the lysine residue at E position E204 with an arginine residue (Guirakhoo et 
al., 2004).  This resulted in reduced neurovirulence and viraemia in suckling mice and 
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monkeys respectively.  Residue E204 resides within the ligand binding site involved in 
virus fusion with cell membranes, and the mutation may have attenuated the virus by 
interfering with this process (Guirakhoo et al., 2004).  Mutations resulting in 
substitutions on the distal face of domain III can affect virulence or cell tropism and it 
has been suggested that this is due to interference with cell attachment, as domain III 
is thought to contain the flavivirus receptor-binding motif (Crill and Roehrig, 2001).  
Neutralisation escape mutations have also been mapped to this part of DV type 2 E 
(Roehrig, Bolin, and Kelly, 1998), consistent with antibody neutralisation of virus by 
blocking cell attachment. 
 
Figure 1.16.  Clustering of mutations at envelope protein structural domain interfaces.   
Figure adapted from Rey et al., 1995. Domain I from each molecule of the dimer is in black, domain II is 
in grey, and domain III is in white.  Blue boxes highlight mutations clustering at the distal face of domain 
III.  Red boxes highlight the clustered mutations at the base of domain II.  Green boxes highlight 
mutations clustered at the domain I/III interface with the domain II conserved region at residues 97-113. 
Mutation positions are labelled according to the positions in TBEV Neudörfl strain.  Mutations are from 
JEV, MVEV, Louping ill, TBEV, DV and TBEV/DV chimera viruses.  Arrows mark sites where 
mutations influence the threshold pH for the fusion-activating conformational change.   
 
Various single amino acid substitutions at residue E390 of DV type 2 E have been 
implicated in phenotypic and virulence changes in the virus.  During plaque purification 
of a Mexican DV type 2 strain (Sanchez and Ruiz, 1996), differences in plaque size were 
observed between clones where the E390 aspartic acid (Asp) residue was substituted 
with either histidine (His) or asparagine (Asn).  The Asp to His change was associated 
with the production of large lytic plaques and the virus was highly virulent in suckling 
mice, whereas the Asp to Asn change was associated with the production of small lytic 
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plaques and the virus was less virulent in suckling mice.  In American genotype dengue 
type 2 viruses known only to cause mild disease in humans, the residue at E390 is Asp 
whereas in Southeast Asian genotype viruses associated with DHF epidemics the 
residue at E390 is Asn (Leitmeyer et al., 1999). Subsequent investigation of these two 
viruses has shown that infectious clones with Asp at E390 (American genotype) display 
reduced viral RNA output from infected cells compared to clones with Asn at E390 
(Southeast Asian genotype; Cologna and Rico-Hesse, 2003).  Substitutions at residue 
E390 of DV type 2 E are thought to affect the ability of the virus to bind to the host cell 
surface.  This residue occurs within one of two putative glycosaminoglycan binding 
motifs (E284 to 310 and E386 to 411) containing many basic amino acids (Chen et al., 
1997), and the change in charge of the substituted residue has the potential to alter 
attachment (Leitmeyer et al., 1999).  Amino acid substitutions in this position have also 
been identified in the YFV 17D strain, which is the attenuated vaccine strain derived 
from the virulent Asibi strain (Hahn et al., 1987), and in attenuated MVEV (Lobigs et 
al., 1990).  In JEV, MVEV and YFV 17D, this site forms part of an Arg-Gly-Asp (RGD) 
sequence implicated in virus-cell attachment.  In the case of both YFV 17D and the 
MVEV strains mentioned above, the E390 mutations were induced by adaptation to 
culture and resulted in virus attenuation in the original host, which is consistent with 
the role of the RGD sequence as a receptor-binding motif (Hahn et al., 1987; Lobigs et 
al., 1990).   
For DVs, E has been shown to contain a binding site (E306-314) for highly sulphated 
heparin sulphate (HSHS) molecules which are present on the surface of cells targeted 
by the virus and appear to mediate infectivity (Chen et al., 1997; Thullier et al., 2001).  
Neutralisation escape mutations that lead to reduced mouse neurovirulence with 
Louping ill virus have been located at E positions E308-311 (Jiang et al., 1993).  
Similarly, neutralisation escape mutations in the DV type 2 E have been described at E 
position E307 (Lin et al., 1994).  The presence of these neutralisation escape mutations 
within the HSHS binding site indicates a mechanism for virus neutralisation by antibody 
binding to the HSHS binding site and thereby preventing attachment of the virus to the 
host cell.   
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During adaptation of a human DV type 1 isolate to grow in suckling mouse brain, 
several amino acid differences were identified between a mouse-passaged variant that 
caused neurovirulence and the original isolate (Despres et al., 1998).  These 
differences were located within both E and NS3 (the NTPase/helicase).  Interestingly, 
all the substitutions in the neurovirulent strain mapped to the interfaces between the 
structural domains of E.  The virus titres were similar in both strains despite there 
being a reduced rate of production of viral proteins in vitro for the neurovirulent 
strain.  The authors suggested this was due to the E mutations (E196 and E405) 
positively affecting assembly of glycoprotein oligomers (Duarte dos Santos et al., 
2000).   
In summary, mutations in the E gene that lead to residue substitutions in E can alter 
the properties of the virus if they occur: 
1. On the surface, in regions involved in antibody recognition, cell attachment or 
oligomer assembly 
2. At the interfaces between structural domains where they can affect the 
conformational changes required for fusion of virus and host cell membranes. 
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1.6 Hypothesis, aims and objectives 
1.6.1 Hypothesis 
DV quasispecies populations affect disease severity in individual patients.   
1.6.2 Aims and objectives 
The overall aim of this study was to provide in-depth characterisation of DV 
quasispecies populations in individual patients, in terms of both the extent of DV E 
gene variation, and the presence of specific variants.   This study also aimed to 
investigate whether there was a relationship between quasispecies variation and 
disease severity, by analysis of DV E gene sequences.  Recombinant E proteins would 
be produced to further investigate the effects of the quasispecies mutations on protein 
function.  Identification of DV quasispecies E variants that do not bind flavivirus cross-
reactive antibodies would lead to improved tools for serodiagnosis of DV infection.  
This work was subdivided into specific objectives which are described in sections 
1.6.2.1 to 1.6.2.5 below. 
1.6.2.1  Objective 1: To investigate the overall extent of dengue virus envelope 
gene quasispecies variation within individual clinical samples and correlations 
with disease severity. 
There have been few studies documenting the extent of variation in DV quasispecies 
populations in individual hosts (Craig et al., 2003; Lin et al., 2004; Wang et al., 2002a).  
These groups focused on the DV type 2 or 3 E genes and the methodologies used were 
not ideal as they permitted the introduction of mutations via the RT-PCR amplification 
process itself.  Both the number of patients (between 3 and 8) and the number of 
clones analysed per patient was low (between 10 and 21).  Only one group (Craig et al., 
2003) looked at the complete E gene sequence and used high-fidelity PCR for gene 
amplification.  Therefore, this study intended to use high-fidelity reverse transcription 
and PCR to look at E genes from all four DV types across a greater number of clinical 
samples from the same outbreak and a greater number of clones per sample.   This 
would determine whether the overall extent of DV E gene variation within a patient 
sample correlates with disease severity.  
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1.6.2.2  Objective 2: To investigate the relationship between the presence of 
specific dengue virus envelope gene variants and disease severity. 
Little progress has been made in linking specific variants within the DV quasispecies 
population to disease severity, although a higher frequency of defective genomes with 
in-frame stop codons have been reported in patients with DHF compared to those with 
DF (Wang et al., 2002a).  This study intended to detail the types of mutation found 
within the DV E gene variants and investigate correlations with disease severity.   
1.6.2.3  Objective 3: To identify the dengue virus genotypes present within the 
intra and inter-host populations and look for evidence of recombination. 
Virus genotype has a direct affect on DV transmission by mosquitoes and pathogenicity 
in humans (Armstrong and Rico-Hesse, 2001; Cologna and Rico-Hesse, 2003; Leitmeyer 
et al., 1999).  The presence of a recombinant DV and both parental DV type 2 strains 
(from different genotypes) within the same mosquito has been documented (Craig et 
al., 2003).  Similar findings were also reported from a human clinical DV type 1 sample 
(Aaskov et al., 2007).  Recombinant viruses could have reduced or increased virulence 
compared to either or both of the parental strains and thus could affect disease 
transmission and pathogenicity. This study would use phylogenetic analyses to 
genotype the DV E gene variants from the samples from the Sri Lankan outbreak, and 
to look for evidence of recombination. 
1.6.2.4  Objective 4: To identify dengue virus envelope gene variants with the 
potential to affect disease severity  
The few published studies of quasispecies populations in DV infections have all looked 
at the E gene sequence but have not progressed to the implications for the E sequence 
and the folded protein.  This study intended to map the locations of the amino acid 
substitutions resulting from nonsynonymous mutations found within the DV E gene 
quasispecies variants, using the linear and three-dimensional structural models of the 
flavivirus E.  This was to identify those amino acid substitutions located in regions of 
the protein involved in virion or oligomer assembly, antibody recognition or virus-cell 
interactions, with the potential to affect disease severity.  
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1.6.2.5  Objective 5: To construct recombinant dengue virus envelope 
glycoproteins (from those identified in the previous objective) that enable 
comparison of quasispecies consensus and variant proteins through binding 
studies. 
This study intended to compare recombinant DV quasispecies consensus and variant E 
by ELISA in terms of binding to cell surface molecules implicated in DV-cell binding 
(HSHS and DC-SIGN), and binding to antibodies (both commercially available and those 
provided by flavivirus-vaccinated individuals).  The antibody and cell surface molecule 
binding experiments would determine whether specific variants within the 
quasispecies population would exhibit altered virus-antibody or virus-cell binding 
affinities compared to the quasispecies consensus E.  The antibody binding 
experiments would aid in comparison of existing commercially available antibodies and 
could potentially identify DV E variants that did not bind flavivirus cross-reactive 
antibodies.  These proteins could be used as improved tools for serodiagnosis of DV 
infection as they would overcome the current difficulties with flavivirus cross-reactivity 
during serological testing.  The recombinant quasispecies consensus and variant DV E 
would also be assessed for differences in their ability to undergo the low pH-induced 
conformational changes required for fusion of virus and host cell membranes, as this 
could potentially affect virulence and disease severity. 
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CHAPTER 2. MATERIALS AND METHODS 
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2.1 General information 
This section provides general information on the chemicals, reagents, oligonucleotides, 
bacterial strains, insect cell lines and culture medium used throughout this thesis. 
2.1.1 Chemicals and reagents 
Unless otherwise stated, general chemicals and reagents were obtained from Sigma 
Chemicals Company Ltd. UK, SAFC Biosciences Ltd. UK, Invitrogen™ UK, Merck 
Chemicals Ltd. UK, Thermo Fisher Scientific Ltd. UK, Promega Ltd. UK and GE 
Healthcare Ltd. UK.  All solution concentrations were weight per volume (w/v) unless 
otherwise indicated as volume per volume (v/v) and where required solutions were 
sterilised by autoclave. Restriction endonucleases and modifying enzymes including 
the appropriate buffers were obtained from Promega Ltd. UK or New England Biolabs 
(NEB) Ltd. UK unless otherwise stated. PCR and RT-PCR kits were obtained from Qiagen 
Ltd. UK, Stratagene Ltd. UK, Applied Biosystems Ltd. UK or Roche Ltd. UK.  DNA ladders 
and loading dyes were obtained from Qiagen Ltd. UK.  Antibodies were obtained from 
Abcam Ltd. UK, eBioscience Ltd. UK or Thermo Fisher Scientific Ltd. UK. 
2.1.2 Oligonucleotides 
All oligonucleotides were custom synthesised by Sigma-Aldrich Ltd. UK and purified by 
desalt. 
2.1.3 Flavivirus RNA used as a positive control template for RT-PCR 
The flavivirus RNA used as positive control template for RT-PCR was obtained from 
HPA CEPR.  Virus strains were: YFV 17D strain, JEV Nakayama strain, TBEV Neudörfl 
strain, DV type 1 Hawaii A strain, DV type 2 New Guinea C strain, DV type 3 H87 strain 
and DV type 4 H241 strain.   
2.1.4 Dengue patient material 
Dengue patient material was kindly donated by Major Mark Bailey of the Royal Army 
Medical Corps (Royal Centre for Defence Medicine, Birmingham, UK).  Serum samples 
were taken from patients presenting with fever on admission to hospitals in and 
around Ragama, Sri Lanka.  Ethical considerations for the use of these samples and 
accompanying clinical data are presented in Appendix L. 
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2.1.5 Bacterial strains and culture media 
The modified Escherichia coli K12 JM109 strain (Promega) was used for cloning and 
plasmid propagation.  The genotype of the strain is endA1, recA1, gyrA96, thi-1, 
hsdR17 (rk
–, mk
+), relA1, supE44, Δ( lac-proAB), [F´ traD36, proAB, laqIqZΔM15].  
Bacterial culture media were obtained from Invitrogen™ UK or bioMérieux UK. 
2.1.5.1  Glossary of mutations 
endA1  This mutation results in improved plasmid yields through inactivation of an 
endonuclease that would otherwise co-purify with plasmids during purification.   
recA1  The recA gene is involved in recombination and DNA repair.  This mutation limits 
recombination of the plasmid with the E. coli genome, making the insert more stable. 
gyrA96  This mutation within the DNA gyrase gene confers resistance to nalidixic acid.  
thi-1  This mutation affects thiamine metabolism so there is a requirement for thiamine for 
growth in minimal media. 
hsdR17 (rk
–, mk
+) This mutation is within the K strain DNA restriction and methylation system.  Cleavage 
of transformed DNA by endogenous restriction endonucleases is prevented (rk
–) but 
methylation by endogenous methylases is permitted (mk
+). 
relA1  This mutation of ppGpp synthetase I enables RNA synthesis in the absence of protein 
synthesis. 
supE44  This mutation suppresses amber (UAG) mutations in termination codons.  
Δ lac  The β-galactosidase gene is deleted on the chromosome.  
proAB  The proAB mutations of proline metabolism confer a requirement for proline for 
growth in minimal media. 
F´  F’ strains are sensitive to infection by M13 phage. 
traD36  The traD36 transfer factor mutation prevents transfer of the F’ episome.    
laqIq  laqIq strains over-produce the lac repressor protein, inhibiting transcription from the 
lac promoter.   
lacZΔM15 The β-galactosidase gene is partially deleted, enabling restoration of β-galactosidase 
activity via an α-complementation sequence carried by some plasmid vectors and 
blue/white screening for positive transformants.   
2.1.6 Insect cell lines and culture medium 
Spodoptera frugiperda (Sf) 9 and Sf21 insect cell lines were obtained from Invitrogen™ 
(UK).  The Sf9 Easy-Titre (Sf9 E-T) insect cell line was kindly provided by Dr. Ralph 
Hopkins of the National Cancer Institute at Frederick, Maryland, USA.   Sf21 and Sf9 E-T 
cells were cultured in Sf900 II serum-free and HyClone SFX insect cell culture medium 
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respectively (Invitrogen™ UK).  Sf9 cells were cultured in Ex-cell 420 serum-free 
medium (SFM) with L-glutamine (AFC Biosciences Ltd. UK).  
2.1.7 Insect viruses and virus transfer vectors 
FlashBAC GOLD™ (Oxford Expression Technologies Ltd. UK) and the transfer vector 
pBAC-2cp (Merck Chemicals Ltd. UK) were used for the construction of recombinant 
baculoviruses (rBVs).    
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2.2 In silico techniques 
This section details the computer-based methodology used for the acquisition and 
analysis of sequence data for RT-PCR or PCR primer design, sequencing and protein 
structure modelling.  Also described is the rationale for primer design. 
2.2.1 Acquisition of published Flavivirus sequence data 
Published sequence data were obtained via the nucleotide or protein sequence 
databases of the National Centre for Biotechnology Information (NCBI) website 
(http://www.ncbi.nlm.nih.gov/) for DV types 1, 2, 3 and 4.  E gene positions were as 
defined in the NCBI Reference Sequences (RefSeqs) NC_001477 (type 1), NC_001474 
(type 2), NC_001475 (type 3) and NC_002640 (type 4).   
2.2.2 Sequence analysis for primer design 
Sequence analysis was performed using DNAStar (Lasergene 7 sequence analysis 
software, DNAStar Inc.).  To identify suitable primer sites, multiple sequence 
alignments were performed on E gene nucleotide or amino acid sequences and the 
flanking regions using the Clustal W algorithm within the alignment program Megalign.   
2.2.3 RT-PCR, PCR and sequencing PCR primer design 
Primers were designed to have a length between 18 and 30 nucleotides and a melting 
temperature (Tm) between 55°C and 80°C.  The 3’ end of each primer was finished with 
a guanine-cytosine (GC) clamp, and mismatches and runs of three or more consecutive 
G or C nucleotides were avoided.  Primers were checked using the Sigma-Aldrich DNA 
Oligo Design Tool (www.sigmaaldrich.com) to estimate their melting temperature and 
ensure they did not have any significant secondary structure or the ability to dimerise.  
They were also checked for specificity using the nucleotide database (blastn algorithm) 
within the NCBI Basic Local Alignment Search Tool (BLAST; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi).   
DV species-specific primers for quasispecies analysis were designed up to 200 
nucleotides outside the E gene.  This was to allow the whole of the E gene to be 
sequenced in subsequent experiments.  Primers were located in conserved regions of 
the alignments to enable them to detect the greatest number of strains.   
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Sequencing primers internal to the DV E genes were designed based on the NCBI 
RefSeqs (section 2.2.1). 
DV species-specific primers for rBV production were designed to amplify only the 
intended gene target and not the flanking regions.  They also incorporated restriction 
endonuclease recognition sequences to facilitate cloning into the baculovirus transfer 
vector pBAC-2cp. 
2.2.4 Analysis of sequencing data 
Sequence chromatograms were viewed and contigs of sequencing reactions 
constructed using SeqMan (Lasergene 7 sequence analysis software, DNAStar Inc.).  
Each clone contig consisted of up to eight sequence reads (four primers in each 
direction) and consensus sequences for each clone were saved as EditSeq files.  
Multiple sequence alignments were performed for all of the clones from each patient 
sample. To minimise errors introduced by the sequencing process, any mismatches 
that were identified from the multiple sequence alignment consensus were compared 
to the contig chromatogram to ensure only definite nucleotide alterations (confirmed 
by multiple sequence reads) were counted.  EditSeq was used to convert nucleotide 
sequence into protein sequence and multiple sequence alignments were performed as 
described in Section 2.2.2.   
Phylogenetic and molecular evolutionary analyses were conducted using MEGA 
version 4 (Tamura et al., 2007), with the neighbour joining method and maximum 
composite likelihood model.  Bootstrapping analysis was conducted using 1000 
replicates and where possible the DV type 1 E gene sequence from the NCBI RefSeq 
NC_001477 was used to root the trees. 
2.2.5 Statistical analysis 
Statistical tests were applied using Minitab version 15 (Minitab, Coventry, UK). 
2.2.6 Protein modelling 
DeepView (Swiss-PdbViewer at http://spdbv.vital-it.ch/) was used to model consensus 
protein sequences onto the appropriate DV E structure and map the locations of the 
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nonsynonymous mutations found within the quasispecies population.  Homology 
modelling was performed by inputting the sample amino acid sequence and 
submitting that sequence to a protein data bank (pdb) to find structures with similar 
sequences.  The structure with the best homology match (1UZG for dengue virus type 
3 and 1OAN for dengue virus types 2 and 4) was downloaded and the sample amino 
acid sequence structure was inferred using the downloaded structure as a reference.  
Transmembrane domains were not included as they are not present in any of the pdb 
files.  To construct the oligomeric protein the sample sequence monomer was opened 
in two layers so that one of the monomers could be re-positioned as the second 
monomer of the dimer using the Matrix co-ordinates provided in the pdb text file from 
the downloaded structure.  The two layers were then merged and the dimer coloured 
according to the protein domains (stated in Rey et al., 1995).  Surface accessible 
residues and residues within 4Å of important structural features were identified. 
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2.3 Nucleic acid manipulations 
2.3.1 Amplification of nucleic acid sequences using the polymerase chain 
reaction 
PCR and RT-PCR amplifications were performed on a GeneAmp 9700 thermocycler 
(Applied Biosystems).  Amplified DNA was visualised using agarose gel electrophoresis 
(Section 2.5.1). 
2.3.1.1  Standard RT-PCR 
Standard RT-PCR reactions were performed using the OneStep RT-PCR Kit (Qiagen) 
according to the manufacturer’s one-step instructions for amplification of long RT-PCR 
products.  Reaction volumes of 25µL consisted of final concentrations of 1x reaction 
buffer (from 5x concentrate of Tris-HCl, KCl, (NH4)2SO4, 12.5mM MgCl2, dithiothreitol 
(DTT); pH 8.7), 1.6mM dNTP mix, 0.6µM each of forward and reverse primer (specific 
to template RNA), 1µL of enzyme mix (containing Omniscript and Sensiscript reverse 
transcriptases and HotStarTaq DNA Polymerase with 1mM DTT, 0.1mM EDTA, 0.5% 
Nonidet® P-40, 0.5% Tween® 20, 50% glycerol, stabilizer; pH 9.0) and 5µL of RNA 
template.  Cycling conditions are detailed in Table 2.1. 
Table 2.1.  Standard RT-PCR thermal cycling conditions 
 
 
 
 
 
2.3.1.2  AccuScript high-fidelity RT-PCR 
AccuScript high fidelity RT-PCR reactions were performed in duplicate for each sample 
in 50µL volumes using the AccuScript High-Fidelity RT-PCR System (Stratagene) 
according to the manufacturer’s two-step instructions for synthesising first-strand 
cDNA and amplifying the cDNA template.  First-strand cDNA synthesis reactions (10µL) 
consisted of a final concentration of 1x AccuScript RT buffer (from 10x concentrate of 
0.5M Tris-HCl (pH 8.3), 0.75M KCl, 0.03 M MgCl2), 4µM dNTP mix, 0.625µM reverse 
Stage Temperature (˚C) Time Cycles 
Reverse transcription 45 30 minutes  
Denaturing 95 15 minutes  
Amplification 
94 15 seconds 
36 cycles 60 1 minute 
68 2.5 minutes 
Extension 68 10 minutes  
Cooling 4 ∞  
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primer (specific to template RNA), 5µL of RNA template, 10mM DTT and 1µL of 
AccuScript reverse transcriptase (RT).  The RT buffer, dNTPs, reverse primer and RNA 
were incubated at 65˚C for five minutes and then allowed to cool at room temperature 
for a further five minutes to anneal the primer to the RNA.  The DTT and AccuScript RT 
were then added and the reaction incubated at 42˚C for 30 minutes to allow reverse 
transcription of the RNA template to cDNA. 
Amplification of cDNA was performed in a total reaction volume of 50µL with a final 
concentration of 1x PCR buffer (formulation not specified by manufacturer), 0.8µM 
dNTP mix, 0.2µM each of forward and reverse primer (specific to template DNA), 2.5 
units of PfuUltra high fidelity DNA polymerase and 5µL of cDNA template.  Thermal 
cycling conditions are detailed in Table 2.2. 
Table 2.2.  AccuScript thermal cycling conditions for PCR amplification of cDNA 
Stage Temperature (˚C) Time Cycles 
Denaturing 95 1 minute  
Amplification 
95 30 seconds 
36 cycles 
60 30 seconds 
68 6 minutes 
Extension 68 10 minutes  
Cooling 4 ∞  
 
2.3.1.3  Expand high-fidelity RT-PCR 
Expand high-fidelity RT-PCR reactions were performed using the Expand reverse 
transcriptase and Expand long template PCR system (Roche) according to the method 
published in (Craig et al., 2003).  First strand synthesis reactions consisted of 20µL total 
reaction volume with a final concentration of 1x Expand RT buffer (formulation not 
specified by manufacturer), 4µM dNTP mix, 0.625µM reverse primer (specific to 
template RNA), 5µL of RNA template, 10mM DTT and 1µL of Expand reverse 
transcriptase.  The reverse primer and RNA were incubated at 65˚C for five minutes 
and then allowed to cool at room temperature for a further five minutes to anneal the 
primers to the RNA.  The DTT and Expand RT were then added and the reaction 
incubated at 30˚C for 10 minutes, followed by 42˚C for 30 minutes to allow reverse 
transcription of the RNA template to cDNA.  
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Reactions for amplifying the cDNA template consisted of 50µL total reaction volumes 
with a final concentration of 1x PCR buffer 1 (formulation not specified by 
manufacturer), 0.8µM dNTP mix, 0.2µM each of forward and reverse primer (specific 
to template DNA), 3.5 units of Expand high fidelity enzyme mix (containing Taq and 
Tgo DNA polymerases) and 5µL of cDNA template.  Thermal cycling conditions are 
detailed in Table 2.3. 
Table2.3.  Expand thermal cycling conditions for PCR amplification of cDNA 
Stage Temperature (˚C) Time Cycles 
Denaturing 94 2 minutes  
Amplification 
94 10 seconds 
36 cycles 
60 30 seconds 
68 2.5 minutes 
Extension 68 10 minutes  
Cooling 4 ∞  
 
2.3.1.4  Standard PCR 
Standard PCR reactions were performed using the Taq PCR Core kit (Qiagen) according 
to the manufacturer’s instructions for PCR using Taq DNA polymerase.  Reaction 
volumes of 25µL consisted of final concentrations of 1x reaction buffer (from 10x 
concentrate of Tris-HCl, KCl, (NH4)2SO4, 15mM MgCl2; pH 8.7), 0.8mM dNTP mix, 
0.3µM each of forward and reverse primer (specific to template RNA), 0.13µL of 
enzyme mix (20mM Tris-HCl, 100mM KCl, 1mM DTT, 0.1mM EDTA, 0.5% Nonidet  P-40, 
0.5% Tween 20, 50% glycerol; pH 8.0) and 5µL of RNA template.  Cycling conditions 
were as detailed in Table 2.4. 
Table 2.4.  Taq PCR core kit thermal cycling conditions 
Stage Temperature (˚C) Time Cycles 
Denaturing 94 3 minutes  
Amplification 
94 15 seconds 
36 cycles 
60 1 minute 
68 2.5 minutes 
Extension 68 10 minutes  
Cooling 4 ∞  
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2.3.2 RNA extraction using commercial spin columns 
The RNA extraction methods in this section use lysis under denaturing conditions to 
inactivate virus and RNases and to ensure isolation of intact RNA.  Nucleic acids are 
then preferentially bound to the silica membrane within a spin column in the presence 
of a chaotropic salt such as guanidine chloride.  Impurities are washed away and RNA is 
subsequently eluted in a low salt concentration elution buffer. 
2.3.2.1  RNA extraction from dengue patient sera 
RNA extractions from dengue patient sera were performed using the QIAamp Viral 
RNA Mini Kit (Qiagen) according to the manufacturer’s protocol for purification of viral 
RNA (Spin protocol).  Samples were first lysed for 10 minutes at room temperature 
using 560µL of AVL buffer containing 5.6µg of carrier RNA.  560µL of 100% ethanol 
(v/v) was added and the sample was loaded onto the QIAamp Mini spin column and 
centrifuged (8000 revolutions per minute (rpm) for one minute; Biofuge Pico, 
Heraeus).  Contaminants were then washed away using 500µL of AW1 buffer and 
centrifugation (8000 rpm for one minute) followed by 500µL of AW2 buffer and 
centrifugation (13000 rpm for three minutes).  RNA was eluted by incubation for one 
minute in 60µL of RNase-free water and collected by centrifugation (8000 rpm for one 
minute). 
2.3.2.2  RNA extraction from pelleted insect cells 
RNA was extracted from pelleted Sf9 or Sf21 cells using an RNeasy Mini kit (Qiagen) 
and on-column DNase digestion using an RNase-Free DNase set (Qiagen) according to 
the manufacturer’s microcentrifuge protocol.  Samples were lysed with 600µL of RLT 
buffer containing 1% β-mercaptoethanol (14.3M stock solution) and homogenised by 
centrifugation through a QIAshredder spin column (2 minutes at 13000 rpm; Biofuge 
Pico, Heraeus).  Ethanol (600µL of 70% v/v) was added and the sample was loaded 
onto the QIAamp Mini spin column and centrifuged (10000 rpm for 15 seconds).  The 
column was washed with 350µL of RW1 buffer and centrifuged (10000 rpm for 15 
seconds) to remove contaminants.  DNase I incubation mix (80µL; 3.4 units of DNAse I 
in RDD buffer) was then added to the spin column and incubated at room temperature 
for 15 minutes.  RW1 buffer (80µL) was added to the spin column and centrifuged 
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(10000 rpm for 15 seconds), followed by 500µL of RPE buffer and centrifugation 
(10000 rpm for two minutes).  RNA was eluted by incubation for one minute in two 
30µL volumes of RNase-free water and collected each time by centrifugation (10000 
rpm for one minute). 
2.3.2.3  RNA purification and concentration from transcription reactions 
RNA was extracted from transcription reactions (section 2.3.10) using an RNeasy 
MinElute Clean-up kit (Qiagen) according to the manufacturer’s protocol for RNA 
cleanup and concentration.  DNase digestion of RNA was performed before RNA clean-
up using an RNase-Free DNase Set (Qiagen).   DNase I stock solution (6.75 units) and 
10µL of RDD buffer were added to each sample and made up to a volume of 100µL 
with nuclease-free water before incubation at room temperature for 10 minutes.  The 
samples were lysed using 350µL of RLT buffer containing 1% β-mercaptoethanol 
(14.3M stock solution).  Ethanol (500µL of 100% v/v) was added and the sample loaded 
onto the QIAamp Mini spin column and centrifuged (10000 rpm for 15 seconds; 
Biofuge Pico, Heraeus).  The column was washed with 500µL of RPE buffer and 
centrifuged (10000 rpm for 15 seconds) to remove contaminants, followed by 500µL of 
80% ethanol (v/v) and centrifugation (10000 rpm for two minutes).  Residual ethanol 
was removed by centrifugation (13000 rpm for five minutes with the spin column lids 
open).  RNA was eluted by incubation for one minute in 20µL of RNase-free water and 
collected by centrifugation (13000 rpm for one minute). 
2.3.3 DNA extraction using commercial spin columns  
The DNA extraction methods in this section use preferential binding of nucleic acid to 
the silica membrane within a spin column at pH less than 7.5 in the presence of a 
chaotropic salt such as guanidine hydrochloride.  Impurities are washed away and DNA 
is subsequently eluted in a low salt concentration pH 7.0 to pH 8.5 elution buffer. 
2.3.3.1  Extraction of DNA from agarose gels 
Amplified PCR products were visualised using a UV transilluminator (GIBCO BRL, TFX-
20M) set at 70% intensity to prevent degradation of DNA.  The required band was 
excised using a sharp sterile scalpel and the DNA extracted using the QIAquick Gel 
Extraction kit (Qiagen) according to the manufacturer’s microcentrifuge protocol.  All 
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centrifugation steps were performed at 13000 rpm for one minute using a Biofuge 
Pico, Heraeus.  To dissolve the agarose, 300µL of QG buffer was added to each 
extracted band and incubated at 50°C for 10 minutes.  The sample was loaded onto 
the QIAquick column and centrifuged.  The DNA from the sample was preferentially 
bound to the membrane during this centrifugation due to the high salt concentrations 
in the sample buffer.  The column was washed with 500µL of QG buffer and 
centrifuged to remove contaminants, followed by 750µL of PE buffer and 
centrifugation.  Residual ethanol was removed by centrifugation.  DNA was eluted by 
incubation for one minute in 50µL of RNase-free water and collected by centrifugation. 
2.3.3.2  Extraction of DNA from enzymatic reactions 
DNA was extracted from restriction digests and PCR reactions using the MinElute PCR 
purification kit (Qiagen) according to the manufacturer’s microcentrifuge protocol.  All 
centrifugation steps were performed at 13000 rpm for one minute using a Biofuge 
Pico, Heraeus.  Five volumes of PB buffer were added to one volume of sample before 
the sample was loaded onto the QIAquick column and centrifuged.  The DNA from the 
sample was preferentially bound to the membrane during this centrifugation due to 
high salt concentrations in the sample buffer.  The column was washed with 750µL of 
PE buffer and centrifuged to remove contaminants.  Residual ethanol was removed by 
centrifugation.  DNA was eluted by incubation for one minute in 50µL of RNase-free 
water and collected by centrifugation. 
2.3.3.3  Viral DNA extraction from insect cells  
Viral DNA was extracted from P2 amplified rBV-infected insect cell culture medium 
using a HighPure Viral Nucleic Acid Kit (Roche) according to the manufacturer’s 
instructions.  Clarified insect cell culture medium (200µL) was incubated for 10 minutes 
at 72°C with 200µL of carrier RNA-supplemented binding buffer and 50µL of proteinase 
K solution.  Binding buffer (100µL) was then added before applying the mixture to the 
HighPure filter tube and centrifugation (10000 rpm for one minute; Biofuge Pico, 
Heraeus).  Inhibitor removal buffer (500µL) was applied to the filter tube and 
centrifuged (10000 rpm for one minute), followed by two 450µL washes with wash 
buffer and further centrifugation (10000 rpm for one minute).   Residual wash buffer 
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was removed by centrifugation (13000 rpm for 10 seconds).  Nucleic acids were eluted 
in 50µL of elution buffer by centrifugation (10 minutes at 10000 rpm). 
2.3.4 Plasmid DNA extraction using commercial filter kits  
2.3.4.1  Plasmid DNA extraction for quasispecies analysis 
Deep 96-well culture plates containing E. coli overnight cultures (section 2.3.5.4) were 
centrifuged to pellet the bacterial cells (1500 xg for seven minutes; Legend RT Plus, 
Sorvall).  The cell culture medium was discarded and plasmid DNA extracted from the 
cells using the Montage Plasmid Miniprep 96 kit (Millipore) according to 
manufacturer’s instructions.  Cell pellets were resuspended in 100μl of Solution 1 and 
lysed in 100μl of Solution 2 with vigorous mixing.  The lysate was neutralised with 
100µL of Solution 3 and then drawn through the clearing plate into the plasmid plate 
by vacuum (8 millimetres of mercury (mmHg); using a Qiagen vacuum pump and 
manifold).  Plasmid DNA was adsorbed to the plasmid plate membrane when the 
clarified lysate was drawn through the plasmid plate by vacuum (24 mmHg).  Plasmid 
DNA was washed with 200μl of Solution 4 and a vacuum applied (24 mmHg).  Plasmid 
DNA was recovered by adding 85μl of Solution 5 (tris-EDTA) and incubating at room 
temperature for 30 minutes before removal to a 96-well storage plate. 
2.3.4.2  Plasmid DNA extraction for recombinant baculovirus production 
Plasmid DNA was extracted from a 200mL culture of E. coli transformed with pBAC-2cp 
(containing DV type 1 prM and patient sample quasispecies E genes; section 2.3.6.2) 
using a QIAfilter plasmid Maxi kit (Qiagen) according to manufacturer’s instructions.  
Briefly, the bacterial pellets were re-suspended in 10mL P1 buffer before alkaline lysis 
with 10mL P2 buffer for four minutes at room temperature.  P3 buffer (10mL) was 
added to the lysate before pouring the lysate into the QIAfilter cartridge and 
incubating at room temperature for 10 minutes.  The cell lysate was filtered into the 
QIAGEN-tips (previously equilibrated with 10mL of buffer QBT; containing an anion-
exchange resin to selectively bind supercoiled plasmid DNA at low salt concentrations) 
and allowed to empty by gravity flow.  The plasmid DNA was washed twice with 30mL 
QC buffer to remove contaminants.  DNA was eluted at high salt concentration with 
15mL QF buffer into 50mL polypropylene falcon tubes.  DNA was precipitated by 
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adding 10.5mL (0.7 volumes) isopropanol to the eluted DNA and centrifuging (5000 xg 
for 60 minutes at 4°C; Legend RT Plus, Sorvall).  Supernatants were carefully decanted 
and the DNA pellets washed with 5mL of 70% ethanol, before centrifugation (5000 xg 
for 60 minutes at 4°C) and careful removal of the supernatant.  Pellets were air-dried 
for 5–10 minutes and re-dissolved in 200µL of EB buffer (10mM Tris-HCl, pH 8.5). 
2.3.5 Cloning of dengue virus quasispecies envelope genes, transformations 
and amplification of positive clones for quasispecies analysis 
Cloning and transformations for DV quasispecies E gene analysis were performed using 
the pGEM®-T Easy Vector System II (Promega).  Confirmation that cloning was 
successful was achieved by a combination of plasmid DNA extraction (Sections 2.3.4.1 
and 2.3.4.2), restriction digest analysis (Section 2.3.8), RT-PCR or PCR (Section 2.3.1), 
sequencing (Section 2.4) and agarose gel electrophoresis (Section 2.5.1). 
2.3.5.1  Poly(A)-tailing of blunt-ended dengue virus envelope gene PCR 
amplicons  
Blunt-ended DNA fragments were generated because of the use of a proofreading DNA 
polymerase for high-fidelity PCR (sections 2.3.1.2 and 2.3.1.3).  These were A-tailed 
prior to cloning to allow them to ligate into the cloning vector (pGEM®-T Easy).  Blunt-
ended gel-extracted PCR products were A-tailed using five units of Taq DNA 
polymerase and 1x reaction buffer with MgCl2 (Taq PCR Core kit; Qiagen) and dATP 
(dNTP set, PCR grade; Qiagen) to a final concentration of 0.2mM.  A 10µL total reaction 
volume was made up by the addition of nuclease-free water (Promega).  Reactions 
were incubated at 70°C for 30 minutes.   
2.3.5.2  Ligation of poly(A)-tailed dengue virus envelope gene PCR amplicons 
into the cloning vector pGEM®-T Easy 
Ligation reactions consisted of Rapid Ligation Buffer at 1x final concentration, 50ng 
pGEM®-T Easy Vector, 2μl A-tailed PCR product (section 2.3.5.1), and three units of T4 
DNA Ligase.  Ligations were incubated at 4°C overnight to maximise the number of 
transformants. 
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2.3.5.3  Transformation of E. coli with the cloning vector pGEM®-T Easy 
containing dengue virus quasispecies envelope gene amplicons  
For transformation of E. coli (with the cloning vector pGEM®-T Easy containing DV E 
gene amplicons), 2μl of ligation reaction (section 2.3.5.2) was added to 50μl of JM109 
cells on ice and gently mixed before incubation on ice for 20 minutes.  The cells were 
heat-shocked at 42˚C for 45 seconds then placed on ice for two minutes.  Room 
temperature SOC medium (950μl; Invitrogen™) was added and the reaction incubated 
(37°C at 220 rpm for 1 hour 30 minutes; Minitron shaking incubator, Infors) for 1 hour 
30 minutes.  Cultures (100μl) were incubated on agar plates (37°C overnight).  To allow 
blue white screening of recombinants, culture plates were made using 200mL L-agar 
(Biomerieux), 100µg/mL ampicillin (Sigma, 100mg/mL), 80µg/mL X-gal (Promega, 
50mg/mL) and 0.5mM IPTG (Novagen, 100mM).   
2.3.5.4  Amplification of positive transformants for quasispecies analysis 
Transformed (white) colonies (section 2.3.5.3) were picked and inoculated into 96-well 
deep-well culture plates (Montage Plasmid Miniprep 96 kit; see Section 2.3.3.1) 
containing 1.5mL L-broth (Biomerieux) with 100µg/mL ampicillin (Sigma).  Cultures 
were then incubated (37°C at 220 rpm for 24 hours; Minitron shaking incubator, 
Infors).  For each patient sample, one 96-well plate consisting of an equal number of 
colonies from each of the duplicate high-fidelity RT-PCR reactions (section 2.3.1.2) was 
cultured. 
2.3.6 Cloning of dengue virus quasispecies envelope genes, transformations 
and amplification of positive clones for recombinant baculovirus 
production 
DV quasispecies E genes were amplified using primers containing specific restriction 
endonuclease sites (section 2.2.3).  Purified DV E gene PCR products (Section 2.3.3.1) 
and pBAC-2cp baculovirus transfer vector (Novagen, Merck) underwent restriction 
digestion (Section 2.3.8) to generate the appropriate termini for ligation. 
2.3.6.1  Ligation of dengue virus quasispecies envelope gene PCR amplicons 
into the baculovirus transfer vector pBAC-2cp   
Ligation reactions were incubated at 4˚C overnight and consisted of a 10µL reaction 
containing 0.1-1 unit of T4 ligase (Promega), T4 ligase buffer at 1x concentration (from 
10x stock of 300mM Tris-HCl; pH 7.8), 100mM MgCl2, 100mM DTT and 10mM ATP; 
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supplied with the enzyme), 2µL of DV prM gene NheI/EagI digest product, 4µL of DV E 
gene EagI/XmaI digest product and 1µL of pBAC-2cp NheI/XmaI digest product.  
Transformations were performed as stated in section 2.3.5.3. 
2.3.6.2  Amplification of positive transformants for recombinant baculovirus 
production 
Small-scale culture was performed as stated in Section 2.3.5.4.  Larger scale culture 
was performed once sequencing (section 2.4) had confirmed the presence and 
authenticity of the DV type 1 prM and quasispecies E gene inserts.  A single 
transformed colony for each sample was used to inoculate a starter culture of 5mL LB 
medium containing 100µg/mL ampicillin, and incubated (37˚C at 200 rpm for eight  
hours; Minitron shaking incubator, Infors).  The starter culture was diluted 1/500 into 
200mL LB medium containing 100µg/mL ampicillin and incubated (37°C for 16 h at 200 
rpm) in a 1L conical flask.  Bacterial cells were harvested by centrifugation (4100rpm 
for 15 minutes at 4°C; Legend RT Plus, Sorvall). 
2.3.7 Storage of transformed E. coli 
Glycerol stocks were made for all clones.  To 500µL of each transformed culture 
(section 2.3.5.4 and 2.3.6.2), 500µL of 30% glycerol (Sigma) was added and the 
bacterial suspension, mixed, and stored at -80°C. 
2.3.8 Restriction digestion of plasmid DNA 
Digest reactions were incubated (37°C for one to three hours; Minitron shaking 
incubator, Infors) and consisted of 5-10 units of enzyme, the appropriate buffer as 
recommended by the enzyme manufacturer at 1x final concentration, 100µg/mL BSA 
and 0.1-0.3µg of plasmid DNA.  Confirmation that DNA was digested appropriately was 
achieved by DNA agarose gel electrophoresis (Section 2.5.1). 
2.3.9 Quantification of nucleic acids 
Plasmid DNA was quantified using a ND1000 spectrophotometer (Nanodrop, Thermo 
Scientific).   
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2.3.10   In vitro transcription of plasmid DNA 
Linearised (section 2.3.8) DV type 3 E gene plasmid DNA (from section 2.3.5) was T7 
transcribed in vitro using a MEGAScript T7 High Yield Transcription kit (Ambion) 
according to manufacturer’s instructions.  The 20µL in vitro transcription reaction 
consisted of 7.5mM each of ATP, CTP, GTP, and UTP; 10x buffer at 1x final 
concentration and 2µL of T7 enzyme solution with between 0.1 and 0.3µg of plasmid 
DNA.  The reaction was incubated at 37˚C for two hours before the addition of two 
units of Turbo DNase and incubation for a further 15 minutes.  RNA transcript size and 
purity was assessed using an RNA denaturing gel (section 2.5.2), RT-PCR and PCR 
(section 2.3.1).  The transcription reaction was also performed in the presence or 
absence of 2µg of thioredoxin (Sigma), which is an accessory protein that improves the 
processivity and fidelity of T7 polymerase (Kunkel, Patel, and Johnson, 1994). 
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2.4 Sequencing  
2.4.1 Sequencing PCR 
Sequencing PCR reactions were performed using the BigDye Terminator v3.1 cycle 
sequencing kit (Applied Biosystems).  pGEM®-T Easy vector M13 forward (5’-
GTTTTCCCAGTCACGAC-3’) and reverse (5’-CAGGAAACAGCTATGAC-3’) primers, and DV 
sequence specific primers (Table 3.6) were used for sequencing.  BigDye PCR reaction 
mix consisted of 0.5μl of 2.5x Ready Reaction Premix, 3.75μl of 5x sequencing buffer, 
3.2pmol of primer, 5μl of plasmid DNA (or gel-extracted high-fidelity RT-PCR product 
when direct sequencing) and nuclease-free water to a final reaction volume of 20μl.  
Thermal cycling conditions are detailed in Table 2.5.    
Table 2.5.  Sequencing PCR thermal cycling conditions 
Stage Temperature (˚C) Time Cycles 
Denaturing 96 1 minute  
Amplification 
96 10 seconds 
25 cycles 
50 5 seconds 
60 4 minutes 
Cooling 4 ∞  
 
2.4.2 Sequencing PCR clean-up 
Clean-up of sequencing PCR reactions was performed using the Montage SEQ96 
Sequencing Reaction Cleanup kit (Millipore).  Briefly, BigDye PCR products were diluted 
with 20μl of injection solution and then added to a SEQ96 plate.  The SEQ96 plate was 
placed on top of a vacuum manifold and vacuum applied until the wells were empty.  
Excess liquid was blotted from the bottom of the SEQ96 plate before returning it to the 
vacuum manifold, adding a further 20μl of injection solution to each well and applying 
the vacuum as before.  20μl of injection solution was used to re-suspend the cleaned-
up sequencing reaction, which was then transferred to a sequencing plate (Greiner Bio 
One).   
2.4.3   Sequencing 
Sequencing was performed using an ABI PRISM 3700 DNA Analyzer (Applied 
Biosystems), and results were analysed as stated in Section 2.2.4 
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2.5 Electrophoretic techniques 
DNA and RNA electrophoresis was carried out using GNA100 gel tanks (Pharmacia 
Biotech).  Bands were visualised under UV light using a Gel Doc™ XR Gel 
Documentation System (Bio-Rad). 
2.5.1 DNA electrophoresis 
Agarose gels consisted of 1% agarose (Sigma) dissolved in 1x Tris-Borate-EDTA (TBE) 
running buffer (Sigma) with ethidium bromide solution (10mg/mL) at a final 
concentration of 9ng/mL (Sigma).  DNA ladders used were either 1kb (NEB) or 100bp 
(GelPilot 100bp Plus Ladder, Qiagen).  Samples were mixed with loading dye (GelPilot 
DNA Loading Dye, Qiagen) before addition to the wells of the gel.  Gels were run in 1x 
TBE running buffer, at 110 volts for 25-60 minutes.   
2.5.2 RNA electrophoresis 
RNA-denaturing gels consisted of 1.5% agarose-LE (Ambion) gel containing 1x 
NorthernMax denaturing gel buffer (Ambion).  2µL of transcript RNA was added to 6µL 
of formaldehyde loading dye (Ambion) and 25ng ethidium bromide (Sigma) and heated 
at 75˚C for 15 minutes.  Samples were run for 90 minutes at 35V in NorthernMax 1x 
denaturing gel running buffer (Ambion). 
2.5.3 Polyacrylamide gel electrophoresis  
Polyacrylamide gel electrophoresis (PAGE) was carried out using XCell SureLock™ Mini-
Cell gel tanks (Invitrogen™). 
2.5.3.1  Denaturing and reducing PAGE 
Samples (9.75µL) were added to NuPAGE 4x LDS Sample buffer and NuPAGE 10x 
Reducing Agent (Invitrogen™) to give a 1x final concentration in 15µL and incubated at 
70˚C for 10 minutes.  Samples were run on NuPAGE 4-12% Bis-Tris gels in 1x NuPAGE 
MOPS SDS running buffer with 500µL NuPAGE antioxidant (Invitrogen™) in the cathode 
buffer chamber at 200 volts for 55 minutes.  Gels were stained using 20mL SimplyBlue 
safe stain (Invitrogen™). 
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2.5.3.2  Native PAGE 
Samples were incubated in 1% triton X-100 (Sigma) for 1 hour at room temperature.  
Samples (9.75µL) were then added to NativePAGE 4x Sample buffer (Invitrogen™) and 
water (molecular biology grade; Promega) to give a 1x final concentration in 15µL.  
Samples were run on NativePAGE 3-12% Bis-Tris gels (Invitrogen™) with Light Blue 
Cathode buffer (1x NativePAGE running buffer with 1x NativePAGE Cathode buffer 
additive; Invitrogen™) in the inner chamber of the gel tank and anode buffer (1x 
NativePAGE running buffer) in the outer chamber of the gel tank.  Gels were run at 150 
volts for two hours.  Gels were fixed in 100mL of fixing solution (40% methanol and 
10% acetic acid) and microwaved for 45 seconds before incubating (room temperature 
and 22 rpm for 15 minutes).  Gels were de-stained in 100mL of 8% acetic acid and 
microwaved for 45 seconds before incubating (room temperature and 22 rpm) until 
the desired background was obtained.  
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2.6 Western blots and immunodetection 
A plate rocker (Mini gyro-rocker SSM3, Stuart) was used during the wash and block 
steps.  SDS-PAGE gels were washed in 1x Tris-Glycine Transfer buffer (Invitrogen™) 
with 20% methanol for 15 minutes.  Native-PAGE gels were washed in 1x Tris-Glycine 
Transfer buffer (no methanol) for five minutes. 0.2µm polyvinylidene fluoride (PVDF) 
transfer membranes (Invitrogen™) were immersed in 100% methanol for 15 seconds 
and then washed in the appropriate transfer buffer.  Two sponge pads and one filter 
paper sandwich (per gel) were immersed in transfer buffer.  Transfer apparatus was 
assembled according to manufacturer’s instructions (Mini Trans-Blot Electrophoretic 
Transfer Cell; Biorad) and wet transfer performed at 100 volts (constant) for two hours 
with ice packs and constant stirring.  After Native PAGE transfer, the PVDF membrane 
was fixed in 8% acetic acid for 15 minutes then rinsed with deionised water.  
Blotted PVDF membranes were blocked in block solution (phosphate buffered saline 
(PBS) with 0.05% Tween 20 and 5% skimmed milk) for one hour with agitation then 
stored overnight at 4˚C in block solution.  For immunodetection using all antibodies, 
membranes were incubated with primary antibody diluted in block solution for three 
hours with gentle agitation.  Membranes were washed three times for five minutes in 
PBS with 0.05% Tween 20 before incubation with HRP-conjugated secondary antibody 
diluted in block solution for two hours with gentle agitation.  Antibodies and 
concentrations used (based on manufacturer’s recommendations) are detailed in Table 
2.6.  Membranes were again washed three times for five minutes in PBS with 0.05% 
Tween 20 before detection using ECL Plus™ (Amersham Biosciences) according to 
manufacturer’s instructions.  Western blots were imaged using a BioRad ChemiDoc™ 
XRS Gel Documentation system. 
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Table 2.6.  Antibodies and dilutions used in immunodetection from Western blots 
Primary antibody Dilution Secondary antibody Dilution 
Mouse monoclonal antibody to 
polyHistidine [His-1] (Sigma, H1029) 
1:3000 Rabbit  polyclonal antibody to mouse 
IgG H&L, HRP conjugated (Abcam, 
Ab6728) 
1:1000 
Mouse monoclonal antibody to 
Flavivirus E [FE1](Abcam, Ab64059; 
Pierce, Thermo Fisher, MA1-71258) 
1:5 Rabbit  polyclonal antibody to mouse 
IgG H&L, HRP conjugated (Abcam, 
Ab6728) 
1:1000 
Rabbit  polyclonal antibody to DV 
types 1, 2, 3 and 4 (Abcam, Ab9202) 
1:1000 Goat  polyclonal antibody to rabbit IgG 
H&L, HRP conjugated (Abcam, 
Ab6721) 
1:3000 
Mouse monoclonal antibody to 
baculovirus envelope glycoprotein 
GP64 [AcV5] (eBioscience, 14-6995-
82) 
1:500 Rabbit  polyclonal antibody to mouse 
IgG H&L, HRP conjugated (Abcam, 
Ab6728) 
1:1000 
Mouse monoclonal antibody to DV 
types 1, 2, 3 and 4 [D1-11(3)] (Abcam, 
Ab9200) 
1:1000 Rabbit  polyclonal antibody to mouse 
IgG H&L, HRP conjugated (Abcam, 
Ab6728) 
1:1000 
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2.7 Baculovirus manipulations 
2.7.1 Insect cell culture 
Sf9, Sf9 E-T or Sf21 cells were grown in suspension culture (27˚C at 150 rpm, HT-Infors 
Labotron orbital shaker) in the appropriate serum-free media as detailed in section 
2.1.6.  Cell density was determined prior to use with a Neubauer haemocytometer.  
Cell viability was determined by trypan blue staining using an equal volume of cells to 
0.4% (w/v) trypan blue (Sigma).  Cells were maintained at a cell density of between 
0.5x106 and 6x106 cells/mL and passage number post recovery of cells from frozen 
stocks did not exceed 30. 
For long term storage, 2x107 cells at low passage number were frozen slowly in liquid 
nitrogen in the appropriate cell culture medium containing 10% dimethyl sulfoxide 
(DMSO) and 30% fetal bovine serum (FBS).  During recovery of cells from frozen stocks 
cells were rapidly thawed and placed in culture initiation medium containing equal 
proportions of conditioned and fresh culture medium appropriate to the cell line.  
Initiation cultures were incubated in suspension (27˚C at 150 rpm, HT-Infors Labotron 
orbital shaker). 
2.7.2 Production of recombinant baculoviruses 
Tissue culture dishes (35mm; Corning, Sigma) were seeded with 1x106 Sf9 cells. Cells 
were allowed to settle (for at least 30 minutes at room temperature) and form an even 
mono-layer. Dishes were observed under an inverted microscope (ID03, Zeiss) to 
confirm seeding density.  To produce rBV, co-transfection reactions containing 5µg of 
Lipofectin™ (Invitrogen™), 985µL of Ex-cell 420 SFM with L-glutamine, 500ng of 
transfer vector (section 2.3.6) and 100ng of FlashBAC GOLD™ (Oxford Expression 
Technologies; OET) were set up.  Reactions were incubated at room temperature for 40 
minutes.  Culture medium (2mL) was removed from the seeded 35mm tissue culture 
dishes and the co-transfection mix gently added.  Co-transfections were placed in a 
sandwich box with a moist tissue to humidify the atmosphere, and incubated at 27°C 
for 24 hours (MIR-253 incubator, Sanyo).  1mL pre-warmed fresh Ex-cell 420 SFM with 
L-glutamine was added before re-incubation at 27°C for a further four days.  Insect cells 
were observed under an inverted microscope (ID03, Zeiss) to confirm infection and 
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passage 0 (P0) recombinant virus stocks (clarified cell culture medium) were harvested 
by centrifugation (3000 rpm for 15 minutes at 4˚C, Sorvall Megafuge 11R centrifuge) 
and stored at 4°C.   
2.7.3 β-galactosidase assay 
After rBV P0 stocks were harvested from the tissue culture dishes (section 2.7.2), 1mL 
pre-warmed Ex-cell 420 SFM with L-glutamine and 0.3mg X-gal (Sigma) were added to 
rBV.lacZ-infected cells.  After re-incubation at 27°C for 24 hours (MIR-253 incubator, 
Sanyo), the culture was analysed for the presence of a blue precipitate.  
2.7.4 Amplification and titration of recombinant baculovirus stocks 
2.7.4.1  P1 amplification of P0 recombinant baculoviruses  
For each virus, a 250mL Erlenmeyer flask (Corning, Sigma) was seeded with 2x106 Sf9 
cells/mL in pre-warmed Ex-cell 420 SFM with L-glutamine.  P0 recombinant virus stock 
(1mL; section 2.7.2) was added to give a final culture volume of 50mL.  Cultures were 
incubated in the dark for five days (27˚C at 150 rpm, HT-Infors Labotron orbital shaker, 
MIR-253 incubator, Sanyo).  P1 recombinant virus stock (clarified medium) was 
harvested by centrifugation (3000 rpm for 15 minutes at 4˚C, Sorvall Megafuge 11R 
centrifuge). 
2.7.4.2  Titration of recombinant baculoviruses 
Recombinant baculoviruses were titred by end-point dilution using Sf9 E-T cells which 
produce enhanced green fluorescent protein (eGFP) when infected by baculoviruses 
(Hopkins and Esposito, 2009).  Starting at a dilution of 10-3, the rBVs were serially 
diluted eight times in HyClone SFX medium (Invitrogen™), in replicates of eight, to a 
final dilution of 10-11.  Sf9 E-T cells (7.5×104 in 100μL HyClone SFX medium) were added 
to each well.  A negative control was also set up in the same way.  Plates were 
incubated at 27°C without shaking (MIR-253 incubator, Sanyo). At three days post-
infection, the plate was scored using a fluorescent microscope (Eclipse TE2000-S 
Progres C5, Nikon) by monitoring wells containing cells producing eGFP.  Wells were 
scored as positive if they contained foci of cells producing eGFP and negative if they 
contained either no cells producing eGFP, or only isolated single cells producing eGFP 
(indicative of replication deficient rBV).  All uninfected control wells were negative for 
Chapter 2: Materials and methods 
65 
 
eGFP.  Titres were calculated according to the Reed-Muench method (Dulbecco and 
Ginsberg, 1988) shown in Figure 2.1. 
 
Figure 2.1.  Example TCID
50
 calculation  
This figure shows the wells scored as positive on the 96-well plate and the resulting calculations to obtain 
virus titre in Pfu/mL 
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2.7.4.3  P2 amplification of P1 recombinant baculoviruses  
For each virus, a 500mL Erlenmeyer flask was seeded with 2x106 Sf9 cells/mL in pre-
warmed Ex-cell 420 SFM with L-glutamine.  P1 recombinant virus stock was added at 
an MOI of 0.1 to give a final culture volume of 160mL.  Cultures were incubated in the 
dark for five days (27˚C at 150 rpm, HT-Infors Labotron orbital shaker, MIR-253 
incubator, Sanyo).  P2 recombinant virus stock (clarified medium) was harvested by 
centrifugation (3000 rpm for 15 minutes at 4˚C, Sorvall Megafuge 11R centrifuge). 
Amplified rBVs were titred (section 2.7.4.2) after each amplification and used for 
dengue virus-like particle (VLP) production if the titre was at least 108 Pfu/mL. 
2.7.5 Recombinant dengue virus-like particle production  
For optimization of recombinant dengue VLP production for each rBV, 250mL 
Erlenmeyer flasks were seeded with 2x106 Sf9 cells/mL in pre-warmed Ex-cell 420 SFM 
with L-glutamine.  P2 recombinant virus stock was added at MOIs of 2, 5 and 10 to give 
a final culture volume of 40mL.  Cultures were incubated in the dark for three days 
(27˚C at 150 rpm, HT-Infors Labotron orbital shaker, MIR-253 incubator, Sanyo).  At 48 
and 72 hours post infection, cells were monitored for signs of infection using an 
inverted microscope (ID03, Zeiss) and clarified medium and pelleted cells were 
harvested from 1mL of culture by centrifugation (3000 rpm for 15 minutes at 4˚C; 
Hettich Mikro 22R). 
Cell pellets from 1mL cultures were re-suspended in Buffer A (50mM tris, 0.5M NaCl, 
8mM imidazole) with 1x protease inhibitor (Calbiochem, Merck) in a total volume of 
333µL.  Samples were then lysed by the addition of 33.3µL Insect PopCulture 
(Novagen, Merck) and 10 units/mL of benzonase (Novagen, Merck) for 15 minutes at 
room temperature with occasional vigorous vortexing.  A 150µL sample of total 
supernatant (T) was removed from each sample before centrifugation (13,000 rpm for 
20 minutes at 4˚C, Hettich Mikro 22R) to pellet insoluble material.  A 150µL sample of 
the soluble fraction (S) was removed from each sample without disturbing the pellets, 
which were discarded.   
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Clarified insect cell culture medium from 1mL cultures (Mneat or Mn) were concentrated 
from 500µL to 50µL (Mconc or Mc) using Ultrafree-0.5 10 kDa centrifugal filter devices 
(Millipore). 
For purification of recombinant dengue VLPs 250mL or 1L Erlenmeyer flasks were 
seeded with 2x106 Sf9 cells/mL in pre-warmed Ex-cell 420 SFM with L-glutamine.  P2 
rBV stock was added at a MOI of 5 to give a final culture volume of 40mL or 200mL for 
larger scale culture.  Cultures were incubated in the dark for two days (27˚C at 150 
rpm, HT-Infors Labotron orbital shaker, MIR-253 incubator, Sanyo).  Cells were 
monitored for signs of infection using an inverted microscope (ID03, Zeiss).  Clarified 
medium was harvested from culture by centrifugation (3000 rpm for 15 minutes at 4˚C, 
Sorvall Megafuge 11R centrifuge).   
Recombinant dengue VLP production was analysed using SDS-PAGE and 
immunodetection from Western blots as described previously (sections 2.5.3 and 2.6). 
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2.8 Dengue virus-like particle concentration, purification and 
quantification 
2.8.1 Ultracentrifugation of recombinant dengue virus-like particles 
Recombinant dengue VLPs (section 2.7.5) were concentrated through a 20% sucrose 
cushion using ultracentrifugation.  Sucrose (6.3mL of 20% sucrose in PBS, Sigma) was 
added to 25x89mm Ultra-Clear open-top centrifuge tubes (Beckman).  Clarified 
medium (approximately 32mL) was gently layered on top of the sucrose cushion to the 
top of the tube.  Samples were centrifuged using a Beckman L7-55 Ultracentrifuge and 
SW32 Ti rotor at 32,000 rpm for two hours.  Pellets were re-suspended in 2mL PBS. 
2.8.2 His GraviTrap purification 
His GraviTrap affinity columns (GE Healthcare) were equilibrated with 10mL of binding 
buffer (for native purification 20mM sodium phosphate, 500mM NaCl and 20mM 
imidazole, pH 7.4; for denaturing purification 20mM Tris-HCl, 8M urea, 500mM NaCl, 
5mM imidazole and 1mM β-mercaptoethanol, pH 8.0).  Recombinant dengue VLPs 
(concentrated by ultracentrifugation, section 2.8.1) were diluted 1:8 using the 
appropriate binding buffer and added to the columns.  Columns were washed with 
10mL of the appropriate binding buffer.  Elution buffer (3mL; for native purification 
20mM sodium phosphate, 500mM NaCl and 500mM imidazole, pH 7.4; for denaturing 
purification 20mM Tris-HCl, 8M urea, 500mM NaCl, 500mM imidazole and 1mM β-
mercaptoethanol, pH 8.0) was applied to the columns and the eluate collected.  For 
the denaturing purification the elution step was performed twice.  
2.8.3 Protein G purification 
2.8.3.1  Crosslink protocol using denaturing or native buffers 
Recombinant dengue VLPs (concentrated by ultracentrifugation, section 2.8.1) were 
purified via immunoprecipitation using a mouse monoclonal antibody to flavivirus 
envelope glycoprotein (Pierce, Thermo Fisher; Table 2.6), Protein G mag sepharose and 
Protein A/G buffer kit (GE Healthcare).  The bead storage solution was removed from 
25µL of magnetic beady slurry (containing 5µL of magnetic beads) and the beads 
equilibrated with 500µL of binding buffer (50mM tris, 150mM NaCl, pH 7.5 (TBS), 
before removal of the liquid.  Antibody solution (diluted 1:5 in 200µL binding buffer) 
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was added to the beads and incubated with slow end-over-end mixing for one hour 
before removal of the liquid.  Beads were washed with 500µL of binding buffer and the 
liquid removed.  Crosslink solution A (500µL of 200mM triethanolamine pH 8.9) was 
added to the beads, and the liquid removed.  Crosslink solution A with dimethyl 
pimelimidate dihydrochloride (DMP; 500µL of 200mM triethanolamine pH 8.9 with 
50mM DMP) was added to the beads and incubated with slow end-over-end mixing for 
one hour before removal of the liquid.  Beads were washed with 500µL of crosslink 
solution A and the liquid removed.  Beads were blocked with 500µL of crosslink 
solution B (1 M ethanolamine, pH 8.9) and incubated with slow end-over-end mixing 
for 15 minutes before removal of the liquid.  Non-bound antibody was removed using 
500µL of elution buffer (0.1M glycine-HCl with 2M urea, pH 2.9 for the denaturing 
protocol; 0.1M glycine-HCl, pH 2.9 for the native protocol) before removal of the liquid 
and two washes with 500µL of binding buffer.  Sample was diluted in binding buffer, 
added to the beads and incubated with slow end-over-end mixing for one hour before 
removal and collection of the non-bound fraction.  The beads were washed three times 
with 500µL of wash buffer (TBS with 2M urea, pH 7.5 for the denaturing protocol; TBS 
with 1% octylglucoside, pH 7.5 for the native protocol).  The liquid was removed and 
collected after each wash.  During the third wash the magnetic bead solution was 
transferred to a fresh tube to prevent potential elution of proteins bound non-
specifically to the plastic of the tube.  Proteins were eluted twice for five minutes in 
50µL of the appropriate elution buffer for the native or denaturing protocol.  Eluted 
proteins were pH neutralized using 5µL Tris pH 8.5. 
2.8.3.2  Classic protocol 
Baculovirus virions in the recombinant dengue VLP samples (concentrated by 
ultracentrifugation, section 2.8.1) were purified via immunoprecipitation using mouse 
monoclonal baculovirus envelope glycoprotein GP64 mAb (eBioscience, Table 2.6), 
Protein G mag sepharose and Protein A/G buffer kit (GE Healthcare).  The bead storage 
solution was removed from 25µL of magnetic beady slurry (containing 5µL of magnetic 
beads) and the beads equilibrated with 500µL of binding buffer (50mM tris, 150mM 
NaCl, pH 7.5; TBS), before removal of the liquid.  Antibody solution (diluted 1:5 in 
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200µL binding buffer) was added to the beads and incubated with slow end-over-end 
mixing for 15 minutes before removal of the liquid.  Beads were washed with 500µL of 
binding buffer and the liquid removed.  Sample was diluted in binding buffer, added to 
the beads and incubated with slow end-over-end mixing for one hour before removal 
and collection of the non-bound fraction (containing the dengue VLPs).  The beads 
were washed three times with 500µL of wash buffer (TBS with 1% octylglucoside, pH 
7.5).  The liquid was removed and collected after each wash.  During the third wash the 
magnetic bead solution was transferred to a fresh tube to prevent potential elution of 
proteins bound non-specifically to the plastic of the tube.  Baculovirus virions were 
eluted twice for five minutes in 50µL of elution buffer (0.1M glycine-HCl, pH 2.9).  
Eluted proteins were pH neutralized using 5µL Tris pH 8.5. 
2.8.4 Anion exchange column purification 
Recombinant DV proteins (concentrated by ultracentrifugation, section 2.8.1) were 
purified via ion exchange chromatography using HiTrap CaptoQ 1mL high capacity 
strong anion exchange columns (GE Healthcare).  Initial purifications were performed 
manually using syringes and later purifications were performed using an ÄKTAFPLC 
automated system.  The sample (1.5-2mL) was first dialysed into 20mM Tris-HCl at pH 
8.5 using a 0.5-3.0mL 10 kDa slide-a-lyzer dialysis cassette (Pierce, Thermo Scientific).  
CaptoQ columns were washed at a flow rate between 0.1 and 1mL/minute with five 
column volumes each of distilled water, start buffer (20mM Tris-HCl at pH 8.5), 100% 
elution buffer (20mM Tris-HCl with 1M NaCl at pH 8.5) and then start buffer again 
before addition of sample.  The sample was bound to the column and washed with five 
column volumes of start buffer before gradient elution using a stepped (manual 
purification) or linear (automated purification) ionic strength gradient of NaCl (5 
column volumes each of elution buffer at 10%, 20%, 30%, 40%, and 50% (v/v diluted in 
start buffer).  Any remaining ionically bound material was eluted using five column 
volumes of 100% elution buffer.  The column was re-equilibrated using five column 
volumes of start buffer and the flow-through from each stage was collected and 
analysed by SDS-PAGE and immunodetection from Western blots (sections 2.5.3 and 
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2.6).  Columns were prepared for storage at room temperature using five column 
volumes each of distilled water followed by 20% ethanol (v/v). 
2.8.5 Quantification of total protein by Bradford assay 
Total protein content of recombinant DV protein samples (sections 2.7.5, 2.8.1, 2.8.2 
and 2.8.4) was quantified using the Coomassie Plus (Bradford) assay kit (Pierce, 
Thermo Fisher) according to manufacturer’s instructions.  Briefly, 10µL of sample or 
BSA protein standard was added to 300µL of Coomassie Plus reagent, and incubated at 
room temperature for 10 minutes.  Sample optical densities were read at 595nm using 
a ND1000 spectrophotometer (Nanodrop, Thermo Scientific).   
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2.9 Enzyme-linked immunosorbent assays (ELISAs) 
All ELISAs were performed using MaxiSorp® flat-bottom 96 well plates (Nunc) and read 
using a Multiskan EX microplate photometer (Thermo Scientific).  Cut-off points or 
thresholds, above which the samples were deemed positive, were calculated using the 
average background absorbance plus three standard deviations, as this accounts for 
99.7% of normally distributed data (Swinscow 1996). 
2.9.1 Dengue virus-like particle ELISAs 
ELISA plate wells were coated with antigen at 1µg/mL in 0.05M carbonate:bicarbonate 
buffer, using 100µL per well, and stored at 4°C overnight.  Wells were washed three 
times using PBS with 0.05% Tween 20 and blocked for 1 hour 30 minutes using 
blocking buffer (300µL per well; PBS with 0.05% Tween 20 and 5% skimmed milk unless 
otherwise stated).  Wells were incubated at 37°C with the appropriate primary 
antibody (100µL per well; Table 2.7) for two hours before washing three times using 
PBS with 0.05% Tween 20.  Wells were incubated at 37°C with the appropriate 
secondary antibody (100µL per well; Table 2.7) for two hours before washing three 
times using PBS with 0.05% Tween 20.  Equal volumes of ABTS™ HRP substrate 
solutions A and B (KPL) were mixed together and added to the wells (100µL per well), 
and incubated at 37°C in the dark for one hour.  ABTS™ stop solution was added 
(100µL per well), and the plate read immediately.   
Table 2.7.  Antibodies and dilutions used in ELISAs 
Primary antibody Dilution Secondary antibody Dilution 
Rabbit  polyclonal antibody to DV 
types 1, 2, 3 and 4 (Abcam, Ab9202) 1:1000 
Goat  polyclonal antibody to rabbit 
IgG H&L, HRP conjugated (Abcam, 
Ab6721) 
1:3000 
Mouse monoclonal antibody to DV 
types 1, 2, 3 and 4 [D1-11(3)] 
(Abcam, Ab9200) 
1:1000 to 
1:250 
Rabbit  polyclonal antibody to mouse 
IgG H&L, HRP conjugated (Abcam, 
Ab6728) 
1:2000 to 
1:500 
Human  polyclonal antibody to DV 
types 1, 2, 3 and 4.  WHO 
International Standard Reference 
Reagent (NIBSC, 02/186) 
1:8 
Goat  polyclonal antibody to human 
IgG, HRP conjugated (Abcam, 
Ab81202) 
1:1000 
Human serum negative for DV 
antibodies (NIBSC, 02/184) 1:8 
Goat  polyclonal antibody to human 
IgG, HRP conjugated (Abcam, 
Ab81202) 
1:1000 
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2.9.2 Heparin and DC-SIGN capture ELISAs 
ELISA plate wells were coated with recombinant DC-SIGN (recombinant human CD209, 
Fc chimera; Creative Biomart) at 1-100µg/mL or heparin sodium salt (Sigma) at 1-
100mg/mL in 0.05M carbonate:bicarbonate buffer, using 100µL per well, and stored at 
4°C overnight.  Wells were washed three times using PBS with 0.05% Tween 20 and 
blocked for 1 hour 30 minutes using blocking buffer (300µL per well; PBS with 0.05% 
Tween 20 and 5% skimmed milk unless otherwise stated).  Wells were incubated at 
37°C with the sample antigens at 1µg/mL in blocking buffer, for two hours before 
washing three times using PBS with 0.05% Tween 20.  Wells were incubated at 37°C 
with primary antibody (100µL per well; mouse monoclonal antibody to DV types 1, 2, 3 
and 4 at 1:1000 dilution) for two hours before washing three times using PBS with 
0.05% Tween 20.  Wells were incubated at 37°C with secondary antibody (100µL per 
well; rabbit  polyclonal antibody to mouse IgG H&L, HRP conjugated at 1:750 dilution) 
for two hours before washing three times using PBS with 0.05% Tween 20.  Equal 
volumes of ABTS™ HRP substrate solutions A and B (KPL) were mixed together and 
added to the wells (100µL per well), and incubated at 37°C in the dark for one hour.  
ABTS™ stop solution was added (100µL per well), and the plate read immediately. 
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2.10  Electron microscopy 
Transmission electron microscopy (TEM) analysis was conducted on the dengue VLP 
samples by Howard Tolley (HPA CEPR).  Briefly, a shallow meniscus (between 2 and 
3 L) of sample suspension was applied to a filmed TEM grid (400 mesh, old pattern, 
formvar/carbon coated copper grid) and left to adhere for approximately 30 seconds.  
Surplus sample suspension was removed by touching the edge of the grid with moist 
filter paper.  Distilled water (between 2 and 3 L) was applied to wash the grid and was 
removed after approximately 10 seconds with moist filter paper.  Negative stain 
(between 2 and 3 L of 2% uranyl acetate) was applied to the grid and removed after 1 
to 10 seconds using moist filter paper.  Grids were air dried prior to TEM examination 
using a CM100 TEM (Philips) operating at 80kV using a lanthanum hexaboride tip. 
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CHAPTER 3. ANALYSIS OF DENGUE 
VIRUS QUASISPECIES POPULATIONS IN 
CLINICAL SAMPLES 
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3.1 Introduction 
A wide spectrum of disease from subclinical to life-threatening is observed in dengue 
virus (DV) infected individuals.  The proposed causes of dengue pathogenicity is a 
subject of much debate and involves complex interactions between host genetics and 
immunity, as well as viral genetic factors.   
In Sri Lanka, the first severe dengue epidemics did not occur until after 1989 (Messer 
et al., 2002).  This was despite Sri Lanka being an area of hyperendemicity for all four 
DV types for many years, and exhibiting large numbers of secondary infections among 
the population.  This coincided with clade replacements in the circulating DV type 3 
genotype 3 strains (Lanciotti et al., 1994).  DV sequence variations at the genotype 
level and the emergence of strains into new areas have also been associated with 
changing patterns in the severity of disease in other parts of the world (Rico-Hesse et 
al., 1997a).   
Recombination of DVs within DV types has been documented in both humans and 
mosquitoes (Aaskov et al., 2007; Craig et al., 2003).  This predicts the possible 
emergence of recombinant strains that differ in pathogenic potential to the parent 
strains.  In addition, the low-fidelity of viral RNA polymerases leads to the 
incorporation of mutations into progeny RNA, and the production of a quasispecies 
population of virus variants within each infected host (DeFilippis and Villarreal, 2001; 
Domingo, 1998).  This intrahost viral sequence diversity suggests that some viral 
variants will be better adapted for survival in the host than others, and that this will be 
reflected in disease pathogenesis.  Quasispecies investigations with poliovirus have 
demonstrated a link between the extent of sequence diversity and pathogenicity; too 
many or too few virus variants within the population results in reduced viral fitness 
and attenuation (Crotty, Cameron, and Andino, 2001; Vignuzzi et al., 2006).  Important 
selective constraints acting on DVs in particular include the requirement for viral 
replication in both humans and mosquitoes, and the antibody dependent 
enhancement of infection by cross-reactive antibodies raised against a previous 
infection with a different DV type. 
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Quasispecies populations have been demonstrated for DV types 2 and 3 in clinical 
samples from patients in Taiwan and Myanmar and also in mosquitoes (Craig et al., 
2003; Lin et al., 2004; Wang et al., 2002a).  As a result of so few studies, little is known 
about how the quasispecies population dynamics vary between different individuals, 
host populations and infecting virus strains.  Previous investigations have focused on 
the DV envelope glycoprotein (E) gene as it encodes the E, which comprises the 
majority of the outer surface of the virion.  E is involved in antibody recognition, 
attachment to host cells and in membrane fusion.  Variations in E constitute potential 
mechanisms for alterations in virus virulence and pathogenicity.   
Studies of DV quasispecies population dynamics are essential for in-depth 
understanding of the biology, epidemiology and evolution of DV.  This has implications 
for disease pathogenesis, vaccine design and safety, and the development of novel 
therapeutic and diagnostic tools.  Improved understanding of dengue epidemiology 
and virus evolution in different regions will enable more effective control programmes 
to be implemented. 
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3.2 Chapter objectives 
The primary objective of this chapter was to investigate DV quasispecies populations 
(by E gene sequence analysis) both within individual patient samples and between 
samples from the same outbreak in Sri Lanka, in 2006.  Specifically, the correlation 
between disease severity and either the extent of quasispecies variation or the 
presence of specific variants was to be investigated.  Quasispecies variants with the 
potential to affect virus virulence or disease pathogenesis would be identified. 
Previous studies of DV quasispecies populations used RT-PCR, ligation independent 
cloning, and sequencing of partial or complete viral E genes; examining between 10 
and 21 clones per sample and reporting mutation rates of between 0.16% and 0.38% 
(Craig et al., 2003; Lin et al., 2004; Wang et al., 2002a).  For this study complete E 
genes would be amplified directly from patient serum without in-vitro passage of the 
virus to avoid the introduction of mutations (Chen, Wu, and Chiou, 2003) using DV 
type-specific primers and high-fidelity RT-PCR.  The use of high-fidelity RT-PCR was 
deemed essential to minimise the number of mutations introduced by the 
amplification process itself.  Amplification of complete rather than partial E genes 
would enable potential identification of recombinant viruses via phylogenetic 
comparison of different regions of the E genes.  The amplified E genes would be cloned 
and multiple clones per sample sequenced.  A greater number of samples would be 
analysed in this study than in previous studies, to provide more data for statistical 
analysis. Sequence data would be analysed to define E gene variants and to investigate 
potential relationships between quasispecies variation and disease severity.  
Using an estimated viral RNA polymerase error rate of 1x10-4 (or 0.01%; Smith et al., 
1997) and a flavivirus E gene length of 1485 nucleotides (correct for DV types 1, 2 and 
4; DV type 3 E gene length is 1479 nucleotides), one mutant clone was expected to be 
found for every 6.7 clones analysed.  From each sample, 96 clones would be studied, 
with the expectation that 15% of clones would contain mutations.  Mutations in up to 
70% of clones have been reported previously (Craig et al., 2003).   
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Phylogenetic analyses would be performed on the consensus and variant E gene clone 
sequences from each patient sample to investigate the variability of the DVs circulating 
during the Sri Lankan outbreak in 2006.  The DV genotypes present would be 
identified, and the variant E gene clone sequences assessed for evidence of 
recombination.  Protein sequence changes caused by the E gene mutations would be 
mapped to the DV E sequences and three-dimensional structures.  This was to identify 
mutations in locations with the potential to affect virulence or pathogenicity, through 
altering virus attachment to the host cell, fusion of viral and host cell membranes or 
antibody recognition and attachment to the virus.  These variant DV E genes would be 
used to construct recombinant DV E (Chapter 4) for use in studies to determine the 
effect of the mutations (Chapter 5).    
Chapter 3: Quasispecies analysis 
80 
 
3.3 Design and testing of primers for amplification of dengue virus 
envelope genes 
To enable the design of primers for DV E gene amplification, published sequences were 
obtained from the NCBI database and aligned for all four DV types (sections 2.2.1 and 
2.2.2).  To ensure detection of the greatest number of strains within each virus type, 
and to allow the entire E gene to be sequenced in subsequent experiments without 
introducing mutations into the E gene sequence via the primers, primers were 
designed up to 200 nucleotides outside of the E gene in conserved regions of the 
sequence alignments (section 2.2.3).  Primer sequences were uploaded to the Sigma-
Aldrich DNA Oligo Design Tool to estimate their melting temperature, secondary 
structure and ability to dimerise.  Primer specificity was predicted using BLAST (NCBI), 
and only primers with 100% correct matches to the appropriate DV type were tested 
further.    
Combinations of primers (Table 3.1) were tested for each DV type using RNA from the 
DV strains detailed in section 2.1.3.  RNA was transcribed to cDNA, and the cDNA 
amplified using standard RT-PCR (section 2.3.1.1); amplicons were analysed by DNA 
agarose gel electrophoresis (section 2.5.1).  Each primer set was optimised for primer 
concentration and annealing temperature before being tested for specificity by RT-PCR 
using RNA from YFV, JEV, TBEV and DV types 1, 2, 3 and 4 as template material (section 
2.1.3 details source and strain information).  As summarised in Table 3.1 (DNA gel 
electrophoresis images not shown), the first DV type 1 (Dengue 1 forward (F) 1 and 
reverse (R) 1) and 4 (Dengue 4 F1 and R1) primer sets tested produced amplicons of 
the expected size (1808 and 1799 nucleotides respectively).  However, the initial DV 
type 2 primer set (Dengue 2 F1 and R1) produced an amplicon of the expected size for 
both DV type 2 and type 3 RNA.  Due to the non-specific nature of this primer set, 
attempts were made to improve specificity by substituting the forward primer (Dengue 
2 F1) for an alternative forward primer (Dengue 2 F2).  The new primer set was 
specificity tested by RT-PCR as before, and only produced amplicons of the expected 
size (1730 nucleotides) using DV type 2 RNA.  The initial DV type 3 primer set (Dengue 
3 F1 and R1) failed to produce an amplicon of the expected size, although several 
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smaller amplicons were observed.  These primers were replaced and the new primer 
set (Dengue 3 F2 and R2) produced an amplicon of the expected size although multiple 
non-specific amplicons were also present.  Attempts to remove the additional non-
specific amplicons by annealing temperature optimisation were unsuccessful, so two 
new reverse primers (Dengue 3 R3 and R4) were designed and tested.  Both 
combinations of primers (Dengue 3 F2 and R3 or R4) were able to produce amplicons 
of the expected size (1801 and 1764 nucleotides respectively).  Specificity tests showed 
the primer set using the R3 primer produced multiple amplicons for all flavivirus RNA 
tested, with the exception of DV type 1; the primer set using the R4 primer was 
specific for DV type 3 RNA. 
Table 3.1.  Primers tested for RT-PCR amplification of dengue virus envelope genes for 
quasispecies analysis.  
Primer Sequence (5’ to 3’) Reason for replacement 
Dengue 1 F1 GGT CTA GAA ACA AGA ACC GAA ACG TGG Not replaced 
Dengue 1 R1 GAC AGT CTT TTT GGG GAG TCA G Not replaced 
Dengue 2 F1 GGA CTG GAG ACA CGA ACT GAA AC Cross-reactivity observed with DV type 
3 RNA 
Dengue 2 F2 TGA GAC ATC CAG GCT TTA CCA TAA TG Not replaced 
Dengue 2 R1 AGC TAG TTT TGA AGG GGA TTC TGG Not replaced 
Dengue 3 F1 CGC ACC CAA ACC TGG ATG TC Failed to produce an amplicon of the 
expected size 
Dengue 3 F2 TGG ATG TCG GCT GAA GGA GCT TGG AG Not replaced 
Dengue 3 R1 CCG AAT ATT ATT TGG TGC ACC ATT TTC CC  Failed to produce an amplicon of the 
expected size 
Dengue 3 R2 CCT ATT CCA ATT TTC ATT ATC CAA G Multiple bands present at all annealing 
temperatures and primer concentrations 
tested Dengue 3 R3 TCC AGG TGT GGA CCT CAT TAG Cross reactivity observed with all 
flavivirus RNA tested except DV type 1 
Dengue 3 R4 GGA GTC TGC TTG AAA TTT GTA TTG CTC Not replaced 
Dengue 4 F1 TCA GTA GCT TTA ACA CCA CAT TCA GG Not replaced 
Dengue 4 R1 TCT GTC CAA GTG TGC ACG TTG TC Not replaced 
 
Finalised primer sets are summarised in Table 3.2.  These primers were chosen to 
amplify DV E genes from clinical samples for quasispecies analysis on the basis of their 
specificity.  The alignment reports for these primer sets are presented in Appendix A.  
Figure 3.1 shows the DNA agarose gel electrophoresis images from the specificity test 
RT-PCRs.  No cross reactivity between flaviviruses was observed as each primer set 
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produced amplicons consistent in size with the DV E gene and flanking regions 
(between 1.5 and 2.0kb) for only its intended DV type. An annealing temperature of 
60°C was adopted for all primer sets to enable parallel amplification of the different DV 
types.  At this annealing temperature the DV type 1, 2 and 3 primer sets each 
produced two amplicons (Figure 3.1), but the complete E gene amplicon could be 
identified between 1.7 and 1.8kb (depending on the primers used).  For DV types 1 and 
2, these additional amplicons were the result of non-specific binding due to the 
presence of excess template RNA in the RT-PCR reaction.  They are not visible at lower 
template concentrations in the high-fidelity RT-PCR positive control reactions (Figure 
3.4 and Figure 3.5).  For DV type 3, reducing the concentration of template RNA 
eliminated some, but not all of the non-specific amplicons. 
Table 3.2.  RT-PCR primers used for amplification of dengue virus envelope genes from patient 
samples for quasispecies analysis. 
Primer Sequence (5’ to 3’) Amplicon size (bp) 
Dengue 1 F GGT CTA GAA ACA AGA ACC GAA ACG TGG 
1808 
Dengue 1 R GAC AGT CTT TTT GGG GAG TCA G 
Dengue 2 F TGA GAC ATC CAG GCT TTA CCA TAA TG 
1730 
Dengue 2 R AGC TAG TTT TGA AGG GGA TTC TGG 
Dengue 3 F TGG ATG TCG GCT GAA GGA GCT TGG AG 
1764 
Dengue 3 R GGA GTC TGC TTG AAA TTT GTA TTG CTC 
Dengue 4 F TCA GTA GCT TTA ACA CCA CAT TCA GG 
1799 
Dengue 4 R TCT GTC CAA GTG TGC ACG TTG TC 
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Figure 3.1.  Analysis of dengue virus envelope gene RT-PCR primer specificity.   
RT-PCRs were performed using the primers from Table 3.2, and RNA from several flaviviruses to assess 
primer specificity. Panels A to D show the DV types 1, 2, 3 and 4 RT-PCR primer sets respectively.  
Lanes 1 and 10 are 1kb DNA ladder, with the 1.5 and 2.0kb fragments highlighted. Lanes 2 to 8 are the 
RT-PCR amplicons generated using YFV, JEV, TBEV, DV type 1, DV type 2, DV type 3, and DV type 4 
RNA respectively as RT-PCR template. Lane 9 is a negative template control.    
 
For quasispecies analysis it was important that the number of mutations introduced 
into the E genes as part of the RT-PCR process itself was as low as possible.  The 
standard RT-PCR kit (section 2.3.1.1) used for the testing and optimisation of the DV E 
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gene primers contained Thermus aquaticus (Taq) polymerase which lacks 3’-5’ 
proofreading activity (Tindall and Kunkel, 1988).   The AccuScript high-fidelity RT-PCR 
kit (Stratagene; section 2.3.1.2) was used for this study because it includes a high-
fidelity reverse transcriptase as well as a high-fidelity polymerase (PfuUltra).  The 
reverse transcriptase combines Moloney murine leukaemia virus (MMLV) reverse 
transcriptase with the E. coli DNA polymerase III ε subunit to give an error rate of 1 
mutation per 62,200 nucleotides (Arezi and Hogrefe, 2007).  PfuUltra comprises 
Pyrococcus furiosus (Pfu) DNA polymerase and a Pfu dUTPase to improve yield 
(compared to Pfu DNA polymerase alone; Hogrefe et al., 2002) and gives an error rate 
of 1 mutation per 2,325,581 nucleotides (Arezi and Hogrefe, 2007).  Initial tests using 
the high-fidelity RT-PCR showed it to be less sensitive than the standard RT-PCR (Figure 
3.2 panels B and A respectively), as determined by visual assessment of comparative 
band intensity, but the DV E gene amplicon was clearly visible between the 1.5kb and 
2.0kb ladder fragments.  This decreased sensitivity would be expected due to the 
lower processivity of the high-fidelity enzymes. 
 
Figure 3.2. Comparison of dengue virus envelope gene reverse transcription and amplification 
using standard and high-fidelity RT-PCR.   
A 1kb DNA ladder is shown in lane 1, with the 1.5 and 2.0kb fragments highlighted. Positive RT-PCR 
reactions (lane 2) used DV type 3 RNA as template material. Negative reactions (lane 3) used molecular 
grade water instead of template RNA. The same DV type 3 RNA and number of PCR amplification 
cycles (36) was used for both methods.  
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3.4 Dengue patient samples used for amplification of dengue virus 
envelope genes and quasispecies analysis 
RNA used as template material for the high-fidelity RT-PCRs was extracted (section 
2.3.2.1) from serum samples obtained from dengue patients admitted to hospitals in 
and around Ragama, Sri Lanka, during a fever study conducted in 2006 by Major Mark 
Bailey (Royal Army Medical Corps, RAMC) and his colleagues Dr. Ranjan Premaratna 
and Prof. Janaka de Silva (Department of Medicine, University of Kelaniya, Sri Lanka).  
Samples were obtained on admission from 617 patients presenting with fever, or a 
history of fever, and sent to the Armed Forces Research Institute of Medical Sciences 
(AFRIMS) in Thailand and Health Protection Agency (HPA) Centre for Emergency 
Preparedness and Response (CEPR) for laboratory diagnosis.  A summary of the 
spectrum of disease diagnosed in these patients is shown in Figure 3.3. 
Of these patients, 143 were diagnosed with dengue by RT-PCRs or ELISAs performed 
previously by HPA CEPR and AFRIMS.  Of these 143, 31 were also diagnosed with 
chikungunya (virus RNA detected by RT-PCR), one also diagnosed with leptospirosis 
(Leptospira bacteria detected by culture and/or antibodies by IgM ELISA), one also 
diagnosed with an unidentified bacterial infection (detected by blood culture), and 
three also diagnosed with Q fever (Coxiella burnetii bacteria DNA detected by PCR 
and/or antibodies by ELISA).  For the purposes of this study, only samples from those 
patients whose records showed a positive result for DV RNA by RT-PCR were used, 
which amounted to 95 samples.  Patients with only positive dengue serology results 
were not included because their samples were less likely to still contain DV, as an 
immune response had already developed (clearing the virus and making E gene 
amplification less likely).  All four DV types were circulating in Sri Lanka at the time the 
fever study samples were collected.  Of the 95 samples positive for DV RNA, 67% were 
DV type 3 infections, 28% were DV type 2 infections and DV type 1 and 4 infections 
represented 2% and 3% of the patients respectively.  There were no occurrences of 
dual infection with multiple DV types. 
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Disease severity for each of the fever study patients was classified (with guidance from 
Major Mark Bailey, RAMC) as mild or severe based on the more relaxed WHO 
guidelines used in the treatment of children or in small hospitals in India, where the 
term ‘severe dengue’ includes any case of dengue displaying fever and one or more of 
theDHF or DSS indicators detailed in the 1997 WHO guidelines (section 1.2.3; World 
Health Organisation, 1997a). Table 3.3 summarises the clinical data for each sample, 
including the infecting DV type and patient’s serological status, the presence of 
haemorrhage, low platelet count or hypotension and the resulting disease severity 
classification.  Patient samples were designated as severe cases where the clinical 
history included haemorrhaging, thrombocytopenia (<100,000 platelets/µL) or 
hypotension.  Mild cases were those in which these symptoms were absent.  Of the 95 
DV RT-PCR positive clinical samples, 57 (60%) were classified as severe cases and 38 
(40%) as mild cases. 
Primary antibody responses occur in people who have not previously been infected (or 
immunised) and are characterised by the presence of IgM antibodies after several days 
of fever, or after the fever has passed.  Secondary responses occur as a result of a 
second flavivirus infection (e.g. sequential infection with different DV types) and it is 
the IgG response that is dominant (Shu and Huang, 2004).  IgG antibodies from 
secondary DV infections can persist in the blood for over 10 months (Gubler, 1996).  
Negative serology is indicative of an early-stage infection prior to immune response 
development.  None of these patients met the 1997 WHO criteria for distinguishing 
between dengue fever and dengue haemorrhagic fever or dengue shock syndrome 
(section 1.2.3; World Health Organisation, 1997a).  This can be attributed to 
incomplete testing or recording of observations such as pleural effusion, ascites or 
hypoproteinaemia and repeat hematocrit results by the hospital staff in Sri Lanka.  This 
information may have enabled four of the patients (R006, R014, R024 and R380) to 
meet the 1997 WHO criteria for DHF and DSS. 
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Table 3.3.  Classification of disease severity for dengue virus RT-PCR positive patient samples.   
Sample DV type Haemorrhage Platelets  
<100,000/µL 
Hypotension Severity  
classification 
R004 3 No No Yes Severe 
R006 3 Yes Yes Yes Severe 
R007 3 No Yes Yes Severe 
R008 3 Yes Yes No Severe 
R011 2 No No No Mild 
R012 3 No Yes No Severe 
R014 3 Yes Yes Yes Severe 
R016 3 No Yes No Severe 
R022 2 No No No Mild 
R024 3 Yes Yes Yes Severe 
R036 3 No No No Mild 
R038 3 No Yes No Severe 
R041 3 No No No Mild 
R054 3 Yes Yes No Severe 
R060 3 No Yes Yes Severe 
R062 2 No No No Mild 
R077 3 Yes Yes No Severe 
R080 3 Yes Yes No Severe 
R095 3 No No No Mild 
R097 3 No Yes No Severe 
R100 3 No Yes No Severe 
R103 2 No Yes No Severe 
R105 2 No No No Mild 
R107 2 Yes No Yes Severe 
R108 3 No No No Mild 
R109 3 No No Yes Severe 
R114 3 No Yes No Severe 
R120 3 No Yes No Severe 
R123 3 No No Yes Severe 
R126 2 No No No Mild 
R128 3 No No No Mild 
R146 2 No Yes Yes Severe 
R149 3 Yes Yes No Severe 
R153 4 No Yes No Severe 
R156 3 No Yes No Severe 
R157 3 No Yes No Severe 
R167 2 No Yes No Severe 
R170 2 No Yes Yes Severe 
R172 3 No Yes No Severe 
R178 2 No Yes No Severe 
R179 3 No Yes No Severe 
R191 2 No No No Mild 
R193 4 No No Yes Severe 
R197 3 No Yes No Severe 
R198 2/3 No Yes No Severe 
R203 3 No Yes No Severe 
R211 2 No Yes No Severe 
R216 3 No No No Mild 
R217 3 No No No Mild 
R221 3 No No No Mild 
R230 3 No No No Mild 
Chapter 3: Quasispecies analysis 
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Sample DV type Haemorrhage Platelets  
<100,000/µL 
Hypotension Severity  
classification 
R232 3 No No No Mild 
R254 3 No Yes No Severe 
R255 3 No No No Mild 
R259 2 Yes Yes No Severe 
R261 3 No No No Mild 
R265 1 No No No Mild 
R267 2 No Yes No Severe 
R282 4 No No No Mild 
R286 2 Yes Yes No Severe 
R290 3 No No No Mild 
R291 2 Yes Yes No Severe 
R299 3 Yes No No Severe 
R316 2 No No No Mild 
R325 3 Yes No No Severe 
R330 3 No Yes No Severe 
R334 3 No No No Mild 
R337 3 No Yes No Severe 
R342 3 No No No Mild 
R352 3 No No No Mild 
R355 2 No Yes No Severe 
R358 2 No Yes Yes Severe 
R363 3 No No No Mild 
R373 3 No No No Mild 
R380 3 Yes Yes Yes Severe 
R384 3 No No No Mild 
R388 3 No No Yes Severe 
R390 3 No No No Mild 
R394 2 No No No Mild 
R410 2 No Yes No Severe 
R421 2 No No No Mild 
R424 3 Yes Yes No Severe 
R433 2 No No No Mild 
R443 3 No No No Mild 
R447 3 No No No Mild 
R452 3 No Yes No Severe 
R478 3 Yes No No Severe 
R512 3 No Yes No Severe 
R513 1 No No No Mild 
R515 3 No Yes No Severe 
R516 2 No No No Mild 
R517 3 Yes Yes No Severe 
R592 3 No No No Mild 
R605 2 No No No Mild 
R617 3 No Yes No Severe 
Table 3.3 continued from page 88. 
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3.5 High-fidelity RT-PCR, cloning and sequencing of dengue virus 
quasispecies envelope genes from patient samples 
High-fidelity RT-PCR (section 2.3.1.2) was performed in duplicate on the 95 DV RNA 
positive samples using the appropriate DV RNA as a positive control (section 2.1.3); 
molecular biology grade water was used in place of template RNA as a negative 
control.  Previous testing of the clinical samples by RT-PCR (conducted by HPA CEPR 
and AFRIMS) identified the DV type for each sample (Table 3.3), which enabled the 
appropriate type-specific primers to be used for E gene amplification.  E gene 
amplification from sample R198A was attempted using both DV type 2 and DV type 3 
primer sets, as previous HPA and AFRIMS RT-PCRs had given conflicting results (data 
not shown).  Analysis of RT-PCR amplicons by DNA agarose gel electrophoresis yielded 
21 amplified DV E genes of between 1.5 and 2.0 kb (Figures 3.4 to 3.7).  All positive and 
negative control reactions yielded the expected results.  Two samples (R265A and 
R513A) were previously identified by diagnostic RT-PCR as containing DV type 1 RNA. 
DV E genes from these samples were unable to be amplified by high-fidelity RT-PCR 
using the DV type 1-specific primers (Figure 3.4).  Twenty-eight samples were 
previously identified by diagnostic RT-PCR as containing DV type 2 RNA. Of these, DV E 
genes from only 6 (R105A, R107A, R126A, R178A, R259A and R267A) were amplified by 
high-fidelity RT-PCR using the DV type 2-specific primers (Figure 3.5).  R105A, R126A, 
R178A and R267A produced very faint positive results which are not easily visible in 
Figure 3.5.  Sixty-five samples were previously identified by diagnostic RT-PCR as 
containing DV type 3 RNA. Of these, DV E genes from only 14 (R004A, R080A, R097A, 
R109A, R114A, R123A, R197A, R203A, R232A, R254A, R255A, R261A, R299A and 
R334A) were amplified by high-fidelity RT-PCR using the DV type 3-specific primers 
(Figure 3.6). R004A, R080A, R109A, R123A, and R254A produced very faint positive 
results which are not easily visible in this figure.  Three samples were previously 
identified by diagnostic RT-PCR as containing DV type 4 RNA. The DV E gene from only 
one of these (R282A) was amplified by high-fidelity RT-PCR using the DV type 4-specific 
primers (Figure 3.7).  Additional amplicons were present in some of the PCR products 
that were not the correct size for the DV E gene.  These are possibly the result of non-
specific amplification where excess RNA template was used.  DV E gene amplicons 
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from 12 of the 21 samples were considered strong positives as they appeared as high 
intensity bands on the gels (summarised in Table 3.4).  DNA amplicons were visualised 
briefly using low intensity UV light to limit any damage to the DNA, and the 
appropriate bands excised and the DNA purified for cloning (section 2.3.3.1).   
 
Figure 3.4.  Dengue virus type 1 patient sample high-fidelity RT-PCR product analysis.   
Positive control RNA (POS) was DV type 1 Hawaii A strain.  Negative (NEG) template control reactions 
showed no amplification.  
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Figure 3.5.  Dengue virus type 2 patient sample high-fidelity RT-PCR product analysis.   
Positive control RNA (POS) was DV type 2 New Guinea C strain.  Negative (NEG) template control 
reactions showed no amplification. The original (unprocessed) gel images used to construct this figure are 
included electronically in Appendix J. 
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Figure 3.6.  Dengue virus type 3 patient sample high-fidelity RT-PCR product analysis.   
Positive control RNA (POS) was DV type 3 H87 strain.  Negative (NEG) template control reactions 
showed no amplification. The original (unprocessed) gel images used to construct this figure are included 
electronically in Appendix J. 
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Figure 3.7.  Dengue virus type 4 patient sample high-fidelity RT-PCR product analysis. 
Positive control RNA (POS) was DV type 4 H241 strain.  Negative (NEG) template control reactions 
showed no amplification.  
 
Table 3.4.  Dengue virus envelope genes amplified from patient samples by high-fidelity RT-PCR 
for cloning.   
Sample number Dengue virus type Severity classification 
R004A 3 Severe 
R080A 3 Severe 
R097A 3* Severe 
R105A 2 Mild 
R107A 2* Severe 
R109A 3 Severe 
R114A 3* Severe 
R123A 3 Severe 
R126A 2 Mild 
R178A 2 Severe 
R197A 3* Severe 
R203A 3* Severe 
R232A 3* Mild 
R254A 3 Severe 
R255A 3* Mild 
R259A 2* Severe 
R261A 3* Mild 
R267A 2 Severe 
R282A 4* Mild 
R299A 3* Severe 
R334A 3* Mild 
From the 95 patient samples known to contain DV, only 21 DV E genes were amplified. Strong positives 
are marked with *, and disease severity classifications are shown. 
 
The DV E gene amplicons produced by the high-fidelity RT-PCRs were blunt-ended so 
were A-tailed (section 2.3.5.1) prior to cloning.  This enabled ligation into the cloning 
vector via the 3’-terminal thymidine overhangs at the insertion site. The A-tailed E 
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gene amplicons were ligated (section 2.3.5.2) into linearised pGEM®-T Easy vector 
(Promega) and transformed into JM109 competent cells (section 2.3.5.3).  The JM109 
strain was chosen for its high transformation efficiency (greater than 108 colony 
forming units per µg). 
JM109 cells transformed with pGEM®-T Easy containing the E gene inserts were 
cultured overnight on selective agar plates (section 2.3.5.3).  From the twenty-one 
high-fidelity RT-PCR-amplified E genes (Table 3.4), nine (R004A, R080A, R105A, R109A, 
R123A, R126A, R178A, R254A and R267A) produced less than ten positive 
transformants using blue/white screening of recombinants.  This could be attributed to 
the comparatively low yield of amplicon from the high-fidelity RT-PCRs performed on 
these samples (Table 3.4).  This resulted in a lower concentration of DNA being used 
for cloning, and consequently fewer transformants.  These samples did not produce 
enough transformants to allow assessment of quasispecies variation.   
Work was continued using the twelve cloned DV E gene samples that produced enough 
positive transformants to enable assessment of the quasispecies variation.  These 
twelve samples consisted of: one DV type 4 (R282A), two DV type 2 (R107A and R259A) 
and nine DV type 3 (R097A, R114A, R197A, R203A, R232A, R255A, R261A, R299A, and 
R334A) E genes (Table 3.4; denoted *).  The DV type 2 and 4 E gene amplicons were 
cloned successfully at the first attempt and a 96-well plate of transformants was 
obtained for each sample.  Cloning of the DV type 3 E gene amplicons proved difficult, 
with some cloning reactions yielding low numbers of positive transformants despite 
the DNA concentration appearing sufficient for cloning, and control reactions 
confirming that the problems were not due to faulty ligation, transformation or culture 
components.  Attempts were made to optimise cloning efficiency and increase the 
number of positive transformants; method optimisation included varying the 
vector:insert ratios, methods of transformation (chemical and electrical), and host cell 
types (ABLE C and K cells which reduce the cloning vector copy number to improve 
cloning of toxic genes; Agilent Technologies).  Incubation at a reduced incubation 
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temperature (28°C) was also attempted, but with little success.  E gene samples R114A 
and R197A, yielded only 64 colonies instead of the intended 96.   
Colonies were cultured for 24 hours in selective medium (section 2.3.5.4) before 
plasmid DNA was extracted (section 2.3.4.1).  The resulting plasmid DNA was used for 
quasispecies analysis.  In order to process the large number of clones generated for 
each sample, the presence of the DV E genes was verified by DNA agarose gel 
electrophoresis (section 2.5.1) of plasmid DNA from all clones, by monitoring 
differences in plasmid DNA migration.  This method of screening was validated by PCR.  
Thirty DV E gene clones from three different patient samples were amplified by PCR 
(section 2.3.1.4) from plasmid DNA using M13 primers (detailed in section 2.4.1).  
Undigested plasmid DNA and PCR products were compared by DNA gel electrophoresis 
(Figure 3.8, panels A and B respectively; results shown are from eight of the thirty 
clones tested).  The PCR products (Figure 3.8, panel B) showed amplicons of between 
1.5 and 2.0kb only for clones containing the DV E gene.  For each clone’s plasmid DNA 
(Figure 3.8, panel A), two bands were observed corresponding to nicked circular 
plasmid DNA (>10kb) and supercoiled plasmid DNA either with (4.8kb) or without (3kb) 
the E gene insert.  The plasmid DNA and PCR product DNA gel electrophoresis results 
correlated for all clones tested with no exceptions, confirming that DNA gel 
electrophoresis of the plasmid DNA was an acceptable method for screening clones for 
the presence of the DV E gene.   
The presence of the DV E gene in the rest of the clones was then verified by DNA 
agarose gel electrophoresis of plasmid DNA (Appendix B; summarised in Table 3.5).  In 
total, 1088 white colonies from 12 patient samples were screened for DV E genes by 
DNA gel electrophoresis of plasmid DNA (Appendix B).  DV E genes were confirmed in 
677 (62%) of these. For each patient sample, the percentage of white colonies found to 
contain the DV E gene ranged from 2% to 99%. For the DV type 2 and 4 clones, almost 
all of the white colonies picked (>95%) contained the DV E gene.  For the DV type 3 
clones, however, the number of white colonies containing the insert varied with each 
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patient sample from 2% to 99%.  These white colonies were ampicillin-resistant, so 
contained vector and an insert at some point during their growth.   
To provide sufficient DV E genes from each sample for quasispecies analysis, it was 
decided to proceed with the samples that had been successfully cloned with more 
than 50% of white colonies containing inserts of the expected size (Table 3.5).  Samples 
identified for sequencing of DV E gene quasispecies variants were R097A, R107A, 
R114A, R197A, R203A, R259A, R261A and R282A.  Sequencing was performed on clone 
plasmid DNA and directly from RT-PCR products (section 2.4).  The first sequencing 
reactions were performed using M13 primers, which flank the multiple cloning site 
(MCS) in the cloning vector.  To obtain sequence data covering the entire E gene 
(1.5kb) internal sequencing primers were designed based on the NCBI RefSeqs (section 
2.2.1) and used (Table 3.6).  The RT-PCR primers listed in Table 3.2 were also used for 
sequencing directly from the RT-PCR amplicons.  This was performed to measure the 
fidelity of the cloning procedure, and to investigate whether the differences in DV type 
3 sample cloning efficiency correlated with sequence differences between the 
infecting strains. 
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Figure 3.8.  M13 PCR validation of plasmid DNA electrophoresis method for verification of dengue 
virus envelope gene presence in cloned plasmid DNA.   
Panel A shows the DNA gel electrophoresis of undigested plasmid DNA for eight of the thirty clones 
analysed. Two bands are observed for each clone, corresponding to nicked circular plasmid DNA (>10 
kb) and supercoiled plasmid DNA either with (4.8 kb) or without (3 kb) the E gene insert. Panel B shows 
the plasmid DNA M13 PCR product analysis by DNA agarose gel electrophoresis for the same 8 clones 
shown in panel A. Bands of 1.5 kb or 0.5 kb are shown where the DV E gene insert is present or absent 
respectively. The original (unprocessed) gel images used to construct panel A of this figure are included 
electronically in Appendix J. 
 
Table 3.5.  Presence of dengue virus envelope gene inserts in picked colonies 
Sample number Dengue virus type No. of inserts/No. 
of white colonies 
% of white colonies 
containing inserts 
R107A 2 94/96 98% 
R259A 2 91/96 95% 
R097A 3 95/96 99% 
R114A 3 52/64 81% 
R197A 3 47/64 73% 
R203A 3 50/96 52% 
R232A 3 23/96 24% 
R255A 3 47/96 49% 
R261A 3 68/96 71% 
R299A 3 14/96 15% 
R334A 3 2/96 2% 
R282A 4 94/96 98% 
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Table 3.6.  Sequencing primers designed for dengue virus envelope gene quasispecies analysis. 
Primer Sequence (5’ to 3’) 
Dengue 2 seq F1 TTG GAA TAC ACC ATT GTG ATA AC 
Dengue 2 seq R1 GGT TGA CTG TAA TCA GGC GAC C 
Dengue 2 seq F2 AGG AAT GTC ATA CTC TAT GTG CAC 
Dengue 2 seq R2 AGC ACT CCA TCG TGA CAG TG 
Dengue 3 seq F1 AGT GGT GCA ACA TGA GAA CCT C 
Dengue 3 seq R1 GGA ATC TTG CAG GGT GCA TC 
Dengue 3 seq F2 TGA GCT ATG CAA TGT GCT TGA ATA C 
Dengue 3 seq R2 GCT TCA GCG GTT GAT GCC TG 
Dengue 4 seq F1 ATT GAG AAC CTT GAA TAC ACA GTG G 
Dengue 4 seq R1 CGA TGG TGA CCT GGG AGT TAT C 
Dengue 4 seq F2 AAT GTC ATA CAC GAT GTG CTC AGG 
Dengue 4 seq R2 CCT TGT TCA CAT CTC TTA TCT CTA TGG 
 
  
Figure 3.9.  Schematic of dengue virus envelope gene sequencing primer read positions.   
M13 (section 2.4.1), RT-PCR (Table 3.2) and sequencing (Table 3.6) primers were used to obtain 
sequence data covering the entire E gene. E gene sequence was flanked by DV prM and NS1 gene 
sequence, which contained the binding sites for the RT-PCR primers. M13 primer binding sites were 
specific to the plasmid and sequencing (seq) primers were internal to the E gene sequences. 
 
Sequence data obtained by sequencing (of both the dengue patient sample clones, and 
directly from the RT-PCR products) was verified as DV E gene sequence using BLAST 
(NCBI).  The following samples produced DV E gene sequence data for most of the 
insert-containing clones: R097A, R107A, R203A, R259A, R261A, and R282A.  This 
equates to one DV type 4, two DV type 2 and three DV type 3 samples.  These data 
were assembled into separate contigs (section 2.2.4) for each clone.  When sequencing 
the clones from samples R114A and R197A, the majority of the sample reads obtained 
were of insufficient length, which meant they were either too short to incorporate into 
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contigs, or the contigs assembled did not cover the entire E gene.  These two samples 
were thus not included in subsequent sequence analyses as the E gene sequence data 
were incomplete.  Direct sequencing of the RT-PCR products and contig assembly were 
successful for samples R004A, R097A, R107A, R114A, R197A, R203A, R232A, R254A, 
R255A, R259A, R261A, R299A, R282A and R334A.  Sequencing directly from the RT-PCR 
product was unsuccessful for samples R080A, R105A, R109A, R123A, R126A, R178A 
and R267A.  This could be attributed to the low DNA concentration of these samples. 
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3.6 Sequence analysis of dengue virus quasispecies envelope genes   
To compare the DV quasispecies E gene sequences from each patient sample, the 
contigs from each clone (section 3.5) were aligned as both nucleotide and amino acid 
sequences (section 2.2.4; see Appendices C and D for sequence alignments).   Tables in 
Appendix E detail the types and positions of mutations in each sample.  This 
information is summarised in Table 3.7.  In total, 299 E gene clones were analysed 
across the six patient samples, a total of 436,909 nucleotides (nt) were sequenced and 
64 nucleotide changes were observed. Overall mean diversity (number of mutations 
per nucleotide) was 0.013%, whereas mean diversity values for individual samples 
ranged from 0.0034% to 0.053% (average 0.018%).  For all 14 of the patient samples 
where direct sequencing of the RT-PCR products was successful, the sequences 
obtained were shown to match the consensus sequence of the clones for that sample 
(data not shown).  This confirmed that no major changes to any of the E gene 
sequences were introduced during the cloning process. 
Table 3.7.  Summary of dengue virus envelope gene sequence diversity observed in clinical samples. 
Sample Infection 
type 
No. of 
clones 
analysed 
No. of 
clones 
containing 
mismatches 
No. of nt 
substitutions 
No. of nt 
deletions 
or 
insertions 
Total No. 
of nt 
sequenced 
Mean 
diversity 
(mutations/
nt) 
R097A 
Dengue 3 
severe 
82 16 (20%) 15 3 119,864 0.015% 
R107A 
Dengue 2 
severe 
40 2 (5%) 1 1 59,400 0.0034% 
R203A 
Dengue 3 
severe 
25 6 (24%) 10 9 35,913 0.053% 
R259A 
Dengue 2 
severe 
45 6 (13%) 3 4 66,822 0.01% 
R261A 
Dengue 3 
mild 
47 13 (28%) 12 1 65,977 0.02% 
R282A 
Dengue 4 
mild 
60 5 (8%) 5 0 88,933 0.0056% 
 
Differences in mean diversity between the severe and the mild dengue cases were 
compared using the Mann-Whitney two-sample rank test (section 2.2.5).  This showed 
no statistically significant difference between the samples from each group (p=1.0). 
Of the 299 cloned DV E genes analysed, nine contained incomplete E gene sequences 
(Table 3.8 and Appendices C and D).  Sequence data from these clones showed 
pGEM®-T Easy vector sequence flanking the incomplete E gene sequence confirming 
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that the problem was not with the sequencing reaction.  These truncated E gene 
clones were considered artefacts of the cloning process rather than genome defective 
quasispecies variants.  All nine clones containing incomplete E gene sequences were 
from patients with DV type 3 infections.  Two common points of E gene truncation 
were observed at E gene positions E772-3 and E1128-32.  For these truncated clones, 
the portion of the E gene sequence up to the point of truncation was included in the 
clone alignments. 
Table 3.8.  Clones containing truncated envelope gene sequences. 
Sample Clone Point of truncation within the 
envelope gene 
R097A 
28 E1128 
93 E773 
R203A 
42 E773 
77 E1132 
R261A 
72 E772 
75 E772 
79 E772 
80 E772 
84 E772 
 
Of the 299 clones analysed, 48 contained at least one mutation, which amounts to 16% 
of the clones differing from their respective consensus sequences.  Substitution, 
insertion and deletion mutations were all observed, with substitutions accounting for 
72% of all nucleotide changes.  Deletion mutations were deletions of one or two 
nucleotides, and accounted for 16% of all nucleotide changes.  Substitution and 
insertion mutations were predominantly single nucleotide mutations, with the 
exception being one clone (R203A clone 54), which carried a mutation where a 
sequence of eight nucleotides were replaced with a different sequence of 14 
nucleotides (substitution of eight nucleotides and insertion of six nucleotides), 
resulting in a protein sequence change of three amino acids and an insertion of 
another two amino acids.  Three clones contained mutations at two separate sites 
(R203A clone 54, E605 and E1032-40; R097A clones 37 and 41, E291 and E736, and 
E163 and E229 respectively), and two clones contained deletions of two consecutive 
nucleotides (R203A clone 21 E914-5; R259A clone 54 E370-1).  For patient sample 
R261A, there were two sites where multiple clones carried the same mutation (E602 
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and E1146; 6 and 3 clones respectively).   These two groups of clones represent distinct 
DV lineages compared to the consensus, and their relative abundance within all of the 
clones analysed amounts to 13% and 6.5% respectively of the quasispecies population.  
In the larger group of clones the mutation causes an amino acid substitution in the 
protein sequence, whereas the mutation in the smaller group of clones does not affect 
the amino acid sequence. 
A transition mutation is one where a purine (A or G) is substituted with another purine, 
or a pyrimidine (C, T or U) with another pyrimidine.  In contrast, a transversion 
mutation is one in which a purine is substituted with a pyrimidine or vice versa.  
Nonsynonymous mutations lead to amino acid sequence changes, whereas 
synonymous mutations do not.  Of the nucleotide substitutions, 29% were 
transversion mutations, and 61% of all the mutations (46 substitutions, 8 insertions 
and 10 deletions) were nonsynonymous (Table 3.9).  Conservative amino acid changes 
occur when an amino acid is substituted for one with similar properties, but drastic 
protein changes occur when amino acids with different properties are substituted (for 
example, a polar amino acid such as threonine for a nonpolar amino acid such as 
leucine).  Of these nonsynonymous mutations, 67% were drastic rather than 
conservative, and 50% of these drastic mutations caused frameshifts by insertion or 
deletion of nucleotides (Table 3.9).  
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Table 3.9.  Summary of dengue virus envelope gene mutation types.  
Sample Infection 
type 
Transversion 
mutations / 
total  
substitution 
mutations 
Nonsynonymous 
mutations / total 
mutations 
Drastic 
mutations / 
Nonsynonymous 
mutations 
Frameshift 
mutations / 
Drastic 
mutations 
R097A 
Dengue 3 
severe 
5/15 9/18 9/9 3/9 
R107A 
Dengue 2 
severe 
1/1 2/2 1/2 1/1 
R203A 
Dengue 3 
severe 
0/2* 4/5 3/4 2/3 
R259A 
Dengue 2 
severe 
1/3 4/6 3/4 3/3 
R261A 
Dengue 3 
mild 
2/12 8/13 2/8 1/2 
R282A 
Dengue 4 
mild 
2/5 3/5 2/3 0/2 
Total  11/38 (29%) 30/49 (61%) 20/30 (67%) 10/20 (50%) 
* The multiple nucleotide substitution and insertion mutation observed in patient sample R203A clone 54 
was not included in the transversion/substitution mutations calculation as it was not clear which 
nucleotides were substituted and which were inserted. This mutation was counted as one mutation rather 
than per nucleotide in all of the subsequent calculations, as were two nucleotide deletion mutations. 
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3.7 Comparison of mutations introduced by the RT-PCR process 
between this study and published data 
Previous studies reported error frequencies for mutations introduced by the RT-PCR 
process of between 0.023 and 0.055% (Lin et al., 2004; Wang et al., 2002a).  These 
values were determined by RT-PCR, cloning and sequencing of DV E gene T7 transcript 
RNA.  To assess how much sequence variation was introduced using the high-fidelity 
RT-PCR amplification methodology used for this study, DV type 3 E gene plasmid DNA 
from a single colony of known sequence was transcribed in vitro using T7 polymerase 
(section 2.3.10).  The resulting transcript was subjected to high fidelity RT-PCR, cloning 
and sequencing using the same methods applied to the Sri Lankan patient samples in 
this study (AccuScript method; section 2.3.1.2).  To enable comparison of mutation 
frequencies between these results and those obtained previously by other groups, the 
same DV E gene RNA control transcript was also subjected to high fidelity RT-PCR, 
cloning and sequencing using published methods (Craig et al., 2003); Expand method; 
section 2.3.1.3).  Sequence contigs were assembled and the clones from each sample 
aligned as both nucleotide and amino acid sequences (section 2.2.4; see Appendices F 
and G for alignments).   Tables in Appendix H detail the types and positions of 
mutations in each sample.  These results are summarised in Table 3.10.  Analysis of the 
RNA transcript data obtained using the Expand and AccuScript RT-PCR methods 
showed that of the clones analysed, 55% and 33% respectively contained at least one 
mutation (Table 3.7).  These values are 3.4-fold (Expand method) and 2.1-fold 
(AccuScript method) higher than the 16% of clones containing mutations observed 
using the AccuScript method and dengue patient samples (Table 3.7).  Alignment 
consensus sequences from both methods using the RNA transcript were shown to be 
identical (data not shown).  The AccuScript method generated fewer mutations than 
the Expand method, but both methods that used the RNA transcript as RT-PCR 
template material produced a greater number of clones containing mutations, and a 
higher mean diversity than was found using the AccuScript method with the dengue 
patient samples as RT-PCR template material. 
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Substitution, insertion and deletion mutations were observed for the methods using 
the RNA transcript, with substitutions accounting for 68% (Expand method) and 46% 
(AccuScript method) of all nucleotide changes.  Deletion mutations were deletions of 
one or two nucleotides.  Substitution and insertion mutations generated using the 
Expand method were all single nucleotide mutations.  Substitution and insertion 
mutations generated using the AccuScript method were predominantly single 
nucleotide mutations, with the exceptions being clones 4, 21, 27 and 38 (Appendix H, 
Table 8).   
Table 3.10.  Summary of mutations generated by the Expand and AccuScript RT-PCR methods.  
Method No. of 
clones 
analysed 
No. of 
clones 
containing 
mismatches 
No. of nt 
substitutions 
No. of nt 
deletions 
or 
insertions 
Total No. 
of nt 
sequenced 
Mean 
diversity 
(mutations/nt) 
Expand 
RNA transcript 
55 30 (55%) 41 19 56,639 0.11% 
AccuScript 
RNA transcript 
55 18 (33%) 18 21 60,453 0.065% 
AccuScript 
Patient samples 
299 48 (16%) 38 18 436,909 0.013% 
 
Table 3.11.  Summary of mutation types generated by the Expand and AccuScript RT-PCR 
methods.   
Method Transversion 
mutations / total  
substitution mutations 
Nonsynonymous 
mutations / total 
mutations 
Drastic mutations 
/ Nonsynonymous 
mutations 
Frameshift 
mutations / 
Drastic mutations 
Expand 
RNA transcript 
5/41 (12%) 48/59 (81%) 37/48 (77%) 17/37 (46%) 
AccuScript 
RNA transcript 
6/8 (75%)* 26/26 (100%) 19/26 (73%) 16/19 (84%) 
AccuScript 
Patient samples 
11/38 (29%) 30/49 (61%) 20/30 (67%) 10/20 (50%) 
* The multiple nucleotide substitution and insertion mutation observed in clone 21 (AccuScript method) 
was not included in the transversion/substitution mutations calculation as it was not clear which 
nucleotides were substituted and which were inserted. This mutation was counted as one mutation rather 
than per nucleotide in all of the subsequent calculations, as were multiple nucleotide insertion or deletion 
mutations. 
Of the substitution mutations, 12% (Expand method) and 75% (AccuScript method) 
were transversion rather than transition mutations.  For both methods a high 
percentage of the mutations were nonsynonymous (Expand 81%; AccuScript 100%) 
and drastic (Expand 77%; AccuScript 73%), which is in accordance with the findings 
from the patient samples (see Tables 3.9 and 3.11).  The percentages of insertion or 
deletion mutations at homopolymeric runs of nucleotides were very similar between 
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the methods using the RNA transcript (Table 3.12).  For the AccuScript method using 
patient samples as RT-PCR template material, compared to the methods using the RNA 
transcript, the percentage of mutations at homopolymeric runs of nucleotides was up 
to 3-fold lower for insertion mutations and up to 1.66-fold higher for deletion 
mutations.  The proportion of these mutations (at homopolymeric runs of nucleotides) 
of the total insertion and deletion mutations was also lower for the patient samples 
than for the methods using RNA transcript. 
Table 3.12.  Comparison of insertion and deletion mutations generated at homopolymeric runs of 
nucleotides by the Expand and AccuScript RT-PCR methods.   
Method Insertion mutations at 
homopolymeric runs / 
total  insertion mutations 
Deletion mutations at 
homopolymeric runs / 
total deletion mutations 
Insertion and deletion 
mutations at homopolymeric 
runs / total insertion and 
deletion mutations 
Expand 
RNA transcript 
6/8 (75%) 3/10 (30%) 9/18 (50%) 
AccuScript 
RNA transcript 
12/18 (67%) 1/3 (33%) 13/21 (62%) 
AccuScript 
Patient samples 
2/8 (25%) 5/10 (50%) 7/18 (39%) 
    
For the patient samples, overall rates of insertion and deletion mutations were 
0.0041% compared to rates of 0.032% (Expand) and 0.035% (AccuScript) for the 
methods using RNA transcript as RT-PCR template material (Table 3.13).  Substitution 
mutation rates were 0.074%, 0.03% and 0.0087% for the Expand RNA transcript 
method, AccuScript RNA transcript method and patient samples respectively (Table 
3.13).  Therefore, although rates of insertion and deletion mutations, and rates of 
substitution mutations were consistently higher for the methods using RNA transcript 
than when the patient samples were used, it is the incorporation of substitution 
mutations rather than insertion and deletion mutations that makes the difference 
between the two RT-PCR methods using the RNA transcript.  The Expand method had a 
substitution mutation rate 2.47-fold greater than the AccuScript method. 
The difference between the mutation rates observed using RNA transcript versus 
patient samples indicated that the presence of such mutations might be attributed to 
the RNA transcript used rather than the high-fidelity RT-PCR, cloning and sequencing.  
Thioredoxin is an accessory protein that improves the processivity of T7 polymerase, 
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reducing substitution mutations by 3-fold, deletion mutations of one and two 
nucleotides by 27- and 9-fold respectively and insertion mutations at homopolymeric 
runs of nucleotides by 46-fold (Kunkel, Patel, and Johnson, 1994).   
Table 3.13.  Comparison of mutations generated by the Expand and AccuScript RT-PCR methods.   
Method Insertion/deletion 
mutation rates 
Substitution 
mutation rates 
Expand 
RNA transcript 
0.032% 0.074% 
AccuScript 
RNA transcript 
0.035% 0.030% 
AccuScript 
Patient samples 
0.0041% 0.0087% 
Substitution mutation rates were calculated by dividing the number of substitution mutations by the total 
number of nucleotides sequenced. 
    
To test whether the mutations in the RNA transcript could be attributed to the 
infidelity of the T7 polymerase during transcript generation, the in vitro transcription 
reaction was repeated using new reagents in the presence and absence of thioredoxin 
(TRX; section 2.3.10).  The resulting DV type 3 E gene transcripts (ETRX+ and ETRX-) were 
subjected to high fidelity RT-PCR, cloning and sequencing using the same methods 
applied to the Sri Lankan patient samples in this study (AccuScript method; section 
2.3.1.2).  Sequence contigs were assembled and the clones aligned as both nucleotide 
and amino acid sequences (section 2.2.4).  In total, 23 clones were analysed; 12 and 11 
clones generated using ETRX+ and ETRX- respectively.  There were no mutations in any of 
the clones generated; all of the clones matched the consensus sequence (data not 
shown).  This consensus sequence also matched those obtained during the AccuScript 
versus Expand method comparison.  Although there was no difference in the numbers 
of mutations between ETRX+ and ETRX-, no mutations were found in clones generated 
from either transcript.  It is hypothesised that the source of the high number of 
mutations observed during the AccuScript versus Expand method comparison was the 
RNA transcript as previously suggested, and that using new reagents for the in vitro 
transcription reaction resulted in the generation of a homogenous RNA transcript 
population.  An error frequency for mutations introduced by the AccuScript RT-PCR of 
less than 0.003% was calculated, based on 33,644 nucleotides sequenced and no 
mutations were found (1/33,645 = 0.003%). 
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3.8 Phylogenetic analysis of dengue virus quasispecies envelope gene 
and glycoprotein sequences 
To investigate sequence variation between the DVs from the dengue patient samples, 
multiple sequence alignments were constructed and phylogenetic analyses performed 
(section 2.2.4).  Alignments were constructed using published DV sequences of known 
genotype and sequences from Sri Lanka (Table 3.14) to identify the genotypes present 
within the DV types circulating in Sri Lanka at the time of the outbreak.  These 
sequences were obtained from NCBI (section 2.2.1).  Consensus E gene sequences for 
the dengue samples from this study were included in their respective multiple 
sequence alignments (separately by DV type) alongside E gene sequences for clones 
containing mutations.  This was to identify whether any of the mutations were present 
in the clones as a result of recombination with a co-infecting genotype.  Evidence of 
recombination would have been observed if any of the mutant clones displayed a 
vastly different percentage sequence identity, or a shift in phylogeny compared to 
their respective consensus sequences. 
The percentage sequence identity between each of the strains was calculated from the 
nucleotide sequence alignments (Appendix I).  The two DV type 2 patient sample 
(R107A and R259A) consensus sequences share 99.5% sequence identity and are 
identical in protein sequence.  The R107A and R259A clones containing mutations 
share 99.9% sequence identity with their respective consensus sequences.  Sequence 
identities between all of the DV type 2 samples used to construct the alignment were 
between 80.7 and 99.9%, with the lowest sequence identities observed with the 
sylvatic strains P8-1407 and Sen70-DAKHD10674.  Sequence identities between the DV 
type 2 sequences and the DV type 1 sequence included in the alignment were around 
66% as would be expected because they are different viruses.   
The DV type 4 patient sample (R282A) clones containing mutations share 99.9% 
sequence identity with the sample consensus sequence.  Sequence identities between 
all of the DV type 4 samples used to construct the alignment were between 91.7 and 
99.9%, with the lowest sequence identities observed with the genotype II strain El 
Salvador 1994.  Sequence identities between the DV type 4 sequences and the DV type   
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Table 3.14.  Published dengue virus envelope gene sequences used for phylogenetic analysis.   
NCBI accession no. Strain DV type 
 
Genotype Reference 
X54319 Tonga 1974 2 American (Twiddy et al., 2002) 
AF264054 Puerto Rico 1969 2 American " 
L10053 Trinidad 1953 2 American " 
L10047 Seychelles 1977 (Sey-42) 2 Cosmopolitan " 
AF10374 India 1994 (CAMR 10) 2 Cosmopolitan " 
AF410376 Far East 1998 (CAMR 13) 2 Cosmopolitan " 
M29095 New Guinea C 2 Asian 2 " 
AF410364 Vietnam 1998 (CTD211) 2 Asian 2 " 
AF295697 Philippines (DOH-005) 2 Asian 2 " 
AF295698 Philippines (DOH-034) 2 Asian 2 " 
AF195040 Thailand (D91-533) 2 American/Asian " 
AF163096 PTCOL96 2 American/Asian " 
AF410350 Vietnam 1997 (CTD20) 2 American/Asian " 
AF410367 Vietnam 1998 (CTD226) 2 American/Asian " 
AF022436 ThNH-52/93 2 Asian 1 " 
AF022434 ThNH-7/93 2 Asian 1 " 
AF022437 ThNH-p11/93 2 Asian 1 " 
AF264053 Thailand 1980 (PUO-312) 2 Asian 1 " 
AF231717 P8-1407 2 Sylvatic " 
AF231720 Sen70-DAKHD10674 2 Sylvatic " 
AF410372 Sri Lanka 1994 (CAMR 7) 2 Cosmopolitan " 
AB194883 Sri Lanka 2004 2 Unknown  
NC_001475 Sri Lanka 2000 3 Unknown  
AF547234 Sri Lanka 1993 3 IIIb (Messer et al., 2003a) 
AY099336 Sri Lanka 2000a 3 Unknown  
DQ518679 Sri Lanka 1999 3 Unknown  
L11438 Sri Lanka 1991 3 IIIb (Lanciotti et al., 1994) 
AF547230 Sri Lanka 1989 3 IIIb (Messer et al., 2003a) 
AF547242 Sri Lanka 1997 3 IIIb " 
AF547232 Sri Lanka 1989b 3 IIIb " 
AF547243 Sri Lanka 1998 3 IIIb " 
AF547235 Sri Lanka 1994 3 IIIb " 
L11429 Malaysia 1974 (1300) 3 I (Lanciotti et al., 1994) 
L11437 Sri Lanka 1989c 3 IIIa " 
AF547229 Sri Lanka 1984 3 IIIa (Messer et al., 2003a) 
AF547225 Sri Lanka 1983 3 IIIa " 
AF547226 Sri Lanka 1983a 3 IIIa " 
AF547228 Sri Lanka 1983c 3 IIIa " 
AF547241 Sri Lanka 1985 3 IIIa " 
AF547231 Sri Lanka 1989a 3 IIIa " 
L11436 Sri Lanka 1985a 3 IIIa (Lanciotti et al., 1994) 
AF547227 Sri Lanka 1983b 3 IIIa (Messer et al., 2003a) 
L11431 Sri Lanka 1981 3 IIIa (Lanciotti et al., 1994) 
L11434 Puerto Rico 1977 (1340) 3 IV " 
L11442 Thailand 1987 (MK315) 3 II " 
U18437 Sri Lanka 1978a 4 I (Lanciotti, Gubler, and 
Trent, 1997) 
" 
U18442 Thailand 1984 4 I 
AY550909 Sri Lanka 1978 4 Unknown  
U18441 Thailand 1978 4 I (Lanciotti, Gubler, and 
Trent, 1997) 
" 
U18433 Philippines 1956 4 I 
U18434 Philippines 1964 4 I " 
U18435 Philippines 1984 4 I " 
U18426 El Salvador 1983 4 II " 
U18432 New Caledonia 1984 4 II " 
U18431 Mexico 1984 4 II " 
U18425 Brazil 1982 4 II " 
U18436 Puerto Rico 1986 4 II " 
U18439 Tahiti 1985 4 II " 
U18438 Tahiti 1979 4 II " 
U18427 El Salvador 1994 4 II " 
U18429 Indonesia 1976 4 II " 
U18430 Indonesia 1977 4 II " 
U18428 Indonesia 1973 4 II " 
U18440 Thailand 1963 4 I " 
All sequences were obtained from NCBI (section 2.2.1). Genotype information was obtained from the 
publications listed. 
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1 sequence included in the alignment were around 63% as would be expected because 
they are different viruses. 
The three DV type 3 patient sample (R097A, R203A and R261A) consensus sequences 
share a sequence identity of 99.1 to 99.6%.  R097A and R203A each differ from the 
R261A sequence by one amino acid.  The R097A and R203A samples share greater 
sequence identity with each other than to the R261A sample.  The clones containing 
mutations share 99.9% sequence identity with their respective consensus sequences.  
R261A clones 4, 29, 34, 37 and 46 share 100% sequence identity, as do clones 49, 52 
and 60.  Sequence identities between all of the DV type 3 samples used to construct 
the alignment were between 92.6 and 100%, with the lowest sequence identities 
observed with the genotype IV strain Puerto Rico 1977.   
Sequence analysis of the RT-PCR amplicons from the DV type 3 patient samples that 
were not cloned (R004A, R114A, R197A, R232A, R254A, R255A, R299A and R334A) 
showed that most of these samples share 99% or more sequence identity with the 
samples that were cloned.  The exceptions to this were samples R197A and R254A, 
which had average sequence identities of 94 and 47% respectively.  These were lower 
because the DV E gene sequences for these samples were incomplete (Appendix C).  
Compensating for the missing portions of sequence (5% and 53% for R197A and R254A 
respectively) increases the sequence identities to over 99% for both samples.  Samples 
R299A and R114A share 99.9% sequence identity with the cloned sample R097A; with 
the R097A and R299A samples having an identical protein sequence and sample R114A 
differing by one amino acid.  All three of these samples were from severe dengue cases 
(Table 3.3).  Sample R004A shares 99.9% sequence identity with the cloned sample 
R203A and the protein sequences were identical.  Both of these samples were from 
severe dengue cases.  Samples R197A, R232A, R254A, R255A and R334A share the 
highest sequence identity with the cloned sample R261A (94.3, 99.5, 46.9, 99.4, and 
99.5% respectively), which was from a mild dengue case.  Samples R232A, R255A and 
R334A were also from mild dengue cases, but samples R197A and R254A were from 
severe dengue cases.  
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Phylogenetic trees were constructed based on the E gene sequence alignments 
(Figures 3.10 to 3.12; alignments not shown).  Bootstrapping statistical analyses of 
1000 replicates was used to assess the integrity of the phylogenetic trees.  Percentage 
values are shown at the major nodes of each tree and values of 70% and above are 
considered acceptable, because 70% of the 1000 generated trees contained that clade.  
Published sequence data from Sri Lankan DV type 2 strains has shown only strains from 
the Cosmopolitan genotype or Asian genotype 2 (Twiddy et al., 2002).  Both of the DV 
type 2 E gene samples, and all of the mutant clones from this study cluster together 
within the Cosmopolitan genotype (Figure 3.10).  The genotype of the Sri Lanka 2004 
strain was previously undetermined and the results of this study show that it also 
belongs to the Cosmopolitan genotype. This genotype contains other strains from Sri 
Lanka as well as strains from India, Southeast Asia, Africa, the Middle East and 
Australia.  Sri Lankan DV type 4 sequences published to date have shown only strains 
from genotype I (Lanciotti, Gubler, and Trent, 1997).  The DV type 4 E gene sample 
from this study, and all of the mutant clones cluster together within genotype I as 
expected (Figure 3.11).  The genotype of the Sri Lanka 1978 strain was previously 
undetermined and the results of this study show that it also belongs to genotype I, 
alongside other Sri Lankan strains, and strains from Thailand and the Philippines.. 
Previously published E gene sequences from Sri Lankan DV type 3 strains have shown 
no strains from genotypes I, II or IV, only genotype III (Messer et al., 2003a).  These 
genotype III strains cluster into two distinct groups: IIIa and IIIb.  Those strains that 
comprise genotype IIIa are all from outbreaks during or prior to 1989, which were not 
associated with epidemics of severe dengue.  Those that form genotype IIIb are all 
from 1989 or later, and have been associated with epidemics of severe dengue 
(Lanciotti et al., 1994; Messer et al., 2003a).  It has been suggested that this genetic 
shift may have increased the virulence of the Sri Lankan strains, and be responsible for 
the increase in cases of severe disease seen on the island after 1988 (Lanciotti et al., 
1994).  A similar DV type 3 genotype IIIb clade replacement has been suggested as the 
cause of a further increase in severe dengue in Sri Lanka since 1999 (Kanakaratne et 
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al., 2009).  The DV type 3 E gene samples from this study were identified as genotype 
IIIb strains, and cluster together with their respective mutant clones within the clade 
containing the more recent samples (since 1999), as expected (Figure 3.12).  The 
genotypes of the Sri Lanka 1999 and 2000 strains were previously undetermined and 
the results of this study show that they also belong to genotype IIIb. 
 
Figure 3.10.  Dengue virus type 2 complete envelope gene phylogenetic tree.   
Samples from this study are highlighted with a red box. The scale represents the evolutionary distance in 
units of the number of base substitutions per site.  
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Figure 3.11.  Dengue virus type 4 complete envelope gene phylogenetic tree.   
The sample from this study is highlighted with a red box. The scale represents the evolutionary distance 
in units of the number of base substitutions per site. 
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Figure 3.12.  Dengue virus type 3 complete envelope gene phylogenetic tree.   
Samples from this study are highlighted with a red box. The scale represents the evolutionary distance in 
units of the number of base substitutions per site. 
 
For the DV type 3 samples, a second tree (Figure 3.13) was constructed to incorporate 
an increased number of Sri Lankan DV sequences (from Messer et al., 2003a) using a 
207 nucleotide region from the 5’ end of the E gene.  In this tree the genotype IIIb 
strains cluster in two temporally distributed clades as with the complete E gene tree 
(Figure 3.12).  There is no indication from these E gene data that any of the mutant DV 
clones result from recombination events between co-infecting genotypes, as the 
samples and mutant clones from this study all cluster as expected within the clade 
containing the more recent samples.  If there had been recombinant E genes present, a 
difference in phylogeny would have been observed between the consensus and 
mutant sequences across the complete and partial E gene trees.  However, compared 
to the complete E gene tree, in this region of the sequence the R261A sample is less 
closely related to the R097A and R203A strains from this study as well as the Sri Lanka 
2000 and 2000a strains.  Also, in the DV type 3 complete E gene phylogram (Figure 
3.12), the genotype I strain Malaysia 1974 appeared most closely related to the 
genotype II strain Thailand 1987, but in the DV type 3 partial E gene phylogram (Figure 
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3.13) the genotype I strain appears more closely related to the genotype IIIb strains.  
The Sri Lanka 1989c strain also shifts phylogeny between the two phylogenetic trees.  
In the complete E gene tree (Figure 3.12) it clusters with Sri Lanka 1991 in genotype 
IIIb, whereas in the partial E gene tree (Figure 3.13) it appears more closely related to 
Sri Lanka 1984 in genotype IIIa.  A shift in phylogeny when different regions of a 
sequence are used for the analysis is indicative of recombination.  In the partial E gene 
tree (Figure 3.13), the presence of a DV strain from 1993 within the clade containing 
the more recent samples (since 1999) is a strong indication that the clade is likely 
derived from strains indigenous to Sri Lanka rather than being imported (Kanakaratne 
et al., 2009). 
The bootstrap values for all of the complete E gene phylogenetic trees were above 
70% at the major nodes, which provides statistical confirmation that the trees are 
accurate.  The bootstrap values for the DV type 3 partial E tree (Figure 3.13) are below 
70%, but this is not uncommon for trees based on shorter sequence lengths and would 
be expected given that DVs are known to undergo recombination within DV types.  
This does emphasise the importance of using larger regions of sequence for 
phylogenetic analyses as trees based on shorter sequence lengths are difficult to 
validate statistically.  Ideally, these analyses would be based on complete genome 
sequences, but that was not feasible for the present study; using the complete E gene 
sequences yielded an appropriate level of statistical confidence.    
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Figure 3.13.  Dengue virus type 3 partial (207 nucleotides at the 5’ end) envelope gene phylogenetic 
tree.   
Samples from this study are highlighted with red boxes. The scale represents the evolutionary distance in 
units of the number of base substitutions per site. 
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3.9 Linear and three-dimensional mapping of dengue virus 
quasispecies envelope glycoprotein amino acid substitutions 
All of the amino acid substitutions resulting from nonsynonymous E gene mutations 
(identified by sequence analysis in section 3.6; detailed in Appendices C to E) were 
mapped to the DV E linear and three-dimensional forms to identify those with the 
potential to affect pathogenicity.  This is, to the best of my knowledge, the first report 
where mapping of DV quasispecies mutations to the structure of E has been 
conducted.  A linear map of DV E was constructed using the flavivirus E antigenic 
structure based on TBEV (Figure 3.14, panel A; Mandl et al., 1989) and the crystal 
structures of TBEV and DV (Figure 3.14, panels B and C respectively; Modis et al., 2003; 
Rey et al., 1995).   The consensus protein sequence for each patient sample was 
applied to the crystal structure of the appropriate DV E using DeepView Swiss Pdb-
Viewer (section 2.2.6 Arnold et al., 2006) to construct a three-dimensional rendering of 
the protein, and the locations of the amino acid substitutions were highlighted (Figure 
3.15).  Substituted amino acids located on the surface of E, and therefore potentially 
involved in interactions with other oligomers, antibodies or host cell receptors were 
identified.  Amino acid substitutions that were within 4Å of the other E protein chain 
within the dimer were also highlighted, as these residues could be involved in oligomer 
assembly.  Similarly, substituted residues within 4Å of the putative highly-sulphated 
heparan sulphate (HSHS) binding site thought to be involved in virus-cell interactions 
(Chen et al., 1997; Thullier et al., 2001), or within 4Å of the fusion peptide, were also 
noted (Table 3.15). 
From a linear perspective, the quasispecies mutations cause amino acid substitutions 
that occur throughout DV E, from residue E29 through to E455 (Figure 3.15, panel D).  
Six quasispecies variant clones were identified with amino acid substitutions located in 
structural domain I, fifteen clones with amino acid substitutions in domain II, seven 
clones with amino acid substitutions in domain III and two clones with amino acid 
substitutions in the transmembrane domain.     
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Figure 3.14.  Linear schematic representation of the dengue virus envelope glycoprotein, detailing 
important structural features and the location of Sri Lankan patient sample quasispecies amino 
acid substitutions.  
(A) Antigenic structure of flavivirus E using TBEV as a model (Mandl et al., 1989). Three antigenic 
domains (A, B and C) and two transmembrane domains are shown. Regions conserved amongst most 
flaviviruses are shown in red. Hypervariable regions are shown in green. The location of a proposed T-
cell antigenic determinant is shown in blue. (B) TBEV E structural domains based on crystal structure 
determination (Rey et al., 1995). Three structural domains (I, II and III) are shown, corresponding to the 
previously identified antigenic domains A, C and B respectively (see panel A). A glycosylation site 
common to most flaviviruses is marked with a triangle. A region highly conserved in flaviviruses and 
implicated in membrane fusion is shown in red with black stripes. (C) DV (DenV) type 2 E structural 
domains based on crystal structure determination (Modis et al., 2003). Three structural domains (I, II and 
III) are shown, corresponding largely with those identified for TBEV (panel B). Two glycosylation sites 
are marked with triangles. One is common to most flaviviruses (Asn-153) and the other is specific to DVs 
(Asn-67). The highly conserved fusion peptide is shown in red with black stripes. A proposed DV 
receptor-binding loop not present in tick-borne flaviviruses is shown in yellow. The kl hairpin loop at the 
domain I/II interface (shown in dark blue) has been implicated in oligomer rearrangements during fusion. 
(D) DV (DenV) E showing the locations of the Sri Lankan patient sample amino acid substitutions 
(Appendix E). 
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Figure 3.15.  Three-dimensional structure of the dengue virus envelope glycoprotein detailing the 
locations of the Sri Lankan patient sample quasispecies amino acid substitutions.  
Panel A shows the three amino acid substitutions for the R282A DV type 4 patient sample (Appendix E, 
Table 6). Panel B shows the nine amino acid substitutions for the R097A DV type 3 patient sample 
(Appendix E, Table 1). Panel C shows the two amino acid substitutions for the R107A DV type 2 patient 
sample (Appendix E, Table 2). Panel D shows the four amino acid substitutions for the R203A DV type 3 
patient sample (Appendix E, Table 3). Panel E shows the four amino acid substitutions for the R259A DV 
type 2 patient sample (Appendix E, Table 4). Panel F shows the two amino acid substitutions for the 
R261A DV type 3 patient sample (Appendix E, Table 5). Images were constructed using DeepView 
Swiss PDB-viewer (section 2.2.6).  
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As expected, none of the amino acid substitutions were observed in positions occupied 
by the 12 conserved cysteine residues required for protein structure (Nowak and 
Wengler, 1987), or within the fusion peptide at residues 100-108 (Modis et al., 2003).  
None of the amino acid substitutions were located at the N-glycosylation sites at 
residues Asn-67 or Asn-153 (Mondotte et al., 2007).  However, one of the amino acid 
substitutions (R107A clone 22, position E113) occurs within the highly conserved 
region surrounding the fusion peptide (residues 98-113; Rey et al., 1995), and two of 
the amino acid substitutions (from patient samples R097A and R282A; positions E29 
and E34 respectively) occur within the conserved region at residues 1-42 (Mandl et al., 
1989). Two amino acid substitutions (R097A E452 and R261A E455) map to the 
transmembrane domain at E position E450 to E472, which functions as the membrane 
anchor for E (Allison et al., 1999).  This region is required for the incorporation of E into 
virus particles and stabilisation of interactions between prM and E in immature virus 
particles (Allison et al., 1999).  Three of the R097A amino acid substitutions (E29, E55 
and E77) and one of the R107A amino acid substitutions (E113) occur at computer-
predicted potential post-translational modification sites for protein kinase C 
phosphorylation, casein kinase II phosphorylation, or N-myristoylation; although the 
significance of these modifications is unknown (Amin et al., 2010).  Six E gene clones 
from patient sample R261A carry the same conservative amino acid substitution at 
residue E201 and patient sample R203A has one clone with a conservative amino acid 
substitution at residue E202.  These occur within a region of domain II (E200-215) that 
has been suggested to be hypervariable amongst flaviviruses (Mandl et al., 1989).  
Three-dimensional modelling identified the E201 amino acid substitution as surface 
accessible and the E202 amino acid substitution as within 4Å of the other E protein 
chain that makes up the dimer (Table 3.15).  Therefore, these amino acid substitutions 
may be of importance in oligomer assembly or oligomeric rearrangements during virus 
fusion with cell membranes.  One clone from patient sample R097A contains an amino 
acid substitution (E151) in another hypervariable region of domain I (E145-170; Mandl 
et al., 1989).  This amino acid substitution was also identified as being within 4Å of the 
other E protein chain that makes up the dimer. 
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Three-dimensional mapping of the amino acid substitutions identified seven of these 
(R097A, E77 and E280; R203A, E225 and E345; R261A, E201; R107A, E343; R259A, 
E345) to be situated on the surface of E (surface accessible, defined as 30% or more of 
the residue surface is accessible to solvent; Table 3.15).  These amino acid 
substitutions were from five different patient samples, across DV types 2 and 3, and 
may be involved in interactions with the DV prM or M protein, the other E protein 
chain that makes up the dimer, other E oligomers, antibodies or host cell receptors. 
Mutations leading to amino acid substitutions in the flavivirus E that alter the 
properties of the virus (e.g. virulence) tend to cluster at three sites:  the distal face of 
domain III, the base of domain II, and the domain I/III interface with the domain II 
conserved region at residues 98-113 (section 1.5.1; Rey et al., 1995).  Three-
dimensional mapping showed that several of the amino acid substitutions identified in 
the dengue patient sample quasispecies variants also map to these sites (Table 3.15).   
Mutations leading to amino acid substitutions at the base of domain II, or at the 
domain I/III interface with the domain II conserved region at residues 98-113 are 
thought to affect virulence by impacting upon the conformational rearrangements that 
lead to fusion of virus and host cell membranes (Rey et al., 1995).  Three amino acid 
substitutions from two patient samples (R097A E151 and E246; R107A E343) were 
identified by three-dimensional mapping as within 4Å of the fusion domain. 
One of the clones isolated from patient sample R097A (clone 43) has a mutation 
causing an amino acid substitution at DV E position E280, which is part of the kl hairpin 
loop at the domain I/II interface, which is implicated in conformational 
rearrangements during fusion (Modis et al., 2003).  Amino acid substitutions at DV E 
structural domain interfaces have also been proposed to affect oligomer assembly 
(Duarte dos Santos et al., 2000).  Amino acid substitutions on the distal face of domain 
III can affect virulence or cell tropism, and it has been suggested that this is due to 
interference with cell attachment as domain III is thought to contain the flavivirus 
receptor-binding motif (Crill and Roehrig, 2001).  One of the clones from patient 
sample R203A (clone 21) has a mutation leading to an amino acid substitution at DV E 
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position E306, which is suggested to form part of a binding site (E306-314) for HSHS 
molecules, which are present on the surface of cells targeted by the virus and appear 
to mediate infectivity (Chen et al., 1997; Thullier et al., 2001).  The amino acid 
substitution at E306 therefore has the potential to directly affect virus attachment to 
the host cell.  A clone from patient sample R097A (clone 13) has a mutation leading to 
an amino acid substitution at E position E320, which was determined by three-
dimensional mapping to be within 4Å of the HSHS binding site (Table 3.15).  It is 
possible that disruption of the binding site by this amino acid substitution could either 
enhance or attenuate virulence by altering virus infectivity.  
Table 3.15.  Summary of dengue virus envelope glycoprotein amino acid substitution locations 
identified through linear and three-dimensional modelling.   
 
E gene mutations leading to a shift in the reading frame are denoted with f. 
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3.10 Identification of dengue virus quasispecies envelope genes for 
recombinant protein production 
Quasispecies variants were chosen from the DV E gene clones for recombinant protein 
production based on the data obtained from the mapping of the mutations (Table 
3.15).  The main criteria for selecting clones for recombinant E production were that 
the clones contained nonsynonymous non-frameshift mutations leading to amino acid 
substitutions with the potential to alter the behaviour of the protein (Table 3.16).  
Clones representative of the DV quasispecies E gene consensus sequence for each 
sample were also selected for recombinant E production.  These would be used in 
future studies of E function, as a control for comparison to the quasispecies variant E.   
Table 3.16.  Summary of quasispecies variants chosen for recombinant protein production. 
Sample Clone Mutated E protein residue(s) 
R097A 
4 None.  Represents sample consensus. 
13 E320; drastic mutation; domain III; within 4Å of the HSHS site 
43 E280; drastic mutation; surface accessible at the base of domain II at the interface 
with domain I; within the kl hairpin 
R203A 
2 None.  Represents sample consensus. 
54 E202; conservative mutation; domain II; within 4Å of the other protein chain 
E345; drastic mutation; surface accessible on the distal face of domain III  
R261A 
1 None.  Represents sample consensus. 
4 E201: conservative mutation; domain II; surface accessible 
R107A 
1 None.  Represents sample consensus. 
22 E113; conservative mutation; domain II; within the conserved region surrounding 
the fusion peptide (E98-113) 
 
Clone 4 from DV type 3 sample R097A (R097A_4) represents the consensus E gene 
sequence for the R097A sample set.  Clone 13 (R097A_13) contains a drastic amino 
acid substitution at protein position E320, which was mapped to within 4Å of the 
residues of the putative HSHS binding site thought to be involved in virus-cell 
interactions.  This amino acid change involves the substitution of a nonpolar amino 
acid (isoleucine) with a large hydrophobic side chain, with a polar amino acid 
(threonine) (Appendix E; Table 1).  Isoleucine will usually orient itself to the interior of 
the folded protein and is important for the correct folding of the protein, whereas 
threonine tends to be located on the outer surface of the protein.  It is possible that 
this amino acid substitution could disrupt the HSHS binding site and impact on virus 
infectivity.  Clone 43 (R097A_43) contains a drastic amino acid substitution at position 
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E280, which is situated on the surface of the protein and therefore may be involved in 
antibody or cell binding.  This substituted residue also forms part of the kl hairpin loop 
at the interface between E structural domains I and III, which is implicated in 
conformational rearrangements during fusion (Modis et al., 2003).  Mutations leading 
to amino acid substitutions within the kl hairpin loop are known to cause virus 
attenuation (Lee, Weir, and Dalgarno, 1997; Monath et al., 2002), and amino acid 
substitutions at the domain I/III interface with the domain II fusion peptide on the 
other monomer are known to affect virulence, with some changing the pH required to 
trigger the conformational changes that lead to membrane fusion (Rey et al., 1995).  
Clone 2 from DV type 3 sample R203A (R203A_2) represents the consensus E gene 
sequence for the R203A sample set.  Clone 54 (R203A_54) contains two amino acid 
substitutions at E202 and E345 (Appendix E; Table 3).  The E202 conservatively 
substituted residue is within 4Å of the other protein chain that makes up the E dimer 
and involves the substitution of a basic amino acid (lysine) with a functionally similar 
basic amino acid (arginine).  The difference in side chains may be of importance in 
oligomer assembly or fusion, as this residue has been proposed to map to a putative 
hinge region between domains I and II, which may be important during fusion (Lee, 
Weir, and Dalgarno, 1997).   The substitution of lysine with arginine at E position E202 
has been shown to occur during routine serial passage of flaviviruses in mammalian 
cells, and therefore may represent an adaptation to growth in mammalian cells (Lee, 
Weir, and Dalgarno, 1997).  The E345 drastic amino acid substitution involves the 
substitution of three amino acids and the insertion of two amino acids (histidine-
asparagine-glycine becomes isoleucine-glutamine-isoleucine-serine-serine; Appendix 
E; Table 3).  Incorporating the two extra residues into the protein chain will impact on 
protein structure.  E345 is situated on the surface of the protein at the distal face of 
domain III.  This part of the domain is thought to contain the flavivirus receptor-
binding motif (Crill and Roehrig, 2001) and amino acid subtitutions in this part of the 
domain are known to affect virulence and cell tropism, presumably through 
interference with cell attachment.   
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Clone 1 from DV type 3 sample R261A (R261A_1) represents the consensus E gene 
sequence for the R261A sample set.  Clone 4 (R261A_4) contains a conservative amino 
acid substitution at E position E201 which is situated on the surface of the protein.  
This residue change involves the substitution of a polar amino acid with a long 
hydrophilic side chain (asparagine), with a polar amino acid (serine; Appendix E; Table 
5). 
Clone 1 from DV type 2 sample R107A_1 represents the consensus E gene sequence 
for the R107A sample set.  Clone 22 (R107A_22) contains a conservative amino acid 
substitution at E position E113, which is located in domain II within the conserved 
region (E98-113) surrounding the fusion peptide.  This residue change involves the 
substitution of a nonpolar amino acid with a large hydrophobic side chain (isoleucine), 
with a nonpolar amino acid with a side chain containing a sulphur atom (methionine; 
Appendix E; Table 2). 
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3.11 Discussion 
DV E gene quasispecies variation was determined by RT-PCR, cloning and sequencing 
of the DV E gene population in individual clinical samples as described in previous 
studies (Craig et al., 2003; Lin et al., 2004; Wang et al., 2002a).   
3.11.1   Patient samples used for dengue virus quasispecies envelope gene 
amplification 
Quasispecies populations were studied in clinical samples from dengue patients 
admitted to hospitals in and around Ragama in Sri Lanka, in 2006.  The detailed clinical 
histories linked to these samples enabled disease severity to be classified as mild or 
severe based on WHO guidelines.  These patient samples were limited to clinically-
apparent DV infections from hospitalised patients.  Samples from non-hospitalised 
dengue patients or asymptomatic patients are rarely studied and reported in the 
literature because it requires surveillance of a prospective cohort in the form of 
regular testing for DV. 
3.11.2   Amplification of dengue virus envelope genes by high-fidelity RT-PCR 
A relatively low number (21/95) of DV E genes were amplified from the patient 
samples by high-fidelity RT-PCR despite them having been confirmed previously by 
HPA CEPR and AFRIMS as DV RT-PCR positive.  For each DV type the RT-PCR primers 
were designed using an alignment of sequences from the NCBI database which 
included examples of each genotype (see Appendix A).  It was only possible to test the 
primers against reference strain RNA (section 2.1.3), as RNA from other strains was not 
available.  Every effort was made in silico to ensure that the primer sequences 
matched as many strains as possible, but it is possible that the samples that were not 
amplified contained strains that were not detected by the primers used in this 
experiment due to nucleotide mismatches between the primer and template 
sequences.  The samples had also been freeze-thawed for diagnostic use prior to this 
study, which may have degraded the viral RNA sufficiently to make low concentrations 
of virus undetectable by the RT-PCR used in this experiment.  High-fidelity RT-PCR is 
not used for diagnostic purposes because the stringency of the high-fidelity enzymes 
makes it less sensitive and more time-consuming than diagnostic methods.  The 
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diagnostic RT-PCR used by both HPA CEPR and AFRIMS was nested, with the first round 
of amplification used to amplify a 511bp amplicon from any DV type and the second 
round of amplification used to amplify type-specific amplicons of varying sizes (119-
482bp; Lanciotti et al., 1992).  The relatively large (up to 1.8kb) DV E gene target in this 
study requires more intact RNA for amplification, compared to the smaller amplicons 
in the AFRIMS and HPA CEPR diagnostic nested RT-PCR.  In support of this, HPA CEPR 
detected fewer DV RNA positive samples during diagnostic testing than had been 
detected previously by AFRIMS using the same method.  Real-time RT-PCRs (amplifying 
a 70bp amplicon) were also performed at HPA CEPR on the same samples, and DV RNA 
was detected in more samples using this method than using the nested RT-PCR.  These 
observations are consistent with sample degradation after repeated freeze-thaw 
cycles.    
3.11.3   Cloning of dengue virus quasispecies envelope genes 
To eliminate bias due to the preferential amplification of certain templates in a single 
PCR, DNA used for cloning was obtained from two separate PCR reactions per sample.  
Nine of the twenty-one DV E genes amplified by high-fidelity RT-PCR produced low 
numbers (less than 10) of positive transformants during cloning.  Assessment of 
quasispecies variation required 96 positive transformants per sample, which was not 
achievable from these nine high-fidelity RT-PCR-amplified E genes.  This was attributed 
to the comparatively low yield of amplicon from the high-fidelity RT-PCRs performed 
on these samples (Table 3.4), resulting in a lower concentration of DNA being used for 
cloning.  Quantification of high-fidelity RT-PCR-amplified E genes and standardisation 
of the amount of DNA used for cloning were not feasible due to the large numbers of 
samples being processed.  This problem of low amplicon yield may have been 
overcome with the design of primers for a second round of amplification (a nested 
PCR), but this would potentially have introduced more mutations into the E gene 
amplicons via the PCR method itself, so the results would not be comparable to those 
produced using the non-nested amplification method.  It was decided to continue 
using the 12 samples that were cloned and produced sufficient positive transformants 
to enable assessment of the DV quasispecies E gene variation. 
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Compared to the DV type 2 and 4 samples, the type 3 sample E gene amplicons proved 
more difficult to clone in terms of obtaining enough positive transformants to enable 
the assessment of quasispecies variation.  Some cloning reactions yielded low numbers 
of positive transformants despite the DNA concentration appearing sufficient for 
cloning, and control reactions confirming that the problems were not due to faulty 
ligation, transformation or culture components.  Attempts were made to optimise 
cloning efficiency and increase the number of positive transformants.  Cloning was 
attempted repeatedly using the same sample amplicons with varying results each 
time.  Attempts made to optimise cloning efficiency and increase the number of 
positive transformants were unsuccessful, so between 64 and 96 white colonies were 
able to be picked for each sample.  Each colony was cultured for 24 hours in selective 
medium before plasmid DNA extraction and verification of the presence of the E gene 
inserts.  Over 95% of the colonies picked from the DV types 2 and 4 samples contained 
the E gene insert.  However, for the DV type 3 clones, the number of white colonies 
containing the insert ranged from 2% to 99% (Table 3.5).  Flavivirus cDNA has been 
reported to be unstable in E. coli (Ward and Davidson, 2008) and differences between 
cloning of DV types 1 to 4 structural genes have been observed, with cloning of the 
type 3 genes being more problematic (Chen et al., 1995), which is in accordance with 
the findings of this study.  Plasmid instability can manifest with rearrangement or 
ejection of part or the entire insert, insertion of foreign sequences into the insert, or 
segregational instability (the production of plasmid-free cells when plasmid-containing 
cells replicate).  This could explain the absence of the DV E gene insert in some of the 
white colonies. It is thought that either the flavivirus cDNA itself is toxic to E. coli, or 
that spurious transcription occurring from cryptic bacterial promoters internal to the 
flavivirus structural gene sequences leads to the synthesis of viral proteins toxic to E. 
coli and destabilises the plasmid (Ward and Davidson, 2008; Yamshchikov, Mishin, and 
Cominelli, 2001).  Several putative prokaryotic promoter sequences have been 
demonstrated within the E gene of a DV type 2 strain (Pu et al., 2011).   
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3.11.4   Sequencing of dengue virus quasispecies envelope genes  
To provide enough DV E genes from each sample for quasispecies analysis, it was 
decided to proceed with sequencing the samples that had been successfully cloned 
with more than 50% of white colonies containing inserts (Table 3.5).  Problems were 
experienced when sequencing the clones from samples R114A and R197A, as many of 
the sample reads obtained were of insufficient length, which meant they were either 
too short to incorporate into contigs, or the contigs assembled did not cover the entire 
E gene.  This was due to an equipment failure, and sequencing could not be repeated 
as the fault was unable to be rectified.  These two samples were not included in 
subsequent sequence analyses as the E gene sequence data were incomplete.  
The reason why insufficient positive transformants were obtained from some of the 
DV type 3 patients samples remains unclear.  Direct sequencing of the RT-PCR 
amplicons from the DV type 3 patient samples that did not produce sufficient numbers 
of positive transformants for quasispecies analysis revealed that these samples shared 
a high level of sequence identity (greater than 99%) with the samples that were 
successfully cloned.  The failure to produce enough positive transformants from these 
samples therefore cannot be attributed to major sequence differences between the 
samples.   
Of the 299 dengue patient sample E gene clones successfully sequenced and analysed, 
nine clones contained truncated E gene sequences flanked by vector sequence.  These 
E gene clones were considered artefacts of the cloning process rather than genome 
defective quasispecies variants.  All nine clones containing incomplete E gene 
sequences were from patients with DV type 3 infections and two common points of E 
gene truncation were identified at E gene positions E772-3 and E1128-1132.  The full-
length E gene templates used for cloning were extracted from appropriately sized RT-
PCR amplicons, so it is unlikely that these truncated sequences originate from the 
cDNA insert.  It is likely that the portions of E gene sequence past the truncation point 
were originally present in the transformed E. coli, but were not tolerated by 
subsequent generations and were rejected due to plasmid instability.  A search for 
prokaryote promoter sites in the E gene sequences obtained from the dengue patient 
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samples using the Berkeley Drosophila Genome Project (BDGP) Neural Network 
Promoter Predictor (http://fruitfly.org/seq_tools/promoter.html) revealed several 
putative promoter sequences in the patient sample sequences (Table 3.17).  This 
suggests that spurious transcription occurring from these prokaryote promoter sites 
may induce the synthesis of part of E downstream of the promoter site.  If these 
proteins are not tolerated by the E. coli, for example if they are inherently toxic, the 
plasmid can be destabilised and part of it ejected, resulting in the E gene truncations 
observed.    
  
Chapter 3: Quasispecies analysis 
133 
 
Table 3.17.  Predicted prokaryote promoter sites within dengue virus envelope genes from patient 
samples. 
Dengue 
patient 
sample 
Start End Promoter sequence 
R097A 
R203A 
R004A* 
R114A* 
R232A* 
R255A* 
R299A* 
and 
R334A* 
312 357 TTGTGGTTTGTTTGGCAAAGGAAGCTTGGTAACATGTGCGAAATTTCAAT 
513 558 CATCTTGCCTGAATATGGAACCCTTGGGCTAGAATGCTCACCACGGACAG 
1131 1176 AATTGGAATTGGAGACAACGCCTTGAAAATCAACTGGTACAAGAAGGGGA 
1362 1407 AATTGGAATAGGTGTCCTCTTGACTTGGATAGGGTTGAATTCAAAGAACA 
1420 1465 TCATTTTCATGCATTGCGATAGGAATCATTACACTCTATCTGGGAGCTGT 
R107A 
and 
R259A 
352 397 ATGTTCACATGCAAAAAAAACATGGAAGGGAAAATTGTGCAACCAGAAAA 
413 458 CCATTGTGGTAACACCTCATTCAGGGGAAGAGAATGCAGTTGGAAATGAC 
575 620 ACTTCAATGAGATGGTGTTGCTGCAAATGGAAAATAAGGCTTGGCTGGTG 
917 962 TTAAAGTTGTAAAGGAAATAGCAGAAACACAACATGGAACAATAGTTGTT 
1201 1246 ATGTTCGAGACAACAATGAGAGGAGCGAAGAGAATGGCCATTTTAGGTGA 
R261A 
312 357 TTGTGGTTTGTTTGGCAAAGGAAGCTTGGTAACATGTGCGAAATTTCAAT 
513 558 CATCTTGCCTGAATATGGAACCCTTGGGCTAGAATGCTCACCACGGACAG 
1131 1176 AATTGGAATTGGAGATAACGCCTTGAAAATCAACTGGTACAAGAAGGGGA 
1307 1352 AAATATTTGGAAGTGCCTACACAGCCCTGTTTAGTGGAGTCTCTTGGGTG 
1362 1407 AATTGGAATAGGTGTCCTCTTGACTTGGATAGGATTGAATTCAAAGAACA 
R282A 
841 886 GGACATTTGAAGTGCAAAGTTCGCATGGAGAAATTGAGGATCAAGGGAAT 
1336 1381 ACTATGTTTGGAGGAGTCTCATGGATGGTTAGAATCCTAATCGGGTTCTT 
1359 1404 GATGGTTAGAATCCTAATCGGGTTCTTAGTATTGTGGATTGGCACGAGTT 
 312 357 TTGTGGTTTGTTTGGCAAAGGAAGCTTGGTAACATGTGCGAAATTTCAAT 
R197A* 513 558 CATCTTGCCTGAATATGGAACCCTTGGGCTAGAATGCTCACCACGGACAG 
 1034 1109 ATAGTAATTGGAATTGGAGATAACGCCTTGAAAATCAACTGGTACAA 
Prokaryote promoter sites were predicted from the DV E gene consensus sequence data from the patient 
samples using the Berkeley Drosophila Genome Project (BDGP) Neural Network Promoter Predictor 
(http://fruitfly.org/seq_tools/promoter.html). No prokaryote promoter sites were predicted for sample 
R254A. The transcription start sites are underlined in the promoter sequences. The start and end positions 
of the promoter sequence are shown; numbers refer to the DV E gene sequence for the respective patient 
samples. 
* denotes patient samples that were amplified by high-fidelity RT-PCR but were unable to be sufficiently 
cloned and sequenced to enable quasispecies analysis 
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3.11.5   Analysis of dengue virus envelope gene quasispecies variation 
To compare the DV quasispecies E gene sequences, the clones from each patient 
sample were aligned as both nucleotide and amino acid sequences, and types and 
positions of mutations were detailed.  Analysis of the clone sequences revealed less 
variation within the virus population of individual patients than was expected based on 
published data.  Nucleotide sequences differing from the consensus have been 
reported for more than 70% of the clones analysed (Craig et al., 2003), whilst this 
study found just 16% differed from the consensus.  Average values for the mean 
diversity of viral quasispecies variants of 0.38% (Lin et al., 2004; Wang et al., 2002a) 
and 0.16% (Craig et al., 2003) were previously reported compared to the  current 
findings of  0.018% (21.1- and 8.9-fold lower respectively; Table 3.10).  However, the 
results of this study, both in terms of the number of clones found to contain mutations 
and the average mean diversity values, are consistent with reported error rates for 
viral RNA polymerases during natural replication.  Mutation rates of 1/10,000 
nucleotides (Smith et al., 1997) give a mean diversity value of 0.01%, and for a 1500 
nucleotide E gene, one mutation will be present for every 6.7 clones analysed, 
corresponding to 15% of clones differing from the consensus. 
Further investigations are required to elucidate how viral quasispecies populations 
vary between the infecting DVs or in the infected human populations studied.  
Previous studies have looked at DV quasispecies populations in patients from Thailand 
(Lin et al., 2004; Wang et al., 2002a) and Myanmar, (Craig et al., 2003) who may have 
an entirely different history of exposure to DV types and genotypes than the Sri Lankan 
patient samples utilised for this study.   
Similar methodologies were used for both studies, although this study used high-
fidelity reverse transcriptase and polymerase enzymes in the RT-PCR.  The difference 
between the amounts of variation observed between this and previous studies could 
be due to the fidelity of the enzymes used for RT-PCR.  Previous studies (Lin et al., 
2004; Wang et al., 2002a) used nested PCR after the RT step (using a standard-fidelity 
RT enzyme), with two rounds of amplification for 30 cycles using Taq polymerase.  This 
produced an average mean diversity value that is 21.1 times greater than the results 
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obtained from this study.  The combination of low-fidelity enzymes and increased 
number of PCR amplification cycles could explain the increased variation observed 
compared to the present study.  Another group (Craig et al., 2003) used a blend of Taq 
and high-fidelity Tgo polymerase after the RT step (using a standard-fidelity RT 
enzyme), over 36 cycles of PCR amplification, and reported an average mean diversity 
value that is 8.9 times greater than this study.  A high fidelity RT-PCR kit (AccuScript) 
was used in this study to try and minimise the number of errors introduced to the DV E 
gene during amplification by RT-PCR.  This combination of high-fidelity reverse 
transcriptase and polymerase enzymes has been shown to produce up to an 8-fold 
reduction in mutation rate when compared to a Taq and high-fidelity DNA polymerase 
blend (Arezi and Hogrefe, 2007).  This is consistent with the 8.9-fold difference in 
average mean diversity between the two studies. 
In accordance with all the previous studies (Craig et al., 2003; Lin et al., 2004; Wang et 
al., 2002a) this study found that the extent of sequence diversity within the viral 
quasispecies population varies between patients.  It also concluded that there was no 
statistical difference (p=1.0) between the extent of sequence diversity in the mild 
compared to the severe dengue cases, which concurs with previous findings (Wang et 
al., 2002a). 
Previous reports stated that 5.8% of the clones analysed contained genome-defective 
DV E gene sequence with insertion or deletion mutations, or substitution mutations 
resulting in in-frame stop codons, and these were found at a higher frequency in 
samples from patients with more severe cases of the disease (Wang et al., 2002a).  
These results were based on data obtained from a 430 nucleotide region of the E gene, 
which codes for all of structural domain III and the hinge junction to domain II, 
whereas this study examined the entire E gene.  This study observed that 3.4% of the 
total number of clones analysed contained genome-defective virus gene sequence 
with insertion or deletion mutations (10/299 clones), and all but one of these were 
found in patients with severe disease.  In this study none of the substitution mutations 
in the patient samples resulted in in-frame stop codons.  Long-term and widespread 
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transmission of a genome defective DV type 1 strain containing a stop codon within E 
has been reported (Aaskov et al., 2006).  The likely mechanism of transmission of the 
defective lineage was proposed to be complementation of the defective virus by 
coinfection of cells with functional virus quasispecies variants.  The prevalence of the 
defective lineage increased in quasispecies populations from different patients in 
successive years in the region sampled and was observed in dengue patients 
thousands of miles away from the initial site.  The increased prevalence of the 
defective lineage was associated with a major reduction in the occurrence of DV type 1 
infections, indicating that the persistence of such deleterious mutations in a 
population has adverse effects on virus fitness (Aaskov et al., 2006).   
3.11.6   Measurement of mutations introduced via high-fidelity RT-PCR 
amplification and comparison of methods used in previous studies 
Previous studies estimated error frequencies for mutations introduced by the RT-PCR 
process of 0.023-0.055% (Lin et al., 2004; Wang et al., 2002a).  These were based on 
previously published error rates for reverse transcriptase and Taq polymerase 
enzymes, and 60 cycles of PCR amplification.  In contrast, the patient samples in this 
study were both reverse transcribed and amplified using high-fidelity enzymes, and 36 
cycles of PCR amplification were conducted, so error frequencies for mutations 
introduced by the RT-PCR process would be expected to be lower.  To determine the 
error frequencies for mutations introduced by this RT-PCR method, DV type 3 E gene 
plasmid DNA (from a single colony of known sequence) was transcribed in vitro using 
T7 polymerase.  The resulting transcripts were subjected to high-fidelity RT-PCR, 
cloning and sequencing as described previously.  High-fidelity RT-PCRs were conducted 
using both the AccuScript method applied to the Sri Lankan patient samples in this 
study and the high-fidelity Expand method used in previous publications (Craig et al., 
2003).  The standard fidelity method used by previous groups was not tested as there 
was not enough information in either of the publications (Lin et al., 2004; Wang et al., 
2002a) to identify the RT-PCR reagents used. 
The Expand method generated more mutations than the AccuScript method, with 1.7-
fold higher mean diversity and number of clones containing mutations.   Comparison 
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of insertion and deletion mutation rates between the AccuScript and Expand methods 
using the RNA transcript revealed them to be very similar (AccuScript 0.032%; Expand 
0.035%).  In contrast, Expand method substitution mutation rates were 2.47-fold 
greater than those generated using the AccuScript method.  These data support the 
hypothesis that differences in the amounts of variation observed between this and 
previous studies are due to the fidelity of the enzymes used for RT-PCR.  In light of 
these results, published data on DV quasipecies variation need to be re-examined to 
account more accurately for mutations introduced by the amplification process itself. 
Both methods using the RNA transcript showed a greater number of clones containing 
mutations (AccuScript 33%; Expand 55%) and a higher overall mean diversity 
(AccuScript 0.065%; Expand 0.11%) than was observed with the Sri Lankan patient 
samples (16% of clones analysed contained mutations; overall mean diversity 0.013%).  
The difference between these mutation rates observed using RNA transcript versus 
patient samples indicated that the presence of so many mutations might be attributed 
to the RNA transcript used rather than the high-fidelity RT-PCR, cloning and 
sequencing.   To test this hypothesis, the in vitro transcription reaction was repeated 
using new reagents in the presence and absence of thioredoxin (section 3.11.6).  The 
resulting transcripts were subjected to high-fidelity RT-PCR, cloning and sequencing 
using the AccuScript method applied to the Sri Lankan patient samples in this study.  In 
total, 23 clones were analysed: 12 and 11 clones from RNA transcript produced in the 
presence and absence of thioredoxin respectively.  All of these clones matched the 
consensus sequence as no mutations were identified.  This RNA transcript consensus 
sequence also matched those obtained during the AccuScript versus Expand method 
comparison.  Although no difference was observed between the RNA transcripts 
generated in the presence and absence of thioredoxin, the fact that no mutations were 
found in any of the clones this time indicated that the RNA transcript used for the 
AccuScript and Expand method comparisons was not a homogeneous population of E 
gene transcripts to begin with.  This explains the increased mutation rates observed 
initially using RNA transcript versus patient samples.  The comparison between the 
mutation rates generated by the AccuScript and Expand methods is still valid, despite 
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the heterogeneous RNA transcript population, as they were conducted at the same 
time using the same RNA transcript as template.  Presumably, using new reagents for 
the in vitro transcription reactions performed in the presence and absence of 
thioredoxin enabled the generation of a homogeneous transcript population.  A 
maximum error rate of 0.003% was determined for mutations introduced by the 
AccuScript RT-PCR.  A more accurate determination of the error rate would require 
sequencing of additional clones until a mutation was found.  All of the patient samples 
have mean diversity values greater than 0.003%, which exceeds the calculated 
maximum error rate for mutations introduced by the AccuScript RT-PCR.        
3.11.7   Phylogenetic analyses of dengue virus envelope gene quasispecies 
variation 
Phylogenetic analyses were conducted to investigate the variability of the DVs 
circulating during the Sri Lankan outbreak in 2006.  All four DV types were circulating 
at the time of the outbreak, but the genotypic composition of strains had not been 
identified.  Alignments and phylogenetic trees were constructed for each DV type 
using E gene sequences of known genotype (Lanciotti, Gubler, and Trent, 1997; 
Lanciotti et al., 1994; Messer et al., 2003b; Twiddy et al., 2002) alongside the 
quasispecies consensus and mutant clone sequences identified from the patient 
samples in this study.  Nucleotide sequence identities between DV strains from the Sri 
Lankan patient samples were shown to be over 99% within DV types.  The two DV type 
2 patient sample consensus sequences were identical in protein sequence, whilst the 
three DV type 3 patient sample consensus sequences each differed by one amino acid. 
It has been reported that intra-virus type recombination occurs in DVs and can 
produce viruses with different properties to the parental strains (AbuBakar, Wong, and 
Chan, 2002; Holmes, Worobey, and Rambaut, 1999; Tolou et al., 2001; Uzcategui et al., 
2001; Worobey, Rambaut, and Holmes, 1999).  The presence of multiple DV genotypes 
and recombinant viruses has been reported in individual mosquito and human hosts 
(Aaskov et al., 2007; Craig et al., 2003).  Evidence of recombination would have been 
observed if any of the mutant clones displayed a shift in phylogeny compared to their 
respective consensus sequences.  All of the patient samples for each DV type studied 
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were identified as the same genotype, and all of the mutant clone sequences were 
shown to cluster together with their respective consensus sequences within genotypes 
containing strains of a similar geographical origin to the samples.  There was no 
evidence of the presence of multiple genotypes in the circulating Sri Lankan strains, 
and there was no indication from these E gene data that any of the mutant dengue 
clones result from recombination events between co-infecting genotypes.  Within DV 
types, all of the samples from this study emerge from a common node on the tree, 
suggesting divergence from a common ancestor.  Therefore, Sri Lankan DVs appear to 
be restricted to single genotypes within a DV type, despite the abundance of different 
genotypes that are present on the mainland; recent introduction of strains from 
outside Sri Lanka is not apparrent from the phylogenetic analyses conducted for this 
study.  This limitation in the number of geneotypes per DV type present in Sri Lanka 
may explain why no evidence of recombination was found.  Given the similarity 
between the patient sample E gene sequences, there was no evidence to suggest that 
the severity of disease experienced by the patient was related to the infecting DV 
genotype. 
The first DV type 3 phylogram (Figure 3.12) was constructed using complete E gene 
sequences.  A second phylogram (Figure 3.13) was constructed using a 207 nucleotide 
region at the 5’ end of the gene to incorporate partial Sri Lankan DV sequences 
available from NCBI (Messer et al., 2003a).   No NCBI sequences were found for Sri 
Lankan strains that fell into genotypes I, II or IV, which concurs with previous findings 
(Messer et al., 2003a). As shown previously (Lanciotti et al., 1994; Messer et al., 
2003a), genotype III clusters into two distinct groups: IIIa and IIIb.  Those strains that 
comprise genotype IIIa are all from outbreaks during or prior to 1989, which were not 
associated with DHF epidemics.  Those that form genotype IIIb are all from 1989 or 
later and have been associated with epidemics of severe dengue (Lanciotti et al., 1994; 
Messer et al., 2003a).  It has been suggested that this genetic shift may have increased 
the virulence of the Sri Lankan strains, and be responsible for the increase in cases of 
severe disease seen on the island after 1988 (Lanciotti et al., 1994).  A similar DV type 
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3 genotype IIIb clade replacement has been suggested as the cause of a further 
increase in severe dengue in Sri Lanka since 1999 (Kanakaratne et al., 2009).   
In the first DV type 3 phylogram (Figure 3.12), the genotype I strain Malaysia 1974 
appeared most closely related to the genotype II strain Thailand 1987.  However, in the 
second DV type 3 phylogram (Figure 3.13) the genotype I strain appears between the 
genotype IIIa and b clades.  The Sri Lanka 1989c strain also shifts phylogeny between 
the two phylogenetic trees.  In the complete E gene tree (Figure 3.12) it clusters with 
Sri Lanka 1991 in genotype IIIb, whereas in the partial E gene tree (Figure 3.13) it 
appears more closely related to Sri Lanka 1984 in genotype IIIa.  A shift in phylogeny 
when different regions of a sequence are used for the analysis is indicative of 
recombination.  A recombination event may have occurred between a genotype IIIa 
strain and a genotype I strain to produce genotype IIIb strains with increased virulence 
compared to IIIa.  The Sri Lanka 1989c strain may represent an early example of this 
recombination as it shifts phylogeny between the genotype IIIa and b strains when 
different regions of the E gene are used for the analysis.  There is no evidence of 
genotype I strains in Sri Lanka so this recombinant must have been imported.   The 
bootstrap values are far from conclusive for the partial E gene phylogenetic tree, but 
further evidence to support this hypothesis could be obtained by comparison of the 
complete genome sequences from strains pre- and post-1989 in order to try and 
identify differences that could have resulted in this increase in virulence.  In addition, 
computational analyses could be performed in order to try and identify recombination 
break points within the post-1989 sequences.  This work is not possible at the present 
time due to a lack of available virus strains from before 1989. 
3.11.8   Linear and three-dimensional mapping of dengue virus quasispecies 
envelope glycoprotein amino acid substitutions 
The amino acid residue substitutions resulting from the nonsynonymous mutations in 
the patient samples were shown to be distributed throughout the DV E by mapping the 
substitutions to the linear protein sequence.  Six clones were identified with amino 
acid substitutions that map to structural domain I; fifteen clones with substitutions 
that map to domain II; seven clones with substitutions that map to domain III, and two 
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clones with substitutions that map to the transmembrane domain.  As expected, none 
of the residue substitutions were in positions occupied by the 12 conserved cysteine 
residues required for protein structure (Nowak and Wengler, 1987), or within the 
fusion peptide at residues E100-108 (Modis et al., 2003).  Mapping of the amino acid 
substitutions also confirmed that they did not occur at or proximal to the N-
glycosylation sites at amino acids Asn-67 or Asn-153 (Mondotte et al., 2007).   
Amino acid substitutions with the potential to affect virulence or cell tropism were 
identified on the basis of their proximity to important structural features within the 
three-dimensional structure of DV E.  Virulence or cell tropism can be affected through 
modulation of oligomer or virion assembly, cell attachment, fusion of virus and cell 
membranes, or antibody recognition.   
Two of the substituted residues (E306 and E320) were shown to be located on domain 
III, at or within 4Å of the binding site for HSHS molecules on the target cell surface 
which mediate infectivity (Chen et al., 1997; Thullier et al., 2001).  Neutralisation 
escape mutations in multiple flaviviruses map to this HSHS binding site (Jiang et al., 
1993; Lin et al., 1994), so whilst these substituted residues are not surface accessible 
they could potentially alter the protein structure enough to disrupt the HSHS-binding 
site and either enhance or attenuate virulence by altering virus infectivity.  Four of the 
substituted residues (E49, E55, E135 and E280) were located at the base of domain II 
at the interface with domain I, with one of these residues (E280) shown to be surface 
accessible and within the kl hairpin loop implicated in conformational rearrangements 
during fusion (Modis et al., 2003).  Attenuated viruses with single amino acid 
substitutions in the kl hairpin loop have been obtained by flavivirus passage in cell 
culture (Lee, Weir, and Dalgarno, 1997; Monath et al., 2002), and neutralising antibody 
epitopes have also been mapped to this region (Beasley and Aaskov, 2001).  A further 
three substituted residues (E151, E246, and E343) were located within 4Å of the fusion 
domain, with one of these located to domain I at the interface of domain III and the 
domain II conserved region on the other monomer at residues 98-113, which houses 
the fusion peptide (Modis et al., 2003; Rey et al., 1995).  One additional substituted 
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residue (E113) was found to be within this conserved region at residues 98-113.  
Mutations leading to amino acid substitutions at the base of domain II or at the 
domain I/III interface with the domain II conserved region at residues 98-113 are 
thought to affect virulence by impacting upon the conformational rearrangements that 
lead to fusion of virus and host cell membranes (Rey et al., 1995).  Some of these 
mutations have been shown to affect fusion by altering the pH required to induce the 
conformational changes (Mandl et al., 1989; Modis et al., 2003; Rey et al., 1995).  Most 
of these mutations involve residues with side-chains that project into the ligand-
binding pockets between the dimers and it has been reported that lowering of the pH 
threshold for fusion is due  to the substitution of longer hydrophobic side chains for 
shorter ones (Modis et al., 2003).   
Seven of the amino acid substitutions (at positions E77, E201, E225 E280, E343 and 
two at E345) from five different patient samples were situated on the surface of the 
protein and therefore may be involved in antibody or cell binding.  Amino acid 
substitutions in flavivirus E that affect the binding of neutralising mAbs have been 
shown to map to the surface of the dimer across all three structural domains (Rey et 
al., 1995).  Of these surface accessible residues, four (E331, E343 and two at E345) 
were on the distal face of domain III, which is reported to contain the flavivirus 
receptor-binding motif (Crill and Roehrig, 2001). The region between E residues E335 
and E351 has been reported to contain an epitope for the binding of neutralising 
antibodies for DV type 2 (Roehrig, Bolin, and Kelly, 1998), so the amino acid 
substitutions at E343 and E345 found in this study could affect virus neutralisation by 
antibodies.  Substitutions at the distal face of domain III have been shown to affect 
virulence or cell tropism via interference with cell attachment (Rey et al., 1995) and 
could also affect virus neutralisation by antibodies.   
In the DV type 3 sample from a patient with mild disease (R261A), three distinct 
lineages of DV were observed within the quasispecies population.  The consensus 
sequence was represented by 72% of clones, 13% of clones carried the same 
nonsynonymous mutation causing a conservative amino acid substitution at E position 
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E201, and 6.5% of clones carried the same synonymous mutation at E gene position 
E1146.  There were also 4 clones (8.5%) shown to contain unique mutations.  The 
relative abundance of the two lineages that differ from the consensus sequence within 
the quasispecies population suggests that either they were derived from virus with the 
consensus sequence, but replicate more efficiently than other variants within the 
population, or they were present in the DV quasispecies population in the mosquito 
along with the consensus sequence and were introduced together when the patient 
was bitten.   Mutations leading to amino acid substitutions at E position E202 
commonly occur during routine serial passage in mammalian cells and have been 
proposed to map to a putative hinge region between domains I and II, which may be 
important during fusion (Lee, Weir, and Dalgarno, 1997).  Taken together with the 
results of this study this suggests that the amino acid substitutions observed at E201 
may represent a beneficial adaptation of the virus to growth in mammalian cells, via a 
mechanism related to membrane fusion.  Quasispecies investigations with poliovirus 
have demonstrated a link between the extent of sequence diversity and pathogenicity; 
too many or too few virus variants within the population results in reduced viral fitness 
and attenuation (Crotty, Cameron, and Andino, 2001; Vignuzzi et al., 2006).  Whilst the 
mean diversity of the R261A sample is comparable to those of the other DV type 3 
samples, the presence of so many clones containing the same mutations means that 
this sample actually exhibits less quasispecies variation than samples where each of 
the variant clones contains different mutations.  This restricted quasispecies 
population could explain why patient R261A exhibited mild disease.   
Amino acid substitutions located at regions involved in cell attachment, membrane 
fusion or antibody recognition were scarce in the samples from patients exhibiting 
mild disease.  In the DV type 4 sample from a patient with mild disease (R282A), none 
of the mutations were surface accessible, or mapped to predicted virulence 
determinants.  With the DV type 3 sample from a patient with mild disease (R261A), 
the only mutation that was located in a region of potential importance for virulence 
was surface accessible, but resulted in a conservative rather than drastic amino acid 
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substitution in E.  This is consistent with a role for individual quasispecies variants in 
the pathogenesis of disease, but is by no means conclusive. 
Because the outer surfaces of mature flavivirus virions are covered with a dense 
network of E dimers, any conformational changes in E are likely to induce concerted 
reorganisation across the surface of the virion (Crill and Chang, 2004; Kuhn et al., 2002; 
Modis et al., 2003).   Three-dimensional mapping was limited in that the proximity of 
substituted residues to important sites was only established for pre-fusion E.  More 
amino acid substitutions with the potential to affect virulence or cell tropism may have 
been identified by three-dimensional mapping using post-fusion crystal structures.   
3.11.9   Identification of dengue virus quasispecies envelope genes for 
recombinant protein production 
Nine of the patient sample DV E gene clones were chosen for recombinant E 
production (Chapter 4) in preparation for binding studies to determine the effects of 
the mutations (Chapter 5).  These clones were from four different patient samples, 
three with severe and one with a mild case of disease, across DV types 2 and 3.  For 
each patient sample, a clone was identified that represents the consensus sequence 
for the quasispecies population for that patient.  These consensus clones would also be 
used to produce recombinant E as a comparison alongside clone variants with 
nonsynonymous, non-frameshift mutations in regions identified as determinants of DV 
pathogenicity. 
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3.12 Conclusions and summary 
The primary objective of the work presented in this chapter was to investigate DV 
quasispecies populations, both within individual patient samples and between samples 
from the same outbreak in Sri Lanka, in 2006.  Previous studies of DV quasispecies 
populations used RT-PCR, ligation independent cloning, and sequencing of partial or 
complete DV E genes obtained directly from patient serum or mosquitoes; examining 
between 10 and 21 clones per sample and reporting average mean diversities of 
between 0.16% and 0.38% (Craig et al., 2003; Lin et al., 2004; Wang et al., 2002a).  The 
work presented in this chapter differed from previously published work in that it was 
intended that more dengue patient samples, and a greater number of complete E gene 
clones per sample would be analysed than in previous studies, to provide more data 
for statistical analysis.  The use of high-fidelity reverse transcriptase and PCR enzymes 
was deemed essential to minimise the number of mutations introduced by the 
amplification process itself.  Potential relationships between quasispecies variation 
and disease severity were also investigated.  
From the 95 dengue patient samples where DV E gene amplification, cloning and 
quasispecies analysis was attempted, only six produced enough clones to permit 
quasispecies analysis.  Therefore the aim of this study to examine more patient 
samples than previous studies was not fulfilled.  This was due primarily to difficulties 
with RNA integrity, and plasmid instability during cloning.  However, from these six 
patient samples, 299 clones were analysed (range 25 to 82 clones per sample), so the 
intention to study a greater number of complete E gene clones per sample than 
previous studies was successful.  Across the six samples, an average mean diversity of 
0.018% (range 0.0034% to 0.053%) was obtained, and no statistically significant 
difference was observed between the extent of quasispecies variation and disease 
severity.  This is less variation than was expected based on previously reported average 
mean diversities of between 0.16% and 0.38% (Craig et al., 2003; Lin et al., 2004; Wang 
et al., 2002a).  However, the results presented in this chapter are more consistent with 
reported error rates for viral RNA polymerases during natural replication (0.01%, Smith 
et al., 1997).  The differences in the amounts of sequence variation between this study 
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and previous studies, were shown to be directly related to the fidelity of the enzymes 
used by each group for RT-PCR amplification of the viral RNA.  This emphasises the 
importance of using high-fidelity enzymes for quasispecies analysis.  In light of these 
results, previously reported levels of variation in DV quasispecies populations need to 
be re-examined to account more accurately for mutations introduced by the 
amplification process itself. 
Phylogenetic analyses were conducted to investigate the variability of the DVs 
circulating during the Sri Lankan outbreak in 2006.  Within each DV type studied, all of 
the DV strains from the Sri Lankan patient samples were identified as the same 
genotype, appropriate to their geographic origin, and with nucleotide sequence 
identities of greater than 99%.  There was no evidence of the presence of multiple 
genotypes in the circulating Sri Lankan strains, and there was no indication from these 
E gene data that any of the mutant dengue clones resulted from recombination of co-
infecting genotypes.  Therefore, no relationship was observed between the infecting 
DV genotype and disease severity. 
Nine of the ten clones observed to contain genome-defective DV E gene sequences 
(with insertion or deletion mutations; 10/299 clones) were found in patients with 
severe disease.  Linear and three-dimensional mapping of the amino acid substitutions 
within the DV quasispecies populations identified residues in locations with the 
potential to affect virulence or pathogenicity.  These were more prevalent in the 
samples from patients with severe disease.  These observations are consistent with a 
role for individual quasispecies variants in the pathogenesis of disease. 
Nine clones from four patient samples were chosen for recombinant E production on 
the basis that they contain a mutation with the potential to alter the behaviour of the 
protein, or represent the consensus sequence for that sample for comparison.  
Studying the effect of these mutations on protein function will provide further insight 
into potential links between quasispecies variation and disease severity. 
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CHAPTER 4. PRODUCTION AND 
PURIFICATION OF RECOMBINANT DENGUE 
VIRUS ENVELOPE GLYCOPROTEINS  
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4.1 Introduction 
Recombinant flavivirus envelope glycoproteins (E) have been transiently produced 
using various expression systems.  Bacterial, yeast, insect and mammalian cells have 
been employed as hosts for recombinant protein production from flavivirus E genes 
delivered by plasmid or viral vectors (Allison et al., 1995; AnandaRao et al., 2006; 
Bielefeldt-Ohmann et al., 1997; Bray et al., 1989; Chang et al., 2003; Delenda et al., 
1994; Liu et al., 2010).  Stable expression of flavivirus E genes using transformed cell 
lines has also been demonstrated, but production of mature, secreted protein is 
complicated in mammalian cells by the inherent toxicity of flavivirus E (Konishi and 
Fujii, 2002).  Similar problems have been reported with flavivirus protein production 
using genome-length infectious clones (Pu et al., 2011; Yamshchikov, Mishin, and 
Cominelli, 2001) which require the same level of biocontainment as live virus 
(Containment Level 3). 
It has been demonstrated that the production of secreted recombinant flavivirus E 
with the correct structural conformation requires either co-expression of the pre-
membrane glycoprotein (prM), or truncation of the E gene to remove the C-terminal 
membrane anchor (Allison et al., 1995).  This allows the protein complex to be 
trafficked through the acidic environment of the endoplasmic reticulum and secreted.  
Co-expression of flavivirus E with prM has been shown to produce a higher yield of 
secreted protein than C-terminal truncation of E (Allison et al., 1995), and results in the 
production of spherical virus-like particles (VLPs; Mason et al., 1991; Schalich et al., 
1996).  These VLPs are approximately 30nm in diameter, and are comparable to virions 
in terms of their antigenic and oligomeric structures, and their ability to undergo 
structural rearrangements at acidic pH (Schalich et al., 1996).  Recombinant VLPs or E 
secreted into cell culture medium are easier to purify and represent a more 
homogenous population than intracellularly, where proteins are at different stages of 
processing and maturation.  Secreted VLPs have an additional advantage over secreted 
E alone, as they are more resistant to proteolytic degradation (Sugrue et al., 1997). 
During natural flavivirus infections, in addition to infectious virions, non-infectious viral 
particles are produced.  These contain flavivirus membrane protein (M) and E but lack 
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the nucleocapsid (Russell, Brandt, and Dalrymple, 1980), and are therefore essentially 
the same as recombinant VLPs.   
The use of eukaryotic expression systems enables the appropriate post-translational 
modifications (such as disulphide bond formation, N-linked glycosylation and furin 
cleavage) for the production of secreted flavivirus E.  The level of post-translational 
modification achieved using insect or mammalian cells as hosts is more complex than 
can be achieved using yeast cells.  However, there are significant differences in the 
post-translational processing of glycoproteins by insects and higher eukaryotes, in 
particular with regards to N-linked glycosylation (reviewed in Jarvis, 2003).  In light of 
the fact that flaviviruses are able to infect and replicate naturally in both human and 
mosquito cells, using an insect or mammalian expression system provides the best 
chance of producing functional flavivirus E with the correct post-translational 
modifications.   
The baculovirus expression system produces increased protein yields and is less 
expensive compared to protein production using a mammalian system.  Flavivirus E 
produced using a baculovirus expression system have been shown to be antigenically 
indistinguishable from those produced by the flavivirus itself (Shiu et al., 1991), and 
are immunogenic in mice (Delenda et al. 1994; Despres et al. 1991; Yang et al. 2005).  
For these reasons, it was decided to use the baculovirus expression system for the 
work described in this chapter. 
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4.2 Chapter objectives 
The primary objectives of this chapter were to produce and purify recombinant 
dengue virus (DV) E, using the DV quasispecies E gene clones identified in Chapter 3.   
The recombinant DV quasispecies E would be produced as secreted VLPs to enable 
accurate antigenic presentation of E.  The VLPs produced would be used in cell surface 
receptor binding studies to determine the effect of the quasispecies mutations on 
protein function, and as a source of antigen in the serodiagnosis of DV infection 
(Chapter 5).  The dengue VLPs would also provide a model for studying the effects of 
the quasispecies E gene mutations on the low pH-induced oligomeric rearrangements 
required for fusion of virus and host cell membranes.  To the best of my knowledge 
this is the first report of recombinant flavivirus E or VLP production from quasispecies 
variants. 
DV quasispecies E gene clones identified in the previous chapter (section 3.10; Table 
3.16) would be amplified by high-fidelity PCR, before cloning with the DV type 1 prM 
gene into the baculovirus transfer vector, pBAC-2cp.  These modified transfer vectors 
would be used to construct recombinant baculoviruses (rBVs) containing the DV prM 
and E genes, which would enable secreted recombinant dengue VLP production upon 
infection of insect cells.  The recombinant dengue VLPs would be purified using His-
tags inserted at the C-terminal of E. 
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4.3 Cloning of dengue virus pre-membrane and quasispecies envelope 
genes into the baculovirus transfer vector, pBAC-2cp 
To produce recombinant proteins using the baculovirus expression system, the genes 
encoding the proteins of interest needed to be amplified and cloned into a transfer 
vector suitable for the production of rBVs.  pBAC-2cp is a 5411bp commercially-
available baculovirus transfer vector (Novagen; Figure 4.1).  This transfer vector 
contains the baculovirus polyhedrin (polh) promoter region and an ATG start codon 
upstream of the MCS, which is flanked by N-terminal His- and S-tag, and C-terminal 
His-tag coding sequences.  Cloning of the DV prM and quasispecies E genes into the 
MCS, and subsequent co-transfection of these plasmids with baculovirus DNA into 
insect cells, was expected to result in the production of rBVs which could then be used 
to produce secreted recombinant dengue VLPs.  The N-terminal His- and S-tags were 
predicted to be detached when prM was cleaved to produce M.  E were expected to 
retain the C-terminal His-tags to aid detection and purification.   
To ensure that any differences in function between the DV quasispecies VLPs could be 
attributed to variations in E, the source of the prM gene was kept consistent for all of 
the DV quasispecies E genes.  DV type 1 (Hawaii strain) prM gene was chosen for co-
expression with all of the DV quasispecies E genes.  PrM and E gene primers (Table 4.1) 
were designed (sections 2.2.2 and 2.2.3) to amplify only the gene of interest and not 
the flanking regions.  Unique endonuclease restriction sites were incorporated six 
bases from the ends of the primers to enable directional ligation-dependent cloning of 
the two genes into pBAC-2cp (Figure 4.2), mimicking the order they are presented in 
the flavivirus genome.  The DV type 1 prM gene forward primer contains a NheI 
restriction enzyme sequence for ligation into the pBAC-2cp MCS.  The reverse primer 
incorporates an EagI restriction enzyme sequence to enable ligation with the EagI 
restriction enzyme sequences within the E gene forward primers, ensuring the E gene 
is inserted downstream of the prM gene.  E gene reverse primers contain XmaI 
restriction enzyme sequences to ligate into the pBAC-2cp MCS downstream of the 
NheI site.  Restriction sites were chosen on the basis that they produced overhanging 
rather than blunt ends, and were unique in pBAC-2cp, but absent in the DV prM and E 
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gene sequences.  Due to the presence of the EagI restriction site, the codons for two 
amino acids (arginine and proline) were inserted between the prM and E genes.   
 
Figure 4.1.  pBAC-2cp baculovirus transfer vector circle map and MCS nucleotide sequence 
Unique restriction sites and sequence landmarks are indicated on the circle map with nucleotide sequence 
positions in brackets). The baculovirus polyhedrin (polh) promoter region (1177-1259) contains the polh 
transcription start (1210-1211) and wild type polh 5’UTR -1 position (1259).  His-tag (1271-1289 and 
1461-1478) and S-Tag (1320-1364) coding sequences are positioned flanking the MCS (SmaI to XhoI, 
1397-1460).  Diagram is from product insert (Novagen). 
 
Using the appropriate primers (Table 4.1), the DV type 1 prM gene was amplified from 
DV type 1 Hawaii strain RNA (section 2.1.3) by high-fidelity RT-PCR (section 2.3.1.2), 
and the DV quasispecies E genes were amplified from plasmid DNA (section 3.5) using 
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only the PCR step of the high-fidelity RT-PCR.  DNA from PCR amplicons of the correct 
size was gel extracted (section 2.3.3.1) before sequential restriction digestion with the 
appropriate restriction enzymes (NheI and EagI for the prM gene; EagI and XmaI for 
the E genes), DNA purification, and ligation into pBAC-2cp, which had undergone a 
double digest with NheI and XmaI (sections 2.3.8, 2.3.3.2 and 2.3.6.1). 
After transformation of each pBAC-2cp ligation reaction into JM109 cells and overnight 
culture on selective agar plates (section 2.3.5.3), standard PCR (section 2.3.1.4) was 
performed on the resulting colonies using the pBAC-2cp polh forward primer (Figure 
4.1) and the appropriate DV quasispecies E gene reverse primer for each patient 
sample (Table 4.1).  DNA agarose gel electrophoresis (section 2.5.1) of the PCR 
amplicons (Figure 4.3) showed an amplicon size of 2kb, confirming that the colonies 
contained the pBAC-2cp transfer vector with the prM (0.5kb) and E (1.5kb) genes in 
the correct order and orientation. 
 
Table 4.1.  Primers used for the amplification of the dengue virus type 1 pre-membrane and dengue 
virus quasispecies envelope genes for generation of rBVs.   
Primer Sequence (5’ to 3’) Product size (bp) 
DV type 1 prM NheI F CAC AGC GCT AGC TTC CAT CTG ACC AC 
528 
DV type 1 M EagI R CAC GCA CGG CCG GGC CAT GGA TG 
R097A E EagI F CGG GAA CGG CCG ATG AGA TGT GTG 
1500 
R097A E XmaI R TTC ACT CCC GGG ATA GCT TGT ACC ACA GC 
R203A/R261A E EagI F CCA TCC CGG CCG ATG AGA TGT GTG GGA G 
1503 
R203A/R261A E XmaI R  ACA CCC CCC GGG AGC TTG TAC CAC AGC 
R107A/R259A E EagI F CCT TCA CGG CCG ATG CGT TGT ATT GG 
1509 
R107A/R259A E XmaI R ACA ACC CCC GGG AGC CTG CAC CAT AAC 
R282A E EagI F CCA TCC CGG CCG ATG CGA TGC GTA G 
1509 
R282A E XmaI R ACA ACC CCC GGG TGC ATG AAC TGT G 
E gene primer sequences were derived from the quasispecies E gene sequencing data (section 3.6, 
Appendix C). DV type 1 prM gene primer sequences were derived from the DV type 1 RefSeq (NCBI; 
section 2.2.1). Primers are labelled according to the gene template source and whether they target prM or 
E genes.  Restriction sites within the primer sequence are highlighted and PCR amplicon product size is 
shown in nucleotide base pairs (bp).  Primers were also used for confirmatory PCRs and sequencing. 
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Figure 4.2.  Schematic representation of the rBV transfer vector pBAC-2cp containing dengue 
virus type 1 pre-membrane and dengue patient sample quasispecies envelope genes. 
Prior to ligation, pBAC-2cp (yellow) was digested with NheI and XmaI, the DV type 1 prM gene (red) 
with NheI and EagI, and the DV quasispecies E genes (blue) with EagI and XmaI.  Digest product sizes 
are shown in nucleotide base pairs (bp) in brackets.  
 
 
Figure 4.3.  Analysis of colonies by PCR for confirmation of the presence of the dengue virus type 1 
pre-membrane and patient sample quasispecies envelope gene inserts in pBAC-2cp 
PCR was performed using the polh forward primer (Figure 4.1) and the appropriate DV E gene reverse 
primer for each dengue patient sample (Table 4.1). Lanes are labelled according to the patient sample 
clone used to source the E gene (section 3.10). A 1kb DNA ladder is shown for comparison, with the 1.5 
and 2.0kb fragments highlighted. PCR amplicons of 2kb are consistent with the size of the prM (0.5kb) 
and E (1.5kb) genes. No amplicons were detected for any of the no template control (NTC) reactions.   
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Colonies with the correct insert underwent further culture and plasmid DNA extraction 
(sections 2.3.6.2 and 2.3.4.1 respectively).  To confirm the DV type 1 prM gene 
sequence, and the presence or absence of the respective quasispecies E gene 
mutations, the plasmid DNA was sequenced (section 2.4) using the Polh and 1629DWN 
primers (Figure 4.1), and primers internal to the E gene sequences (Table 3.6).  The 
sequence of the prM-E reading frame was verified to confirm that the genes were in-
frame with the pBAC-2cp start codon and His- and S-tags (data not shown).  Culture of 
the sequence verified clones  was then scaled-up (section 2.3.6.2) and plasmid DNA 
purified (section 2.3.4.2) for subsequent rBV production. 
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4.4 Production of recombinant baculoviruses containing dengue virus 
pre-membrane and envelope genes 
To maximise the yield of secreted dengue VLPs, FlashBAC GOLD™ (Oxford Expression 
Technologies, OET) was chosen as the source of parental baculovirus DNA for 
transfection.  FlashBAC GOLD™ is modified AcMNPV DNA lacking the polyhedrin gene, 
part of open reading frame (ORF) 1629 (which renders it non-infectious), and the non-
essential auxiliary genes chiA and v-cath, which would otherwise compete with the 
recombinant protein for cellular resources during gene expression.  Removal of the 
auxiliary genes improves the efficiency of the secretory pathway leading to a greater 
yield of secreted or membrane-targeted recombinant proteins (Hitchman et al., 2010).   
The transfer vectors containing the DV prM and E genes were co-transfected with 
FlashBAC GOLD™ baculovirus DNA into Sf9 cells to generate rBV (section 2.7.2).  A 
baculovirus transfer vector containing the lacZ gene was used as a positive control for 
the transfection reactions, as a β-galactosidase assay (section 2.7.3) could then be 
performed to determine the transfection reagents were working correctly.  The lacZ 
rBV-infected culture produces β-galactosidase (116 kDa for each of the four subunits) 
intracellularly under the control of the baculovirus polyhedrin promoter.  When 5-
bromo-4-chloro-3-indolyl- beta-D-galactopyranoside (X-gal) is added to the culture it is 
cleaved by β-galactosidase into galactose and 5-bromo-4-chloro-3-hydroxyindole, 
which is then oxidized to 5,5'-dibromo-4,4'-dichloro-indigo, an insoluble blue product.  
Recombinant baculoviruses were designated rBV.xxxxx according to either the patient 
sample clone yielding the quasispecies E gene, or the inserted gene in the case of the 
LacZ rBV (Table 4.2). 
Each dengue rBV underwent two successive amplifications (passages 1 and 2; P1 and 
P2) and was titred (sections 2.7.4.1 and 2.7.4.3).  Titration of rBVs was performed by 
end-point dilution using Sf9 Easy-Titre (E-T) cells (kindly provided by Dr. Ralph Hopkins, 
National Cancer Institute at Frederick, Maryland, USA; Hopkins and Esposito, 2009).  
This cell line consists of Sf9 cells stably transfected with the enhanced green 
fluorescent protein (eGFP) gene under the control of the baculovirus polyhedrin pro-
moter. Fluorescence can be detected from rBV-infected Sf9 E-T cells due to the 
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activation of the polyhedrin promoter/eGFP complex by baculovirus early gene 
products expressed during the infection.  To verify that the cells express eGFP when 
infected with rBV, the Sf9 E-T cells were infected with rBV.lacZ.  After a three day 
incubation at 27°C in the dark, cells were visualised using a fluorescent microscope and 
green cell foci were observed (Figure 4.4).  Confirmation of β-galactosidase production 
(and therefore rBV infection) was obtained by β-galactosidase assay (section 2.7.3).  
End-point dilution titrations were carried out according to the method detailed in 
section 2.7.4.2.  The results are shown in Table 4.3. 
Table 4.2.  rBVs generated for this study 
Inserted genes Recombinant baculovirus 
prM and R097A_4 E rBV.R097A_4 
prM and R097A_13 E rBV.R097A_13 
prM and R097A_43 E rBV.R097A_43 
prM and R203A_2 E rBV.R203A_2 
prM and R203A_54 E rBV.R203A_54 
prM and R261A_1 E rBV.R261A_1 
prM and R261A_4 E rBV.R261A_4 
prM and R107A_1 E rBV.R107A_1 
prM and R107A_22 E rBV.R107A_22 
lacZ rBV.lacZ 
 
 
Figure 4.4. Sf9 Easy-Titre cells express eGFP when infected with rBV 
Sf9 Easy-Titre cells infected by rBV.lacZ are shown under white light (panel A) and blue light 
(wavelength 488nm; panel B) using a fluorescent microscope. Green (wavelength 509nm) cell foci (panel 
B) are indicative of replication-competent rBV-infection.  
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Table 4.3.  Dengue rBV titres 
Recombinant baculovirus TCID
50
 (10
exp
) TCID
50
 pfu/mL 
rBV.R097A_4 8.8 6.81x10
8
 4.77x10
9
 
rBV.R097A_13 8.33 2.13x108 1.49x109 
rBV.R097A_43 7.6 3.99x107 2.79x108 
rBV.R203A_2 10.1 1.26x1010 8.81x1010 
rBV.R203A_54 8.71 5.12x108 3.59x109 
rBV.R261A_1 8.61 4.11x108 2.88x109 
rBV.R261A_4 7.34 2.17x107 1.52x108 
rBV.R107A_1 7.5 3.16x107 2.21x108 
rBV.R107A_22 10.12 1.32x1010 9.23x1010 
 
The presence of the DV prM and E genes in the rBVs was confirmed by PCR of DNA 
extracted from culture medium from insect cells infected with P2 amplified rBVs 
(Figure 4.5).  After DNA extraction (section 2.3.3.3), standard PCR (section 2.3.1.4) was 
performed using the polh forward primer (Figure 4.1) and the appropriate DV E gene 
reverse primer for each patient sample (Table 4.1).  DNA agarose gel electrophoresis 
(section 2.5.1) of the PCR amplicons (Figure 4.5) showed an amplicon size of 2kb, 
confirming that the rBVs contained the prM (0.5kb) and appropriate E (1.5kb) genes in 
the correct order and orientation. 
 
Figure 4.5.  Analysis of dengue rBVs by PCR to confirm the presence of dengue virus type 1 pre-
membrane and patient sample quasispecies envelope genes 
PCR was performed on P2 rBV-infected insect cell culture medium using the polh forward primer (Figure 
4.1) and the appropriate DV E gene reverse primer for each dengue patient sample (Table 4.1). Lanes are 
labelled according to the patient sample clone used to source the E gene (section 3.10). A 1kb DNA 
ladder is shown for comparison, with the 1.5 and 2.0kb fragments highlighted. PCR amplicons of 2kb are 
consistent with the size of the DV prM (0.5kb) and E (1.5kb) genes. No PCR products were detected for 
any of the no template control (NTC) reactions. The original (unprocessed) gel images used to construct 
this figure are included electronically in Appendix J. 
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4.5 Optimisation of dengue virus-like particle production 
Secreted DV E (C-terminally truncated) have been successfully produced using the 
baculovirus expression system with rBVs infecting Sf21 cells at a multiplicity of 
infection (MOI) greater than five, and proteins harvested from the culture supernatant 
at 48 hours post infection (Bielefeldt-Ohmann et al., 1997).  For this study, 
optimisation experiments were conducted to determine the optimal cell line, 
multiplicity of infection (MOI) and post infection interval before harvesting the dengue 
proteins as secreted VLPs (section 2.7.5).  Infections were set up using rBV.R097A_4 at 
three MOIs (2, 5 and 10) in both Sf9 and Sf21 cells.  Samples were taken at 48 and 72 
hours post infection and both the lysed cell pellet and clarified cell culture medium 
were analysed via SDS-PAGE for the presence of the DV 54 kDa E (section 2.5.3.1; 
Figure 4.6).  Proteins of approximately 64 kDa and 54 kDa were visible in the infected 
clarified cell culture medium samples, but not visible in the mock-infected control 
samples.  The 64 kDa protein was present at higher concentration than the 54 kDa 
protein (as judged by visual analysis of stained SDS-PAGE gels), and represented a 
secreted baculovirus or insect cell protein, as comparison of these results to similar in-
house experiments using rBVs containing genes for non-DV proteins (Ebola virus 
glycoprotein (rBV.EBOV-GP) and 40 kDa viral protein (rBV.EBOV-VP40), and Crimean-
Congo haemorrhagic fever virus nucleoprotein (rBV.CCHFV-NP) revealed that the 64 
kDa protein was consistently present (data not shown).  The 54 kDa protein was 
consistent with the size of DV E, and was not present in samples from cultures infected 
with rBV.EBOV-GP, rBV.EBOV-VP40 or rBV.CCHFV-NP.  For the 54 kDa protein, there 
was no observable difference in protein production between cell lines.  However, from 
visual analysis of protein band intensity, the 54 kDa protein production appeared 
greatest using a MOI of 5, and harvesting protein at 48 hours post infection.   
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Figure 4.6.  Analysis of optimisation of recombinant dengue virus envelope protein production 
Infections with rBV.R097A_4 were conducted in Sf9 and Sf21 cell lines, at MOIs of 2, 5 and 10, and 
proteins harvested at 48 and 72 hours post infection. Total cell lysate (T), the soluble fraction of the total 
cell lysate (S) and clarified insect cell culture medium, neat (Mn) or concentrated using a centrifugal filter 
device (Mc), were analysed by SDS-PAGE. The original (unprocessed) gel images used to construct this 
figure are included electronically in Appendix J. 
 
To confirm the presence of His-tagged DV E, denatured proteins from the SDS-PAGE 
gels were transferred onto a PVDF membrane by Western blot and immunodetection 
attempted using a monoclonal antibody (mAb) to the His-tag (section 2.6).  
Unexpectedly, His-tagged protein was not detected in any of the samples (data not 
shown).  Only the His-tagged control protein was detected, confirming that the 
Western blot and immunodetection antibodies were working.  This led to two 
hypotheses.  The first hypothesis was that the C-terminal His-tag on DV E was either 
not present or not accessible to the His-tag mAb, preventing the DV E from being 
detected using this antibody.  A different antibody was sourced to directly detect the 
DV E (flavivirus E mAb, Abcam) so as not to rely on the presence of the His-tag.  The 
second hypothesis was that R097A_4 E was either not being produced or only being 
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produced at very low levels, below the limit of detection using the His-tag mAb.  From 
previously published work it became apparent that concentration of the rBV-infected 
insect cell culture medium was required to detect E (Bielefeldt-Ohmann et al., 1997; 
Jaaskelainen et al., 2003).  It was decided that samples would be concentrated via 
ultracentrifugation through sucrose before attempting detection of DV E again, as this 
method had been used successfully previously to concentrate flavivirus VLPs from cell 
culture supernatant (Jaaskelainen et al., 2003; Schalich et al., 1996). 
As previously described (section 4.4, page 158, Figure 4.5), PCR performed on the rBV DNA had 
confirmed that the rBV genomes contained the DV prM and E genes.  To determine whether 
these genes were being transcribed in preparation for translation and protein production, total 
RNA (including mRNA) was isolated (section 2.3.2.2) from rBV.R097A_4-infected Sf9 cells 
harvested for the protein production optimisation experiment (Figure 4.6).  These samples 
were subjected to RT-PCR (section 2.3.1.1) using the R097A_4 E gene primers (Table 4.1).  PCR 
(section 2.3.1.4) was also performed using the same primers to ensure there was no DNA 
contamination of the RNA extract (so no baculovirus DNA containing the DV genes was 
present).  Analysis of the RT-PCR and PCR products by DNA gel electrophoresis (section 2.5.1) 
showed DV E mRNA (1.5kb) at all MOIs and time-points from infected, but not mock-infected 
cells (Figure 4.7).  No DNA contamination of the RNA extract was detected in the PCR products 
(data not shown).  
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Figure 4.7.  Analysis of dengue virus envelope gene mRNA transcripts produced in R097A_4 rBV-
infected Sf9 cells 
RT-PCR (section 2.3.1.1) was performed on total RNA extracted from rBV.R097A_4-infected Sf9 cells 
(section 2.3.2.2) using R097A_4 E gene primers (Table 4.1).  Amplicons of 1.5 kb are consistent with the 
DV E gene. The original (unprocessed) gel images used to construct this figure are included electronically 
in Appendix J. 
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4.6 Concentration of dengue virus-like particles  
A review of published literature revealed that previous studies concentrated rBV-
infected insect cell culture medium prior to detection of recombinant flavivirus E 
(Bielefeldt-Ohmann et al., 1997; Jaaskelainen et al., 2003).  Secreted flavivirus VLPs 
have been concentrated successfully from cell culture medium by ultracentrifugation 
through sucrose (Jaaskelainen et al., 2003; Schalich et al., 1996).  For this study, 
clarified medium from rBV.R097A_4-infected Sf9 cells was concentrated by 
ultracentrifugation through a 20% sucrose cushion (section 2.8.1).  Negative control 
samples were included from similarly concentrated clarified medium from mock-
infected Sf9 cells, and Sf9 cells infected with rBV.CCHFV-NP, rBV.EBOV-GP or 
rBV.EBOV-VP40.  This was to confirm that the antibodies used for immunodetection 
were specific for flavivirus E, and did not detect other viral proteins or components of 
the insect cell culture medium.  Samples were taken pre and post concentration and 
were analysed by SDS-PAGE and Western blot (sections 2.5.3.1 and 2.6).  
Immunodetection was conducted using antibodies to the His-tag or flavivirus E, using a 
recombinant His-tagged WNV E (Abcam) as a positive control.  Immunodetection using 
the His-tag mAb only showed the presence of the His-tagged WNV E positive control.  
As before, R097A_4 E was not detected in the pre-concentration sample.  It was also 
undetected in the concentrated sample (data not shown).  However, immunodetection 
using the flavivirus E mAb was successful, as a protein of between 50 and 60 kDa was 
detected in the concentrated R097A_4 sample (Figure 4.8).  The His-tagged WNV E 
positive control (50 kDa) was also detected using this mAb.  This flavivirus E mAb was 
shown to be specific for flavivirus E, as it did not detect any proteins in samples from 
mock-infected, rBV.CCHFV-NP, rBV.EBOV-GP or rBV.EBOV-VP40-infected Sf9 cells.  This 
confirmed that the rBV.R097A_4-infected Sf9 cells were producing DV E, and it was 
being secreted into the culture medium.  These results also indicated that the DV E C-
terminal His-tag was either not present or accessible to the His-tag mAb, even under 
the denaturing conditions used for SDS-PAGE and Western blot, suggesting that 
purification of the dengue VLPs using the E His-tags might not be possible. 
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At this point dengue VLPs were produced using the rest of the rBVs from section 4.4 
(Table 4.2).  Infections were performed using Sf9 cells infected at a MOI of 5, with 
proteins harvested from the culture medium 48 hours post infection, in accordance 
with the SDS-PAGE results in Figure 4.6.  Proteins were concentrated by 
ultracentrifugation through a 20% sucrose cushion, and detected using the flavivirus E 
mAb (Figure 4.9).  Immunodetection using the His-tag mAb was unsuccessful for all of 
the dengue VLP samples tested (data not shown).  Quasispecies E from samples 
R097A_4, R097A_13 and R261A_1 were detected using the original batch of flavivirus E 
mAb, which was obtained from Abcam.  However, Abcam removed this mAb from 
their catalogue so it had to be sourced from elsewhere.  Subsequent suppliers 
provided the same mAb, but titre and stability were reduced compared to the original 
mAb sourced from Abcam.  The mAb concentration used for immunodetection could 
not be increased to improve the sensitivity of detection as the dilution of mAb used for 
immunodetection was already 1:5.  DV E from samples R097A_43, R203A_2, 
R203A_54, R261A_4, R107A_1 and R107A_22 were detected, although only as low 
intensity chemiluminescence, which was attributed to reliability issues with the 
replacement flavivirus E mAb. 
 
Figure 4.8  Immunodetection of dengue virus envelope glycoprotein from clarified medium from 
rBV.R097A_4-infected cells after concentration by ultracentrifugation  
Immunodetection was performed using a flavivirus E mAb. Clarified medium from mock or rBV-infected 
(rBV.R097A_4, rBV.CCHFV-NP, or rBV.EBOV-GP and rBV.EBOV-VP40) Sf9 cells was analysed pre 
and post concentration by ultracentrifugation through a 20% sucrose cushion. The 50 and 60 kDa 
fragments of a molecular weight marker (MW) are shown for comparison, as is a 50kDa WNV E positive 
(+ve) control. The original (unprocessed) blot images used to construct this figure are included 
electronically in Appendix J.  
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Figure 4.9.  Immunodetection of dengue virus envelope glycoproteins from clarified medium from 
dengue rBV-infected cells after concentration by ultracentrifugation 
Immunodetection was performed using a flavivirus E mAb on proteins secreted from Sf9 cells infected 
with rBV.R097A_4, rBV.R097A_13, rBV.R097A_43, rBV.R203A_2, rBV.R203A_54, rBV.R261A_1, 
rBV.R261A_4, rBV.R107A_1 and rBV.R107A_22. Clarified medium from dengue rBV-infected Sf9 
cells was analysed post concentration by ultracentrifugation through a 20% sucrose cushion. The 50 and 
60 kDa fragments of a molecular weight marker (MW) are shown for comparison, as is a 50kDa WNV E 
positive (+ve) control. The original (unprocessed) blot images used to construct this figure are included 
electronically in Appendix J.  
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4.7 Purification of dengue virus-like particles  
The dengue VLPs were originally intended to be purified using immobilised metal 
affinity chromatography (IMAC) to bind the C-terminal His-tags on the DV E.  However, 
as the DV E were unable to be detected using the His-tag mAb (sections 4.5 and 4.6), it 
was likely that purification using this method would be unsuccessful.  To address this 
issue, it was decided to compare several protein purification methods to determine 
which method yielded the best results in terms of quantity and purity.  The methods 
chosen included IMAC, immunoprecipitation (via Protein G and flavivirus E mAb) and 
ion exchange chromatography (using CaptoQ resin).  Each method was evaluated using 
clarified medium from rBV.R097A_4-infected Sf9 cells which had been concentrated by 
ultracentrifugation through a 20% sucrose cushion (section 4.6).  Similarly 
concentrated clarified medium from mock-infected Sf9 cells was included as a negative 
control.  The R097A_4 sample was diluted to the limit of immunodetection using the 
flavivirus E mAb, and then purification was attempted using each of the methods.   
4.7.1 Immobilised metal affinity chromatography 
Purification by IMAC is dependent on the His-tags attached to the DV E binding to 
nickel ions in a sepharose gravity-flow column.  Purifications were performed under 
native and denaturing conditions (section 2.8.2) but neither method yielded purified 
DV E (data not shown).  This result was not unexpected given the inability to detect DV 
E from Western blots using the His-tag mAb (sections 4.5 and 4.6). 
4.7.2 Immunoprecipitation 
The immunoprecipitation method chosen relies on the binding of DV E to the flavivirus 
E mAb, which is bound to sepharose and protein G-coated magnetic beads.  Protein G 
was chosen over Protein A as a ligand because the flavivirus E mAb is raised in mouse 
and the Protein G ligand has a higher affinity for mouse IgG than Protein A.  
Purifications were performed under native and denaturing conditions (section 2.8.3.1) 
using a protocol that cross-linked the flavivirus E mAb to the Protein G ligand in an 
attempt to elute only the purified DV E or dengue VLPs (depending on whether the 
denaturing or native protocols were used respectively), and not the flavivirus E mAb. 
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Using the flavivirus E mAb for immunodetection, a protein of between 50 and 60 kDa, 
which is consistent in size with DV E (54 kDa) was detected in the R097A_4 sample pre-
purification (Figure 4.10).  A protein of lower molecular weight (50 kDa) was observed 
in the post-purification native and denaturing elution fractions.  This 50 kDa protein 
was also present in the post-purification native and denaturing elution fractions from 
the mock-infected negative control sample.  The 50 kDa protein was not consistent 
with the size of DV E.  To determine whether the flavivirus E mAb was being eluted and 
detected, it was analysed by SDS-PAGE, and Western blot, and was immunodetected 
as a 50 kDa protein (Figure 4.10; FV E mAb).  This indicated that despite cross-linking 
the flavivirus E mAb to the Protein G ligand, the antibody was in fact being eluted 
(using both the native and denaturing protocols), and was subsequently detected by 
the anti-mouse IgG secondary pAb (pAb) used for immunodetection. 
 
Figure 4.10.  Immunodetection of dengue virus envelope glycoprotein from concentrated clarified 
medium from rBV.R097A_4-infected cells after purification by immunoprecipitation.  
Immunodetection was performed using the flavivirus E mAb. Clarified medium from mock or 
rBV.R097A_4-infected Sf9 cells was concentrated by ultracentrifugation through a 20% sucrose cushion. 
Pre-purification samples (Pre) were diluted 1/20 (to the limit of R097A_4 E immunodetection using the 
flavivirus (FV) E mAb) and then immunoprecipitated (section 2.8.3.1). The 50 and 60 kDa fragments of a 
molecular weight marker (MW) are shown for comparison, as is a 50kDa WNV E positive (+ve) control. 
The original (unprocessed) blot images used to construct this figure are included electronically in 
Appendix J. 
 
Further investigation of the purification fractions revealed that the DV E in the 
R097A_4 sample was not binding to the flavivirus E mAb during the sample binding 
step, as it was observed in the non-bound fraction sampled after incubation of the 
sample with the Protein G-bound antibody (data not shown).  Increasing the 
incubation times during cross-linking and sample binding appeared to solve the 
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problem of flavivirus E mAb elution, but did not improve sample binding (data not 
shown).  With hindsight, it is probable that variability in the quality of the flavivirus E 
mAb was responsible for these observations (section 4.6, discussed further in sections 
4.7.3 and 4.9.5). 
4.7.3 Ion exchange chromatography      
The principle of purification by ion exchange chromatography is that the charged 
protein to be purified binds to the ion exchange media, contaminants are washed 
away, and the purified protein is eluted using an ionic strength gradient.  The 
isoelectric points and pH-dependent net charges of DV E were predicted based on the 
amino acid sequences using the EMBL WWW Gateway to Isoelectric Point Service 
(http://www3.embl.de/cgi/pi-wrapper.pl).  This determined that DV E have a net 
negative charge at pH 7.0 and above.  As a result, the CaptoQ strong anion exchange 
media was deemed to be the most suitable media for purification of the dengue VLPs.  
Initial purification attempts were performed manually using a syringe (section 2.8.4), 
and the purification fractions analysed by SDS-PAGE and Western blot.  Both flavivirus 
E mAb and baculovirus envelope glycoprotein (GP64) mAb were used for 
immunodetection to determine the success of the purification (Figure 4.11).  From the 
SDS-PAGE results it was clear that the anion exchange column purification removed 
many of the impurities that were in the pre-purification sample.  The greatest amount 
of purified protein was present in the fraction eluted using 20% sodium chloride (20% 
NaCl; Figure 4.11, panel A, lane 5) with decreasing amounts of protein also present in 
the 30 to 50% NaCl elution fractions.  Using the flavivirus E mAb, a protein of 50 to 60 
kDa was detected in the 20 to 50% NaCl elution fractions, and pre-purification sample 
(Figure 4.11, panel B).  Consistent with the SDS-PAGE image, the greatest amount of 
purified protein was present in the 20% NaCl elution fraction.     
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Figure 4.11.  Analysis of R097A_4 anion exchange column purification fractions by SDS-PAGE and 
immunodetection from Western blots. 
Immunodetection was performed using mAbs to flavivirus E or baculovirus GP64. Clarified medium 
from rBV.R097A_4-infected Sf9 cells was concentrated by ultracentrifugation through a 20% sucrose 
cushion. Pre-purification sample (lane 1) was diluted 1/20 (to the limit of R097A_4 immunodetection 
using the flavivirus E mAb) and then purified by anion exchange column chromatography (section 2.8.4). 
Lane 1 shows R097A_4 pre-purification sample; Lane 2 shows flow-through (non-bound) from the 
sample loading step; Lane 3 shows flow-through from the sample wash step; lanes 4 to 9 are the fractions 
eluted using 10, 20, 30, 40, 50 and 100% NaCl respectively; lane 10 is flow-through from the column re-
equilibration step. The original (unprocessed) gel and blot images used to construct this figure are 
included electronically in Appendix J.  
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Using the GP64 mAb, proteins consistent in size with GP64 (64 kDa) were detected in 
all fractions except the flow-through from the sample wash step (Figure 4.11, panel C, 
lane 3).  Interestingly, GP64 was even detected in lanes where it was not visible on the 
SDS-PAGE gel, indicating that the GP64 mAb is extremely sensitive.  As with the SDS-
PAGE and immunodetection results obtained using the flavivirus E mAb, the greatest 
amount of purified protein was present in the 20% elution fraction (Figure 4.11, lane 
5).  There were also decreasing amounts of protein present in the 30-50%, 10% and 
100% elution fractions and the flow-through fraction from the sample load step 
respectively.  The presence of GP64 in the flow-through from the sample load step 
indicates that not all of the baculovirus present in the sample was binding to the 
column. 
Despite using a new batch of flavivirus E mAb for immunodetection (Figure 4.11, panel 
B), the level of detection was poor compared to that achieved with the same pre-
purification sample previously (see Figure 4.8).  At this point it was decided to source a 
new antibody for the detection of the DV quasispecies E because this one had become 
so unreliable.  Several primary antibodies were tested (Table 4.4), and a pAb raised in 
rabbit against DV types 1, 2, 3 and 4 was chosen based on its superior detection 
sensitivity compared to the other antibodies tested (data not shown). 
Anion exchange column purification was chosen as the method that would be used to 
purify the dengue VLPs.  This was because despite being shown to co-purify GP64 and 
dengue VLPs, a reduction in other background proteins had been demonstrated by 
SDS-PAGE analysis (Figure 4.11).  It was intended that the dengue VLPs and baculovirus 
would be separated post anion exchange column purification, by immunoprecipitation. 
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Table 4.4.  Antibodies tested for dengue virus envelope glycoprotein immunodetection 
Antibody Source Immunogen 
Mouse monoclonal to flavivirus E 
[FE1]1 
Abcam (Ab64059) Flavivirus E 
Mouse monoclonal to flavivirus E 
[FE1]2 
Pierce (MA1-71258) Flavivirus E 
Dengue antibody positive human control 
serum 
Focus Diagnostics dengue IgG 
DxSelect ELISA kit (EL1500G) 
DV 
Mouse monoclonal to DV (pan) E 
[dengue 1-11(3)]* 
Acris Antibodies, GmbH 
(AM01108PU) 
DV types 1, 2, 3 and 4 
Mouse monoclonal to DV E [dengue 1-
11(3)]* 
Antibodies-online (ABIN180831) DV types 1, 2, 3 and 4 
Rabbit polyclonal to DV types 1, 2, 3 
and 43 
Abcam (Ab9200) DV types 1, 2, 3 and 4 
Mouse monoclonal to DV E  Abcam (Ab41349) Purified DV type 2 E 
Rabbit polyclonal to DV types 1, 2, 3 
and 4 
Abcam (Ab26837) DV types 1, 2, 3 and 4 
Mouse monoclonal to DV E [dengue 1-
11(3)]* 
Abcam (Ab9202) DV types 1, 2, 3 and 4 
After the original flavivirus E mAb1 used for this work was discontinued by the supplier, a new flavivirus 
E mAb2 was sourced to replace it. This antibody exhibited reduced detection sensitivity and stability 
compared to the original antibody. Commercially-available antibodies were tested until a replacement3 
was identified. 
*detects a DV E specific band of 61 kDa under reducing conditions from Western blots. A weak 
secondary band of 80 kDa may also be apparent. 
 
4.7.4 Removal of baculovirus from virus-like particle samples by 
immunoprecipitation 
To assess the feasibility of removing the contaminating baculovirus from the dengue 
VLP samples, a baculovirus-derived Ebola VLP preparation was subjected to 
immunoprecipitation using the baculovirus GP64 mAb bound to Protein G and 
sepharose-coated magnetic beads.  The Ebola VLP preparation was used in place of the 
dengue VLPs to avoid using valuable dengue VLP material whilst testing the 
immunoprecipitation method.  Purifications were performed using a classic, non-cross-
linking protocol (section 2.8.3.2) under native buffer conditions.  Immunodetection 
was performed using both Ebola virus (data not shown) and baculovirus GP64 mAbs 
(Figure 4.12).  The Ebola VLPs were detected in the non-bound and wash fractions 
from the sample binding step, but not the elution fractions (data not shown), 
confirming that they did not bind to the GP64 mAb.  Baculovirus GP64 was detected in 
the elution fractions, indicating that the purification was at least partly successful.  
However, comparatively more GP64 was present in the non-bound and wash fractions 
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from the sample binding step, suggesting that only a small proportion of the 
baculovirus contamination was removed from the VLP preparation using this method.  
Therefore this method was unsuitable for removing the contaminating baculovirus 
from the dengue VLP samples.  However, it was still hoped that the dengue VLPs and 
baculovirus could be separated post anion exchange column purification, by 
immunoprecipitation using a DV antibody.  
 
Figure 4.12.  Immunodetection of GP64 in a baculovirus-derived Ebola VLP sample pre and post 
purification by immunoprecipitation. 
Immunodetection was performed using a mAb to baculovirus GP64. Clarified medium from rBV.EBOV-
GP and rBV.EBOV-VP40-infected Sf9 cells was concentrated by ultracentrifugation through a 20% 
sucrose cushion, and purified by immunoprecipitation using the GP64 mAb (section 2.8.3.2). Proteins 
were eluted using a stepped ionic strength gradient of 10 to 100% NaCl. A molecular weight marker 
(MW) is shown for comparison.  Lane 1 shows pre-purification Ebola VLPs; Lane 2 shows flow-through 
(non-bound) from the sample loading step; lanes 3, 4 and 5 show flow-through from sample wash steps 1, 
2 and 3 respectively; lane 6 shows the elution fraction. The original (unprocessed) blot image used to 
construct this figure is included electronically in Appendix J.  
 Chapter 4: Recombinant protein production  
173 
 
4.8 Scaled-up production and purification of dengue virus-like 
particles 
Production of all of the dengue VLPs (section 4.6, Figure 4.9) was scaled up from 50mL 
to 200mL cultures using the same conditions described previously (section 2.7.5).  The 
clarified medium from rBV-infected insect cell culture was concentrated by 
ultracentrifugation through a 20% sucrose cushion prior to anion exchange column 
purification using an ÄKTAFPLC automated system (section 2.8.4).  The automated 
liquid chromatography system was advantageous for two reasons.  Firstly, using this 
system it was possible to reduce the sample flow-rate in an attempt to improve sample 
binding to the column.  Secondly, it was thought that using a linear ionic elution 
gradient (rather than a stepped gradient as had been used previously when purifying 
manually) might enable further separation of the dengue VLPs and baculovirus into 
different elution fractions. 
To determine whether reducing the sample flow-rate improved sample binding to the 
column, the concentrated R097A_4 sample was purified using sample flow rates of 
1mL per minute and 0.1mL per minute during the sample load and wash steps.  The 
purification fractions were analysed by SDS-PAGE and Western blot.  Using the rabbit 
pAb to DV types 1, 2, 3 and 4 for immunodetection, a large amount of protein was 
shown to be present in the flow-through from the sample load and wash steps when 
the sample flow-rate was 1mL per minute (Figure 4.13; Panel A).  Decreasing the 
sample flow-rate to 0.1mL per minute (Figure 4.13; Panel B) resulted in a reduction of 
protein in the flow-through from these steps, indicating that sample binding to the 
column had increased.  It also resulted in improved purification quality as judged by 
visual inspection of protein staining after SDS-PAGE. 
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Figure 4.13.  Analysis of R097A_4 anion exchange column purification fractions obtained using 
different sample flow-rates. 
Immunodetection was performed using a rabbit pAb to DV types 1, 2, 3 and 4. Clarified medium from 
rBV.R097A_4-infected Sf9 cells was concentrated by ultracentrifugation through a 20% sucrose cushion 
before anion exchange column purification. Proteins were eluted using a linear ionic strength gradient of 
10 to 100% NaCl. Two molecular weight markers (MW) are shown for comparison.  The purification in 
Panel A was performed using a sample flow-rate of 1.0mL per minute during the sample loading step; the 
purification in Panel B used a sample flow-rate of 0.1mL per minute.  Lane 1 shows R097A_4 pre-
purification; lanes 2 and 3 show flow-through from the sample loading and wash steps respectively; lanes 
4 to 9 show the fractions eluted using 0-10, 10-20, 20-30, 30-40, 40-50 and 50-100% NaCl respectively; 
lane 10 shows flow-through from the column re-equilibration step. The original (unprocessed) gel and 
blot images used to construct this figure are included electronically in Appendix J.  
 
To serve as a control sample representative of the background of baculovirus and 
insect cell-generated proteins present in the dengue VLP samples, the clarified 
medium from rBV.lacZ-infected Sf9 cells was concentrated by ultracentrifugation 
through a 20% sucrose cushion and purified by anion exchange column purification in 
the same way as the dengue VLPs.  This will be referred to from this point on as the 
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lacZ sample.  Purification fractions from the lacZ and R097A_4 samples showed similar 
profiles after analysis by immunodetection using the GP64 mAb.  This was to be 
expected, as they both contain baculovirus (Figure 4.14).  However, they also 
unexpectedly demonstrated a similar profile after immunodetection using the rabbit 
pAb to DV types 1, 2, 3 and 4 (Figure 4.15.), indicating that this antibody was not 
specifically detecting the DV proteins.  Clarified medium from mock-infected insect 
cells, concentrated by ultracentrifugation through a 20% sucrose cushion was not 
detected by this antibody (data not shown), suggesting that the source of the cross-
reactivity was a baculovirus protein. 
 
Figure 4.14.  Analysis of R097A_4 and lacZ sample anion exchange column purification fractions 
using the baculovirus GP64 mAb. 
Immunodetection was performed using a baculovirus GP64 mAb. Clarified medium from rBV.R097A_4 
and rBV.lacZ-infected Sf9 cells was concentrated by ultracentrifugation through a 20% sucrose cushion 
before anion exchange column purification (section 2.8.4). The sample flow-rate was 0.1mL per minute, 
and proteins were eluted using a linear ionic strength gradient of 10 to 100% NaCl. A molecular weight 
marker (MW) is shown for comparison.  Panel A shows the purification fractions from the R097A_4 
sample. Panel B shows the purification fractions from the lacZ sample. Lane 1 shows the pre-purification 
20% sucrose pellet concentrated sample; lanes 2 and 3 show flow-through from the sample loading and 
wash steps respectively; lanes 4 to 9 show the fractions eluted using 0-10, 10-20, 20-30, 30-40, 40-50 and 
50-100% NaCl respectively; lane 10 shows flow-through from the column re-equilibration step. The 
original (unprocessed) blot images used to construct this figure are included electronically in Appendix J.  
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Figure 4.15.  Analysis of R097A_4 and lacZ sample anion exchange column purification fractions 
using the rabbit pAb to dengue virus types 1, 2, 3 and 4. 
Immunodetection was performed using a rabbit pAb to DV types 1, 2, 3 and 4. Clarified medium from 
rBV.R097A_4 and rBV.lacZ-infected Sf9 cells was concentrated by ultracentrifugation through a 20% 
sucrose cushion before anion exchange column purification. The sample flow-rate was 0.1mL per minute, 
and proteins were eluted using a linear ionic strength gradient of 10 to 100% NaCl. A molecular weight 
marker (MW) is shown for comparison.  Panel A shows the purification fractions from the lacZ sample. 
Panel B shows the purification fractions from the R097A_4 sample. Lane 1 shows the pre-purification 
20% sucrose pellet concentrated sample; Lane 2 shows the 20% NaCl elution fraction; Lane 3 shows the 
30% NaCl elution fraction. The original (unprocessed) blot images used to construct this figure are 
included electronically in Appendix J.  
 
To determine whether the DV E could be reliably detected against the background of 
non-DV proteins, immunodetection was performed using three different commercially-
available antibodies (mouse mAbs to the flavivirus and DV E, and the rabbit pAb to DV 
types 1, 2, 3 and 4) and baculovirus-derived samples (concentrated clarified medium 
from rBV.R097A_4, rBV.lacZ, and rBV.EBOV-GP and rBV.EBOV-VP40-infected Sf9 cells).  
All three antibodies detected a 60 kDa protein in all of the samples tested (Figure 
4.16).  As this protein was present in all three samples it was concluded not to be a DV 
protein.  Additionally, using the flavivirus and DV E mAbs, a protein consistent in size 
with the predicted molecular weight of the DV E was detected in the R097A_4 sample 
but not the two non-dengue baculovirus-derived samples (lacZ and Ebola VLPs).  This 
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protein was not detected using the rabbit pAb to DV types 1, 2, 3 and 4.  From these 
results it was concluded that none of the antibodies tested were specific enough to 
unambiguously detect DV E from the denaturing Western blots used up to this point.  
It was hypothesised that the 60 kDa protein reacting non-specifically during 
immunodetection using the DV antibodies could be baculovirus GP64.  Purified GP64 
(kindly provided by Prof. Ian Jones, Reading University) was analysed using the mouse 
mAbs to the flavivirus and DV E, and the rabbit pAb to DV types 1, 2, 3 and 4.  
Baculovirus GP64 was identified as the source of antibody cross-reactivity (data not 
shown).   
 
Figure 4.16.  Analysis of baculovirus-derived R097A_4, lacZ and Ebola VLP samples using several 
different antibodies 
Immunodetection was performed using mouse mAbs to the flavivirus and DV E (Panel A and Panel C 
respectively), and a rabbit pAb to DV types 1, 2, 3 and 4 (Panel B). For each sample, clarified medium 
from rBV-infected Sf9 cells was concentrated by ultracentrifugation through a 20% sucrose cushion 
before analysis. A molecular weight marker (MW) is shown for comparison.  Lane 1 shows R097A_4; 
Lane 2 shows Ebola VLPs; Lane 3 shows lacZ. The original (unprocessed) blot images used to construct 
this figure are included electronically in Appendix J. 
 
To try to confirm the presence of DV E in the dengue VLP samples, other methods 
were attempted.  These included glycoprotein deglycosylation analysis to attempt to 
distinguish between baculovirus GP64 and DV E.  Endoglycosidase H cleaves only high 
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mannose N-linked glycans, whereas peptide:N-glycosidase F (PNGase F) is also able to 
cleave more complex glycans.  Concentrated clarified medium from rBV.R097A_4 and 
rBV.lacZ-infected Sf9 cells, was denatured and digested using either endoglycosidase H 
or PNGase F, and analysed using the rabbit pAb to DV types 1, 2, 3 and 4 (Figure 4.17).  
Proteins of around 64 kDa were detected in both the R097A_4 and lacZ undigested 
samples.  These proteins demonstrated increased mobility upon digestion with 
endoglycosidase H, and a further increase in mobility upon digestuib with PNGaseF.  
These findings are consistent with the size of baculovirus GP64 (64 kDa), which 
contains four N-linked glycans, at least one of which is endoglycosidase H resistant 
(Jarvis and Garcia, 1994).  Several lower molecular weight proteins between 45 and 55 
kDa were detected in the R097A_4 sample but were absent in the lacZ sample, one of 
which may represent DV E.  The DV E contains two N-linked glycans, one of which is 
endoglycosidase H sensitive and one is resistant (Hacker, White, and de Silva, 2009), 
consistent with the electrophoretic shifts observed in the digested sample using the 
different glycosidases. 
 
Figure 4.17.  Glycosylation analysis of R097A_4 and lacZ samples using endoglycosidase H and 
PNGase F. 
Immunodetection was performed using the rabbit pAb to DV types 1, 2, 3 and 4. For each sample, 
clarified medium from rBV-infected Sf9 cells was concentrated by ultracentrifugation through a 20% 
sucrose cushion before analysis. A molecular weight marker (MW) is shown for comparison. Panel A is 
the R097A_4 sample. Panel B is the lacZ sample. Lane 1 shows undigested (glycosylated) sample; Lane 2 
shows endoglycosidase H-digested sample; Lane 3 shows PNGase F-digested sample. The original 
(unprocessed) gel images used to construct this figure are included electronically in Appendix J. 
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To determine whether antibodies detecting conformational epitopes would exhibit 
less cross-reactivity with baculovirus GP64 than antibodies detecting linear epitopes, 
the R097A_4 and lacZ samples were analysed by native PAGE and Western blot 
(sections 2.5.3.2 and 2.6).  Several DV antibodies were tested, including pAbs, and 
mAbs known to bind to conformation-dependent epitopes.  Using the rabbit pAb to DV 
types 1, 2, 3 and 4 used previously, a protein was detected in the R097A_4 sample but 
not the lacZ sample, indicating that it is DV E (Figure 4.18).  This suggests that the 
baculovirus GP64 cross-reactivity observed previously with this antibody may be 
dependent on epitopes that are only accessible under denaturing conditions. 
The samples used for the native PAGE and Western blot analysis were first incubated 
with 1% triton X-100 for one hour to solubilise the lipid membranes.  Previous 
attempts to perform native PAGE and Western blot analysis on the R097A_4 sample 
without first incubating with 1% triton X-100 resulted in immunodetection of a high 
molecular weight protein (data not shown).  Taken together, these results support the 
presence of DV E in a lipid-enveloped form, consistent with VLPs.    
 
Figure 4.18.  Analysis of R097A_4 and lacZ samples in their native conformation. 
Immunodetection was performed using the rabbit pAb to DV types 1, 2, 3 and 4. For each sample, 
clarified medium from rBV-infected Sf9 cells was concentrated by ultracentrifugation through a 20% 
sucrose cushion before analysis. Samples were incubated in 1% triton X-100 for 1 hour to solubilise the 
lipid membranes, before native PAGE and immunodetection from a Western blot. Panel A shows the 
R097A_4 sample; Panel B shows the lacZ sample. The original (unprocessed) blot images used to 
construct this figure are included electronically in Appendix J. 
 
4.8.1 Detection of dengue virus-like particles using transmission electron 
microscopy 
To visualise the dengue VLPs, concentrated clarified medium from R097A_4 rBV-
infected Sf9 cells was sent to Howard Tolley (HPA CEPR) for analysis by transmission 
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electron microscopy (section 2.10; Figure 4.19, panels D and E).  Previous studies 
demonstrated that flavivirus virions are observed as spherical structures of 
approximately 50nm in diameter, whilst flavivirus VLPs range in diameter between 30 
and 55nm (Schalich 1996; Lin & Wu 2005).  Spherical structures consistent in size with 
published transmission electron micrographs of flavivirus VLPs (Figure 4.19, panels B 
and C) were observed in the dengue VLP sample (Figure 4.19, panels D and E).  Whilst 
similar structures were also observed in a baculovirus-derived Ebola VLP sample 
(Figure 4.19, panel F) included as a negative control, these were fewer in number and 
were smaller (less than 25nm) than those in the dengue VLP sample.   
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Figure 4.19.  Transmission electron micrographs of flavivirus virions and VLPs stained with uranyl 
acetate. 
All images are at the same magnification, and a 500nm scale bar is shown.  Panels A and B are purified 
TBEV virions and VLPs respectively (Schalich et al., 1996). Panel C is purified JEV VLPs (Lin and Wu, 
2005). Panels D and E are unpurified dengue VLPs from this study (clarified medium from 
rBV.R097A_4-infected Sf9 cells, concentrated by ultracentrifugation through a 20% sucrose cushion). 
Examples of dengue VLPs are marked with arrows, and the diameters shown.  Panel F is unpurified Ebola 
virus VLPs, included as a negative control (kindly provided by Dr. Kevin Richards, HPA CEPR). 
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4.9 Discussion 
The objective for this chapter was to produce recombinant DV E from those 
quasispecies E genes containing mutations with the potential to affect virulence or 
pathogenicity, as identified in the previous chapter.  It was decided that the DV E 
would be produced in the form of secreted VLPs, consisting of DV type 1 membrane 
and quasispecies E.  This was to replicate as closely as possible the natural antigenic 
presentation of E within the dengue virion, as flavivirus VLPs have been shown to 
exhibit the same antigenic and oligomeric structure as virions (Schalich et al., 1996).  
Studies using recombinant vaccinia viruses encoding combinations of JEV prM, E and 
NS1 genes, demonstrated that the co-expression of prM and E genes induced the 
highest levels of neutralising antibody and protection in mice, and these antibody 
levels correlated with the ability of the recombinant viruses to induce the synthesis of 
extracellular VLPs in vitro (Konishi et al., 1991; Konishi et al., 1992).  DV E in the form of 
VLPs is more resistant to proteolytic degradation than secreted E alone (Sugrue et al., 
1997).  VLPs secreted into the insect cell culture medium represent a more 
homogenous VLP population than intracellular VLPs, which are at different stages of 
processing and maturation. The production of DV quasispecies E as VLPs also provides 
a model for studying the effects of the quasispecies E gene mutations on E 
conformational changes and membrane fusion in response to low pH.        
A eukaryotic expression system was required to enable the appropriate post-
translational modifications for the production of authentic secreted DV E.  The use of a 
yeast expression system was discounted because its level of post-translational 
modification is less than can be achieved using baculovirus or mammalian systems.  
Yeast cells have also been shown to accumulate dengue VLPs intracellularly as 
secretion is prevented (Sugrue et al., 1997).  Despite the differences in post-
translational processing between the baculovirus and mammalian expression systems, 
and since DV is able to infect and replicate naturally in both mosquito (insect) and 
human (mammalian) cells, the baculovirus expression system was chosen over a 
mammalian expression system based on its comparatively higher protein yields, ease 
of use and lesser expense. 
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4.9.1 Cloning of dengue virus pre-membrane and envelope genes into the 
baculovirus transfer vector 
The pBAC-2cp baculovirus transfer vector was used for the production of rBVs as it 
contains an ATG start codon and incorporated a His-tag sequence onto the C-terminal 
of the DV E genes inserted into the MCS, which was intended to be used for VLP 
purification.  Rather than using the corresponding prM genes from the patient 
samples, the same DV type 1 prM gene was ligated into the baculovirus transfer vector 
with each DV quasispecies E gene.  This was to ensure any differences between the 
dengue VLPs were not attributed to differences in prM.  Ligation-dependent cloning of 
DV prM and E genes with restriction enzyme-digested 5’ and 3’ ends enabled 
directional cloning of the genes into the MCS so that the genes were inserted in the 
correct order (prM followed by E as in the DV genome), and in-frame with the pBAC-
2cp start codon and C-terminal His-tag coding sequences.  This was confirmed for each 
of the clones by sequencing. 
4.9.2 Production of recombinant baculoviruses containing dengue virus 
pre-membrane and envelope genes 
Transfer vectors containing DV prM and quasispecies E genes were co-transfected with 
baculovirus DNA into insect cells to generate nine rBVs (rBV.R097A_4, rBV.R097A_13, 
rBV.R097A_43, rBV.R203A_2, rBV.R203A_54, rBV.R261A_1, rBV.R261A_4, 
rBV.R107A_1 and rBV.R107A_22), containing quasispecies consensus and variant E 
genes from four of the dengue patient samples.  To serve as a control for the 
transfection reactions and rBV titrations, rBV.lacZ was also generated.  In subsequent 
experiments, culture medium from rBV.lacZ-infected cells was used as a control to 
represent the background of non-DV proteins present in the dengue VLP preparations.  
After successive rBV amplifications and titrations, the presence of the DV prM and E 
genes in the rBVs was confirmed by PCR.   
4.9.3 Optimisation of dengue virus-like particle production 
Optimisation experiments were conducted to determine the optimal cell line, 
multiplicity of infection (MOI) and post infection interval before harvesting the dengue 
VLPs.  Sf9 and Sf21 cells were infected with rBV.R097A_4 at MOIs of 2, 5 and 10, and 
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samples of lysed cell pellet and clarified culture medium were analysed at 48 and 72 
hours post infection.  SDS-PAGE analysis revealed proteins of approximately 64 kDa 
and 54 kDa in the clarified medium from rBV-infected cells, but these were not visible 
in mock-infected samples.  Comparison of these results to similar in-house 
experiments using rBVs containing genes for non-DV proteins (rBV.EBOV-GP, 
rBV.EBOV-VP40 and rBV.CCHFV-NP) revealed that the 64 kDa protein was present in all 
of these samples, suggesting that this was a baculovirus protein rather than a DV 
protein.  The 54 kDa protein was not present in samples from the non-dengue rBVs, 
and was consistent with the size of DV E. 
To confirm the presence of the His-tagged DV E, immunodetection was performed 
using a mAb to the His-tag.  His-tagged protein was not detected in any of the samples.  
Only the His-tagged WNV E positive control protein was visible, confirming that the 
method and reagents used were working effectively.  To overcome this problem, a 
different mAb was sourced to directly detect the DV quasispecies E in case the His-tag 
was either not present or accessible.  The clarified medium from rBV-infected cells was 
also further concentrated by ultracentrifugation through a sucrose cushion before re-
analysing, in case production of only low quantities of dengue VLPs had made the His-
tags undetectable.  Ultracentrifugation through a sucrose cushion had been used 
previously to concentrate secreted flavivirus VLPs (Jaaskelainen et al., 2003; Schalich et 
al., 1996).   
As the recombinant dengue VLPs were not able to be detected using this His-tag mAb, 
the presence of mRNA for DV E was confirmed by RT-PCR in the rBV.R097A_4-infected 
insect cells at all MOIs and both post infection harvest intervals.  The presence of 
mRNA for the DV E was not confirmation of protein production but was a positive 
indication that the gene was transcribed, ready for protein synthesis.  
Optimal conditions for the production of dengue VLPs were determined based on the 
SDS-PAGE results, as immunodetection of DV E using the His-tag mAb had not been 
successful.  Subsequent production of dengue VLPs using rBV.R097A_4, rBV.R097A_13, 
rBV.R097A_43, rBV.R203A_2, rBV.R203A_54, rBV.R261A_1, rBV.R261A_4, 
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rBV.R107A_1 and rBV.R107A_22 was performed in Sf9 cells infected at a MOI of 5, and 
culture medium harvested at 48 hours post infection.  Although no difference in 
protein production was observed between the cell-lines used in the optimisation 
experiments, Sf9 cells were chosen due to their increased replication rate and ability to 
reach higher cell densities compared to the Sf21 cells they are derived from (Smith and 
Summers, 1987). 
4.9.4 Concentration of dengue virus-like particles 
Clarified medium from rBV.R097A_4-infected insect cell culture was concentrated by 
ultracentrifugation through a 20% sucrose cushion before immunodetection using 
either His-tag or flavivirus E mAbs.  DV E was not detected using the His-tag mAb, but 
was detected using the flavivirus E mAb.  At this stage of the work, the flavivirus E mAb 
was shown to be specific for DV E, as it did not detect any proteins in concentrated 
clarified medium from rBV.CCHFV-NP or rBV.EBOV-GP and rBV.EBOV-VP40-infected 
cells. 
These results indicated that the C-terminal His-tags on the R097A_4 DV E were either 
not present or not accessible to the His-tag mAb, even under the denaturing 
conditions used for SDS-PAGE.  This suggested that purification of the dengue VLPs 
using the DV E His-tags as originally intended might not be possible.  It has been 
proposed that the C-terminal of flavivirus E may contain a signal for retention of this 
protein in intracellular compartments (Allison et al., 1995).  Cleavage of this signal may 
be required for VLP assembly and/or secretion, which would explain the inability to 
detect the C-terminal His-tag in the secreted VLPs under denaturing conditions.  In 
support of this, C-terminal His-tags have been used previously to purify JEV E and prM 
produced separately from cell lysates, but failed in purification of these proteins from 
insect cell culture medium (Yang et al., 2005). 
At this point recombinant VLPs were concentrated and detected for the rest of the 
dengue VLPs (R097A_13, R097A_43, R203A_2, R203A_54, R261A_1, R261A_4, 
R097A_1 and R107A_22; Figure 4.9). 
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4.9.5 Purification of dengue virus-like particles 
Three methods of purification were compared using the R097A_4 dengue VLP sample 
and native conditions to preserve the structure of the dengue VLPs.  These were: 
immobilised metal affinity chromatography (IMAC), immunoprecipitation (Protein G-
bound flavivirus E mAb) and anion exchange chromatography (CaptoQ resin).  The 
IMAC purification method was unsuccessful.  This was expected because this 
purification method relies on the presence of the His-tag on the DV E, which had not 
been detected using the His-tag mAb.   
The immunoprecipitation purification method was also unsuccessful despite 
optimisation of antibody cross-linking to protein G and sample incubation durations.  
This was shown to be the result of poor sample binding to the flavivirus E mAb.  This 
was the first indication of problems with the replacement flavivirus E mAb.  This 
antibody had been originally sourced from Abcam, and was shown to be sensitive 
enough to detect DV E once samples had been concentrated by ultracentrifugation 
through a 20% sucrose cushion (Figure 4.8).  This antibody was also shown to be 
specific, with no cross-reactivity observed with samples from infections with rBVs 
containing genes for non-DV proteins (rBV.CCHFV-NP or rBV.EBOV-GP and rBV.EBOV-
VP40).  When this antibody was discontinued from the Abcam catalogue,  a 
replacement monoclonal antibody from the same hybridoma clone was subsequently 
sourced from Thermo Fisher (Pierce), but the antibody titre was much lower and 
antibody stability varied between lots compared to when sourced from Abcam.  It was 
intended that the immunoprecipitation method would be revisited once a new DV E 
antibody was sourced. 
Anion exchange column purification of the dengue VLPs was attempted, and 
performed manually initially using syringes and a stepped ionic elution gradient.  
Analysis of the SDS-PAGE results showed a reduction in the presence of background 
protein in the elution fractions compared to the pre-purification sample (Figure 4.11).  
Proteins of between 51 and 64 kDa were clearly visible and detected using the 
flavivirus E mAb.  However, immunodetection of the same samples using the 
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baculovirus GP64 mAb demonstrated co-purification of baculovirus in the same elution 
fractions as the dengue VLPs.   
The level of detection achieved using the replacement flavivirus E mAb was poor 
compared to that achieved previously using the original antibody and the same 
R097A_4 pre-purification sample (Figure 4.8 and Figure 4.11 respectively).  
Comparison of the SDS-PAGE results with those from previous experiments using the 
R097A_4 sample (data not shown), indicated that the loss of sensitivity during 
detection was not due to sample degradation, but was likely due to the flavivirus E 
mAb.  As a result of the declining quality of this antibody it was decided that a new 
antibody was required for the detection of DV E.  After testing several potential 
replacement antibodies, a pAb raised in rabbit against DV types 1, 2, 3 and 4 was 
chosen based on its superior detection sensitivity compared to the other antibodies 
tested (Table 4.4).   
Attempts to remove the baculovirus virions from baculovirus-derived VLP preparations 
by immunoprecipitation using a baculovirus GP64 mAb (bound to Protein G-coated 
magnetic beads) were unsuccessful, despite the high sensitivity of the antibody.  
Immunodetection from Western blots showed that although some of the baculovirus 
virions were immunoprecipitated, the vast majority did not bind to the antibody and 
remained with the VLPs in the un-bound fraction during sample loading (Figure 4.12).  
Some of the GP64 is present in the dengue VLP preparation in the form of baculovirus 
virions which might be able to be separated from the dengue VLPs by further 
purification, for example by size-exclusion, immunoprecipitation (once a suitable 
antibody is sourced) or further sucrose density gradient ultracentrifugation.  However, 
some of the GP64 could be present within the envelope of the dengue VLPs due to 
insertion into the lipid bilayer during VLP formation, so would be unable to be 
separated from the DV proteins without dissolving the dengue VLPs.   
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4.9.6 Scaled-up production, purification and detection of dengue virus-like 
particles 
To produce enough dengue VLPs for analysis, production of the dengue VLPs was 
scaled-up by increasing the volume of rBV-infected insect cell culture from 50mL to 
200mL.  To concentrate and purify the dengue VLPs, ultracentrifugation through a 20% 
sucrose cushion, and anion exchange column purification were used as described 
previously.  Unlike previous manual purifications, anion exchange column purification 
was this time performed using an ÄKTAFPLC automated system.  This was to enable 
further optimisation of the sample loading step, by reducing the sample flow-rate, 
thereby increasing sample binding to the column.  Also, it was hoped that by using a 
low sample flow-rate, and a linear rather than stepped ionic elution gradient, further 
separation of the dengue VLPs and baculovirus into different elution fractions might be 
possible.  As a control representative of the non-dengue proteins present in the 
baculovirus-derived samples, clarified medium from rBV.lacZ-infected cultures was 
concentrated and purified in the same way as described for the dengue VLP 
preparations.  Anion exchange column purified lacZ samples were analysed alongside 
corresponding dengue samples by immunodetection using the baculovirus GP64 mAb, 
and both were shown to have similar profiles.  This confirmed that the lacZ sample was 
an appropriate background control for the baculovirus proteins present in the dengue 
VLP samples.  Unexpectedly, comparison of the same lacZ and dengue samples using 
the rabbit pAb to DV types 1, 2, 3 and 4, also demonstrated similar immunodetection 
profiles for both samples.  This indicated that the rabbit pAb to DV types 1, 2, 3 and 4 
was cross-reacting with a non-DV protein of around 64 kDa.  This left the anion 
exchange column purification results from the scaled-up cultures (section 4.8) in 
question, as it was not clear what protein was being detected. 
Subsequent testing of the rabbit pAb to DV types 1, 2, 3 and 4, the flavivirus E mAb 
used previously, and another commercially available mAb to DV E, showed all three 
antibodies cross-reacted with a non-DV protein consistent in size with the known 
molecular weight of baculovirus GP64 (64 kDa).  However, the two mAbs tested were 
both able to detect an additional protein with a lower molecular weight in the 
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R097A_4 sample, but not the lacZ sample.  This protein was consistent in size with the 
known molecular weight of DV E (54 kDa).  Baculovirus GP64 was confirmed as the 
source of the antibody cross-reactivity by immunodetection of purified GP64 using the 
mouse mAbs to the flavivirus and DV E, and the rabbit pAb to DV types 1, 2, 3 and 4.  
To the best of my knowledge, cross-reactivity between flavivirus antibodies and GP64 
has not been previously reported, and further purification of VLP preparations may 
resolve the issue.  Antibody cross-reactivity with GP64 may have been expected had 
the antibodies been generated using baculovirus-derived antigen, but the antigens 
used to produce the antibodies used in this experiment were derived from live 
flaviviruses grown in mosquito cell lines.  It is feasible that there could be antibody 
cross-reactivity to insect cell-derived protein because of the use of mosquito cell lines 
to culture the flaviviruses used for antibody production.   
To assess whether the observed antibody cross-reactivity was due to sequence 
homology between DV E and baculovirus GP64, their respective amino acid sequences 
were aligned, which revealed a reasonable degree of sequence similarity between 
them (Figure 4.20).  This is not unexpected as they are both major viral envelope 
glycoproteins responsible for receptor-binding and membrane fusion, and both bind to 
insect cells.  A review of the literature has shown that a crystallographically-
determined structural model for pre-fusion GP64 has not been eluded to date, so a 
structural comparison was not able to be made with the DV E pre-fusion structure.  
Structural domain III of flavivirus E is known to contain an immunoglobulin C-like fold 
common to cell adhesion proteins that has also been identified on the outer surface of 
an insect virus, although this virus was non-enveloped (Rey et al., 1995).  
Analysis of protein glycosylation was performed using glycosidases to attempt to 
distinguish between baculovirus GP64 and DV E in the lacZ and R097A_4 samples.  The 
glycosylation profile produced by the 64 kDa protein in both samples was consistent 
with that of GP64, which contains four N-linked glycans, at least one of which is 
endoglycosidase H resistant (Jarvis and Garcia, 1994).  Several proteins with lower 
molecular weights of between 45 and 55 kDa were detected in the R097A_4 sample, 
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but were absent in the lacZ sample, one of which could represent DV E.  The DV E 
contains two N-linked glycans, one of which is endoglycosidase H sensitive and one is 
resistant (Hacker, White, and de Silva, 2009), consistent with the electrophoretic shifts 
observed in the digested sample using the different glycosidases.  
The lacZ and R097A_4 samples were also analysed by native PAGE and 
immunodetection from Western blots, using the rabbit pAb to DV types 1, 2, 3 and 4.  
A protein was detected in the R097A_4 sample but not the lacZ sample, indicating that 
it is DV E (Figure 4.18).  This suggested that the GP64 cross-reactivity observed 
previously with this antibody is dependent on epitopes that are only accessible under 
denaturing conditions, so there may be a better chance of conclusively detecting the 
dengue VLPs using methods that enable the proteins to remain in a native 
conformation, for example by ELISA or immunofluorescence. 
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Figure 4.20.  Amino acid sequence alignment of AcMNPV GP64 and the dengue virus envelope 
glycoprotein. 
Amino acid sequences were obtained from NCBI for baculovirus GP64 (AcMNPV; GenBank accession 
L22858) and DV type 3 E (GenBank accession NC_001475), and aligned using ClustalW (section 2.2.4).  
Amino acids are colour-coded according to physiochemical properties, with red representing nonpolar, 
green representing polar, pink representing basic, and blue representing acidic.  Aligned matching amino 
acids are marked *, and amino acids with similar properties are marked . or : depending on the degree of 
similarity (: indicating more similarity than .). 
 
4.9.7 Detection of dengue virus-like particles using transmission electron 
microscopy 
Transmission electron micrographs of the R097A_4 dengue VLP sample confirmed that 
spherical structures consistent in size with published transmission electron 
micrographs of flavivirus VLPs were present (Figure 4.19, panels D and E).  Whilst 
similar structures were also observed in a baculovirus-derived Ebola VLP sample 
(Figure 4.19, panel F) included as a negative control, these were fewer in number and 
smaller in diameter than those observed in the dengue VLP sample.  Confirmation that 
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the spherical structures seen in the dengue VLP sample were actually dengue VLPs 
could be obtained using immunogold labelling.  Provided a primary antibody could be 
sourced that was specific for the dengue VLPs, and did not cross-react with 
baculovirus, a gold-conjugated secondary antibody could then be added and the 
sample re-analysed by transmission electron microscopy.  Accumulation of gold 
particles on the spherical structures would confirm that the particles observed are in 
fact the dengue VLPs.  
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4.10 Conclusions and summary 
The intention for this part of the study was to generate rBVs containing the DV type 1 
prM gene and the quasispecies E genes identified in Chapter 3 (section 3.10; R097A_4, 
R097A_13, R097A_43, R203A_2, R203A_54, R261A_1, R261A_4, R107A_1 and 
R107A_22).  These would be used to produce dengue VLPs for each of the E gene 
variants, which could be purified in preparation for use in studies to determine the 
effect of the mutations on protein function, and assessment of their value as 
diagnostic tools.  
The DV quasispecies E genes identified in the previous chapter were each successfully 
cloned alongside the DV type 1 prM gene into the baculovirus transfer vector, pBAC-
2cp.  Co-transfection of pBAC-2cp containing the inserted genes with baculovirus DNA 
into insect cells resulted in the production of rBVs, which were subsequently amplified 
and titred.  Optimisation experiments were conducted to determine the optimal cell 
line, multiplicity of infection (MOI) and post infection interval before harvesting the 
dengue VLPs.  However, problems were encountered in detecting the dengue VLPs 
using the C-terminal His-tags on the DV E, which meant that optimised expression 
conditions could only be determined based on the SDS-PAGE results.    
Clarified medium from dengue rBV-infected cells (containing secreted dengue VLPs) 
was concentrated by ultracentrifugation and re-analysed by immunodetection.  Again, 
the DV E were not detected using the His-tag mAb, but proteins of 50 to 60 kDa, 
consistent with the known molecular weight of DV E (54 kDa) were detected for all of 
the dengue VLP samples using a mouse mAb demonstrated to be specific for flavivirus 
E.  
Purification of the dengue VLPs as originally intended using IMAC to bind the C-
terminal His-tags on the DV E was thought to be unlikely, given the failure to detect 
the DV E using the His-tag mAb.  As a result three methods of purification were 
attempted, namely IMAC, immunoprecipitation and anion exchange column 
chromatography.  Purification by IMAC proved to be unsuccessful as predicted.  
Purification by immunoprecipitation was hampered by problems with the quality of 
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the flavivirus E mAb used.  Preliminary anion exchange column purification results 
were promising, but the flavivirus E mAb was no longer sensitive and reliable enough 
for use as determined by repeat analysis of the same sample over time (data not 
shown), and co-purification of baculovirus was demonstrated.  A rabbit pAb to DV 
types 1, 2, 3 and 4 was sourced to analyse the anion exchange column purification 
fractions, but on closer examination, it was found to cross react with a non-DV protein 
in all of the baculovirus-derived samples tested.  The source of the cross-reactivity was 
determined to be baculovirus GP64.  Similar cross-reactivity was subsequently 
demonstrated using two other commercially available mouse mAbs (flavivirus and DV 
E antibodies), although an additional protein of lower molecular weight was also 
detected.  The size of this additional protein was consistent with the known molecular 
weight of DV E (54 kDa), and it was not evident in non-DV rBV-derived samples.  There 
are not many commercially available antibodies for DV proteins, and of those tested 
for this study, poor sensitivity and stability were commonly encountered.  These 
results identify a need for better quality DV-specific antibodies to be made available to 
the wider scientific community.  Other purification methods would need to be 
attempted to obtain dengue VLP preparations that do not contain baculovirus, which 
should solve the problem of antibody cross-reactivity.  Additionally, the use of virus-
free expression systems for protein production (using plasmid rather than viral gene-
delivery vectors) would remove the potential for virus-contamination of the dengue 
VLP preparations, thus simplifying purification.  
DV E was detected in clarified insect cell culture medium from rBV-infected cultures 
concentrated by ultracentrifugation through a 20% sucrose cushion.  Detection of DV E 
in subsequent purified samples is ambiguous due to antibody cross-reactivity.  DV E 
was also detected in the R097A_4, but not lacZ samples analysed by native PAGE and 
Western blots.  These data also provided supportive evidence that the DV E are 
present in a lipid enveloped form consistent with VLPs.  This was further supported by 
transmission electron micrographs, which showed spherical structures consistent in 
size with published transmission electron micrographs of flavivirus VLPs.  Future 
detection of dengue VLPs may need to be undertaken by ELISA, as this may circumvent 
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the antibody cross-reactivity problem as it allows the proteins to remain in their native 
conformation. 
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CHAPTER 5. ANALYSIS OF DENGUE VIRUS-
LIKE PARTICLES TO DETERMINE THE 
EFFECTS OF THE QUASISPECIES ENVELOPE 
GENE MUTATIONS 
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5.1 Introduction 
Dengue virus (DV) infectivity is directly related to the ability of the DV envelope 
glycoprotein (E) to evade neutralisation by antibodies, attach to target cells within the 
host, undergo low pH-induced conformational change, and mediate fusion of virus and 
host cell membranes.  Mechanisms of DV neutralisation by host antibodies include 
preventing virus-cell attachment and inhibiting membrane fusion (Roehrig, 2003; 
Roehrig, Bolin, and Kelly, 1998).  Single nucleotide mutations within the E gene that 
cause amino acid substitutions in E have been shown to be associated with altered DV 
virulence and disease pathogenicity (Cecilia and Gould, 1991; Guirakhoo et al., 2004; 
Hahn et al., 1987; Hasegawa et al., 1992; Holzmann et al., 1990; Jiang et al., 1993; 
Nitayaphan et al., 1990).  The amino acid substitutions caused by these mutations 
cluster on the outer surface of the virion and at the interfaces between E structural 
domains (Rey et al., 1995).  They are thought to act either through altering accessibility 
to neutralising antibodies, or through direct modulation of the processes of 
attachment to host cells or membrane fusion (Rey et al., 1995).   
Although a definitive antibody-independent cellular receptor for DV has yet to be 
elucidated, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) and other lectins have been proposed as DV receptors on DCs, 
endothelial cells and macrophages (Miller et al., 2008; Navarro-Sanchez et al., 2003; 
Tassaneetrithep et al., 2003).  Cryoelectron microscopy of the DV E-DC-SIGN complex 
has shown interaction of the lectin with the N-linked glycan at Asn-67 (Pokidysheva et 
al., 2006).  The DV E glycans have been shown to play an important role in infectivity 
and virus growth in mammalian cells (Bryant et al., 2007; Mondotte et al., 2007).  
Highly sulphated heparan sulphate (HSHS), a glycosaminoglycan on the surface of 
target cells has also been shown to bind DV E (Chen et al., 1997), and is thought to 
concentrate the virus on the cell surface, enabling subsequent higher-affinity 
interactions with specific receptors (Martinez-Barragan and del Angel, 2001).  Two 
HSHS-binding sites have been proposed for DV E at positions E284 to 310, and E386 to 
411 (Chen et al., 1997).  The first of these is on the distal face of E domain III, where 
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gene mutations leading to amino acid substitutions in several flaviviruses have been 
shown to affect virus virulence (Rey et al., 1995). 
DV E is a class II fusion protein that exists as a dimer in the pre-fusion state.  Cleavage 
of the pre-membrane glycoprotein (prM) by furin is required to prime E for fusion.  In 
response to the acidic environment of the endosome, the E dimer undergoes an 
irreversible conformational change to a trimeric form that exposes the previously 
inaccessible fusion peptide, and enables fusion of virus and host cell membranes 
(Modis et al., 2004).  E gene mutations that cause amino acid substitutions at the 
interface of E structural domains I and II have been shown to affect fusion by altering 
the pH required for fusion-induced conformational change (Modis et al., 2003). 
In addition to their use in studying the effect of E gene mutations on protein function, 
the dengue virus-like particles (VLPs) produced in Chapter 4 may be a useful source of 
antigen for the serodiagnosis of DV infection.  The similarity between flavivirus Es leads 
to significant antibody cross-reactivity between different flaviviruses.  In addition, 
flaviviruses often co-circulate in the same regions, further complicating serodiagnosis if 
antibodies are present from a previous infection or vaccination against a different 
flavivirus to the current infection.  The use of recombinant proteins as antigen permits 
the introduction of gene mutations that lead to amino acid substitutions in the protein 
that may alleviate the antibody cross-reactivity observed using wild-type proteins.  It 
also avoids the need to culture and purify large quantities of DV, traditionally sourced 
from tissue culture or suckling mouse brain, which requires high-containment facilities 
(Containment Level 3).  A further advantage of recombinant dengue VLPs is that they 
closely resemble the native conformation of dengue virions, so antigen presentation is 
likely to be superior compared to using recombinant E alone.  Enzyme-linked 
immunosorbent assays (ELISAs) using flavivirus VLP antigens (St. Louis encephalitis 
virus, SLEV; West Nile virus, WNV; DV types 1 to 4 and Japanese encephalitis virus, JEV) 
have demonstrated similar or improved sensitivity and specificity compared to those 
that use suckling mouse brain-derived antigens (Chang et al., 2003; Holmes et al., 
2005; Hunt, Cropp, and Chang, 2001; Purdy, Noga, and Chang, 2004). 
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5.2 Chapter objectives 
The primary objective for this chapter was to use the recombinant dengue VLPs 
produced in Chapter 4 to investigate the effects of the DV quasispecies E gene 
mutations on protein function.  The specific functions examined would be dengue VLP 
attachment to host cell surface molecules (DC-SIGN and HSHS), and the low pH-
induced DV E oligomeric rearrangements required for virus and host cell membrane 
fusion.   
In Chapter 4, using immunodetection from Western blots, the denatured DV E were 
unable to be clearly distinguished from the baculovirus proteins present in the dengue 
VLP preparations, due to antibody cross-reactivity (discussed in section 4.9.6).  
However, using the same detection antibodies, immunodetection of native dengue 
VLPs from Western blots was successful in detecting only the DV proteins.  This 
indicated that the antibody cross-reactivity observed was restricted to denatured but 
not native dengue VLPs.  An ELISA would be developed and optimised to enable 
detection of the recombinant dengue VLPs in their native conformation.  The antibody 
cross-reactivity observed previously would be overcome during ELISA development 
and optimisation.  To enable differences in cell attachment capabilities between the 
quasispecies variant and consensus dengue VLPs to be identified, this ELISA was then 
to be performed with an additional capture step using recombinant DC-SIGN, or 
heparin (as a HSHS analogue). 
Dengue VLPs would also be subjected to low pH, and the oligomeric conformation 
assessed.  This was to compare the ability of the quasispecies consensus and variant 
VLPs to undergo low pH-induced E oligomeric rearrangements. 
One of the aims of this work from the beginning was to compare the quasispecies 
consensus and variant VLPs in terms of cross-reactivity with antibodies to other non-
dengue flaviviruses.  Initial ELISAs would be performed using the dengue VLPs as 
antigen, and human serum containing antibodies to DV.  This was to assess the affinity 
of the dengue VLPs for human DV antibodies and lead to subsequent examinations of 
sensitivity, specificity and cross-reactivity.  To our knowledge, such investigations using 
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quasispecies variants have not been reported.  However, since beginning this work, 
flavivirus VLPs constructed using SLEV, WNV and JEV prM and E genes with mutations 
in the fusion peptide, have been shown to exhibit dramatically reduced flavivirus 
antibody cross-reactivity, compared to wild-type VLPs using IgM capture ELISAs (Chiou 
et al., 2008; Roberson, Crill, and Chang, 2007).     
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5.3 Development and optimisation of an ELISA using recombinant 
dengue virus-like particles as antigen 
Previous attempts to detect the denatured dengue VLPs by immunodetection from 
Western blots had proved difficult, as the antibodies used for immunodetection were 
unexpectedly shown to cross-react with baculovirus proteins present in the VLP 
preparations (discussed in section 4.9.6).  By developing and optimising an indirect 
ELISA, using the dengue VLPs in their native conformation as antigen, it was thought 
that the cross-reactivity observed previously could be overcome.  Concentrated 
clarified medium from rBV.lacZ-infected Sf9 cells was used as a background control 
antigen (this protein sample is referred to as lacZ throughout the chapter), as it was 
previously shown to be representative of the non-DV proteins present in the dengue 
VLP preparations (section 4.8).  The dengue VLP samples had also been concentrated 
from clarified insect cell culture medium by ultracentrifugation through a sucrose 
cushion.  The total protein content of the dengue VLP and lacZ samples was quantified 
by Bradford assay (section 2.8.5), and ELISA plates were consistently coated with 
samples at a concentration of 1µg/mL (0.1µg/well), unless otherwise stated.  
5.3.1 Initial ELISA evaluation 
Three primary antibodies were used in the previous chapter.  These were: a mouse 
monoclonal antibody (mAb) to flavivirus E, a rabbit polyclonal antibody (pAb) to DV 
types 1, 2, 3 and 4, and a mouse mAb to DV E.  The mouse mAb to flavivirus E was not 
tested for use in the ELISA because it had proved to be unreliable previously (discussed 
in section 4.9.5).  The mouse mAb to DV E and rabbit pAb to DV types 1, 2, 3 and 4 
were compared in preliminary ELISAs (mAb and pAb ELISA; Figure 5.1 and Figure 5.2 
respectively) to determine which provided a better distinction between the dengue 
VLPs and baculovirus proteins present in the VLP preparations (section 2.9.1).  The 
secondary antibodies used were horse radish peroxidise (HRP)-conjugated rabbit anti-
mouse IgG and goat anti-rabbit IgG, respectively.  All samples were tested in triplicate 
and the bar charts display the average absorbance for each sample, with error bars 
representing one standard deviation.  A positive threshold value was calculated based 
on the average lacZ sample absorbance plus three standard deviations.  Absorbance 
readings above this threshold were considered positive and those below were negative 
Chapter 5: Recombinant dengue VLP analysis 
202 
 
for dengue VLP detection.  For the mAb ELISA (Figure 5.1), this threshold was 0.228, 
and five of the dengue VLP samples (R203A_2, R261A_1, R261A_4, R107A_1 and 
R107A_22) displayed average absorbance values greater than this, so were considered 
positive for dengue VLPs.  For the pAb ELISA (Figure 5.2), the threshold was 0.728, and 
six of the dengue VLP samples (R097A_4, R203A_2, R203A_54, R261A_1, R107A_1 and 
R107A_22) displayed average absorbance values greater than this, so were considered 
positive for dengue VLPs.  
In addition to the lacZ sample background control, purified baculovirus GP64 and 
concentrated clarified medium from mock-infected cells were used as negative 
controls.  Both ELISAs showed similar absorbance readings for the lacZ and purified 
GP64 samples, providing further confirmation that GP64 is the source of the antibody 
cross-reactivity observed.  The mock-infected sample served to establish a background 
level of absorbance from the culture medium of uninfected insect cells.  For the mAb 
ELISA (Figure 5.1), this signal was below that of any of the other samples, as would be 
expected.  However, for the pAb ELISA (Figure 5.2), this signal was greater than all but 
one of the samples tested. 
In both ELISAs, uncoated wells lacking sample antigen were included as negative 
controls and no binding was observed (data not shown).  For each sample antigen, 
control wells lacking the primary antibodies were also included to measure any direct 
binding of the secondary antibodies to the samples (Figure 5.3).  For the mAb ELISA, 
the absorbance signals from lacZ sample and purified GP64-coated wells in which both 
primary and secondary antibodies were used were similar to dengue VLP, lacZ and 
purified GP64 sample-coated wells containing secondary antibody only.  This indicates 
that the antibody cross-reactivity observed for this mAb ELISA is baculovirus GP64-
specific, and due to the secondary rather than the primary antibody as was first 
thought.  For the pAb ELISA, the absorbance signals from wells containing secondary 
antibody only were similarly low for dengue VLP, lacZ and purified GP64 sample-
coated wells, indicating that the signal observed is background fluorescence and the 
secondary antibody does not bind significantly to them.  However, high absorbance 
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signals were observed for the pAb ELISA where both primary and secondary antibodies 
were used in wells coated with the dengue VLPs or any of the background or negative 
control samples (mock, lacZ and purified GP64).  This confirms that the primary 
antibody for the pAb ELISA is binding non-specifically to baculovirus GP64 and a 
component of the insect cell culture medium.  The similarity between the dengue VLP 
sample signals and the lacZ sample signals generated using only the mAb ELISA 
secondary antibody (non-specifically detecting background proteins rather than DV E) 
indicates that all of these samples contain a similar amount of background protein.   
Signal to noise ratios were calculated for each dengue VLP sample from the 
preliminary mAb and pAb ELISA data, by dividing the average absorbance signal from 
the dengue VLP sample replicates by the average signal from the lacZ background 
sample replicates (Table 5.1).  Using the mAb ELISA, all but one of the dengue VLP 
samples (R097A_13) had a signal to noise ratio greater than 1.0.  Using the pAb ELISA, 
all but two of the dengue VLP samples (R097A_43 and R261A_4) had a signal to noise 
ratio greater than 1.0.  In general, the mAb ELISA produced better signal to noise ratios 
than the pAb ELISA.  This difference was statistically significant using a paired t-test 
(p=0.026). 
The mAb ELISA was chosen to take forward for further optimisation.  This was because 
the positive threshold value for this ELISA was 3-fold lower than the pAb ELISA (0.228 
compared to 0.728), and the signal to noise ratios for each sample were better for the 
mAb ELISA.  The pAb ELISA also displayed a high level of reactivity to the mock-infected 
sample, which was not observed with the mAb ELISA.  Also, the antibody cross-
reactivity in the mAb ELISA was shown to result from the secondary detection antibody 
rather than the primary DV-specific antibody (which was not the case with the pAb 
ELISA), indicating that further optimisation of the ELISA might improve the signal to 
noise ratio. 
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Figure 5.3.  Comparison of dengue VLP mAb and pAb ELISAs using both primary and secondary 
antibodies, and secondary antibodies only. 
The primary and secondary antibodies were as detailed in Figure 5.1 and Figure 5.2 for the mAb and pAb 
ELISAs respectively. Error bars represent the standard deviation of the replicates for each sample. For the 
mock, lacZ and purified GP64 negative and background control samples three replicates were performed, 
whereas the dengue VLP error bars correspond to the standard deviation for all of the dengue VLP 
samples in triplicate. Where error bars are not shown (wells coated with negative and background control 
sample antigens and probed using the secondary antibody only), no replicate samples were tested.  
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Table 5.1.  Signal to noise ratios for the dengue VLP samples in the mAb and pAb ELISAs.  
Dengue VLP sample mAb ELISA 
S:N 
pAb ELISA  
S:N 
R097A_4 1.28 1.09 
R097A_13 0.85 1.02 
R097A_43 1.03 0.96 
R203A_2 1.53 1.14 
R203A_54 1.32 1.04 
R261A_1 1.57 1.04 
R261A_4 1.42 0.99 
R107A_1 2.76 1.18 
R107A_22 2.12 1.05 
 
5.3.2 Dengue virus-like particle mAb ELISA optimisation 
Optimisation experiments were conducted using the R097A_13 and R107A_1 dengue 
VLP samples because they displayed the lowest and highest signal to noise ratios 
respectively in the initial experiment (Table 5.1).  The lacZ sample was included as a 
background control as before.  Four different blocking buffers were tested to optimise 
the blocking step of the mAb ELISA (Figure 5.4).  These were 10% fetal calf serum (FCS) 
in phosphate buffered saline with 0.05% tween 20 (PBST), protein-free (Thermo 
Fisher), StartingBlock T20 (Thermo Fisher) and 5% skimmed milk in PBST.  Positive 
threshold values were 0.080 using both 10% FCS in PBST and 5% skimmed milk in PBST, 
0.099 using StartingBlock T20, and 0.193 using the protein-free blocking buffer.  The 
R097A_13 sample average absorbance signals were not greater than the positive 
threshold values for any of the blocking buffers tested, but the R107A_1 sample 
average absorbance signals were greater than the positive threshold values for all of 
the blocking buffers tested.  Signal to noise ratios were calculated for the two dengue 
VLP samples (Table 5.2), with the best ratio observed for the R107A_1 sample using 
the StartingBlock blocking buffer (1.97) and for the R097A_13 sample using the 
protein-free blocking buffer (1.27). 
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Table 5.2.  Signal to noise ratios for the dengue VLP samples using different blocking buffers in the 
mAb ELISA.   
Dengue VLP sample 10% FCS in 
PBST S:N 
Protein-free 
S:N 
StartingBlock 
S:N 
5% skimmed milk 
in PBST S:N 
R097A_13 1.00 1.27 1.08 0.91 
R107A_1 1.43 1.73 1.97 1.78 
 
Future mAb ELISAs were conducted using 5% skimmed milk in PBST as the blocking 
buffer.  This was chosen over the other blocking buffers primarily due to the low 
positive threshold value (0.080), which it shared with the 10% FCS in PBST blocking 
buffer.  The signal to noise ratio for the R107A_1 dengue VLP sample was greater using 
5% skimmed milk in PBST than for 10% FCS in PBST.  
The concentration of primary and secondary antibodies was optimised in the same 
experiment by checkerboard titration (Figure 5.5).  This was to attempt to improve 
signal to noise ratios by reducing the background detection of non-DV proteins, and 
consequently reducing the positive threshold value.  The lowest positive threshold 
value (0.189) was observed at primary and secondary antibody concentrations of 
1/500 and 1/2000, respectively.  Both the R097A_13 and R107A_1 average sample 
absorbance signals were greater than the positive threshold values at all but four of 
the antibody concentration combinations tested (the exceptions being primary and 
secondary antibody concentration combinations respectively of 1/1000 and 1/2000, 
1/1000 and 1/1000, 1/750 and 1/2000, and 1/750 and 1/1000).  Signal to noise ratios 
were calculated for each dengue VLP sample at all of the antibody concentrations used 
(Table 5.3).  The greatest signal to noise ratios were achieved for sample R107A_1 
(3.28) using primary and secondary antibody concentrations of 1/1000 and 1/750 
respectively, and for sample R097A_13 (2.12) using primary and secondary antibody 
concentrations of 1/750 and 1/500 respectively. 
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Table 5.3.  Signal to noise ratios for the dengue VLP samples using different concentrations of 
primary and secondary antibody in the mAb ELISA. 
Dengue VLP 
sample 
Primary antibody 
concentration 
Secondary antibody concentration 
1/2000 1/1000 1/750 1/500 
R097A_13 
1/1000 1.10 1.37 1.72 1.59 
1/750 1.30 1.50 1.93 2.12 
1/500 1.48 1.76 1.87 1.92 
1/250 1.58 1.70 1.92 1.98 
R107A_1 
1/1000 2.13 2.19 3.28 2.05 
1/750 2.80 2.34 2.77 2.93 
1/500 2.83 2.91 2.74 2.87 
1/250 3.06 2.84 2.92 2.80 
 
It was decided to use a primary antibody concentration of 1/1000 and a secondary 
antibody concentration of 1/750 for future dengue VLP mAb ELISAs.  Although the 
positive threshold value at these antibody concentrations (0.338) was not as low as 
with other antibody concentrations, this combination of antibody concentrations had 
produced the greatest signal to noise ratio (3.28) for sample R107A_1.  This 
combination of antibody concentrations also enabled conservative use of the limited 
stocks of primary antibody that were available. 
5.3.3 Analysis of the dengue virus-like particle samples using the optimised 
mAb ELISA 
Following optimisation of the blocking buffer and antibody concentrations, the dengue 
VLP mAb ELISA was performed using all of the dengue VLP samples (Figure 5.6).  All 
nine of the dengue VLP samples were detected and distinguished as positive compared 
to the lacZ background control sample.  Signal to noise ratios were calculated (Table 
5.4), and ranged from 1.54 to 3.60.   
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Table 5.4.  Signal to noise ratios for the dengue VLP samples using the optimised mAb ELISA. 
Dengue VLP sample Signal to noise ratio 
R097A_4 3.60 
R097A_13 1.76 
R097A_43 1.79 
R203A_2 2.08 
R203A_54 2.31 
R261A_1 2.35 
R261A_4 2.40 
R107A_1 1.54 
R107A_22 3.31 
 
Comparing these results (Figure 5.6) to those obtained during the optimisation of 
antibody concentrations (Figure 5.4), the signal generated by the R107A_1 sample has 
decreased (from 0.569 to 0.181 after subtraction of the background signal), along with 
the signal to noise ratio (from 3.28 to 1.54).  In contrast, the signal from the R097A_13 
sample (0.190 and 0.257 after subtraction of the background signal) and signal to noise 
ratios (1.72 and 1.76) have increased slightly.  This is likely due to the freeze-thaw 
status of the samples as a fresh aliquot of sample R097A_13 was used for each 
experiment, whereas the R107A_1 sample had been freeze-thawed between 
experiments.  For future ELISAs, fresh sample aliquots were used for each experiment 
wherever possible, but most of the optimisation experiments were performed using 
freeze-thawed sample aliquots. 
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5.4 Comparison of dengue virus-like particle samples binding to DC-
SIGN via a capture ELISA 
To compare differences in DC-SIGN-binding capabilities between the variant and 
consensus dengue VLPs, an additional capture step was added to the dengue VLP mAb 
ELISA optimised in section 5.3 by coating the ELISA plate with DC-SIGN instead of the 
dengue VLP samples (Figure 5.7; section 2.9.2).  Plates were then blocked using 5% 
skimmed milk with PBST before addition of antigen (dengue VLP samples or lacZ 
background control sample).  Primary and secondary antibodies (mouse mAb to DV E 
and HRP-conjugated rabbit pAb to mouse IgG respectively) were used at 1/1000 and 
1/750 dilutions respectively, as these were previously determined as optimal.   
Because the dengue VLP sample antigens were unpurified, it was not clear what 
proportion of the total protein concentration measured by Bradford assay consisted of 
dengue VLPs and what proportion consisted of non-DV proteins.  However, the 
amount of non-DV proteins present that were able to bind non-specifically to the 
secondary antibody and cause background absorbance signals had been previously 
shown to be consistent across the dengue VLP and lacZ background control samples 
(Figure 5.3).  Initial ELISAs were performed on all of the dengue VLP samples using 
both the dengue VLP mAb ELISA and the DC-SIGN capture ELISA.  For the DC-SIGN 
capture ELISA, wells were initially coated with DC-SIGN at 1µg/mL (0.1µg/well).  The 
dengue VLP mAb ELISA was performed to provide a standard measurement of VLP 
detection by the antibodies.  This enabled comparisons to be made between the 
relative signals generated by the consensus and variant proteins for each patient 
sample.  The DC-SIGN capture ELISA results were compared to the dengue VLP mAb 
ELISA results to see if the relative signal intensities changed due to differences in the 
dengue VLPs binding to DC-SIGN (Figure 5.8).  Positive threshold values and signal to 
noise ratios (Table 5.5) were calculated for each ELISA as before.  All of the dengue VLP 
sample average absorbance signals from the dengue VLP mAb ELISA were greater than 
the calculated positive threshold value (0.180), and signal to noise ratios ranged from 
1.87 to 4.19.  However, for the DC-SIGN capture ELISA, none of the dengue VLP sample 
signals were greater than the calculated positive threshold value (0.212) and poor 
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signal to noise ratios (ranging from 0.92 to 1.18) were observed.  This indicated that 
the dengue VLP samples were not binding to the DC-SIGN-coated ELISA plates.   
 
Figure 5.7.  Schematic diagram showing the dengue VLP mAb ELISA and dengue VLP capture 
ELISA procedures. 
An additional capture step was added to the dengue VLP mAb ELISA to compare differences in DC-
SIGN-binding capabilities between the variant and consensus dengue VLPs (section 2.9.2). Wells were 
washed with PBST between each of steps 1 to 6. For the dengue VLP mAb ELISA, plates were coated 
overnight with dengue VLP sample antigens (Ag; step 1), before blocking with 5% skimmed milk in 
PBST (B; step 2), addition of primary and secondary antibodies (steps 4 and 5), substrate addition, 
stopping the reaction and reading the absorbance at 405nm (steps 6 and 7). For the capture ELISA, plates 
were coated overnight with DC-SIGN (step 1), before blocking with 5% skimmed milk in PBST (B; step 
2), and addition of the dengue VLP sample antigens (Ag; step 3).  Steps 4 to 7 were as described for the 
dengue VLP mAb ELISA. 
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Table 5.5.  Signal to noise ratios for the dengue VLP samples using the dengue VLP mAb ELISA 
and the DC-SIGN capture ELISA. 
Dengue VLP sample Dengue VLP mAb ELISA 
S:N 
DC-SIGN capture ELISA 
S:N 
R097A_4 1.87 1.17 
R097A_13 1.87 1.18 
R097A_43 2.50 1.08 
R203A_2 3.42 1.11 
R203A_54 3.51 1.08 
R261A_1 4.19 0.98 
R261A_4 2.62 0.96 
R107A_1 3.67 0.94 
R107A_22 3.37 0.92 
 
To attempt to improve dengue VLP binding to DC-SIGN, the DC-SIGN capture ELISA was 
repeated using the R107A_1 dengue VLP and lacZ background control samples at DC-
SIGN coating concentrations of 1, 10, 50 and 100µg/mL (Figure 5.9).  Positive threshold 
values and signal to noise ratios (Table 5.6) were calculated for each DC-SIGN coating 
concentration as before.  As with the previous DC-SIGN capture ELISA, the dengue VLP 
sample average absorbance signals were not greater than the calculated positive 
threshold value at any of the DC-SIGN coating concentrations tested.  Average signals 
from both the R107A_1 dengue VLP and lacZ background control samples increased 
with increasing DC-SIGN coating concentration, and signal to noise ratios decreased.  
This showed that the dengue VLP samples were not binding to DC-SIGN at any of the 
DC-SIGN concentrations tested.  
For the DC-SIGN capture ELISA, uncoated wells lacking DC-SIGN were included as 
negative controls and no binding was observed (data not shown).  Control wells coated 
with DC-SIGN but lacking sample antigen were used to measure any direct binding of 
the antibodies to DC-SIGN (Figure 5.10).  The absorbance signals from these wells 
showed very little difference to those containing either dengue VLP or lacZ background 
control sample antigens.  In addition, similar absorbance signals were generated from 
wells in which both primary and secondary antibodies were used, compared to wells in 
which only secondary antibody was used.  This indicated that the signal was due to the 
secondary antibody binding directly to DC-SIGN, and as a result it was decided to move 
on to testing the dengue VLP samples using a heparin capture ELISA.   
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Figure 5.9.  Optimisation of DC-SIGN coating concentration for the DC-SIGN capture ELISA. 
ELISA plate wells were coated using DC-SIGN at 1, 10, 50 and 100µg/mL (0.1, 1, 5 and 10µg/well), and 
lacZ background control or dengue VLP (R107A_1) sample antigens added at 1µg/mL (0.1µg/well). The 
primary and secondary antibodies were as detailed in Figure 5.1, at 1/1000 and 1/750 dilutions 
respectively. Positive threshold values (broken lines) were calculated for each DC-SIGN-coating 
concentration based on the average lacZ sample absorbance plus three standard deviations. Error bars 
represent the standard deviation of the three sample replicates.  
 
Table 5.6.  Signal to noise ratios for the dengue VLP sample R107A_1 using different DC-SIGN 
coating concentrations for the DC-SIGN capture ELISA. 
DC-SIGN coating concentration Signal to noise ratio 
1µg/mL 1.36 
10µg/mL 1.15 
50µg/mL 1.18 
100µg/mL 1.04 
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Figure 5.10.  Comparison of absorbance signals generated by the DC-SIGN capture ELISA using 
both primary and secondary antibodies, and secondary antibodies only. 
ELISA plate wells were coated using DC-SIGN, and sample antigens added at 1µg/mL (0.1µg/well). The 
primary and secondary antibodies were as detailed in Figure 5.1, at 1/1000 and 1/750 dilutions 
respectively. Error bars represent the standard deviation of the three replicates for the lacZ and No sample 
antigen wells, whereas the dengue VLP error bars correspond to the standard deviation for all of the 
dengue VLP samples in triplicate.  
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5.5 Comparison of dengue virus-like particle samples binding to 
heparin via a capture ELISA 
To compare differences in HSHS-binding capabilities between the variant and 
consensus dengue VLPs, a heparin capture ELISA was performed in the same way as 
the DC-SIGN capture ELISA (Figure 5.7), except that ELISA plates were coated with 
heparin rather than DC-SIGN.   Initial ELISAs were performed on all of the dengue VLP 
samples using both the dengue VLP mAb ELISA and the heparin capture ELISA.  For the 
heparin capture ELISA, wells were initially coated with heparin at 1mg/mL (0.1mg per 
well). 
As before, the dengue VLP mAb ELISA was performed as a reference, and the heparin 
capture ELISA results were compared to the dengue VLP mAb ELISA results (Figure 
5.11).  This was to see if the relative signal intensities changed due to differences in the 
dengue VLPs binding to heparin.  Positive threshold values and signal to noise ratios 
(Table 5.7) were calculated for each ELISA as before.  All of the dengue VLP sample 
average absorbance signals from the dengue VLP mAb ELISA were greater than the 
calculated positive threshold value (0.180), and signal to noise ratios ranged from 1.87 
to 4.19.  For the heparin capture ELISA, only one of the dengue VLP sample signals 
(R107A_22) was greater than the calculated positive threshold value (0.109) and signal 
to noise ratios ranged from 1.15 to 1.41.   
To attempt to improve dengue VLP binding to heparin, the heparin capture ELISA was 
repeated using the R107A_1 dengue VLP and lacZ background control samples at 
heparin coating concentrations of 1, 10, 50 and 100mg/mL (Figure 5.12).  Positive 
threshold values and signal to noise ratios (Table 5.7) were calculated for each heparin 
coating concentration as before.  The dengue VLP sample average absorbance signals 
at the 1mg/mL and 10mg/mL heparin coating concentrations were not greater than 
the calculated positive threshold value for these coating concentrations (0.121 and 
0.150, respectively).  However, the dengue VLP sample signals at the 50mg/mL and 
100mg/mL heparin coating concentrations were greater than the calculated positive 
threshold value for these coating concentrations (0.144 and 0.151, respectively).   
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Table 5.7.  Signal to noise ratios for the dengue VLP samples using the dengue VLP mAb ELISA 
and the heparin capture ELISA. 
Dengue VLP sample Dengue VLP mAb ELISA 
S:N 
Heparin capture ELISA 
S:N 
R097A_4 1.87 1.32 
R097A_13 1.87 1.15 
R097A_43 2.50 1.19 
R203A_2 3.42 1.24 
R203A_54 3.51 1.18 
R261A_1 4.19 1.25 
R261A_4 2.62 1.24 
R107A_1 3.67 1.32 
R107A_22 3.37 1.41 
 
 
 
Figure 5.12.  Optimisation of heparin coating concentration for the heparin capture ELISA. 
ELISA plate wells were coated using heparin at 1, 10, 50 and 100mg/mL (0.1, 1, 5 and 10mg/well), and 
lacZ or dengue VLP (R107A_1) sample antigens added at 1µg/mL (0.1µg/well). The primary and 
secondary antibodies were as detailed in Figure 5.1, at 1/1000 and 1/750 dilutions respectively. Positive 
threshold values (broken lines) were calculated for each heparin-coating concentration based on the 
average lacZ sample absorbance plus three standard deviations. Error bars represent the standard 
deviation of the three sample replicates.  
In general, average absorbance signals from both the R107A_1 dengue VLP and lacZ 
background control samples increased with increasing heparin coating concentration; 
the exception being the lacZ sample signal from the 10mg/mL heparin coating 
concentration, which also exhibited greater standard deviation of sample replicates at 
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this heparin coating concentration compared to the other concentrations.  Signal to 
noise ratios (Table 5.8) also increased with increasing heparin coating concentration, 
ranging from 1.16 to 2.60.  This demonstrated that at the higher heparin coating 
concentrations (50 and 100 mg/mL), the dengue VLP sample was binding to the 
heparin with a greater binding affinity than the lacZ background control sample. 
Table 5.8.  Signal to noise ratios for the dengue VLP sample R107A_1 using different heparin 
coating concentrations for the heparin capture ELISA. 
Heparin coating concentration Signal to noise ratio 
1mg/mL 1.16 
10mg/mL 1.41 
50mg/mL 2.54 
100mg/mL 2.60 
 
The heparin capture ELISA was then performed in parallel with the dengue VLP mAb 
ELISA using new aliquots (not previously freeze-thawed) of all of the dengue VLP 
samples and the lacZ background control sample (Figure 5.13).  For the heparin 
capture ELISA, a heparin coating concentration of 100mg/mL was used because at this 
concentration the lacZ sample background was acceptably low (Figure 5.12; positive 
threshold value 0.151) and the signal to noise ratio using the R107A_1 dengue VLP 
sample was greatest (Table 5.8; signal to noise ratio 2.60).  Positive threshold values 
were calculated as before for both ELISAs.  All of the dengue VLP sample signals were 
greater than the calculated positive threshold (0.345) for the dengue VLP mAb ELISA, 
and all but one of the dengue VLP sample signals (the exception being sample 
R097A_13) were also greater than the calculated positive threshold value (0.237) for 
the heparin capture ELISA. 
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The amount of non-DV proteins present that were able to bind non-specifically to the 
secondary antibody and cause background absorbance signals had been previously 
shown to be consistent across the dengue VLP and lacZ background control samples 
(Figure 5.3).  All of the dengue VLP mAb ELISA results (obtained using both primary and 
secondary antibodies) show differences in the absorbance values between the dengue 
VLP samples, indicating that the amount of dengue VLPs present varies between 
samples.  To simplify analysis of the results from the dengue VLP mAb and heparin 
capture ELISAs (Figure 5.13), the data was first normalised to account for the 
background signal generated by the secondary antibody binding non-specifically to 
non-DV proteins (by subtracting the lacZ negative control signal from the dengue VLP 
signal; Table 5.9).  The normalised average dengue VLP absorbance values from the 
dengue VLP mAb ELISA were used as a measure of the amount of dengue VLPs 
available to bind to the heparin in the capture ELISA.  The normalised average dengue 
VLP absorbance values from the heparin capture ELISA were used as a measure of the 
amount of dengue VLPs actually bound to the heparin in the capture ELISA.  The 
proportion of available dengue VLPs bound to heparin was then calculated (Table 5.9).  
For each dengue VLP sample set, the consensus protein representative sample 
(R097A_4, R203A_2, R261A_1 and R107A_1) was used as a basis for comparison with 
the variant protein samples. 
For the R097A sample set, the consensus protein sample R097A_4 showed 97% of the 
available dengue VLPs bound to heparin, whereas for the variant protein samples 
R097A_13 and R097A_43, 0% and 20% respectively of the available dengue VLPs 
bound to the heparin.  For the R203A sample set, the consensus protein sample 
R203A_2 demonstrated 49% of the available dengue VLPs bound to heparin, whereas 
for the variant protein sample R203A_54, 78% of the available dengue VLPs bound to 
the heparin.  For the R261A sample set, the consensus protein sample R261A_1 
showed 51% of the available dengue VLPs bound to heparin whereas for the variant 
protein sample R261A_4, 64% of the available dengue VLPs bound to the heparin.  For 
the R107A sample set, the consensus protein sample R107A_1 demonstrated 57% of 
the available dengue VLPs bound to heparin whereas for the variant protein sample 
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R107A_22, 56% of the available dengue VLPs bound to the heparin.  When this 
experiment was repeated similar results were obtained (data not shown). 
 
Table 5.9.  Proportion of available dengue VLPs bound to heparin after normalisation of dengue 
VLP mAb and heparin capture ELISA data 
Dengue VLP 
sample 
Available dengue 
VLPs 
Heparin-bound 
dengue VLPs 
Proportion of available dengue 
VLPs bound to heparin 
R097A_4c 0.199 0.194 97% 
R097A_13 0.053 -0.023 0% 
R097A_43 0.219 0.043 20% 
R203A_2c 0.391 0.191 49% 
R203A_54 0.108 0.084 78% 
R261A_1c 0.245 0.125 51% 
R261A_4 0.250 0.159 64% 
R107A_1
c
 0.284 0.162 57% 
R107A_22 0.544 0.304 56% 
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5.6 Comparison of dengue virus-like particle samples oligomeric 
rearrangements in response to low pH 
It was intended as part of this chapter to determine whether the low pH-induced DV E 
oligomeric rearrangements (required for virus and host cell membrane fusion) were 
prevented in any of the dengue VLP quasispecies variant samples with residue 
substitutions in areas of E known to be important during conformational change.  
Initial experiments were intended to be performed as described previously (Allison et 
al., 1999) by subjecting the dengue VLPs to low pH (pH 6.0), before neutralising and 
cross-linking oligomers together using dimethyl pimelimidate.  The lipid bilayer would 
then be solubilised using 1% triton X-100 for 1 hour before SDS-PAGE, Western blot, 
and immunodetection of proteins.  It was expected from previously published 
experiments using TBEV VLPs, that low pH-treated VLPs would exhibit DV E in trimeric 
form, whereas without low pH-treatment, E would be predominantly in dimeric form, 
and no trimers would be evident (Figure 5.14; Allison et al., 1999). 
 
Figure 5.14.  Expected dengue virus envelope glycoprotein oligomeric state after low pH treatment 
and chemical cross-linking. 
Figure modified from Allison et al., 1999. Flavivirus (TBE) VLPs pretreated at pH 6.0 before cross-
linking and detergent solubilisation show E in three distinct oligomeric states: trimer, dimer and 
monomer. Without low pH pre-treatment (pH 8.0), only dimer and monomer form are visible. At pH 6.0, 
the dimer and monomer forms, and at pH 8.0, the monomer form are visible because cross-linking is 
incomplete. 
 
However, baculovirus was known to be present in the dengue VLP samples, as 
purification attempts had failed to separate the baculovirus from the dengue VLPs 
(Chapter 4).  Baculovirus GP64 is a class III fusion protein, which forms a trimeric 
structure in both the pre- and post-fusion states (Kadlec et al., 2008).  Baculovirus 
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GP64 and DV E are similar in size (64 kDa and 54 kDa respectively), and the antibodies 
used in Chapter 4 for immunodetection of DV E from Western blots were shown to 
cross-react with baculovirus GP64 (discussed in section 4.9.6).  It was therefore 
decided that it was unfeasible at this time to attempt analysis of low pH-induced DV E 
oligomeric rearrangements using this method, as clear distinction from baculovirus 
GP64 was not possible.  Once purification of the dengue VLPs is successful it is 
intended that this experiment will be re-visited. 
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5.7 Dengue virus-like particle ELISA using human serum 
To assess the suitability of the dengue VLPs as a source of diagnostic antigen, an ELISA 
was performed using human serum containing DV antibodies (Figure 5.15; section 
2.9.1).  DV antibody negative human serum was used as a negative control.  ELISA 
plates were coated with dengue VLP or lacZ samples at 1µg/mL (0.1µg/well), as with 
the dengue VLP mAb ELISAs performed previously (sections 5.3 to 5.5).  DV antibody 
positive and negative human sera were obtained from the National Institute for 
Biological Standards and Control (NIBSC) for use as the primary antibody.  The 
secondary antibody used was HRP-conjugated goat polyclonal anti-human IgG.  A 
positive threshold value (1.019) was calculated as with previous ELISAs based on the 
average lacZ sample absorbance plus three standard deviations.  This positive 
threshold value was far greater than any observed previously with the dengue VLP 
mAb ELISA as the average signal from the lacZ sample was so high, indicating non-
specific binding to a non-DV protein was occurring.  Only four of the dengue VLP 
samples (R097A_4, R097A_13, R097A_43 and R203A_2) enabled detection of the DV 
antibodies with average absorbance signals that were greater than this positive 
threshold value.  Whilst the DV antibody negative sera produced average signals for all 
of the dengue VLPs (range 0.521 to 0.892) that were less than the positive threshold 
value, the negative serum had not been expected to bind to the dengue VLP samples 
at all as it did not contain DV antibodies.  Signal to noise ratios (Table 5.10) were 
calculated as before, and were shown to be similar in range for both DV antibody 
positive (range 0.89 to 1.53) and negative (range 0.88 to 1.50) human serum.  
For each sample antigen, control wells lacking the DV antibody positive or negative 
human serum were also included to measure any direct binding of the secondary 
antibody to the sample antigens.  The absorbance values from these wells were the 
same as for non-coated wells (data not shown), confirming that the secondary 
antibody was not binding directly to the dengue VLP or lacZ sample antigens.  This 
indicated that the absorbance signals observed from the lacZ sample-coated wells 
were due to non-specific binding of the human serum to non-DV proteins in the 
samples.   
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Table 5.10.  Signal to noise ratios for the dengue VLP samples using human serum as primary 
antibody in the dengue VLP ELISA. 
Dengue VLP 
sample 
DV antibody positive 
human serum 
S:N 
DV antibody negative 
human serum 
S:N 
R097A_4 1.27 1.11 
R097A_13 1.53 1.50 
R097A_43 1.09 0.93 
R203A_2 1.12 1.15 
R203A_54 1.01 0.95 
R261A_1 0.97 1.06 
R261A_4 0.93 1.06 
R107A_1 0.92 0.94 
R107A_22 0.89 0.88 
 
Optimisation of the human serum concentration may have reduced the observed 
cross-reactivity and improved signal to noise ratios between the dengue VLP and lacZ 
samples.  However, it was decided not to proceed until the dengue VLPs samples had 
been further purified to reduce the potential for cross reactivity. 
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5.8 Discussion 
The first objective for this chapter was to develop and optimise a dengue VLP ELISA 
using the recombinant dengue VLPs produced in Chapter 4 as antigen.  This was to 
enable detection of the dengue VLPs over the non-DV background proteins present in 
the dengue VLP samples.  The optimised ELISA was then intended to be used as the 
basis for capture ELISAs using recombinant DC-SIGN and heparin, as DC-SIGN and HSHS 
(a heparin analogue) are implicated in DV attachment to host cells.  These capture 
ELISAs would allow comparison of the host cell attachment capabilities of the DV 
quasispecies consensus and variant VLPs within each patient sample set.  To compare 
the ability of the quasispecies consensus and variant VLPs to undergo low pH-induced 
E oligomeric rearrangements, dengue VLPs were intended to be subjected to low pH 
and the oligomeric conformation assessed.  The dengue VLPs were also to be tested by 
ELISA using human serum containing DV antibodies, to assess their suitability as source 
of antigen for diagnostic ELISAs. 
5.8.1 Development and optimisation of an ELISA using recombinant dengue 
virus-like particles as antigen 
Initially two ELISAs were tested to compare dengue VLP and non-DV protein 
background detection using either a mouse mAb to DV E (mAb ELISA; Figure 5.1) or a 
rabbit pAb to DV types 1, 2, 3 and 4 (pAb ELISA; Figure 5.2) as the primary antibody.  
The lacZ sample (concentrated clarified medium from rBV.lacZ-infected cells) was used 
as a background control, representative of the non-DV proteins present in the dengue 
VLP samples.  A statistical positive threshold value was calculated for each ELISA based 
on the average lacZ sample absorbance (from three replicates) plus three standard 
deviations, as this encompasses 99.7% of normally distributed data (Swinscow, 1996).  
The mAb ELISA proved superior to the pAb ELISA both in terms of a lower positive 
threshold value and greater signal to noise ratios (Table 5.1) for all but one (R097A_13) 
of the dengue VLP samples tested.  However, both ELISAs still displayed significant 
antibody cross-reactivity with the lacZ background control sample. 
Baculovirus GP64 was confirmed as the source of the antibody cross-reactivity 
observed using purified GP64 as antigen (Figures 5.1 to 5.3).  For the pAb ELISA, results 
indicated that it was the primary antibody (rabbit pAb to DV types 1, 2, 3 and 4) that 
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was binding non-specifically to baculovirus GP64 (Figure 5.3).  For the mAb ELISA, the 
secondary antibody (HRP-conjugated rabbit pAb to mouse IgG) was identified as the 
source of the non-specific binding (Figure 5.3).  Reactivity to baculovirus GP64 was not 
observed when the pAb ELISA secondary antibody (HRP-conjugated goat pAb to mouse 
IgG) was used alone.  Taken together, these results suggest that a component of rabbit 
serum is able to bind to baculovirus GP64, and that sourcing antibodies raised in a 
species other than rabbit might alleviate the cross-reactivity.  No polyclonal DV 
antibodies raised in mouse or goat were able to be sourced commercially, so the pAb 
ELISA was not tested further.  Non-specific antibody reactivity to non-DV proteins in 
the samples was shown to be consistent across all of the dengue VLP samples and the 
lacZ background control sample, based on the absorbance values generated by the 
mAb ELISA using only the secondary antibody (Figure 5.3).  This confirmed that the lacZ 
sample was an appropriate background control for these ELISAs.  Even without 
substituting the secondary antibody for the mAb ELISA, after optimisation of blocking 
conditions, and primary and secondary antibody concentrations, all nine of the dengue 
VLP samples were able to be detected over the non-DV protein background signal.   
5.8.2 Comparison of dengue virus-like particle samples binding to DC-SIGN 
via a capture ELISA 
DC-SIGN and other similar lectins have been proposed as DV receptors both at the 
initial site of infection (DCs; Tassaneetrithep et al., 2003) and also at secondary sites 
(endothelial cells and macrophages; Miller et al., 2008; Navarro-Sanchez et al., 2003).   
The ability of the dengue VLP samples to bind to recombinant DC-SIGN was assessed 
using the dengue VLP mAb ELISA with an additional DC-SIGN capture step.  The dengue 
VLP mAb ELISA was performed in parallel to the capture ELISA using the same samples, 
so the relative absorbance signals could be directly compared between the two ELISAs.  
Lectins such as DC-SIGN bind high-mannose glycans in the presence of calcium ions 
(Feinberg et al., 2001).  To the best of my knowledge, binding of baculovirus GP64 to 
DC-SIGN has not been shown, but was a possibility due to GP64s glycosylated status.   
The initial DC-SIGN capture ELISA (Figure 5.8) was performed using all of the dengue 
VLP samples, and ELISA plates coated with DC-SIGN at 1 µg/mL.  The dengue VLP 
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samples displayed a similarly low affinity for DC-SIGN as the lacZ sample, so the ELISA 
was repeated (Figure 5.9) using just the R107A_1 dengue VLP and lacZ samples, and 
ELISA plates coated with DC-SIGN at increasing concentrations (1 µg/mL to 100 µg/mL).  
The dengue VLP sample average absorbance signal was not greater than the calculated 
positive threshold value at any of the DC-SIGN coating concentrations tested.  
Although the average signals increased, the signal to noise ratios (Table 5.6) decreased 
with increasing DC-SIGN coating concentration.  The absorbance signals generated 
were shown to result from the secondary antibody (HRP-conjugated rabbit pAb to 
mouse IgG) binding directly to DC-SIGN.  The recombinant DC-SIGN used for the 
capture ELISA was a chimeric fusion protein, with the extracellular domain of human 
DC-SIGN fused to the Fc region of human IgG1.  It may be that the secondary antibody 
was binding directly to the human IgG1 Fc region of the chimeric protein rather than 
the DC-SIGN region.   
Both the dengue VLP and lacZ samples showed no affinity for DC-SIGN at any of the 
concentrations tested.  This was unexpected for the dengue VLP samples and may 
indicate that the recombinant DV E glycans were not sufficiently processed by the 
insect cells, affecting binding of the dengue VLPs to DC-SIGN.  It may be that further 
increasing the DC-SIGN coating concentration would enable the dengue VLPs to bind to 
the DC-SIGN.  However, as an alternative recombinant DC-SIGN protein (not fused to 
the human IgG1 Fc region) would be required to overcome the problem of the 
secondary antibody binding to the recombinant DC-SIGN, it was decided to move on to 
testing the dengue VLP samples using a heparin capture ELISA. 
5.8.3 Comparison of dengue virus-like particle samples binding to heparin 
via a capture ELISA 
HSHS expressed on the surface of target cells has been shown to bind DV E (Chen et 
al., 1997), and is thought to concentrate the virus on the cell surface, enabling 
subsequent higher-affinity interactions with specific receptors.  Heparin is also highly 
sulphated, with close structural homology to heparan sulphate.  As such, heparin is an 
acceptable surrogate for HSHS in binding studies, and has been previously used in 
investigations of DV E binding to host cells (Chen et al., 1997; Marks et al., 2001; 
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Thullier et al., 2001).  The ability of the dengue VLP samples to bind to heparin was 
assessed using the dengue VLP mAb ELISA with an additional heparin capture step.  
The dengue VLP mAb ELISA was performed in parallel to the capture ELISA using the 
same samples, and the lacZ sample was used as a background control. 
The initial heparin capture ELISA (Figure 5.11) was performed using ELISA plates coated 
with heparin at 1 mg/mL.  As the dengue VLP samples displayed a similarly low affinity 
for heparin as the lacZ sample, the ELISA was repeated (Figure 5.12) using just the 
R107A_1 dengue VLP and lacZ samples, with ELISA plates coated with increasing 
concentrations of heparin (1 mg/mL to 100 mg/mL.  The dengue VLP sample average 
absorbance signal was greater than the calculated positive threshold at the highest 
heparin coating concentrations (50 and 100 mg/mL).  The signal to noise ratios (Table 
5.8) also increased with increasing heparin coating concentration, so that at the 50 and 
100mg/mL heparin coating concentrations, the signal from the dengue VLP sample was 
clearly distinguishable from the background signal measured using the lacZ sample.   
The heparin capture ELISA was then performed on all of the dengue VLP samples using 
ELISA plates coated with heparin at 100mg/mL, which had been shown to produce an 
optimal signal to noise ratio, and a low positive threshold value (Figure 5.12).  The 
dengue VLP mAb ELISA was performed in parallel to the capture ELISA using the same 
samples so the absorbance signals could be directly compared between the two ELISAs 
(Figure 5.13).  A measure of the dengue VLPs for each sample that were available to 
bind to the heparin was obtained using the dengue VLP mAb ELISA, and the proportion 
of these actually bound to heparin was calculated from the heparin capture ELISA 
results (Table 5.9).  The R097A sample set showed the greatest discrepancy between 
the amount of available dengue VLPs and those able to bind to the heparin.  The 
contrast between the quasispecies consensus and variant VLP samples was also more 
extreme for the R097A sample set than was seen with any of the other sample sets.  
For the consensus protein sample R097A_4, 97% of the available dengue VLPs bound 
to heparin, whilst for the variant protein samples R097A_13 and R097A_43, 0% and 
20% respectively of the available dengue VLPs bound to heparin.  The R203A and 
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R261A sample sets both exhibited an increase in the proportion of available dengue 
VLPs bound to heparin in the variant (R203A_54, 78%; R261A_4, 64%) compared to 
consensus protein samples (R203A_2, 49%; R261A_1, 51%).  The R107A sample set 
showed almost no difference in heparin binding between consensus (R107A_1, 57%) 
and variant (R107A_22, 56%) protein samples. 
The R097A_13 quasispecies variant VLP sample contains a single residue substitution 
in E compared to the R097A_4 quasispecies consensus VLP sample.  This residue 
substitution is at position E320, and involves the substitution of a nonpolar amino acid 
with a large aliphatic hydrophobic side chain (isoleucine) with a polar amino acid 
(threonine).  DV E position E320 was demonstrated by three-dimensional modelling 
(section 3.9) to be within 4Å of a proposed HSHS binding site implicated in DV binding 
to host cells (Chen et al., 1997; Thullier et al., 2001).  Neutralisation escape mutations 
in multiple flaviviruses map to this HSHS binding site (Jiang et al., 1993; Lin et al., 
1994).  Isoleucine is often important for the correct folding of protein, so it may be 
that the substitution of isoleucine for threonine is sufficient to disrupt the protein 
structure around the HSHS binding site so that binding to heparin is prevented.  This 
would be consistent with the heparin capture ELISA results, which showed no heparin 
binding for this dengue VLP sample. 
The R097A_43 quasispecies variant VLP sample also contains a single residue 
substitution in E compared to the R097A_4 quasispecies consensus VLP sample.  This 
residue substitution is at position E280 and involves the substitution of a basic amino 
acid with an imidazole ring (histidine) for a nonpolar amino acid with a large aliphatic 
hydrophobic side chain (leucine).  DV E position E280 was demonstrated by three-
dimensional modelling (section 3.9) to be surface accessible, and located within the kl 
hairpin loop at the domain I/II interface, which is implicated in conformational 
rearrangements during fusion (Modis et al., 2003).  Removal of the histidine residue at 
this location was predicted to impact on the protein’s response to acidic environments, 
not cell attachment.  However, although E position E280 is distant from the HSHS 
binding site, it does reside at the interface between structural domains I and II. 
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Flavivirus E amino acid substitutions that affect virulence have been shown to cluster 
at the interfaces between E structural domains (Rey et al., 1995); Figure 1.16).  In this 
case, the substituted amino acid leucine will tend to orient to the interior of the folded 
protein due to its hydrophobic nature, which may impact upon protein folding.  
Changes in structure at protein domain interfaces could have magnified consequences 
for other domains within the protein as the interfaces between domains often act as 
hinge regions during conformational change.  This residue substitution at such an 
important location may alter the relative orientations of the other protein domains 
such that the HSHS binding site is less accessible (relative to the quasispecies 
consensus VLP sample R097A_4).  This would be consistent with the heparin capture 
ELISA results for this sample, which showed only 20% of the available dengue VLPs 
bound to heparin. 
Decreased ability to bind HSHS might be expected to confer a selective disadvantage 
for the DV quasispecies variant, as the cell attachment process would be less efficient.  
This would lead to decreased infectivity compared to variants demonstrating a higher 
affinity for HSHS.  However, quasispecies variants with lower HSHS affinity would still 
be able to enter cells in an antibody-dependent manner by forming a complex with 
non-neutralising antibodies from a previous DV infection.  Such quasispecies variants 
would then enter leukocytes via fc receptor-mediated endocytosis, but remain in a 
non-neutralised state and be able to replicate and disseminate more virus.  The 
production and secretion of chemokines and cytokines by the cell in response to the 
subsequent increase in viral replication is thought to lead to the increase in vascular 
permeability that is the hallmark of severe dengue (Halstead, 1988).  The R097A 
sample was obtained from a patient with severe dengue, which was later confirmed to 
be a secondary infection.  Therefore, this patient had pre-existing antibodies to a 
previous DV infection, which would have enabled uptake of quasispecies variants with 
low heparin binding affinity into the host cells.  
The R203A_54 and R261A_4 quasispecies variant VLPs each contain amino acid 
substitutions within E compared to their respective quasispecies consensus VLPs 
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(R203A_2 and R261A_1).  For R203A_54 there are amino acid substitutions at two 
locations.  One of these is at position E202, and involves a conservative amino acid 
change where a basic amino acid (lysine) is replaced with a functionally similar basic 
amino acid (arginine).  Three-dimensional modelling (Table 3.15) demonstrated DV E 
position E202 to be within 4Å of the other protein chain that makes up the dimer.  
Mutations leading to amino acid substitutions at E position E202 commonly occur 
during routine serial passage in mammalian cells (Lee, Weir and Dalgarno 1997).  
Therefore, as suggested in Chapter 3, this mutation may represent a beneficial 
adaptation of the virus to growth in mammalian cells.  The other amino acid change in 
R203A_54 is at position E345, and involves a drastic amino acid substitution where 
three amino acids (histidine-asparagine-glycine) are replaced with five amino acids 
(isoleucine-glutamine-isoleucine-serine-serine).  Incorporating the two extra residues 
into the protein chain was predicted to impact on protein structure (section 3.10).  
Three-dimensional modelling (section 3.9) demonstrated DV E position E345 to be 
situated on the surface of the protein at the distal face of domain III.  This part of the 
domain is thought to contain the flavivirus receptor-binding motif (Crill and Roehrig, 
2001) and amino acid subtitutions in this part of the domain are known to affect 
virulence and cell tropism, presumably through interference with cell attachment.  This 
is consistent with the heparin capture ELISA results for this sample, which showed 
increased ability to bind heparin compared to the quasispecies consensus dengue VLP 
for this sample set (R203A_2). 
The R261A_4 amino acid substitution is at position E201 and involves a conservative 
amino acid change where a polar amino acid with a long hydrophilic side chain 
(asparagine) is replaced with a polar amino acid (serine).  Three-dimensional modelling 
(Table 3.15) demonstrated DV E position E201 to be surface accessible, and located 
within the same hinge region at the domain I/II interface as the R097A_43 drastic 
amino acid substitution and the R203A_54 conservative substitutions.  This 
conservative protein change at this location may alter the relative orientations of the 
other protein domains, such that the HSHS binding site is more accessible (relative to 
the quasispecies consensus VLP sample R261A_1).  This would be consistent with the 
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heparin capture ELISA results, which showed increased ability to bind heparin for the 
R261A_4 dengue VLP sample compared to the quasispecies consensus VLP for this 
sample set (R261A_1).   
Increased ability to bind HSHS could be predicted to confer a selective advantage for 
the DV quasispecies variant, as the cell attachment process would be more efficient.  
This could lead to increased infectivity compared to variants demonstrating a lower 
affinity for HSHS, which would be reflected in the quasispecies population, as variants 
with high affinity for HSHS would be expected to replicate faster and comprise a higher 
proportion of the population.  In support of this, the residue substitution at E position 
E201 was identified in six (13%) of the clones from the DV quasispecies population 
from patient R261A.  In Chapter 3 it was proposed that the relative abundance of this 
lineage within the quasispecies population for this sample could be due to increased 
replication efficiency.  However, routine passage of a DV type 4 vaccine candidate in 
fetal rhesus lung cells yielded a virus variant with increased HSHS binding affinity, 
which predominated over other quasipecies variants within three passages, but 
exhibited reduced infectivity and immunogenicity in rhesus monkeys (Anez et al., 
2009).  This virus variant became less dominant within the quasispecies population 
when the virus population was transferred from mammalian cell culture into a 
mosquito cell line (C6/36); selection of the parental wild-type virus was favoured in the 
mosquito cells.  Rapid clearance from the bloodstream and reduced ability to cause 
disseminated infection were proposed as the explanation for virus attenuation despite 
increased HSHS binding affinity (Anez et al., 2009).  HSHS is a component of 
extracellular matrices so it is conceivable that increased heparin binding ability could 
result in the virus becoming trapped extracellularly and therefore being cleared more 
rapidly from the host. 
The R203A sample was obtained from a patient with severe dengue, which was later 
confirmed to be a secondary infection.  The R261A sample was obtained from a patient 
with mild dengue, but follow-up samples after discharge from hospital were not taken, 
so serological confirmation of the type of infection (primary or secondary) could not be 
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obtained.  If patient R261 had a primary infection, and therefore no pre-existing DV 
antibodies, this could explain the difference in disease severity between patient R261 
and patient R203 (who had a secondary infection), despite the increased heparin 
binding ability of the quasispecies variants.   
5.8.4 Comparison of dengue virus-like particle samples oligomeric 
rearrangements in response to low pH  
It had been intended to compare the quasispecies consensus and variant dengue VLPs 
in terms of their ability to undergo conformational rearrangements in response to low 
pH.  These conformational rearrangements are required during DV infection to enable 
fusion of virus and cell membranes and subsequent replication of the virus genome by 
the host cell.  However, given the similarities between DV E and baculovirus GP64, it 
was decided that it would be too difficult to distinguish between them using this 
method.  This experiment was therefore put on hold until the dengue VLPs and 
baculovirus had been separated by further purification. 
5.8.5 Dengue virus-like particle ELISA using human serum 
To assess the suitability of the dengue VLPs as source of antigen for diagnostic ELISAs, 
a dengue VLP ELISA was performed using human serum containing antibodies to all 
four DV types (Figure 5.15).  High levels of binding were observed between the human 
serum and the lacZ background control sample, indicating that the human serum was 
binding non-specifically to non-DV proteins within the sample.  The same problem had 
been observed previously in the dengue VLP pAb ELISA, which used rabbit polyclonal 
serum containing DV antibodies as the primary antibody, and to a lesser extent in the 
dengue VLP mAb ELISA, which used rabbit pAb to mouse IgG as the secondary 
detection antibody.  In both of these cases, baculovirus GP64 was shown to be the 
source of the cross-reactivity, using purified GP64, so it is likely that is also the case 
with the human serum. 
It was therefore demonstrated that these dengue VLP samples were unsuitable for use 
as antigen in diagnostic ELISAs due to the cross-reactivity observed.   Although this 
cross-reactivity may have been reduced by optimisation of the human serum 
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concentration, it was decided not to proceed with this until the dengue VLP samples 
had been further purified to remove the contaminating baculovirus.   
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5.9 Conclusions and summary 
As set out in the objectives for this chapter, an ELISA was developed and optimised 
that enabled detection of all of the recombinant dengue VLPs produced in Chapter 4.  
With this ELISA it was demonstrated that similar levels of background (non-DV) protein 
were present in the dengue VLP and lacZ background control samples, confirming the 
suitability of the lacZ sample as a background control using this ELISA method.  
Baculovirus GP64 was indicated as the primary cause of the antibody cross-reactivity 
using purified GP64. 
To assess the cell-attachment capabilities of the dengue VLPs, and perform 
comparisons between the quasispecies consensus and variant VLPs from each sample 
set, DC-SIGN and heparin capture ELISAs were performed.  The DC-SIGN capture ELISA 
was unsuccessful as no dengue VLP binding to DC-SIGN was detected over that 
observed from the lacZ background control.  The absorbance signals generated were 
shown to result from the secondary antibody binding directly to the recombinant DC-
SIGN.  It was decided not to proceed with the DC-SIGN capture ELISA until an 
alternative source of either recombinant DC-SIGN or secondary antibody that 
overcame these problems could be acquired.   
The heparin capture ELISA was developed and optimised, and showed differences in 
heparin binding ability of four of the variant VLP samples compared to their respective 
consensus VLPs.  Reductions in heparin binding ability were observed for both of the 
variant VLP samples (R097A_13 and R097A_43) from the R097A sample set.  The 
R097A_13 sample contained a drastic residue substitution within 4Å of the proposed 
HSHS binding site, so alterations in heparin binding had been predicted previously 
(Table 3.15) for this sample.  The R097A_43 sample contained a drastic residue 
substitution at the interface of DV E structural domains I and II, which had been 
predicted to impact upon low pH-induced conformational change and fusion rather 
than cell attachment.  Improvements in heparin binding ability were observed for the 
variant VLP samples (R203A_54 and R261A_4) from both the R203A and R261A sample 
sets.  The R203A_54 VLP sample contained amino acid substitutions in two locations.  
One of these was a drastic residue substitution on the distal face of domain III, which 
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had been predicted to potentially alter cell attachment.  The other amino acid 
substitution in the R203A_54 sample was a conservative residue substitutions at E201.  
A similar conservative amino acid change was observed in the R261A_4 VLP sample at 
E202, within the interface between structural domains I and II, as described for the 
R097A_43 VLP sample.  It is proposed that, as the interfaces between DV structural 
domains function as hinge regions during conformational changes, residue 
substitutions in these positions may alter the relative orientation of other domains 
within the protein.  This could be either detrimental (as in the case of the R097A_43 
drastic residue substitution) or beneficial (as in the case of the R203A_54 and R261A_4 
conservative residue substitutions) to heparin binding affinity, by altering the 
accessibility of the HSHS binding site.  Further support could be lent to these 
conclusions by computational modelling of the effects of these residue substitutions 
on the structure of DV E.  These results are a preliminary indication of differences in 
infectivity possessed by DV variants within the quasispecies population.  Linking these 
observations to disease severity is complex, as quasispecies variants with low heparin 
binding affinity can still enter cells in an antibody-dependent manner and 
subsequently replicate, provided pre-existing antibodies to a previous DV infection are 
present.  Secondary DV infections were confirmed in patients R097 and R203, who 
both experienced severe disease.  However, for patient R261, who experienced mild 
disease, but also exhibited an abundance of quasispecies variants with increased 
heparin binding affinity, serological confirmation of the type of infection (primary or 
secondary) could not be obtained. 
To assess the suitability of the dengue VLPs as source of antigen for diagnostic ELISAs, 
assays were performed using human serum containing antibodies to DV as the primary 
antibody.  These ELISAs were unsuccessful as it was found that human serum (both 
positive and negative for DV antibodies) bound to the lacZ background control sample 
similarly to the dengue VLP samples.  Similar cross-reactivity was observed previously 
using rabbit serum in the initial dengue VLP mAb and pAb ELISAs, and baculovirus 
GP64 identified as the likely cause using purified GP64.  Further analysis was deemed 
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unfeasible until the dengue VLPs had been effectively purified to remove the 
contaminating baculovirus. 
It was also intended as part of this chapter to investigate the ability of the dengue VLPs 
to undergo low pH-induced oligomeric rearrangements required for membrane fusion.  
However, due to the similarities between DV E and baculovirus GP64, this experiment 
was postponed until the dengue VLPs could be further purified. 
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CHAPTER 6. FINAL DISCUSSION, 
CONCLUSIONS AND FUTURE WORK 
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The work presented in this thesis was undertaken to improve the available knowledge 
surrounding dengue virus (DV) quasispecies populations and to investigate links with 
disease severity.  The hypothesis was that DV quasispecies populations affect disease 
severity in individual patients.  Work previous to this thesis demonstrated that DVs 
exist as quasispecies populations within individual mosquito and human hosts (Chao et 
al., 2005; Craig et al., 2003; Lin et al., 2004; Wang et al., 2002a; Wang et al., 2002b).  
Initial studies looked at DVs from patients or mosquitoes in Taiwan (Lin et al., 2004; 
Wang et al., 2002a) and Myanmar (Craig et al., 2003), and focused on the DV envelope 
glycoprotein (E) gene, as it encodes E, which comprises the majority of the outer 
surface of the virion.  Subsequent work has shown that the DV E gene region exhibits 
greater heterogeneity than any other region of the genome (Chao et al., 2005; Wang 
et al., 2002b).  As a result of so few studies, little is known about how DV quasispecies 
population dynamics vary between different individuals, host populations and 
infecting virus strains.  Expanding the knowledge in this area is essential for in-depth 
understanding of the biology, epidemiology and evolution of DV.  This has implications 
for disease pathogenesis, vaccine design and safety, the implementation of effective 
control and treatment programs, and the development of novel therapeutic and 
diagnostic tools.   
The primary aim of the work presented in this thesis was to investigate DV 
quasispecies populations, both within individual patient samples and between samples 
from the same outbreak in Sri Lanka, in 2006.  Relationships between quasispecies 
variation and disease severity were also examined.  Across the six dengue patient 
samples successfully analysed, an average mean diversity of 0.018% (range 0.0034% to 
0.053%) was obtained for the intrahost quasispecies populations, which is consistent 
with reported error rates for viral RNA polymerases during natural replication (0.01%; 
Smith et al., 1997).  No statistically significant correlations were observed between the 
extent of quasispecies variation and disease severity.  Compared to previously 
reported mean diversities of between 0.22% and 0.47% (Craig et al., 2003; Lin et al., 
2004; Wang et al., 2002a), the results from this study show considerably less 
quasispecies variation in all of the patient samples analysed.  This difference in the 
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extent of quasispecies sequence variation was shown to be directly related to the 
fidelity of the enzymes used by each group for RT-PCR amplification of the DV RNA.  
These results have demonstrated clearly that future work of this kind must be 
conducted using high-fidelity enzymes for both reverse transcription and amplification 
of cDNA by PCR.  In light of the results from this study, previously reported DV 
quasispecies mean diversities need to be re-examined to account more accurately for 
mutations introduced by the amplification process itself.   
Consistent with previous reports (Wang et al., 2002a), genome-defective quasispecies 
variants with insertion or deletion mutations were observed predominantly in samples 
from patients with severe cases of dengue.  These observations are consistent with a 
role for specific quasispecies variants in the pathogenesis of disease; however, further 
work would be required to determine their contribution to disease pathogenesis.  It 
has been suggested previously that the transmission of defective quasispecies variants 
may be selectively advantageous for co-infecting non-defective variants by ensuring 
the presence of viruses differentially adapted to human or mosquito cells, modulating 
host immune responses, or allowing the production of extra C and prM (Aaskov et al., 
2006).  Longer-term studies of DV quasispecies populations from humans and 
mosquitoes in Sri Lanka would be required to determine whether the genome-
defective quasispecies variants identified in this study were stably transmitted, and 
were present after the 2006 dengue season.  
Given the technological advances that have occurred since beginning this work, in 
particular with regards to next-generation sequencing, it is likely that studies like this 
will be conducted very differently in future.  Massively parallel ultra-deep 
pyrosequencing has been used for the detailed analysis of human immunodeficiency 
virus (HIV) quasispecies populations from individual patients (Rozera et al., 2009).  PCR 
products were clonally amplified on capture beads in water-in-oil emulsion micro-
reactors, abolishing the need for cloning into E. coli.  The quantity of data generated 
(13,456 reads per sample) was several orders of magnitude higher than any previously 
obtained using conventional approaches based on cloning of PCR products or limiting 
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dilution PCR.  Similarly, next-generation sequencing has been used to examine 
quasispecies populations of foot and mouth disease virus (Wright et al., 2011) and the 
2009 pandemic influenza A virus (Kuroda et al., 2010).  The current limitations to this 
approach include the requirement for large quantities of DNA (µg) as starting material, 
short sequence read lengths, high intrinsic error frequency, high cost, and difficulties 
with computational analysis of such large data sets.  These are likely to be improved as 
development of the technology progresses. 
To investigate relationships between the infecting DV genotype and disease severity, 
phylogenetic analyses of the intrahost quasispecies populations were conducted for 
the six dengue patient samples using the quasispecies E gene sequences.  Within each 
DV type, strains (quasispecies consensus sequences) from different patients were 
identified as having greater than 99% sequence homology, and were shown to be the 
same genotype, appropriate to the geographic origin of the samples.  No relationship 
was observed between the infecting DV genotype and disease severity, because within 
DV types, all of the quasispecies consensus and variant E gene sequences were 
identified as the same genotype, regardless of the severity of disease experienced by 
the patient.  Consistent with this observation, there was no evidence of intra-DV type 
(inter-genotype) recombination in the quasispecies populations from any of the 
patient samples. However, sequencing the rest of the genome for the DV quasispecies 
populations from these patient samples could yield further differences between them 
that could account for the differences in disease severity, and would enable 
identification of recombination events outside of the E gene.  Mutations in the 5’ and 
3’ non-coding regions and the non-structural-5 (NS5) gene of DVs have been shown to 
be associated with changes in viral replication efficiency (Leitmeyer et al., 1999; Tajima 
et al., 2007; Zhao et al., 2010).  Increased viral replication efficiency has been linked to 
high viral loads in blood, and severe disease presentation (Wang et al., 2006).    
The locations of amino acid substitutions encoded by the DV quasispecies E gene 
mutations were mapped to the three-dimensional structure of DV E.  This was to 
identify those mutations with the potential to affect virulence or cell tropism on the 
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basis of their proximity to important structural features.  Amino acid substitutions that 
were surface accessible, or proximal to the fusion peptide, proposed HSHS binding site 
or the other protein chain within the E dimer, were highlighted.  Amino acid 
substitutions were less frequently observed at these locations in the samples from 
patients with mild disease than in those from patients with severe disease, which is 
also consistent with a role for specific quasispecies variants in the pathogenesis of 
disease.  Using this method, nine E gene clones were identified for recombinant 
protein production to further investigate the effects of the mutations on protein 
function.  These nine variants were from four different patient samples, and were 
chosen because they either represented the quasispecies consensus E gene sequence 
for that patient sample, or they contained a nonsynonymous non-frameshift mutation 
with the potential to affect virulence or cell tropism.   
Recombinant baculoviruses (rBVs) were produced containing the DV type 1 pre-
membrane glycoprotein (prM) gene, and each of the quasispecies variant E genes.  
Upon infection of insect cells with the rBVs, secreted dengue virus-like particles (VLPs) 
were produced, comprising DV type 1 membrane (M) and quasispecies E.  The source 
of the prM gene was kept consistent so that any differences in protein function 
between the VLPs could be attributed to variations in E.  Attempts to purify the dengue 
VLPs were unsuccessful, and there were problems with immunodetection of the 
dengue VLPs from Western blots due to antibody cross-reactivity with baculovirus 
GP64.  Production of dengue VLPs in a plasmid vector based expression system would 
provide a cleaner VLP preparation in that there would not be baculovirus, or other viral 
vectors present.  This would overcome the problems observed with antibody cross-
reactivity with baculovirus GP64, thus enabling efficient purification by 
immunoprecipitation and also improving immunodetection.   
The use of recombinant proteins as antigen avoids the need to culture and purify large 
quantities of DV, traditionally sourced from tissue culture or suckling mouse brain, 
which requires high-containment facilities (Containment Level 3).  It also permits the 
introduction of gene mutations that lead to amino acid substitutions in the protein 
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that may alleviate the flavivirus antibody cross-reactivity observed using wild-type 
proteins.  To assess the suitability of the dengue VLPs as a source of antigen for 
diagnostic ELISAs, assays were performed using human serum containing antibodies to 
DV.  Unexpectedly the human serum was shown to bind non-specifically to a non-DV 
component of the clarified culture medium from rBV-infected insect cells.  This cross-
reactivity prevented assessment of the dengue VLPs for sensitivity and specificity in 
diagnostic ELISAs using human serum.  Similar cross-reactivity was observed previously 
using rabbit serum, and baculovirus GP64 was identified as the cause.  Further 
purification of the dengue VLPs to remove the contaminating baculovirus would 
enable these assays to be repeated, and for the dengue VLPs to be tested against 
serum collected from individuals vaccinated against non-DV flaviviruses.  Quasispecies 
variants demonstrating reduced flavivirus cross-reactivity could then be used to 
develop improved assays for the diagnosis of DV infection, as was intended during this 
study.  To the best of my knowledge, quasispecies variants have not been previously 
assessed in this way.  However, during the course of this work it was reported that 
flavivirus VLPs constructed using SLEV, WNV and JEV prM and E genes with mutations 
in the fusion peptide exhibit dramatically reduced flavivirus antibody cross-reactivity 
compared to wild-type VLPs using IgM capture ELISAs (Chiou et al., 2008; Roberson, 
Crill, and Chang, 2007).  The work presented in this study also identified a need for 
more DV-specific antibodies to be made available to the wider scientific community, as 
many of the commercially available antibodies tested for this work were found to be 
not sensitive, specific or reliable enough for use.  Purified quasispecies variant dengue 
VLPs demonstrating reduced flavivirus cross-reactivity could also be used as 
immunogen to produce more effective DV-specific antibodies. 
This study demonstrated alterations in heparin binding ability in four of the 
quasispecies variant VLP samples (R097A_13, R097A_43, R203A_54 and R261A_4) 
compared to their respective consensus VLPs (R097A_4, R203A_2 and R261A_1).  Both 
samples displaying reductions in heparin binding ability were from the same patient 
(R097A), who exhibited severe disease.  The two samples that showed increased 
heparin binding ability were from different patients, one of which had mild disease 
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(R261A), and one had severe disease (R203A).  The R097A_13 and R203A_54 dengue 
VLP samples contained nonsynonymous E gene mutations in close proximity to the 
putative highly-sulphated heparan sulphate (HSHS) binding region of E.  The R097A_43 
and R261A_4 dengue VLP samples contained nonsynonymous E gene mutations at the 
interface of E structural domains I and II, which is thought to act as a hinge region 
during low pH-induced conformational changes that lead to fusion of virus and host 
cell membranes.  It is hypothesised that residue substitutions in these positions may 
alter the relative orientation of other domains within the protein, thus altering the 
accessibility of the HSHS binding site.  Given the status of HSHS as a putative receptor 
for DV, it is tempting to predict that increased heparin binding ability would lead to 
increased viral replication and correlate with severe disease.  However, quasispecies 
variants with low heparin binding affinity can still enter cells in an antibody-dependent 
manner and subsequently replicate, provided pre-existing antibodies to a previous DV 
infection are present.  Also, HSHS is a constituent of extracellular matrices, as well as 
being present on the surface of cells targeted by DVs.  Therefore, increased heparin 
binding affinity could result in the virus becoming trapped extracellularly.  This may aid 
the formation of immune complexes containing DV, but whether this would result in a 
more rapid clearance of the virus from the system, or whether the increased heparin 
binding affinity would slow down the process of virus clearance remains to be 
determined.  During defervescence, slower rates of clearance of DV and immune 
complexes have been associated with subsequent immune activation and progression 
to severe disease (Wang et al., 2006).  Further work is required to determine whether 
the differences in heparin binding ability observed during this study result in altered 
cell attachment capabilities and subsequent changes in the efficiency of viral 
replication.  Potential future work includes using surface plasmon resonance (SPR) to 
monitor the interactions between the quasispecies dengue VLPs and heparin in real-
time and obtain more data regarding the binding affinity and kinetics.  Cells expressing 
HSHS on their surface could also be used in place of heparin, to provide a better 
measure of the cell attachment capabilities of the quasispecies variant dengue VLPs.  
This method could also be used to investigate potential anti-viral compounds that act 
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by inhibiting virus attachment to host cells, as has been recently shown for 
noroviruses, using VLPs (Rademacher et al., 2011).   
For this study, a limited number of the identified quasispecies variants were produced 
as recombinant DV E in the form of dengue VLPs, to study the effects of the E gene 
mutations on E function.  An alternative methodology would have been to use the 
quasispecies E gene variants to construct genome-length infectious clones.  Positive 
strand RNA virus (e.g. flavivirus) genomes are infectious, as RNA acts directly as mRNA 
for protein synthesis.  Therefore, when flavivirus cDNA is transfected into susceptible 
eukaryotic cells, it undergoes nuclear transcription to RNA, which is then replicated 
and viral protein synthesis is initiated.  Flavivirus genome-length infectious clones 
require the same level of bio-containment (Containment Level 3) as wild-type 
flaviviruses, and are difficult to produce, as flavivirus cDNA is unstable in E. coli (Ward 
and Davidson, 2008).  To circumvent the problem of instability, infectious clones have 
been produced in vitro by ligation or long-template high-fidelity PCR (Campbell and 
Pletnev, 2000; Sumiyoshi, Hoke, and Trent, 1992), or in E. coli with the addition of 
short introns to prevent spurious expression (Yamshchikov, Mishin, and Cominelli, 
2001).  The use of genome-length infectious clones incorporating the quasispecies 
variant E genes would enable the cell-attachment capabilities of E to be tested using 
live virus.  It had been intended as part of this study to subject the quasispecies 
dengue VLPs to low pH and assess their ability to form E trimers; however, due to the 
problems experienced with dengue VLP purification and immunodetection, this was 
not possible.  This methodology would have yielded limited results as it would only 
have identified dengue VLP quasispecies variants where trimerisation was either 
permitted or prohibited due to the mutations present.  Using genome-length 
infectious clones, E oligomer and virion assembly, and the ability of E to undergo low 
pH-induced oligomeric rearrangements required for membrane fusion could be 
studied.  The use of genome-length infectious clones and cell-based fusion assays 
would permit more in-depth analysis of the pH required, and time taken for each of 
the quasispecies variant E to undergo the low pH-induced oligomeric rearrangements 
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required for membrane fusion.  The subsequent fusion, replication and virus 
dissemination processes could also be examined by monitoring the cells. 
Quasispecies variants that escape neutralisation by pre-existing heterotypic antibodies 
will be able to replicate, and therefore when inoculated into a new host, they will 
comprise a greater proportion of the quasispecies population.  This could potentially 
lead to increased disease severity and case fatality rates as an epidemic progresses 
(Guzmán et al., 2000).  Genome-length infectious clones incorporating the 
quasispecies variant E genes could be used in neutralisation assays to assess 
neutralisation of the specific variants within the quasispecies population using serum 
from the Sri Lankan patients.  This would identify quasispecies variants with 
neutralisation escape mutations, and enable assessment of potential links between the 
presence of such variants and disease severity in the patient.  Differences in replication 
efficiency between quasispecies consensus and variant viruses could also be 
determined using these genome-length infectious clones and primary human and 
mosquito cells.  To determine transmissibility of different variants within the 
quasispecies population, genome-length infectious clones representing different 
quasispecies variants could be co-infected into live mosquitoes and used to determine 
the susceptibility of the mosquito population to infection with the different 
quasispecies variants.  When this method was used to compare the replication 
efficiency and dissemination of South East Asian and American genotype DV type 2 
strains, the more virulent South East Asian genotype strains were shown to replicate to 
higher titres in the midgut and disseminate to the salivary glands (and therefore be 
available to transmit to humans) up to seven days faster than the less virulent 
American genotype strains, which do not cause epidemics of severe disease (Anderson 
and Rico-Hesse, 2006).  This increase in vectorial capacity for the more virulent strains 
was proposed as a mechanism by which the less virulent American genotype strains 
have been displaced by the South East Asian genotype strains causing severe disease 
(Anderson and Rico-Hesse, 2006).  It would be interesting to investigate whether the 
same was true for the quasispecies variants compared to their respective consensus 
viruses.  Restricted quasispecies populations have been reported for naturally infected 
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mosquitoes compared to those found in patient samples during the same outbreak 
(Lin et al., 2004).  This suggests that the quasispecies variants observed in the patient 
samples will experience selection pressure when transmitted to the mosquito vector, 
as some will be better adapted to survival in the mosquito cells than others.  
Chapter 6: Final discussion 
255 
 
6.1 Conclusions 
In conclusion, the hypothesis that DV quasispecies populations affect disease severity 
in individual patients was neither proven nor disproven.  No correlation was observed 
between the overall extent of quasispecies variation and disease severity.  However, 
genome-defective quasispecies variants, and variants with mutations leading to amino 
acid substitutions that were surface accessible, or proximal to the fusion peptide, 
proposed HSHS binding site, or the other protein chain within the E dimer, were 
observed predominantly in samples from patients with severe cases of dengue.  For 
four of these quasispecies variants, the mutations in the E gene were shown to cause 
alterations in the heparin binding ability of the recombinant E.  Further work will be 
required to confirm that these differences represent varying cell attachment 
capabilities of the quasispecies variants compared to their respective consensus VLPs.  
It is important to remember that for this study, recombinant dengue VLPs were only 
able to be produced for a very small subset of the DV quasispecies populations, so it is 
difficult to link these observations with disease severity, as the net effect of the entire 
population needs to be taken into account.  The production of dengue VLPs, or 
genome-length infectious clones for more of the quasispecies variants identified in this 
study would subsequently provide more data for analysis.   
It is extremely difficult to correlate in vitro observations of DV behaviour to disease 
pathogenesis and epidemiology.  This is predominantly because dengue pathogenicity 
results from the complex interactions of both viral and host factors, and there is a lack 
of suitable animal models for dengue, as DVs only cause symptomatic disease in 
humans.  The majority of the available information regarding DVs has been obtained 
from patients with clinically apparent illness, and there are very few samples available 
from asymptomatic human infections.  For these reasons, the natural spectrum of DV 
variation, and the relative virulence and transmissibility of strains, let alone 
quasispecies variants are difficult to determine with any confidence.  The mechanisms 
of dengue pathogenesis are therefore likely to remain controversial until appropriate 
in vivo models representing the entire spectrum of disease have been developed. 
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Appendix A.  Dengue RT-PCR primer alignments 
These alignments are included as an electronic version only. 
Nucleotide sequence alignments for the regions flanking the dengue virus envelope genes 
are included, with the NCBI accession number for each sequence shown at the start of each 
row.  These alignments were used to design forward and reverse primers for envelope gene 
amplification.  For each alignment, nucleotides matching the consensus sequence are shown 
as dots, with mismatches shown in full.  The final primer sequences used for dengue virus 
envelope gene amplification from patient samples are highlighted in the consensus 
(Majority) sequence.     
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Appendix B.  Gel electrophoresis images of plasmid DNA for each 
dengue virus quasispecies envelope gene clone.  
 
Figure 1.  Dengue virus envelope gene clone plasmid DNA gel electrophoresis images. 
For each patient sample (R097A, R107A, R114A, R197A, R203A, R232A, R255A, R259A, R261A, 
R282A, R299A, R334A), each lane consists of eight clones with a 1kb ladder at one end.  Ladder band 
sizes from the bottom upwards are 0.5kb, 1.0kb, 1.5kb, 2.0kb, 3.0kb (brightest band), 4.0kb, 5.0kb, 
6.0kb, 8.0kb and 10.0kb.  For each clone two bands were observed corresponding to nicked circular 
plasmid DNA (>10 kb) and supercoiled plasmid DNA either with (4.8 kb; example shown in a green 
box) or without (3 kb; example shown in a red box) the envelope gene insert. 
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Appendix C.  Quasispecies envelope gene nucleotide sequence 
alignments 
These alignments are included as an electronic version only. 
Nucleotide sequence alignments for the cloned dengue virus quasispecies envelope genes 
are included below for each patient sample (R097A, R107A, R203A, R259A, R261A, R282A).  
The clone number for each sequence is shown at the start of each row.  These alignments 
were used to identify mutations within the quasispecies populations.  For each alignment, 
nucleotides matching the consensus sequence are shown as dots, with mismatches shown in 
full.  The quasispecies consensus (Majority) sequence is shown along the top of each 
alignment.  Mutations are summarized in Appendix E, tables 1 to 6.   
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Appendix D.  Quasispecies envelope glycoprotein amino acid 
sequence alignments 
These alignments are included as an electronic version only. 
Amino acid sequence alignments for the cloned dengue virus quasispecies envelope genes 
are included below for each patient sample (R097A, R107A, R203A, R259A, R261A, R282A).  
The clone number for each sequence is shown at the start of each row.  These alignments 
were used to identify amino acid sequence changes resulting from the envelope gene 
mutations within the dengue virus quasispecies populations that were identified in the 
alignments in Appendix 3.  For each alignment, amino acids matching the consensus 
sequence are shown as dots, with mismatches shown in full; stop codons are represented 
with a slash (/).  The quasispecies consensus (Majority) sequence is shown along the top of 
each alignment.  Protein sequence changes are summarized in Appendix E, tables 1 to 6.                                                                                                          
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Appendix E.  Summary of dengue virus quasispecies envelope gene 
mutations 
The dengue virus quasispecies envelope gene mutations and amino acid sequence changes 
identified from the sequence alignments shown in Appendices C and D are summarised for 
each dengue patient sample (R097A, R107A, R203A, R259A, R261A, R282A).  A transition 
mutation is one where a purine (A or G) is substituted with another purine, or a pyrimidine 
(C, T or U) with another pyrimidine.  In contrast, a transversion mutation is one in which a 
purine is substituted with a pyrimidine or vice versa.  Nonsynonymous mutations lead to 
protein sequence changes whereas synonymous mutations do not.  Conservative protein 
changes occur when an amino acid is substituted for one with similar properties, but drastic 
protein changes occur when amino acids with different properties are substituted (for 
example, a polar amino acid such as glycine for a nonpolar amino acid such as leucine).
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Appendix F.  AccuScript versus Expand method comparison: dengue 
virus type 3 clone envelope gene nucleotide sequence alignments 
These alignments are included as an electronic version only. 
Nucleotide sequence alignments for the cloned dengue virus type 3 envelope genes are 
included below for each RT-PCR amplification method tested (AccuScript or Expand).  The 
clone number for each sequence is shown at the start of each row.  These alignments were 
used to identify differences in the numbers of mutations generated using the two 
methodologies.  For each alignment, nucleotides matching the consensus sequence are 
shown as dots, with mismatches shown in full.  The consensus (Majority) sequence is shown 
along the top of each alignment.  Mutations are summarized in Appendix 9, tables 7 and 8. 
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Appendix G.  AccuScript versus Expand method comparison: dengue 
virus type 3 clone envelope glycoprotein amino acid sequence 
alignments 
These alignments are included as an electronic version only. 
Amino acid sequence alignments for the cloned dengue virus type 3 envelope genes are 
included below for each RT-PCR amplification method tested (AccuScript or Expand).  The 
clone number for each sequence is shown at the start of each row.  These alignments were 
used to identify amino acid sequence changes resulting from the envelope gene mutations  
identified in the alignments shown in Appendix 7.  For each alignment, amino acids matching 
the consensus sequence are shown as dots, with mismatches shown in full; stop codons are 
represented with a slash (/).  The consensus (Majority) sequence is shown along the top of 
each alignment.  Protein sequence changes are summarized in Appendix 9, tables 1 and 2. 
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Appendix H.  Expand versus AccuScript method comparison: 
summary of dengue virus type 3 envelope gene mutations 
The dengue virus type 3 envelope gene mutations and amino acid sequence changes 
identified from the sequence alignments shown in Appendices F and G are summarised for 
each RT-PCR amplification method (Expand or AccuScript).  A transition mutation is one 
where a purine (A or G) is substituted with another purine, or a pyrimidine (C, T or U) with 
another pyrimidine.  In contrast, a transversion mutation is one in which a purine is 
substituted with a pyrimidine or vice versa.  Nonsynonymous mutations lead to protein 
sequence changes whereas synonymous mutations do not.  Conservative protein changes 
occur when an amino acid is substituted for one with similar properties, but drastic protein 
changes occur when amino acids with different properties are substituted (for example, a 
polar amino acid such as glycine for a nonpolar amino acid such as leucine). 
Table 7.  Expand method mutations  
Clone 
No. 
Mutation 
position 
(nt) 
Nt change Transition / 
Transversion 
Synonymous / 
Nonsynonymous 
Mutation 
position 
(protein) 
Protein 
change 
Conservative 
/ drastic 
5 E7 
E231 
E531 
E1365 
T→C 
A→G 
A→G 
T→C 
Transition 
Transition 
Transition 
Transition 
Nonsynonymous 
Synonymous 
Synonymous 
Synonymous 
E3 
E77 
E177 
E455 
C→R 
None 
None 
None 
Conservative 
91 E27 A→G Transition Synonymous E9 None  
32 E37 
E245 
E1037 
G→A 
T deletion 
A→G 
Transition 
N/A 
Transition 
Nonsynonymous 
Nonsynonymous 
Synonymous 
E13 
E82 
E346 
E→K 
Frameshift 
N/A 
Drastic 
Drastic 
92 E131 
E248 
E964 
E1069 
A→G 
C deletion 
G→T 
A→G 
Transition 
N/A 
Transversion 
Transition 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E44 
E83 
E322 
E357 
E→G 
Frameshift 
N/A 
N/A 
Drastic 
Drastic 
 
52 E139 A→G Transition Nonsynonymous 
 
E47 K→E Drastic 
3 E222 
E734 
E1051 
T→C 
A deletion 
A→G 
Transition 
N/A 
Transition 
Synonymous 
Nonsynonymous 
Nonsynonymous 
 
E74 
E245 
E351 
None 
Frameshift 
H→R 
 
Drastic 
Conservative 
31 E304-305 
E357 
E374 
E735 
GG deletion 
T→C 
T→A 
A insertion 
N/A 
Transition 
Transversion 
N/A 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E102 
E119 
E125 
E246 
Frameshift 
N/A  
N/A  
N/A 
Drastic 
 
49 E277 A→G Transition Nonsynonymous 
 
E93 K→E Drastic 
25 E319 T→C Transition Synonymous E107 None  
24 E324 
E438 
E1410 
T insertion 
A→G 
A insertion 
N/A 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E109 
E146 
E470 
Frameshift 
N/A 
N/A 
Drastic 
 
30 E355 
E735  
T→C 
A insertion 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E119 
E246 
F→L 
Frameshift 
Conservative 
Drastic 
59 E329 
E1114 
A→G 
T insertion 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E110 
E372 
K→R 
Frameshift 
Conservative 
Drastic 
93 E319 T→C Transition Synonymous E107 None  
1 E426 
E651 
A→G 
A→G 
Transition 
Transition 
Synonymous 
Synonymous 
E142 
E217 
None 
None 
Drastic 
16 E407 A→T Transversion Nonsynonymous 
 
E136 K→I Drastic 
83 E407 
E530 
A→G 
G deletion 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E136 
E177 
K→R 
Frameshift 
Conservative 
Drastic 
19 E489 A→G Transition Synonymous E163 None  
65 E500 C→T Transition Nonsynonymous 
 
E167 S→L Drastic 
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Clone 
No. 
Mutation 
position 
(nt) 
Nt change Transition / 
Transversion 
Synonymous / 
Nonsynonymous 
Mutation 
position 
(protein) 
Protein 
change 
Conservative 
/ drastic 
48 E550 
E774 
E1410 
T→C 
G→A 
A insertion 
Transition 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E184 
E258 
E470 
S→P 
M→I 
Frameshift 
Drastic 
Conservative 
Drastic 
12 E734 
E1242 
A deletion 
A deletion 
N/A 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E245 
E414 
Frameshift 
Frameshift 
Drastic 
Drastic 
20 E695 
E1009 
A→G 
A→G 
Transition 
Transition 
Nonsynonymous 
Nonsynonymous 
 
E232 
E337 
K→R 
T→A 
Conservative 
Drastic 
50 E667 
E1009 
A→T 
A→G 
Transversion 
Transition 
Nonsynonymous 
Nonsynonymous 
 
E223 
E337 
T→S 
T→A 
Conservative 
Drastic 
71 E715 
E750 
E936 
A→T 
C→T 
A→G 
Transversion 
Transition 
Transition 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E239 
E521 
E313 
K→Stop 
N/A 
N/A 
Drastic 
 
72 E697 
E720 
G→A 
A insertion 
Transition 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E233 
E240 
E→K 
Frameshift 
Drastic 
Drastic 
94 E735 
E1295 
A insertion 
A→G 
N/A 
Transition 
Nonsynonymous 
Nonsynonymous 
 
E246 
E432 
Frameshift 
N/A 
Drastic 
 
14 E766 G→A Transition Nonsynonymous 
 
E256 G→R Drastic 
33 E812 T deletion N/A Nonsynonymous 
 
E272 
 
Frameshift Drastic 
41 E774 G→A Transition Nonsynonymous E258 M→I Conservative 
11 E964 
E998 
G deletion 
C insertion 
N/A 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E322 
E334 
Frameshift 
Frameshift 
Drastic 
Drastic 
42 E1062 A→G Transition Synonymous 
 
E354 None  
Table 7 continued from page p 
 
Table 8.  AccuScript method mutations  
Clone 
No. 
Mutation 
position 
(nt) 
Nt change Transition / 
Transversion 
Synonymous / 
Nonsynonymous 
Mutation 
position 
(protein) 
Protein 
change 
Conservative 
/ drastic 
15 E95 C→G Transversion Nonsynonymous 
 
E32 T→S  Conservative 
84 E79 
E1410 
C→A 
A insertion 
Transversion 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E27 
E470 
H→N 
Frameshift 
Drastic 
Drastic 
71 E539 
E1427 
T insertion 
T insertion 
N/A 
N/A 
Nonsynonymous 
Nonsynonymous 
 
E180 
E476 
Frameshift 
Frameshift 
Drastic 
Drastic 
89 E573 T insertion N/A Nonsynonymous E191 Frameshift Drastic 
4 E677 AA insertion N/A Nonsynonymous 
 
E226 Frameshift Drastic 
91 E673 G→A Transition Nonsynonymous 
 
E225 E→K Drastic 
35 E767 G deletion N/A Nonsynonymous 
 
E256 Frameshift Drastic 
73 E847 A insertion N/A Nonsynonymous 
 
E282 Frameshift Drastic 
31 E1005 T insertion N/A Nonsynonymous 
 
E335 Frameshift Drastic 
37 E1005 T insertion N/A Nonsynonymous 
 
E335 Frameshift Drastic 
21 E1038-1039 TG→ATTTCAA N/A Nonsynonymous 
 
E346 Frameshift Drastic 
52 E1166 G→A Transition Nonsynonymous 
 
E389 W→Stop Drastic 
27 E1349 
E1352 
E1355 
E1359-62 
C→G 
G→T 
T deletion 
GAAA→TTGT 
Transversion 
Transversion 
N/A 
Both 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
 
E450 
E451 
E452 
E453-4 
S→C 
W→L 
Frameshift 
M→F 
Conservative 
Conservative 
Drastic 
Conservative 
38 E1349 
E1352 
E1355 
E1359-62 
C→G 
G→T 
T deletion 
GAAA→TTGT 
Transversion 
Transversion 
N/A 
Both 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
Nonsynonymous 
 
E450 
E451 
E452 
E453-4 
S→C 
W→L 
Frameshift 
M→F 
Conservative 
Conservative 
Drastic 
Conservative 
50 E1410 A insertion N/A Nonsynonymous 
 
E470 Frameshift Drastic 
51 E1410 A insertion N/A Nonsynonymous 
 
E470 Frameshift Drastic 
53 E1410 A insertion N/A Nonsynonymous 
 
E470 Frameshift Drastic 
65 E1410 A insertion N/A Nonsynonymous 
 
E470 Frameshift Drastic 
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Appendix I.  Percentage sequence identities calculated from dengue 
virus nucleotide sequence alignments for phylogenetic analysis   
 
 
 
F
ig
u
re
 2
. 
 P
e
rc
e
n
ta
g
e
 s
e
q
u
e
n
ce
 i
d
e
n
ti
ti
e
s 
ca
lc
u
la
te
d
 f
r
o
m
 d
e
n
g
u
e
 v
ir
u
s 
ty
p
e 
2
 n
u
c
le
o
ti
d
e
 s
e
q
u
e
n
ce
 a
li
g
n
m
e
n
ts
 f
o
r 
p
h
y
lo
g
e
n
e
ti
c
 a
n
a
ly
si
s 
Appendix I 
 
s 
 
 
 
 
 
F
ig
u
re
 3
. 
 P
e
rc
e
n
ta
g
e
 s
e
q
u
e
n
ce
 i
d
e
n
ti
ti
e
s 
ca
lc
u
la
te
d
 f
r
o
m
 d
e
n
g
u
e
 v
ir
u
s 
ty
p
e 
3
 n
u
c
le
o
ti
d
e
 s
e
q
u
e
n
ce
 a
li
g
n
m
e
n
ts
 f
o
r 
p
h
y
lo
g
e
n
e
ti
c
 a
n
a
ly
si
s 
Appendix I 
 
t 
 
 
 
 
F
ig
u
re
 4
. 
 P
e
rc
e
n
ta
g
e
 s
e
q
u
e
n
ce
 i
d
e
n
ti
ti
e
s 
ca
lc
u
la
te
d
 f
r
o
m
 d
e
n
g
u
e
 v
ir
u
s 
ty
p
e 
2
 n
u
c
le
o
ti
d
e
 s
e
q
u
e
n
ce
 a
li
g
n
m
e
n
ts
 f
o
r 
p
h
y
lo
g
e
n
e
ti
c
 a
n
a
ly
si
s 
Appendix J 
 
u 
 
Appendix J.  Original images 
 
These images are included as an electronic version only. 
 
The original (unprocessed) gel and blot images used to construct figures 3.5, 3.6, 3.8a, 4.3, 
and 4.5 to 4.18 are included in the file labelled Appendix J on the disc included with this 
thesis. 
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Appendix K.  List of presentations 
 
Flaviviruses. 
Oral presentation to the Novel and Dangerous Pathogens group at HPA CEPR on November 
15th 2007. 
 
Investigation of envelope gene variation in clinical samples from patients with dengue virus 
infections. 
Oral presentation to the Novel and Dangerous Pathogens group at HPA CEPR on February 
26th 2009. 
 
Investigation of dengue virus envelope gene variation in clinical samples from Sri Lanka. 
Hannah Love, Dr Jane Burton, Dr Daniel Bailey, Prof. David Cullen.  Conference poster 
presentation for FEMS (Federation of European Microbiological Societies) 3rd congress of 
European microbiologists.   Gothenburg, Sweden; June 28th – July 2nd 2009. 
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Appendix L.  Ethical considerations relating to the Sri Lankan patient 
samples and clinical data 
 
Copies of letters confirming that ethical approval was obtained from both the University of 
Kelaniya in Sri Lanka and the Liverpool School of Tropical Medicine in the UK, and the 
corresponding summaries of the Sri Lanka Fever Study protocol are provided as an electronic 
version only, in the file labelled Appendix L on the disc included with this thesis. 
Briefly, ethical approval was obtained for extra blood samples to be taken from consenting 
adults with fever, or fever history who were admitted to hospitals in Ragama, Sri Lanka.  The 
aim of the study was to identify the specific infections that cause febrile illnesses in Sri 
Lanka. This would assist in making clinical diagnoses of febrile illnesses, provide useful 
microbiological surveillance data and indicate which infections require local laboratory 
confirmation in the future. It would also enable various serological tests to be calibrated for 
use in local populations.  Approval was granted for the anonymised samples and clinical data 
to be sent to collaborating institutions, including HPA CEPR in the UK, for testing for 
arboviruses including dengue virus, and for these anonymised electronic records and 
biomedical samples to be kept permanently by the laboratories involved for possible non-
commercial use in the future. 
For the work presented in this thesis, therefore, further ethical approval was not required 
for the following reasons: 
1. The samples and clinical data were anonymised. 
2. The work was restricted to amplification of the dengue viruses already known to be 
present in the samples, and the clinical data pertaining to the dengue virus infection.   
The work would lead to diagnostic service improvement at HPA CEPR. 
 
